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Abstract 
The principle aim of this project is the investigation of metabolism and 
mechanisms of pentamidine resistance in trypanosomatids. An understanding of 
these mechanisms may allow the development of novel drugs to treat 
Leishmaniasis and human African trypanosomiasis (HAT), caused by the 
protozoan parasites Leishmania spp and Trypanosoma brucei. In this study a 
pentamidine resistance L. mexicana promastigote cell line was generated in 
vitro. This cell line was 20-fold resistant to pentamidine when compared to the 
parental wild type cells. Furthermore, these lines were cross resistant to other 
diamidine compounds. A proteomic analysis of these cell lines revealed 
numerous changes to the proteome, with the down regulation of several flagellar 
proteins. A hypothesis to investigate a role of the voltage dependent anion 
channel (VDAC) in pentamidine resistance was also explored. The metabolomic 
approach involved the investigation of transketolase and the pentose phosphate 
pawthway. A previous study involving a transketolase knockout T. brucei cell 
line indicated that an increased sensitivity to pentamidine and methylene blue. 
A transketolase deficient L. mexicana cell line was generated to test this 
hypothesis in Leishmania, however the differences were minimal. A 
metabolomic analysis of the L. mexicana tkt null cell line (lmtkt-/-) revealed an 
increase in ribose 5-phosphate, a key substrate of transketolase. Erythrose 4-
phosphate also increased in the lmtkt-/- cells, indicating a source of this 
metabolite independent of TKT. It appears that the deletion of TKT prevents any 
flux through the oxidative branch of the PPP returning to the glycolytic pathway. 
Interestingly, the lmtkt-/- cells do not acidify the medium to the same extent as 
the wild type cells; however a glucose assay indicated that both cell lines used 
similar quantities of glucose. This would suggest that there is a change in the 
metabolites excreted by the lmtkt-/- cell line. Finally, a global metabolomics 
approach was investigated using high resolution mass spectrometry. 
Metabolomics is a rapidly developing field in systems biology, and whilst 
significant improvements have been made in mass spectrometry; the ability to 
analyse and interpret raw metabolomic datasets on a global scale has been 
largely neglected. Consequently, a database program to query these complex 
datasets was constructed. 
iii 
Table of contents 
Author’s declaration............................................................................................... i 
Abstract............................................................................................................. ii 
Table of contents .................................................................................................iii 
List of figures ......................................................................................................vi 
List of tables ..................................................................................................... viii 
Definitions..........................................................................................................ix 
Acknowledgements .............................................................................................. xii 
1 General Introduction ..................................................................................... 14 
1.1 Leishmania and trypanosomes ................................................................... 15 
1.2 Leishmaniasis........................................................................................ 15 
1.3 Leishmania Life Cycle.............................................................................. 18 
1.4 African Trypanosomiasis........................................................................... 20 
1.5 Trypanosome Life Cycle ........................................................................... 22 
1.6 Kinetoplastid morphology and ultrastructure ................................................. 23 
1.7 Diagnosis ............................................................................................. 28 
1.7.1 Visceral Leishmania............................................................................. 28 
1.7.2 HAT ................................................................................................ 28 
1.8 Vaccine prospects .................................................................................. 29 
1.9 Vector Control ...................................................................................... 30 
1.10 Chemotherapy....................................................................................... 31 
1.10.1 Pentamidine .................................................................................. 32 
1.10.2 Melarsoprol.................................................................................... 33 
1.10.3 Eflornithine ................................................................................... 34 
1.10.4 Suramin ........................................................................................ 35 
1.10.5 Nifurtimox..................................................................................... 36 
1.10.6 Antimony ...................................................................................... 36 
1.10.7 Paromomycin ................................................................................. 37 
1.10.8 Amphotericin B ............................................................................... 38 
1.10.9 Miltefosine .................................................................................... 39 
1.10.10 Drug summary ................................................................................ 39 
1.11 Metabolism........................................................................................... 40 
1.11.1 Glucose metabolism ......................................................................... 40 
1.11.2 Amino-Acid Metabolism ..................................................................... 43 
1.11.3 Metabolic differences between trypanosomatids ...................................... 44 
1.11.4 Electron transport chain.................................................................... 46 
1.12 Proteomics ........................................................................................... 48 
1.12.1 DIGE ............................................................................................ 48 
1.12.2 Labelling proteins............................................................................ 49 
1.12.3 Trypsin ......................................................................................... 50 
1.13 Mass Spectrometry ................................................................................. 51 
1.13.1 Ionisation ...................................................................................... 52 
1.13.2 Mass to charge analysis ..................................................................... 53 
1.13.3 TOF ............................................................................................. 53 
1.13.4 Ion-trap ........................................................................................ 53 
1.13.5 Orbitrap........................................................................................ 53 
1.13.6 HPLC............................................................................................ 54 
1.13.7 HILIC............................................................................................ 54 
1.13.8 MS/MS .......................................................................................... 55 
1.14 The identification of proteins .................................................................... 56 
1.15 Metabolomics........................................................................................ 56 
1.15.1 Sample preparation.......................................................................... 57 
1.15.2 Data acquisition .............................................................................. 59 
1.15.3 Data analysis.................................................................................. 59 
1.15.4 Applications of metabolomics ............................................................. 61 
2 Materials and methods ................................................................................... 62 
2.1 Cell culture .......................................................................................... 63 
2.1.1 Leishmania ....................................................................................... 63 
2.1.2 Trypanosomes.................................................................................... 63 
2.1.3 Determining cell density ....................................................................... 63 
2.1.4 Preparation of stabilates....................................................................... 64 
iv 
2.2 Isolation of genomic DNA.......................................................................... 64 
2.2.1 Phenol-Choloroform Method .................................................................. 64 
2.2.2 DNeasy Blood and Tissue Kit (QIAGEN) ...................................................... 64 
2.3 Molecular Cloning Techniques.................................................................... 65 
2.3.1 Polymerase Chain Reaction.................................................................... 65 
2.3.2 Cloning PCR products ........................................................................... 66 
2.3.3 Olignucleotides .................................................................................. 66 
2.3.4 DNA gel electrophoresis and gel extraction ................................................ 66 
2.3.5 Ligations .......................................................................................... 66 
2.3.6 Transformations ................................................................................. 68 
2.3.7 Plasmid generation.............................................................................. 69 
2.3.8 Preparation of glycerol stocks ................................................................ 69 
2.4 Southern Blotting ................................................................................... 69 
2.4.1 Eluting the probe from a membrane......................................................... 70 
2.5 Species Identification.............................................................................. 71 
2.6 Transfection of Leishmania promastigotes..................................................... 71 
2.6.1 Preparation of DNA ............................................................................. 71 
2.6.2 Transfection and cloning....................................................................... 71 
2.7 Alamar Blue Assay .................................................................................. 72 
2.8 Proteomic Analysis ................................................................................. 72 
2.8.1 Protein Preparation and Precipitation....................................................... 72 
2.8.2 Bradford Assay ................................................................................... 73 
2.8.3 Cyanine Dye Labelling .......................................................................... 73 
2.8.4 DiGE ............................................................................................... 74 
2.8.5 Colloidal Coomassie Staining .................................................................. 74 
2.8.6 SYPRO Orange Staining ......................................................................... 75 
2.8.7 Spot Picking and protein identification ..................................................... 75 
2.9 Metabolomics........................................................................................ 76 
2.9.1 Determining Glucose Concentration ......................................................... 76 
2.9.2 Preparation of metabolite extracts for FT-MS analysis................................... 77 
2.9.3 Liquid Chromatography Mass Spectrometry ................................................ 77 
2.9.4 Metabolomic data processing ................................................................. 78 
2.9.5 Database development ......................................................................... 78 
3 Developing a database to analyse Kinetoplastid metabolomic experiments ................... 80 
3.1 Introduction ......................................................................................... 81 
3.2 Experimental approach............................................................................ 84 
3.3 Aim .................................................................................................... 85 
3.4 Simple Metabolite Table .......................................................................... 86 
3.5 A suitable database program ..................................................................... 88 
3.5.1 Creating a flat file system ..................................................................... 90 
3.5.2 Creating a relational database................................................................ 93 
3.5.3 The database Schema .......................................................................... 99 
3.6 MetaSearch for analysis ..........................................................................100 
3.6.2 User friendly ....................................................................................102 
3.6.3 Analysing a dataset ............................................................................103 
3.6.4 Searching datasets for a single metabolite or mass......................................111 
3.7 Searching the KEGG Database...................................................................114 
3.7.1 Mass Searches ...................................................................................115 
3.7.2 Molecular Formula Search ....................................................................115 
3.7.3 Metabolite Name Search ......................................................................115 
3.7.4 KEGG Compound ID Search ...................................................................116 
3.7.5 Defining the shortlist ..........................................................................117 
3.8 The metaSearch Database .......................................................................118 
3.9 Pathos ...............................................................................................119 
3.10 Discussion ...........................................................................................121 
4 Genetic manipulation of L. mexicana transketolase...............................................126 
4.1 The Pentose Phosphate Pathway ...............................................................127 
4.1.1 Oxidative Branch ...............................................................................127 
4.1.2 Non-oxidative Branch..........................................................................128 
4.1.3 PPP activity in Trypanosomatids ............................................................129 
4.1.4 Roles in Biology .................................................................................129 
4.2 Transketolase ......................................................................................130 
4.2.1 Structure.........................................................................................132 
4.2.2 Reaction mechanism...........................................................................136 
4.2.3 Localisation......................................................................................137 
v 
4.3 Aim ...................................................................................................138 
4.4 Targetted Gene Disruption of the L. mexicana TKT gene ..................................139 
4.4.1 Constructs .......................................................................................139 
4.4.2 First round transfection.......................................................................141 
4.4.3 PCR Screen ......................................................................................142 
4.4.4 Second round transfection....................................................................145 
4.4.5 Southern Blot Analysis.........................................................................147 
4.5 Ribosomal expression of transketolase ........................................................150 
4.6 Over-expression of TKT in L. mexicana........................................................151 
4.7 Transketolase sequence ..........................................................................154 
4.8 Phenotypic Analysis ...............................................................................154 
4.8.1 Growth curve....................................................................................154 
4.8.2 Over-expression of Transketolase ...........................................................156 
4.8.3 Medium colour change ........................................................................160 
4.8.4 Glucose Utilisation .............................................................................161 
4.8.5 Sensitivity of L. mexicana to oxidative stress and drugs................................163 
4.8.6 Metabolomic Analysis ..........................................................................166 
4.8.7 Interaction of TKT with PEX5 ................................................................176 
4.9 Discussion ...........................................................................................180 
5 Pentamidine resistance in L. mexicana ..............................................................183 
5.1 Introduction ........................................................................................184 
5.1.1 Cellular target of diamidines.................................................................184 
5.1.2 Biological target of diamidines ..............................................................185 
5.2 Pentamidine and trypanosomatids .............................................................186 
5.2.1 Pentamidine transport in trypanosomes ...................................................186 
5.2.2 Pentamidine transport and efflux in Leishmania .........................................187 
5.2.3 Accumulation of pentamidine in trypanosomatids .......................................189 
5.2.4 Summary of pentamidine and trypanosomatids ..........................................190 
5.2.5 Pentamidine in Yeast ..........................................................................191 
5.3 Summary of L. donovani pentamidine resistance............................................192 
5.4 Species Identification.............................................................................195 
5.5 Generating pentamidine resistant promastigotes ...........................................199 
5.6 Species Identification.............................................................................202 
5.7 Phenotypic Analysis ...............................................................................204 
5.7.1 Growth phenotype .............................................................................204 
5.7.2 Alamar Blue Assay..............................................................................204 
5.8 DiGE Analysis .......................................................................................212 
5.8.1 The down-regulation of flagellar proteins .................................................213 
5.8.2 Unidentfied protein............................................................................217 
5.9 Voltage Dependent Anion Channel .............................................................218 
5.10 Pentamidine susceptibility of cells grown in different carbon sources ..................220 
5.11 Discussion ...........................................................................................222 
6 General Discussion .......................................................................................226 
7 Appendices ................................................................................................230 
7.1 Cell Culture medium ..............................................................................231 
7.1.1 HOMEM ...........................................................................................231 
7.1.2 SDM-80 ...........................................................................................232 
7.2 Molecular Biology Reagents......................................................................233 
7.2.1 Cell lysis buffer A ..............................................................................233 
7.2.2 1x TAE ............................................................................................233 
7.2.3 Depurination solution..........................................................................233 
7.2.4 Denaturation solution .........................................................................233 
7.2.5 Neutralisation solution ........................................................................233 
7.2.6 20x SSC...........................................................................................233 
7.2.7 50x Denhardts...................................................................................233 
7.3 Proteomics ..........................................................................................233 
7.3.1 Cell Lysis Buffer B ..............................................................................233 
7.3.2 Protein Inhibitor Cocktail .....................................................................234 
7.3.3 DiGE Rehydration Buffer ......................................................................234 
7.3.4 DiGE Equilibration Buffer 1 ...................................................................234 
7.3.5 DiGE Equilibration Buffer 2 ...................................................................234 
7.3.6 DiGE fixing solution ............................................................................234 
8 Supplementary Data .....................................................................................235 
9 References.................................................................................................248 
 
vi 
List of figures 
Figure 1-1. Global distribution of Leishmaniasis in 2010. ................................................ 17 
Figure 1-2. The life cycle of Leishmania. ................................................................... 19 
Figure 1-3. Distribution of Human African Trypanosomiasis in 1999.................................... 21 
Figure 1-4. The life cycle of Trypanosoma brucei ......................................................... 23 
Figure 1-5. Schematic representation of the principle structures of trypanosomatids. ............ 27 
Figure 1-6. Differences in Trypanosomatid amino acid metabolism.................................... 45 
Figure 1-7. Electron Transport Chain......................................................................... 46 
Figure 1-8. CyDye labelling reaction of lysine residues. .................................................. 49 
Figure 3-1. Metabolics pipeline................................................................................ 82 
Figure 3-2. Databases. .......................................................................................... 95 
Figure 3-3. metaSearch relational schema. ................................................................. 99 
Figure 3-4. MetaSearch main switchboard. ................................................................102 
Figure 3-5. ‘Analysis’ SQL statement........................................................................104 
Figure 3-6. MetaSearch Input Data Form. ..................................................................107 
Figure 3-7. MetaSearch ‘Analysis’ Tab – analysing a dataset. ..........................................108 
Figure 3-8. The output of the analysis query. .............................................................110 
Figure 3-9. Searching for a specific metabolite. ..........................................................112 
Figure 3-10. Searching for a specific mass. ................................................................113 
Figure 3-11. Searching the KEGG database. ...............................................................114 
Figure 3-12. Compiling a shortlist............................................................................118 
Figure 3-13. Metabolomics Web Facility - screenshot. ...................................................120 
Figure 4-1. The Pentose Phosphate Pathway. .............................................................128 
Figure 4-2. Schematic diagram of the interactions of TPP at the cofactor binding site of L. 
mexicana transketolase........................................................................................133 
Figure 4-3. Schematic view of the interactions of erythrose 4-phosphate with L. mexicana holo-
transketolase. ...................................................................................................134 
Figure 4-4. Transketolase reaction mechanism. ..........................................................136 
Figure 4-5. pMB-G40 – Transketolase Knockout Vector. .................................................140 
Figure 4-6. Transketolase knockout cassette with the Hygromycin B phosphotransferase drug 
marker. ...........................................................................................................141 
Figure 4-7. PCR analysis of L. mexicana single allele transketolase knockout clones. .............143 
Figure 4-8. PCR analysis of L. mexicana double allele transketolase knockout clones.............146 
Figure 4-9. Schematic representation of the L. mexicana Transketolase locus. ....................148 
Figure 4-10. Southern blot demonstrating knockout of the transketolase gene for L. mexicana.150 
Figure 4-11. Determining the correct orientation of the transketolase ORF.........................152 
Figure 4-12. PCR analysis of L. mexicana TKT over-expression cell lines.............................153 
Figure 4-13. Alignment of transketolase residues 241 to 280 from several Leishmania spp. .....154 
Figure 4-14. Growth of genetically manipulated L. mexicana promastigotes........................155 
Figure 4-15. Effect on the growth of L. mexicana wild type cells transfected with episomal 
constructs. .......................................................................................................157 
Figure 4-16. Effect on the growth of L. mexicana TKT null (∆TKT) cells transfected with episomal 
constructs. .......................................................................................................158 
Figure 4-17. Mean generation time of L. mexicana promastigotes transfected with episomal 
constructs. .......................................................................................................159 
Figure 4-18. L. mexicana promastigote HOMEM acidification...........................................160 
Figure 4-19. Utilisation of glucose by L. mexicana promastigotes. ....................................162 
Figure 4-20. A comparison of intracellular levels of ribose 1-phosphate (R1P) in L. mexicana...167 
Figure 4-21. A comparison of intracellular levels of ribose 5-phosphate (R5P) in L. mexicana...167 
Figure 4-22. A comparison of intracellular levels of sedoheptulose 7-phosphate (S7P) in L. 
mexicana. ........................................................................................................170 
Figure 4-23. A comparison of intracellular levels of erythrose 4-phosphate (E4P) in L. mexicana.
.....................................................................................................................170 
Figure 4-24. Alternative methods of E4P production. ....................................................172 
Figure 4-25. A comparison of intracellular concentrations of phosphoenolpyruvate (PEP) in L. 
mexicana. ........................................................................................................173 
Figure 4-26. Proposed model for glucose catabolism in the glycosome...............................174 
Figure 4-27. Interaction of Pex5 and PTS1. ................................................................177 
Figure 4-28. The alternating position of the Leishmania transketolase (tkt) PTS-1 (SKM) targeting 
signal. .............................................................................................................178 
Figure 4-29. Interaction of LdTKT with LdPEX5. ..........................................................179 
vii 
Figure 5-1. Model for pentamidine uptake in Leishmania mexicana promastigotes. ...............189 
Figure 5-2. Leishmania Species Identification. ............................................................196 
Figure 5-3. L. donovani species identification.............................................................198 
Figure 5-4. Acquisition of resistance to pentamidine over time in L. mexicana wild type 
promastigotes. ..................................................................................................201 
Figure 5-5. Species Identification............................................................................202 
Figure 5-6. Effect on the growth of wild type and pentamidine resistant L. mexicana 
promastigotes. ..................................................................................................204 
Figure 5-7. Alamar Blue Assay Graphs.......................................................................207 
Figure 5-8. Drug structures of compounds tested.........................................................208 
Figure 5-9. TEM image of the L. mexicana cytoskeletan ................................................213 
Figure 5-10. DIGE comparison images of the Paraflagellar Rod 1 (PFR-1D) and Paraflagellar Rod 2 
(PFR-2C) proteins ...............................................................................................214 
Figure 5-11. DIGE comparison images of a component of the axoneme. .............................215 
Figure 5-12. DIGE comparison of the unidentified protein illustrated by 3D intensity map.......217 
Figure 8-1. L. mexicana Transketolase amino acid seqeuence alignment. ...........................236 
Figure 8-2. L. mexicana Transketolase DNA sequence alignment. .....................................237 
Figure 8-3. Alignment of transketolase amino acid sequences from L. donovani and L. mexicana.
.....................................................................................................................239 
Figure 8-4. VDAC-1 DNA sequence alignment..............................................................240 
Figure 8-5. VDAC-2 DNA sequence alignment..............................................................241 
Figure 8-6. Alignment of VDAC-1 amino acid sequences from L. mexicana. .........................242 
Figure 8-7. Alignment of VDAC-2 amino acid sequences from L. mexicana. .........................242 
Figure 8-8. Alignment of VDAC-1 and VDAC-2 amino acid sequences from L. mexicana...........243 
Figure 8-9. SQL: 065_Analysis ................................................................................244 
Figure 8-10. SQL: 071_Delete_all_records_in_131........................................................244 
Figure 8-11. SQL: 070_Delete_all_records_in_132........................................................244 
Figure 8-12. SQL: 069_Add_Unique_Masses_To_New_Table_132.......................................244 
Figure 8-13. SQL: 078_delete_values_from_139 ..........................................................244 
Figure 8-14. SQL: 077_Specific_Metabolite_Search.......................................................245 
Figure 8-15. SQL: 081_search_the_masses_table_for_specific_metabolite ..........................245 
Figure 8-16. SQL: Mass Search (037).........................................................................245 
Figure 8-17. SQL: Mass (MIM) Search (038) .................................................................245 
Figure 8-18. SQL: Molecular Formula Search (019) .......................................................245 
Figure 8-19. SQL: Metabolite Search (018) (A11)..........................................................246 
Figure 8-20. SQL: KEGG CompCode Search (031) (A12) ..................................................246 
 
viii 
List of tables 
Table 1-1. Drugs currently used to treat leishmaniasis and trypanosomiasis ......................... 32 
Table 2-1. Oligonucleotide Sequences used in this study................................................. 67 
Table 2-2. Plasmid constructs used in this study........................................................... 69 
Table 2-3. Iso-Electric Focusing conditions. ................................................................ 74 
Table 3-1. Naturally occurring isotopes of carbon. ........................................................ 87 
Table 3-2. Basic metabolite information extracted from KEGG......................................... 91 
Table 3-3. Total KEGG Database .............................................................................. 92 
Table 3-4. Synonyms – (metaSearch ‘Table_147’) ......................................................... 93 
Table 3-5. The synonyms for trypanothione listed in the KEGG database............................. 94 
Table 3-6. InChI (metaSearch ‘Table_112’) ................................................................. 94 
Table 3-7. KEGG biochemical reactions ..................................................................... 96 
Table 3-8. KEGG biochemical reactions and metabolites................................................. 97 
Table 3-9. KEGG biochemical reactions and EC numbers................................................. 97 
Table 3-10. Pathway Names ................................................................................... 98 
Table 3-11. Intermediate Compound-Pathway table ...................................................... 98 
Table 3-12. Information stored in the user defined ‘metabolite’ table ..............................101 
Table 3-13. Experimental masses (metaSearch ‘masses’) ...............................................101 
Table 3-14. Event procedure for the ‘Analysis’ command button. ....................................104 
Table 3-15. Analysis 131_Results.............................................................................105 
Table 3-16. Analysis 132_Unique_Formula_RESULTS .....................................................106 
Table 3-17. Event procedure for the ‘Show metabolites’ command button. ........................111 
Table 3-18. Comparing the number of metabolite hits from KEGG website and Microsoft Access 
searches for metabolite names. Unique hits are shown in brackets...................................116 
Table 4-1. Analysis of the first round transfection. ......................................................142 
Table 4-2. Summary of PCR analysis for potential TKT single allele gene knockouts ..............144 
Table 4-3. Analysis of the first round transfection. ......................................................145 
Table 4-4. Summary of PCR analysis for potential TKT double allele gene knockouts .............146 
Table 4-5. Pentamidine EC50 values for L. mexicana promastigotes...................................164 
Table 4-6. Methylene blue EC50 values for L. mexicana promastigotes. ..............................164 
Table 4-7. Pentamidine EC50 values for L. mexicana wild type promastigotes transfected with the 
TKT over-expression construct. ..............................................................................165 
Table 4-8. Methylene Blue EC50 values for L. mexicana wild type promastigotes transfected with 
the TKT over-expression construct. .........................................................................165 
Table 4-9. Metabolic fates of Ribose 5-phosphate. .......................................................169 
Table 4-10. Impact of transketolase deletion in L. mexicana on the concentration of intracellular 
metabolites. .....................................................................................................175 
Table 5-1. Proteins down-regulated in the L. donovani pentamidine resistant (R8) cells. ........193 
Table 5-2. Proteins up-regulated in the L. donovani pentamidine resistant (R8) cells. ...........193 
Table 5-3. Growth of wild type L. mexicana at various concentration of pentamidine............199 
Table 5-4. Summary of EC50 values for compound tested for their Leishmaniacidal effects. .....209 
Table 5-5. Proteins upregulated greater than 3-fold in the pentamidine resistant cell line......212 
Table 5-6. Pentamidine EC50 values for T. brucei 427 procylic form trypanosomes grown in 
different carbon sources.......................................................................................220 
Table 5-7. Methylene blue EC50 values for T. brucei 427 procylic form trypanosomes grown in 
different carbon sources.......................................................................................221 
Table 8-1. Fluorescence readings used to calculate the methylene blue EC50 values ..............247 
 
ix 
Definitions 
ASCT acetate:succinate CoA transferase  
ADP  adenosine diphosphate  
ATP adenosine triphosphate  
AVGM Average Mass 
AD aromatic diamidines 
AIA arylimidamine 
amu atomic mass unit 
bp base pair  
BLAST Basic Local Alignment Search Tool 
BBB blood brain barrier  
BSF bloodstream form  
CNS central nervous system  
CSF cerebro-spinal fluid  
Da Dalton 
°C degrees Celsius  
DB75 2,5 bis (4-amidinophenyl) furan 
2-DOG 2-deoxy-D-glucose  
DAPI 4', 6-Diamidino-2-phenylindole 
DNA deoxyribonucleic acid  
DFMO difluoromethylornithine  
DMSO dimethylsulfoxide  
2DE Two dimensional gel electrophoresis 
DHAP dihydroxyacetone phosphate 
DiGE Differential Gel Electrophoresis 
DDT dichlorodiphenyltrichloroethane 
ES electo spray 
ELISA Enzyme linked immuno serum assay 
EDTA ethylenediamine tretraacetic acid  
EtOH Ethanol 
ESI Electrospray Surface Ionization  
ExPASy Expert Protein Analysis System 
FCS foetal calf serum  
FTP File Transfer Protocol 
FT-MS Fourier Transform Mass Spectrometry 
g gram  
gDNA genomic DNA 
hsDNA herring sperm DNA 
h hour  
HAT human African trypanosomiasis  
HAPT High Affinity Pentamidine Transporter 
HPLC High Pressure Liquid Chromatography 
HILIC Hydrophilic Interaction Chromatography 
IC50 50% Inhibitory Concentration 
IAEA International Atomic Energy Agency  
IEF isoelectric focussing 
IPTG isopropylthio-ß-D-galactoside  
ITS1 internal transcribed spacer 1 
InChI IUPAC International Chemical Identifier 
ITNs insecticide treated bednets 
kb kilobase 
kDa Kilodalton 
kg kilogram  
kDNA kinetoplast DNA 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LB Luria-Bertani medium  
LAPT Low Affinity Pentamidine Transporter 
LIT linear ion traps  
LC-MS Liquid Chromatography-Mass Spectrometry  
MS Mass spectrometry 
MALDI Matrix assisted laser desorption ionisation 
x 
Tm melting temperature  
mRNA messenger RNA  
Km Michaelis constant  
µg microgram  
µl microlitre  
µM micromolar  
mg milligram  
ml millilitre  
mM millimolar  
min minutes  
M molar  
MF Molecular Formula 
MOWSE MOlecular Weight SEarch 
MIM Mono-Isotopic Mass 
MelB Melarsoprol 
MelOx Melarsen Oxide 
mtDNA mitochondrial DNA 
MCS multiple cloning site 
MMP mitochondrial membrane potential 
nm nanometre  
nM nanomolar  
NCBI National Centre for Biotechnology Information 
NAD+ nicotinamide adenine dinucleotide  
NADPH nicotinamide adenine dinucleotide phosphate (reduced form)  
nt nucleotide 
ORF open reading frame  
OD Optical Density 
ODC Ornithine decarboxylase 
OP oxidative phosphorylation 
pI Isoelectric point 
ppm  parts per million 
PMF Peptide Mass Fingerprinting 
PBS phosphate buffered saline  
PEPCK phosphoenol pyruvate carboxylase 
pmol picomole 
PAGE Poly-Acrylamide Gel Electrophoresis 
PCR polymerase chain reaction  
PPP Pentose Phosphate Pathway 
PEP phosphoenolpyruvate 
PFR paraflagellar rod 
PSG promastigote secretion gel 
RFLP Restriction enzyme Fragment Length Polymorphism 
RNA ribonucleic acid  
RNAi RNA interference  
SHAM salicylhydroxamic acid 
SSC saline sodium citrate  
SDS-PAGE SDS polyacrylamide gel electrophoresis 
s second  
SDM semi-defined medium  
SDS sodium dodecylsulphate  
SEM standard error around the mean  
SILAC Stable isotope labelling by amino acids in cell culture 
SLP substrate level phosphorylation 
SQL Structured Query Language 
SMILES simplified molecular-input line-entry system 
SIT sterile insect technique (SIT) 
TEMED N,N,N',N'-tetramethyl ethylenediaminide 
Taq Thermus aquaticus  
TOF Time of flight 
TM transmembrane  
TbAATP Trypanosoma brucei amino acid transporter  
TbAT1 T. brucei adenosine transporter 1 
TKT Transketolase gene (functional) 
TKT Transketolase protein 
TMD Transmembrane domain 
xi 
UV ultraviolet  
UTR Untranslated Region 
VSG variable surface glycoprotein  
V volt 
VBA visual basic application 
WHO  World Health Organisation 
wt wild type 
X-Gal 5-bromo-4-chloro-3-indol-ß-D-galactopyranoside  
xii 
Acknowledgements 
First and foremost, I would like to thank my supervisors, Prof. Mike Barrett and Dr. 
Richard Burchmore. I will never be able to repay them for their patience, guidance, 
advice and support throughout my PhD. Thank you. I would also like to thank my 
assessors, Prof. Sylke Müller and Prof. Andy Waters, for their support and advice. 
I would also like to acknowledge the assistance of Pius Alibu, Gordon Campbell, 
Charles Ebikeme, and Christina Naula who were invaluable at the start of my 
project, and to everyone else in the Barrett and Burchmore lab groups, both past 
and present, for their knowledge and help over the years – it was much appreciated. 
An enormous thank you to the Mottram Group (in particular Jim Hilley, Lesley 
Morrison), and to Ryan Bissett, who took the time to provide help with various 
aspects of molecular biology and culturing Leishmania parasites. Additionally, I 
would like to thank Fabien Jourdan, Richard Scheltema, Ludovic Cottret, Richard 
Orton, and David Leader for their invaluable guidance and advice on the 
computational elements of this project. 
This project was funded by the Medical Research Council. I would like to thank them 
for providing me with the opportunity to do a PhD. 
As well as those metioned above, I would also like to thank the following people; 
Aga, Alli, Amy C, Amy G, Anne, Anu, Ben, Caroline, Cat, Corinna, Daniela, Darren, 
Ed, Elmarie, Federica, Fed, Flo, Georgie, Jana A, Jana R, Jane, Janet, Jo, Joe, Kat, 
Liam, Marta, Matt, Mhairi, Mona, Nadja, Nath, Neil, Nick, Nicola, Nisha, Raquel, 
Richard, Rod, Sam, Seb, Sonia, and Will (and any I have accidentally missed). Their 
friendship over the years has been important to me, and hopefully will continue in 
the years to come.  
The numerous Scotland football trips I’ve endured over the last few years have been 
a welcome break from my studies. Thanks to all that I’ve travelled with, and to 
those I’ve met along the way. From the impressive Macedonian cuisine, to the 
breathtaking nature of Iceland, and from Colditz Castle in Saxony, to the glacial 
Swiss Alps, it’s been an experience! 
I am very grateful to Cristina Costa, who generously gave a lot of her time and 
energy over the last 4 years (irrespective of geographical location!), and has been a 
fantastic friend throughout. Thank you. 
Finally, I would like to thank my parents and family. Without their encouragement, 
support and love throughout my many years of education, I would not be where I am 
today. Thank you. 
xiii 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quia quamdiu Centum ex nobis viui remanserint, nuncquam Anglorum dominio 
aliquatenus volumus subiugari. Non enim propter gloriam, diuicias aut honores 
pugnamus set propter libertatem solummodo quam Nemo bonus nisi simul cum 
vita amittit. 
Declaration of Freedom, 
An extract from the Declaration of Arbroath, 1320 AD
Chapter 1, 14 
1 General Introduction
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1.1 Leishmania and trypanosomes 
Leishmania and trypanosomes are obligate protozoan parasites of the family 
Trypanosomatidae and order Kinetoplastida. The Kinetoplastida are defined by 
the presence of a kinetoplast, an intercatenated network of circular 
mitochondrial DNA molecules located within the single mitochondrion. The 
kinetoplast can be distinguished as a clearly distinct DNA containing structure, 
separate from the nucleus, using fluorescent DNA binding compounds such as 
DAPI. 
Both Leishmania and Trypanosoma have digenetic life cycles with a vertebrate 
host and an insect vector. Leishmania is transmitted by sandflies of the genera 
Lutzomyia (in the New World) and Phlebotomus (in the Old World). African 
trypanosomes are transmitted by the tsetse flies of the genus Glossina. 
1.2 Leishmaniasis 
Leishmaniasis, caused by a variety of Leishmania species, describes a wide range 
of zoonotic diseases with a spectrum of clinical manifestations (Herwaldt, BL 
1999). There are 21 species of Leishmania that are known to be infectious to 
humans, and are transmitted by approximately 30 species of phlebotomine 
sandflies (Bates, PA 2007).  
There are several clinical manifestations of the disease; 
Visceral Leishmaniasis (VL), also known as kala-azar, was independently 
described by Leishman and Donovan in India in 1903. Today, the main causative 
agent of VL is known as Leishmania donovani; prevalent in the Indian sub-
continent and eastern Africa. However, New World and Mediteranean VL is 
caused by L. infantum and L. chagasi. Symptoms include fever, weight loss, 
anaemia, hepatosplenomegaly, pancytopenia, and hypergammaglobulinaemia. 
Failure to treat VL results in death. 
Cutaneous Leishmaniasis (CL), representing 50-75 % of new cases (WHO, 2001), is 
the most common form of Leishmaniasis causing skin lesions at the site of the 
phlebotomine sandfly bite. Whilst the lesions usually self heal, the patient can 
be left with disfiguring scars. The causative agents are Leishmania species found 
in both the Old World and New World.   
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Diffuse Cutaneous leishmaniasis (DCL) is a chronic and progressive form of the 
disease characterised by disseminated skin lesions which resemble those of 
lepromatous leprosy. Unlike CL, the lesions do not heal spontaneously, and are 
not easily treated. The causative agents are L. aethiopica in the Old World, or 
the L. mexicana species complex in the New World.  
Mucocutaneous leishmaniasis (ML), also known as espundia, is a metastatic 
complication of CL, primarily caused by Leishmania braziliensis involving the 
infection, and subsequent destruction of the naso-oropharyngeal mucosal 
membranes. Manifestation of the disease may arise concurrently with the 
cutaneous lesions or several years later. Early symptoms include chronic nasal 
problems. This form of the disease is extremely disfiguring, and many untreated 
patients die as a consequence of secondary bacterial infections of the open 
wounds. 
The global distribution of leishmaniasis is shown in Figure 1-1. Currently, the 
disease is endemic in 88 tropical and sub-tropical countries with twelve million 
people infected, and a further 200 million at risk (Singh, VP et al. 2012). 
However, it is likely that there is considerable under-reporting of the disease 
with an estimated 500,000 new cases of VL, and 1.5 million new cases of CL 
annually. Over 90 % of VL cases are found in Bangladesh, India, Nepal, Sudan, 
and Brazil; whereas 90 % of CL cases are found in Afghanistan, Algeria, Iran, 
Iraq, Saudi Arabia, Syria, Brazil, and Peru. Leishmania mexicana, the organism 
used in this study, is responsible for CL in Mexico and Argentina. 
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Figure 1-1. Global distribution of Leishmaniasis in 2010.
Chapter 1, 18 
Figure 1-1, continued from Page 17. A – The geographical distribution of visceral leishmaniasis in 
the Old and New world. B – The geographical distribution of Old World cutaneous leishmaniasis 
caused by L. major. C – The geographical distribution of Old World cutaneous leishmaniasis 
caused by L. tropica and related species, and L. aethiopica. D – Geographical distribution of 
cutaneous and mucocutaneous leishmaniasis in the New World. WHO1 
1.3 Leishmania Life Cycle 
The life cycle of Leishmania involves an invertebrate host, the female 
phlebotomine sandfly, and a vertebrate host, often a warm blooded mammal 
(Figure 1-2). In the midgut of the sandfly Leishmania exist as motile dividing 
promastigotes, and as they migrate to the foregut they differentiate into 
metacyclic promastigotes, the mammalian infective form.  
When the sandfly has a bloodmeal, these metacyclic promastigotes are 
introduced into the bloodstream, and within 24 hours they are phagocytosed by 
neutrophils (Ribeiro-Gomes, FL and Sacks, D 2010). The Leishmania 
promastigotes inhibit apoptosis of the PMN cells, and within two days, 
macrophages are recruited to the site of infection, where they phagocytose the 
PMNs (Aga, E et al. 2002). At this point, promastigotes differentiate into non-
motile amastigotes where they undergo proliferation at the acidic pH of the 
parasitophorus vacuole (PV). The size of the PV depends on the infecting 
species, and thus harbours single or multiple amastigotes. For example L. 
donovani produce small vacuoles which contain few amastigotes, whereas L. 
mexciana produce larger vacuoles containing many amastigotes (Rittig, MG and 
Bogdan, C 2000; Handman, E and Bullen, DV 2002). When the amastigotes are 
released from the macrophage, they infect other macrophages. 
The life cycle is complete when the sandfly takes a bloodmeal from an infected 
mammal; amastigotes are released from the macrophages, and differentiate into 
promastigotes. There are four main stages of promastigote development as the 
parasites move from the abdominal midgut through the thoracic midgut towards 
the foregut and stromodeal valve. These stages are as follows; procyclic 
promastigotes, nectomonad promastigotes, leptomonad promastigotes, and 
metacyclic promastigotes (Gossage, SM et al. 2003). Depending on the species of 
Leishmania, the process takes between six and nine days. Accumulation of the 
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infective metacyclic promastigotes at the stromdeal valve allows transmission to 
occur when the sandfly takes a bloodmeal (Rogers, ME et al. 2002). A 
combination of high promastigote infection and the presence of the 
promastigote secretory gel (PSG) plug reduce the efficiency of blood uptake 
during a bloodmeal. Consequently, the sandfly must make more bites, thus 
increasing the chance of transmission (Rogers, ME et al. 2004). 
 
Figure 1-2. The life cycle of Leishmania. 
Female phlebotomine sandflies inject infective promastigotes from their proboscis during a blood 
meal. The immune system of the mammalian host responds, primarily through macrophage 
phagocytosis, although other phagocytic cells are involved. Residing in the macrophage, the 
promastigotes transform into infective amastigotes, which are capable of infecting other phagocytic 
cells. The clinical manifestation of the disease depends on the infecting species. If an infected 
macrophage is ingested during a blood meal, amastigotes released from the macrophage will 
develop into promastigotes in the midgut, which then migrate to the proboscis. CDC2. 
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1.4 African Trypanosomiasis 
The prevalence of African trypanosomiasis, a disease affecting mammals, is 
strongly correlated with the distribution of the tsetse fly, Glossina spp, which 
acts as the insect vector, and is restricted to sub-Saharan Africa. This discovery 
was made by David Bruce in 1895 when he discovered that trypanosomes were 
the causative agent of Nagana, trypanosomiasis of livestock (Connor, RJ 1994). 
Human African trypanosomiasis (HAT) is caused by Trypanosoma brucei 
gambiense and Trypanosoma brucei rhodesiense. It is estimated that HAT 
threatens 60 million people in 36 sub-Saharan African countries, with around 
300-500 thousand people infected at the end of the twentieth century; although 
recent data indicates that numbers are falling (Barrett, MP 2006). In addition to 
the species that cause HAT, a number of trypanosomes species are also 
infectious to domestic livestock including Trypanosoma brucei brucei, 
Trypanosoma congolense, and Trypanosoma vivax. The economic consequences 
and impact on food security caused by these parasites is very serious running 
into billions of dollars (Connor, RJ 1994). 
As previously mentioned there are two clinically significant species which infect 
humans; consequently HAT occurs in two forms. Chronic HAT, caused by T. b. 
gambiense, generally located in the tropical regions of Central and West Africa. 
Whilst the disease is inevitably fatal, patients can survive with chronic HAT for 
many years before symptoms are apparent. However, acute HAT is caused by T. 
b. rhodesiense, and is restricted to East and Southern Africa. Disease progression 
is rapid in acute HAT, with death occurring in a matter of weeks or months. The 
distribution of these two species is depicted in Figure 1-3. 
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Figure 1-3. Distribution of Human African Trypanosomiasis in 1999. 
Countries at high risk (endemic) of trypanosomiasis are shown in dark blue, whereas countries at 
no risk are shown in white. The black line represents the divide between T. b. gambiense and T. b. 
rhodesiense as the causative species. WHO3 
HAT has two stages. In stage 1, or the haemolyphatic phase, the trypanosomes 
are present in the bloodstream. In stage 2, or the neurological phase, the 
parasites invade the central nervous system, with profound neurological 
consequences. Symptoms in the early stage of both chronic and acute HAT are 
non-specific, including headaches and general malaise. Therefore, an early 
diagnosis is imperative as progression to the late stage is inevitably fatal in the 
absence of chemotherapy (Barrett MP et al 2003). As the disease progresses to 
the late stage, disruption of the circadian rhythm is evident with many patients 
suffering from sleep disorders. This observation gave rise to the colloquial name 
‘sleeping sickness’. 
                                         
3
 http://www.who.int/csr/resources/publications/CSR_ISR_2000_1tryps/en/index.html 
Chapter 1, 22 
1.5 Trypanosome Life Cycle 
An infected tsetse fly bites a mammalian host, introducing metacyclic form 
trypanosomes into the blood stream. The metacyclic form is pre-adapted for 
survival in the mammalian host in that it already expresses the dense 
glycoprotein coat, which can be systematically altered through the process of 
antigenic variation, to evade the mammalian host’s immune system. This is 
known as the variant surface glycoprotein (VSG) coat. 
Metacylic trypanosomes transform into the long slender bloodstream form, which 
proliferate in the blood and lymph (Pays, E et al. 2006). As these parasites reach 
their maximum density, they are thought to secrete Stumpy Induction Factor 
(SIF) which, when accumulated, promotes differentiation into the short stumpy 
form, which do not divide as the cell cycle is arrested (Vassella, E et al. 1997). 
Physiological changes pre-adapt these short stumpy cells for life within the 
tsetse fly midgut. For example, the mitochondrion is more developed to allow 
the metabolism of amino acids (Jensen, BC et al. 2009). This differentiation 
mechanism also limits parasitaemia (Tyler, KM et al. 2001). 
Transmission to the tsetse fly occurs during a blood meal. The change in 
physiological conditions, such as temperature and pH, and also the presence of 
cisaconitate (CCA; C00417) or citrate (C00158) triggers the rapid differentiation 
from the short stumpy form to the procyclic form (Szoor, B et al. 2010). It is at 
this point that the VSG coat is lost, and replaced with an invariant GPEET or EP 
procyclin coat (Butikofer, P et al. 1997; Vassella, E et al. 2004). The procyclic 
cells proliferate in the tsetse midgut; undergo differentiation to the non-dividing 
proventricular mesocyclic form, a process which takes three to four weeks 
(Aksoy, S et al. 2003). The proventricular mesocyclic forms differentiate to the 
epimastigote form whilst migrating to the salivary glands. The epimastigote 
attaches itself to the microvilli of the gland; this proliferative form is believed 
to undergo sexual genetic change (Jenni, L et al. 1986; Peacock, L et al. 2011). 
Further differentiation steps occur, culminating in the mature metacyclic which 
is the only stage infective to mammals. These metacyclics are adapted for life in 
the mammal, expressing a VSG coat, and are transferred during a blood meal. A 
detailed overview of all trypanosome differentiation stages is provided in 
(Vickerman, K 1985). 
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Figure 1-4. The life cycle of Trypanosoma brucei 
The life cycle of T. brucei alternates between the insect host and a mammalian host. Procyclic form 
cells, residing in the tsetse fly midgut, transform to a metacyclic form, pre-programmed for life in 
the mammalian bloodstream. These cells then migrate to the salivary gland where they are passed 
to the mammalian host. The proliferative long slender blood stream form is capable of evading the 
immune system through changes in the VSG. Differentiation to the non-diving short stumpy 
bloodstream form adapts the cells for the mid-gut of the tsetse fly. Pays, E et al. 2006. Permission 
to reproduce this image has been granted by Nature Publishing Group. 
1.6 Kinetoplastid morphology and ultrastructure 
The Kinetoplastida are defined by the presence of a kinetoplast, an 
intercatenated network of circular mitochondrial DNA molecules located within 
the single mitochondrion. Leishmania and trypanosomes contain many organelles 
found in higher eukaryotic cells, although also contain a number of specialised 
organelles, such as glycosome and acidicalcisome. A schematic representation of 
the principle structures of trypanosomatids is depicted in Figure 1-5. 
The kinetoplast can be distinguished as a clearly distinct DNA containing disc-
shaped structure, separate from the nucleus, using fluorescent DNA binding 
compounds such as DAPI. This mitochondrial DNA, known as kinetoplast DNA 
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(kDNA), accounts for 10-20 % of the total cell DNA, and is arranged in 30-50 
maxi-circles and 5,000-10,000 mini-circles (Stuart, K 1983; Liu, B et al. 2005). 
Like higher eukaryotes, the maxi-circles encode genes for rRNA and subunits of 
the respiratory complex (Simpson, L and Shaw, J 1989; Shaw, J et al. 2003). The 
mini-circles maintain the organised kDNA structure, and also encode guide RNAs, 
which facilitate the RNA editing of the maxi-circle transcripts through insertion 
of uridylate residues at specific locations (Liu, B et al. 2005). The kinetoplast is 
located at the posterior end of the single mitochondrion. 
Kinetoplastid organisms possess a single mitochondrion, with the degree of 
development dependent on the life cycle stage. In trypanosomes, the procyclic 
form derives energy from oxidative phosphorylation, and as a consequence in the 
mitochondrion is well developed with many cristae. In contrast, the bloodstream 
form has a poorly developed mitochondrion, as energy is derived from substrate 
level phosphorylation, which occurs in the glycosomal and cytosolic 
compartments (Michels, PA et al. 2000; Coustou, V et al. 2006). 
Glycosomes are small spherical organelles, closely related to perixosomes. In the 
bloodstream form of T. brucei the glycosome contains the first seven enzymes of 
the glycolytic pathway, converting D-glucose (C00009) to 1,3 
bisphosphoglycerate (C00236) or 3-phosphoglycerate (C00197) (Coustou, V et al. 
2005). Compartmentalisation of these enzymes increases the concentration of 
these enzymes, and consequently, flux through the glycolytic pathway (Michels, 
PA et al. 2000). The remaining steps occur in the cytosol, where ATP for cellular 
processes is generated. In the bloodstream form trypanosome over 90% of the 
total protein content of the glycosome is glycolytic enzymes (Aman, RA et al. 
1985; Misset, O et al. 1986), compared to 40-50% in procyclic trypanosomes 
(Hart, DT et al. 1984). 
Acidicalcisomes, spherical organelles containing electron dense granules, 
located at the periphery of the cell. They are believed to be storage 
compartments for several cations, dications, and phosphate, important for 
homeostatic regulation (Docampo, R and Moreno, SN 1999; Rodrigues, CO et al. 
1999). 
Chapter 1, 25 
Kinetoplastid organisms possess a single flagellum; the most obvious function of 
this organelle is for motility (Santrich, C et al. 1997). However, the flagellum 
also facilitates the attachment of Leishmania promastigotes to the epithelium of 
the sandfly gut (Killick-Kendrick, R et al. 1974; Killick-Kendrick, R et al. 1974), 
and is thought to act as an environmental sensor (Bastin, P et al. 2000). The 
Leishmania flagellum begins at the basal body, physically linked to the 
mitochondrion, located at the posterior of the cell, and emerges from the 
flagellar pocket. In promastigotes the flagellum is not attached to the cell body, 
whereas in the amastigote stage, the flagellum is much shorter and not visible 
externally. Amastigotes are non-motile. However, in trypanosomes, the 
flagellum arises from the basal body at the anterior of the cell, extending along 
the entire length of the cell body, attached by an undulating membrane. 
The surface of Leishmania is covered with a glycocalyx consisting of glycolipids, 
which varies in thickness depending on the life cycle stage. The promastigote 
has a relatively thick glycocalyx allowing survival in the sand fly (Turco, SJ et al. 
2001). In contrast, the amastigote has a thin glycocalyx, as the intracellular 
environment of the macrophage provides the parasite with protection from the 
immune system. Multiple phosphoglycans constitute the glycocalyx, however the 
predominant surface molecule is the lipophosphoglycan (LPG), a 
hyperglycosylated form of glycoinositol-phospholipid (GPI). Many of these 
phosphoglycans (PGs) are essential for survival in the sandfly (Sacks, D and Sher, 
A 2002). Furthermore, a lack of PGs results in a reduced ability of promastigotes 
to infect macrophages, although there is no effect on amastigote infections 
(Capul, AA et al. 2007). As previously mentioned, the amastigote glycocalyx is 
thinner, consisting of free GPIs and host derived glycophospholipids (McConville, 
MJ et al. 2002). 
Bloodstream form trypanosomes express Variant Surface Glycoproteins (VSGs), 
which form a dense surface coat that covers the entire cell body (Englund, PT et 
al. 1982). These proteins are synthesised at the Golgi apparatus, transported 
through the cytosol, and are excreted at the flagellar pocket (Vickerman, K et 
al. 1993). The VSG functions to protect surface proteins and receptors from the 
host immune system (Vickerman, K and Luckins, AG 1969). The host immune 
system will produce antibodies to recognise the VSG, thus reducing the level of 
parasitaemia. However, the process of antigenic variation allows the 
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trypanosome to express an alternative VSG (Barry, JD et al. 1979), allowing 
some parasites to evade the immune system and proliferate (Sternberg, JM 
1998), thus increasing parasitaemia. In procyclic trypanosomes, the VSG coat is 
replaced with and invariant coat of EP or GPEET procyclins (Roditi, I et al. 1989; 
Butikofer, P et al. 1997; Roditi, I et al. 1998). Silencing hexokinase, 
phosphofructokinase, and the hexose transporter resulted in a switch from EP to 
GPEET, indicating a link between glucose availability and expression of procyclin 
(Morris, JC et al. 2002; Vassella, E et al. 2004). Whilst EP is expressed 
throughout the procyclic life cycle, GPEET is down-regulated in late procyclics 
(Vassella, E et al. 2000; Acosta-Serrano, A et al. 2001), as the parasite prepares 
for the amino acid to glycolytic metabolic shift.
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Figure 1-5. Schematic representation of the principle structures of trypanosomatids. 
A – The long thin Leishmania promastigote possesses a visible flagellum, arising from the flagellar pocket at the anterior end of the cell, is shown on the 
left. The round amastigote form with an internal flagellum is shown on the right. Besteiro, S et al. 2007. Permission to reproduce this image has been 
granted by Elsevier. B – The T. brucei  trypomastigotes Vickerman, K et al. 1993 
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1.7 Diagnosis  
1.7.1 Visceral Leishmania 
VL is a fatal condition, with untreated patients acting as a reservoir for the 
parasites, thus contributing to the spread of the disease. Consequently, an early 
diagnosis of VL is essential (Chappuis, F et al. 2007). As the drugs used to treat 
VL are toxic, an accurate and sensitive diagnosis is necessary. The classical 
confirmatory test of VL is the use of microscopy to identify the presence of 
amastigotes in spleen, bone marrow, or lymph node aspirates, although a high 
level of technical expertise and care are required. Alternatively, the presence of 
Leishmania DNA can be detected with a diagnostic PCR test (Schonian, G et al. 
2003; Reithinger, R and Dujardin, JC 2007), although this can prove impractical 
in the field.  
Other diagnostic approaches, which vary in sensitivity and specificity, include 
the identification of pancytopenia, the formol-gel test (FGT), the indirect 
fluorescence antibody test (IFAT), the direct agglutination test (DAT), and the 
rK39 dipstick test (Boelaert, M et al. 2004). The DAT and rK39 dipstick test were 
specifically developed for use in the field (Chappuis, F et al. 2007). 
1.7.2 HAT 
An accurate diagnosis of HAT is essential for treatment and control of the 
disease (Chappuis, F et al. 2005). There are two methods in which HAT may be 
suspected; patient history or population screening. Local knowledge of endemic 
diseases, pathology, and epidemiology are extremely useful. Patient history can 
be difficult to interpret as the clinical presentations of early stage HAT are 
variable, can be non-specific, and thus are often confused with other tropical 
diseases and ailments. These symptoms include headache, relapsing fever, 
general malaise, anaemia, and cutaneous lesions (Kennedy, PG 2006). 
Alternatively, populations can be screened for HAT. The Card Agglutination Test 
for Trypanosomiasis (CATT), developed at the Institute of Tropical Medicine in 
Antwerp, is the preferred option for cheap, reliable diagnosis in the field, 
although is specific for T. b. gambiense infections (Chappuis, F et al. 2005). 
If HAT is suspected, either through the patient history or screening, then it is 
necessary to detect trypanosomes in the lymphatic system. This can prove 
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difficult as parasitaemia will fluctuate in relation to VSG expression, thus there 
may be very few parasites present in any sample. Consequently, multiple 
samples taken at different time points are necessary. Parasitaemia is higher in 
T. b. rhodesiense infections when compared to T. b. gambiense infections, 
which can make the diagnosis procedure easier. Given the toxicity and stage 
specific nature of the drugs currently available, determining the stage of the 
disease is critical for the patient to receive the appropriate treatment. The 
identification of live trypanosomes in the CSF after an invasive lumbar puncture 
is the definitive diagnosis of late stage trypanosomiasis (Enanga, B et al. 2002). 
However, the WHO also recognises a CSF protein content of greater than 370 
mg/l or a CSF white blood cell count greater than 5 cells/µl as defining 
parametes of late stage trypanosomiasis (WHO); although neither of these are 
specific to trypanosomiasis. The methods of stage determination are identical 
for both T. b. gambiense and T. b. rhodesiense infections. 
1.8 Vaccine prospects 
Trypanosomatids introduced to the mammalian host through the bite of an 
infected tsetse fly or sandfly are immediately exposed to the host immune 
system. The surface proteins present on these parasites provide an abundance of 
epitopes which could potentially be exploited in the development of a vaccine. 
The discovery of the VSG coat provided a focus for vaccine research in 
trypanosomes (Magez, S et al. 2009). Unfortunately, the process of antigenic 
variation (Van der Ploeg, LH et al. 1992), combined with a larger diversity of 
possible expressed VSGs than initially thought (McCulloch, R and Horn, D 2009), 
hindered research using VSG epitopes for the development of a vaccine. 
It has been documented that patients with CL maintain residual parasites, 
however are also resistant to re-infection (Handman, E 2001). This obervation 
has not only stimulated interest in the development of a vaccine against 
Leishmaniasis, but also indicated that vaccination is realistic option. Similar to 
the use of the cowpox virus or vaccinia virus to prevent smallpox, the deliberate 
and controlled Leishmania infection on unexposed areas of the skin to prevent 
lesions of visible parts of the skin were previously used in some parts of the 
Middle East and former USSR (Handman, E 1997). In recent years, attention has 
focused on killed Leishmania vaccines (Handman, E 1997; Chappuis, F et al. 
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2007), genetically manipulated parasites for the creation of live attenuated 
vaccines (Alexander, J et al. 1998; Uzonna, JE et al. 2004), purified Leishmania 
proteins or peptides (Handman, E 2001), recombinant DNA (Handman, E 2001; 
Kedzierski, L et al. 2006), and the Leish-111f multi-epitope subunit vaccine 
(Skeiky, YA et al. 2002; Coler, RN and Reed, SG 2005; Coler, RN et al. 2007). 
The development of suitable vaccines would greatly enhance the ability to 
control both trypanosomiasis and Leishmaniasis, with research into a potential 
Leishmania vaccine at a more advanced stage than any trypanosome vaccine. 
1.9 Vector Control 
Several vector control schemes have been developed over the years with a view 
to decreasing the tsetse fly population. Edward Knipling, an American 
entomologist, first proposed the idea of controlling or eradicating a species by 
altering its reproduction (Knipling, EF 1946). Initiated in 1994, a program was 
conducted by the International Atomic Energy Agency, which targeted tsetse 
flies on the island of Unguja, Zanzibar, 35km from mainland Africa. The sterile 
insect technique (SIT) was used successfully to eradicate tsetse flies over a 
period of four years, during which 8.5 million sterile males were released into 
the environment (Vreysen, MJ et al. 2000; Vreysen, MJ 2001). Whilst this 
program was expensive, however the area is now free from trypanosomiasis. 
Yet, great care must be taken to ensure that tsetse flies are not re-introduced. 
Whilst the expensive SIT program was effective, there are cheaper alternatives. 
These include aerial and ground spraying of insecticides, and the deployment of 
tsetse traps. These traps are use black or blue cloth, colours which are visually 
attractive to the fly. Chemicals such as acetone, which mimics cows’ breath, can 
be used to further increase the chance of attracting the flies (Barrett, MP et al. 
2003). Treating the traps with insecticides, or applying insecticides to animals, 
in an attempt to kill the flies are alternative options of reducing transmission. 
Visceral Leishmaniasis almost disappeared from the Indian subcontinent in the 
1950’s following large scale antimalarial insecticide campaigns (sandflies are 
also susceptible to DDT), although the disease re-emerged when these 
campaigns were stopped (Chappuis, F et al. 2007). The use of insecticide 
treated bednets (ITNs) can prevent VL and other vector borne diseases such as 
malaria (Ritmeijer, K et al. 2007). The identification of other host animals is 
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also necessary; for example, dogs are the main reservoir of L. infantum in 
zoonotic VL (Chappuis, F et al. 2007). In Iran, the use of deltramethrine treated 
collars reduced the risk of infection (Gavgani, AS et al. 2002). 
There are several factors which make vector control programs difficult to 
achieve; notably poor infrastructure and a lack of funding. However, a co-
ordinated effort from multiple governments and organisations is required, 
although can be difficult to achieve given the political instability in these 
regions. 
1.10 Chemotherapy 
Chemotherapy remains the most effective method of controlling trypanosomiasis 
and leishmaniasis, as the transmission of the parasite is interrupted. There are a 
limited number of licensed drugs available to treat HAT, Chagas’ disease (caused 
by American trypanosomes) and leishmaniasis ( 
Table 1-1). Unfortunately, many of these drugs tend to be disease, or stage 
specific, thus further narrowing the available treatments. Furthermore, the 
available drugs are expensive, difficult to administer, and often induce 
detrimental side effects. Most drugs are administered by multiple intramuscular 
injections, although oral therapy for leishmaniasis is now available (Croft, SL et 
al. 2006). 
The general lack of progress in drug development is disappointing to say the 
least. Three out of the five licensed drugs for treating trypanosomiasis have 
been in use for more than 50 years, and only one has been introduced in the last 
20 years. However, there have been encouraging advances in the treatment of 
leishmaniasis with introduction of miltefosine, although this is still far from 
ideal. Recently, there has been a focus on reducing the toxicity of existing 
compounds. Clinical interventions aim to reduce mortality from VL, and 
morbidity from CL. 
Surprisingly, drug resistance in the field is a widespread problem, despite the 
length of time drugs have been used for. This would indicate that these drugs 
have multiple targets, and multiple routes of entry. 
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Table 1-1. Drugs currently used to treat leishmaniasis and trypanosomiasis 
Drug Information Species and disease Dosage Route References
Amphotericin B
AmBisome®, 
Fujisawa Healthcare and
Gilead Sciences, US
[CID 5280965]
Antimony gluconate
Solustibosan®
BCM Corporation, India
[CID 16683012]
Eflornithine
Ornidyl®
Sanofi-Aventis, France
[CID 3009]
Meglumine antimoniate
Glucantime®,
Sanofi-Aventis, France
[CID 64953]
Melarsoprol
Arsobal®
Sanofi-Aventis, France
[CID 10311]
Miltefosine
Impavido® and Miltex®
Zentaris GmbH, Germany
[CID 3599]
Nifurtimox
Lampit®
Bayer, Germany
[CID 6842999]
Paromomycin sulfate
Humatin®  
[CID 165580]
Pentamidine isethionate
Pentacarinat®
Sanofi-Aventis, France 
[CID 4735]
Sodium stibogluconate
Pentostam®
GlaxoSmithKline, UK
[CID 16683881]
Suramin
Germanin®
Bayer, Germany   
[CID 5361]
T. b. gambiense  (early stage) 4 mg/kg, daily or alternate days (7-10 doses) i.m. injection Sands, M et al.  1985,
Leishmania  (VL) 2-4 mg/kg on alternate days for 30 days i.m. injection
Sundar, S & Rai, M 2002
10 mg/kg, 3-4 doses per 
day for 60-120 days orally Wilkinson, SR et al. 2011
Leishmania  (VL, CL) 11 mg/kg/day for 21 days Sundar, S et al.  2009
Croft, SL & Yardley, V 2002,
i.v. injection5 mg/kg, single doseLeishmania  (VL, ML)
Leishmania  (VL) 15-20 mg/kg/day for 21-28 days
i.m. injection
i.v. injection
i.v. injection100 mg/kg, 4 times per daily, for 7 - 14 daysT. b. gambiense  (late stage)
Leishmania  (VL, CL) 15-20 mg/kg/day for 21-28 days
i.v. injection
i.m. injection
2.2 mg/kg/day for 10 days i.v. injection
T. b. gambiense  (late stage)
T. b. rhodesiense (late stage)
Leishmania  (VL, CL) 100 mg/kg/day for 28 days orally
Leishmania  (VL, CL) 15-20 mg/kg/day for 21-28 days
i.m. injection 
(VL)
topical (CL)
i.v. injection
i.m. injection
T. b. gambiense  (late stage)
Croft, SL et al.  2006
20 mg/kg/day on days 3, 10, 
17, 24, and 31
T. b. gambiense  (early stage)
T. b. rhodesiense  (early stage)
Jannin, J & Cattand, P 2004i.v. injection
Berman, JD et al.  1997,
Fairlamb, AH 2003
 Burri, C & Brun, R 2003 
Croft SL, & Yardley, V 2002,
Croft, SL et al. 2006, 
Jha, TK et al.  1999
Sundar, S et al. 1998,
Croft SL, & Yardley, V 2002
Khoo, SH et al. 1994,           
Sundar, S et al.  2003
 
 
i.v. = intravenous 
i.m. = intramuscular 
CID = PubChem Compound Identifier 
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1.10.1 Pentamidine 
Pentamidine isethionate, an aromatic diamidine, is used to treat the early stages 
of T. b. gambiense infection, and is used as a second line drug against antimony 
resistant Leishmania (Sundar, S and Rai, M 2002; Bray, PG et al. 2003).  
Treatment failures are rare for trypanosomiasis; the likely causes being 
misdiagnosis of late stage HAT, for which pentamidine is known to be 
ineffective. The treatment involves a dose of 4 mg/kg for 7-10 days by 
intramuscular injection (Sands, M et al. 1985). For the treatment of visceral 
leishmaniasis in India, treatment consists of 2-4 mg/kg on alternate days for 30 
days by intramuscular injection (Sundar, S and Rai, M 2002). However, since the 
1980s, cure rates have dropped from 100 % to 70 %, despite an increase in 
dosage. This has caused problems with toxicity, cost, and availability of 
treatment. 
A detailed overview of pentamidine is provided in Chapter 5. 
1.10.2 Melarsoprol 
Melarosoprol, an organic arsenical, was introduced in 1949 and can be used to 
treat the late stage infection of both T. b. gambiense and T. b. rhodesiense. The 
lipophilic properties allow the drug to cross the blood brain barrier into the CNS. 
The major drawback of melarosoprol is the potential risk of a reactive 
encephalopathy that occurs in around 5-10 % of patients who are treated; 
approximately half of these are fatal (Pepin, J and Milord, F 1994). For this 
reason, along with increasing incidence of treatment failures with melarsoprol 
(Brun, R et al. 2001), eflornithine has recently emerged the drug of choice for T. 
b. gambiense infections. 
Currently, melarsoprol treatment involves the intravenous administration of 2.2 
mg/kg for 10 days. This superseded the previous treatment regime which 
involved increasing the melarsoprol dosage from 1.2 – 3.6 mg/kg for 4 days, 
followed by 7 - 10 days no treatment (Fairlamb, AH 2003). This is repeated a 
further two or three times. Unfortunately, it has been reported that the 
differences in the treatment schedules do not alter the incidence of reactive 
encephalopathy (Burri, C et al. 2000). 
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The mode of action for melarsoprol has yet to be determined. In the patient, 
melarsoprol is rapidly converted to melarsen oxide, the active compound, which 
in turn in selectively taken up by the parasite by the P2 transporter (Carter, NS 
and Fairlamb, AH 1993; de Koning, HP and Jarvis, SM 1999). Several mutations, 
leading to six amino acid changes, were identified in the P2 transporter isolated 
from an arsenical resistant T. brucei cell line, which consequently led to an 
inability to transport adenosine (Maser, P et al. 1999). Analysis of field isolates 
from the north west of Uganda, derived from patients who had relapsed after 
melarsoprol treatment, indicated that 38 out of 65 patients had the same six 
amino acid changes (Matovu, E et al. 2003). Whilst mutations in the P2 
transporter suggest that this transporter is responsible for a decrease in the 
accumulation of arsenical compounds, resistance to melarsen oxide in the P2 
knockout cell line is less pronounced (Matovu, E et al. 2001). This indicates that 
an additional transporter carries the drug across the membrane, with the HAPT a 
likely candidate (Bridges, DJ et al. 2007). 
1.10.3 Eflornithine 
Eflornithine, or difluoromethylornithine (DFMO), is a suicide inhibitor of 
ornithine decarboxylase (ODC; E.C. 4.1.1.17), therefore inhibiting polyamine 
biosynthesis. Originally developed as an anti-cancer drug, it was introduced in 
1990 to treat both early and late stages of T. b. gambiense infections, primarily 
due to the high toxicity of melarsoprol. Unfortunately the drug is ineffective 
against Rhodesian sleeping sickness (Iten, M et al. 1995).  
Eflornithine has relatively few side effects in comparison to melarsoprol, but can 
include seizures, myelosuppression, and gastrointestinal problems (Priotto, G et 
al. 2006). Treatment involves intravenous doses of 100 mg/kg at six hour 
intervals, for 14 days (Burri, C and Brun, R 2003). When given orally, eflornithine 
has poor bioavailability, and the high EC50 determines that large doses are 
required (Vincent, IM et al. 2012) which is a logistical problem in rural 
communities. In recent years, nifurtimox has been given in combination with 
eflornithine for the treatment of HAT (Priotto, G et al. 2009). These drugs are 
thought to act in synergy, thus permitting the administration of lower doses of 
both drugs, thus reducing any adverse side-effects and costs. 
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Eflornithine has similar affinity for both T.b. gambiense and mammalian ODC; 
however the latter is replenished at a faster rate, thus giving a selective 
advantage (Iten, M et al. 1997). Irreversible inhibition of ODC occurs when 
eflornithine binds at the active site (Poulin, R et al. 1992). This inhibition leads 
to changes in the polyamine levels. Ornithine (C00077), S-adenosyl methionine 
(C00019) and decarboxylated S-adenosyl methionine (C01137) all increase, 
whereas putrescine (C00134), spermidine (C00315), and trypanothione (C02090) 
all decrease (Bacchi, CJ et al. 1983; Fairlamb, AH et al. 1987; Xiao, Y et al. 
2009). Polyamines are crucial for a number of cellular processes that include the 
production of trypanothione, which protects the trypanosome from oxidative 
stress (Krauth-Siegel, RL et al. 2003), and G-S phase transition in the cell cycle 
(Li, F et al. 1996). Eflornithine is a trypanostatic compound, thus preventing the 
long slender blood stream forms from proliferating. Instead, they are forced to 
differentiate to the non-proliferative stumpy forms which are auxotrophic for 
polyamines (Barrett, MP et al. 2007). The immune system is then able to kill the 
parasites. It was suggested that a transport route for eflornithine uptake was 
likely (Phillips, MA and Wang, CC 1987). This was confirmed when TbAAT6 
(Tb927.8.5450), an amino acid transporter, was lost in eflornithine resistant 
cells, indicating that this transporter is capable of transporting eflornithine 
(Vincent, IM et al. 2010). 
1.10.4 Suramin 
Suramin, introduced in 1922, remains the drug of choice for early stage T. b. 
rhodesiense infections as the drug does not cross the blood brain barrier. 
Treatment with suramin involves an initial test dose of 4-5 mg/kg, followed by 
doses of 20 mg/kg (maximum 1 g) on days 3, 10, 17, 24, and 31 (Jannin, J and 
Cattand, P 2004). Treatment failures are not uncommon; however, similar to 
pentamidine treatment failure, the likely cause is due to the misdiagnosis of late 
stage disease. At therapeutic levels of suramin, approximately 1.1 mM, it is 
estimated that 85% of the total drug concentration is bound to plasma proteins, 
15% of which is low density lipoprotein (LDL). It has been reported that suramin 
bound to LDL enters trypanosomes via receptor mediated endocytosis 
(Vansterkenburg, EL et al. 1993), however there is evidence that in procylic 
form trypanosomes uptake is via LDL independent receptor mediated 
endocytosis (Pal, A et al. 2002). 
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Whilst the mode of action remains unclear, suramin is a large polyanion, and 
consequently has inhibitory effects on a large number of enzymes including; 6-
phosphogluconate dehydrogenase (E.C. 1.1.1.49) (Barrett, MP et al. 2007); 
dihydrofolate reductase (E.C. 1.5.1.3); fumarate hydratase (E.C. 4.2.1.2); 
glycerol-3-phosphate dehydrogenase (E.C. 1.1.99.5); hexokinase (E.C. 2.7.1.1); 
thymidine kinase (E.C. 2.7.1.21) (Delespaux, V and de Koning, HP 2007). The 
large number of targets provides a possible reason as to why no resistance to 
suramin has emerged for almost a century (Fairlamb, AH 2003), however there 
have been reports of resistance in field isolates of T. b. rhodesiense (Bacchi, CJ 
et al. 1990) and T. evansi (El Rayah, IE et al. 1999). A recent article revealed 
that suramin resistance can be selected by knockdown of expression of a series 
of genes associated with an endocytic pathway related to binding of ISG75 
(Alsford, S et al. 2012). 
1.10.5 Nifurtimox 
Nifurtimox has been used to treat Chagas disease, American trypanosomiasis, 
since the 1960’s (Hall, BS et al. 2011). The drug is not registered to treat HAT, 
however in cases where eflornithine and melarsoprol have been unsuccessful in 
the treatment of late stage infections; it may be given on compassionate 
grounds (Bouteille, B et al. 2003). 
Nifurtimox is a pro-drug, which requires reduction of the nitro group to activate 
the drug. In trypanosomes, this process is enzymatic through NADH-dependent 
type 1 nitroreductases. The precise mode of action is unknown, however it is 
hypothesised that reduced nifurtimox induces the production of hydroxylamine 
derivative, which in turn generates cytotoxic metabolites and free radicals, 
which are capable of interacting with numerous biomolecules (Fairlamb, AH 
2003; Wilkinson, SR and Kelly, JM 2009; Wilkinson, SR et al. 2011). 
Treatment regimes require doses of 10 mg/kg in three or four doses per day, 
over a 60- to 120-day period. Side effects include CNS toxicity, seizures, muscles 
weakness (Wilkinson, SR et al. 2011). 
1.10.6 Antimony 
Trivalent antimonial compounds were first used to treat leishmaniasis in 1913, 
and pentavalent antimonials were introduced in the 1920s, leading to synthesis 
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of several drugs which are currently used today (Croft, SL and Yardley, V 2002). 
Antimony gluconate (Solustibosan®) was introduced in 1937, with sodium 
stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®) in the 
1940s (Croft, SL and Yardley, V 2002). 
The exact treatment regime with antimonial compounds differs depending on 
the infecting species and the health of the patient, although it is likely to be in 
the region of 15-20 mg SbV/kg per day. Treatment usually lasts for a period of 
21-28 days (Berman, JD 1997; Croft, SL and Yardley, V 2002), allowing the drug 
to accumulate  to levels which are toxic to the parasite. However, this long 
treatment course can result in side effects including hepatitis, pancreatitis and 
cardiac arrhythmia. 
The use of pentavalent antimonial compounds in the Indian sub-continent is no 
longer recommended are due to widespread resistance (Sundar, S et al. 2000); 
however these drugs are used elsewhere in the world (Croft, SL et al. 2005). 
The cellular targets of antimonial compounds remain unknown; however 
inhibition of ADP phosphorylation, DNA I topoisomerase, trypanothione, and 
beta-oxidation of fatty acids have all been proposed as a mode of action (Croft, 
SL et al. 2005). 
1.10.7 Paromomycin 
Paromomycin, an aminoglycoside antibiotic, isolated from Streptomyces spp was 
introduced in the early 1960s and shown to exhibit anti-leishmanial (Kellina, OI 
1963) anti-protozoan activity (Croft, SL and Yardley, V 2002). Renewed interest 
in the early 1980s led to the development of various topical formulations which 
were shown to be effective in several clinical studies (Croft, SL and Yardley, V 
2002). There were however several problems with this approach. First, 
Leishmania amastigotes reside deep in the dermal layer and are subsequently 
not exposed to therapeutic concentrations. Second, amastigotes for some 
Leishmania spp are not confined to the site of the lesion due to dissemination 
throughout the lymphatic system (Croft, SL and Yardley, V 2002). 
Consequently, intramuscular formulations were investigated for the treatment of 
VL, and phase III clinical trials were completed in India in 2005. The current 
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treatment with paromomycin is a single daily intramuscular injection of 11 
mg/kg/day for 21 days (Sundar, S et al. 2009). Despite being the cheapest anti-
leishmanial compound available, a shorter treatment regime or combination 
therapy would be advantageous. 
Aminoglycosides are known to bind to the ribosome small subunit in bacteria, 
thus inhibiting protein synthesis, although the mode of action for Leishmania has 
not been fully determined. Dissociation of ribosomal sub-units and effects on 
mitochondrial function has been suggested as a possible mechanism (Croft, SL 
and Yardley, V 2002). 
1.10.8 Amphotericin B 
Ampotericin B, isolated from Streptomyces nodosus, was shown to have 
antileishmanial activity in the 1960s (Yardley, V and Croft, SL 2000). 
Amphotericin B binds to sterols present in the plasma membrane leading to the 
formation of aqueous pores. Ergosterol is present in plasma membrane of 
Leishmania, whereas the mammalian plasma membrane contains cholesterol. 
Amphotericin B has a higher affinity for ergosterol than cholesterol, and 
therefore the mammalian plasma membrane is less susceptible to the drug 
(Croft, SL and Yardley, V 2002). At concentrations greater than 0.1 µM, the 
influx of cations and anions promote osmotic changes resulting in cell lysis, 
whereas a collapse in the membrane potential due to cation influx occurs at 
concentrations below 0.1 µM (Ramos, H et al. 1996). 
Despite the selective advantage of targeting the Leishmania plasma membrane, 
the drug exhibits delayed side effects, thus reducing the attractiveness of this 
drug and was consequently regarded as an alternative treatment for MCL and VL 
(Khoo, SH et al. 1994). However, subsequent problems in treating MCL, and the 
emergence of resistance to antimonial compounds for VL, led to renewed 
interest in the drug and a desire to improve the formulation. 
These improvements include using lipid formulations for drug delivery, thus 
reducing the toxicity to enable higher concentrations of active compound to be 
used (Croft, SL et al. 2005). For example, AmBiosome is registered for the 
treatment of VL, where a single does of 5 mg/kg has been reported to cure 90 % 
of patients (Sundar, S et al. 2003).  There have also been reports of curing cases 
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of VL where the patient no longer responds to antimonial compounds, with 
Amphotericin B now used as first line treatment in India (Chappuis, F et al. 
2007). 
1.10.9 Miltefosine 
Miltefosine, an alkylphosphocholine, is effective against both CL and VL (Sundar, 
S et al. 2002; Soto, J et al. 2004). Anti-leishmanial activity was first reported in 
1987 against L. donovani promastigotes (Achterberg, V and Gercken, G 1987) and 
L. donovani amastigotes in BALB/c mice models (Croft, SL et al. 1987). 
Miltefosine has been registered for treatment in India since 2002 (Davies, CR et 
al. 2003).  
Treatment involves a dose of 100 mg/kg/day for 28 days, and has been reported 
to cure 95 % of patients with mild-moderate VL during clinical trials in the Bihar 
region (Sundar, S et al. 1998; Jha, TK et al. 1999). 
Importantly, miltefosine has several advantages when compared to other 
antileishmanial compounds. These include, the availability of the drug as an oral 
formulation, and that miltefosine has been used to successfully treat cases of 
antimonial resistance VL (Sundar, S et al. 1999). Additionally, side effects are 
minimal, although due to teratogenic properties it should not be administered to 
pregnant women (Sundar, S et al. 2002). The mode of action remains unknown, 
although lipid metabolism, cell signalling, and the induction of apoptosis have 
been suggested (Croft, SL and Yardley, V 2002). 
1.10.10 Drug summary 
In summary, the drugs currently used in treatment of HAT and leishmaniasis all 
suffer from similar problems. Many are toxic; most have to be given 
parenterally, and for long treatment durations. Costs can be high and 
distribution difficult to the areas in which they are given. Only recently is insight 
into modes of action becoming clear. The recent emergence of pipelines of new 
compounds, particularly through the Drugs for Negleced Diseases initiative 
(DNDi), does offer hope,although as yet the pipelines are not sufficiently robust 
to offer optimism that the recently announced WHO goals of HAT elimination 
and leishmaniasis control by 2020 will be met. 
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1.11 Metabolism 
The protozoan parasite Trypanosoma brucei must adapt to different host 
organisms throughout its complex lifecycle. The contrasting environments of 
these host organisms present the parasite with many challenges that include 
host defence mechanisms and energy metabolism. 
1.11.1 Glucose metabolism 
Glycolysis is the conversion of one mole of D-glucose (C00031) to two moles 
pyruvate (C00022), with the net production of 2 moles of ATP (C00002). Energy 
metabolism in the bloodstream form of the parasite is simple; the glycolytic 
pathway is the sole mechanism of deriving ATP. The mammalian infective form 
of the parasite resides in the bloodstream, an environment abundant in D-
glucose. Glucose enters the parasite through a high capacity facilitative diffusion 
hexose transporter (Tb10.6k15.2040) (Bakker, BM et al. 1999). 
In bloodstream form T. brucei, the first seven steps of the gycolytic pathway 
occur in the glycosome, producing two moles of 3-phosphoglycerate (C00197) 
per mole of D-glucose. The remaining three steps occur in the cytosol; producing 
pyruvate, which is not metabolised further, and consequently excreted by the 
parasite. 
The glycosomal ATP/ADP balance is maintained as the two moles of ATP 
consumed by hexokinase (EC 2.7.1.1) and phosphofructokinase (EC 2.7.1.11) are 
replaced by two moles of ATP produced via the phosphoglycerate kinase (EC 
2.7.2.3) reaction. The net ATP gain occurs in the cytosol through the conversion 
of phosphoenolpyruvate (PEP; C00074) to pyruvate (C00022) by pyruvate kinase 
(EC 2.7.1.40).  
Similarly, the glycosomal redox balance is maintained as the NADH produced by 
glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) is re-oxidised by 
glycerol-3-phosphate dehydrogenase (EC 1.1.1.8). Consequently, glycerol 3-
phosphate (G3P; C00093) is transported to the mitochondrion and converted to 
dihyroxyacetone phosphate (DHAP; C00111) via a FAD-dependent glycerol-3-
phosphate dehydrogenase (EC 1.1.99.5) and alternative oxidase; with oxygen 
acting as the final acceptor (Pollakis, G et al. 1995). The DHAP produced in the 
mitochondrion is transported back to the glycosome.  
  Chapter 1, 41 
 
In the absence of oxygen the G3P/DHAP mitochondrial shuttle does not operate. 
However, bloodstream form trypanosomes can survive by producing ATP through 
the conversion of glycerol 3-phosphate (G3P; C00093) to glycerol (C00116) by 
glycerol kinase (EC 2.7.1.30). Under anoxic conditions the reduction in NADH 
levels reduces the flux of glyceraldehyde 3-phosphate through the glycolytic 
pathway. Whilst D-glucose consumption remains constant, the production of 
pyruvate and glycerol is equimolar. Consequently, cytosolic ATP production is 
reduced (Opperdoes, FR 1995). 
Glycolytic activity is ten times higher in the bloodstream form trypanosomes 
than in typical cells of the mammalian host (Cazzulo, JJ 1992). This observation 
can be explained as the net gain of ATP in the trypanosome is only two moles 
per mole of glucose, and thus the parasite must rely on a high glycolytic activity 
to meet energy demands. 
Bloodstream form trypanosomes have reduced mitochondrial metabolism, 
reflected in the underdeveloped mitochondrian representative of this stage of 
the parasite. In the procyclic form trypanosomes the situation is more complex; 
glucose is generally less abundant in the tsetse fly (with the exception of 
immediately after a blood meal).  
The procyclic form trypanosomes have a fully developed mitochondrion with a 
functional electron transport chain capable of generating ATP via the F0/F1-ATP 
synthase. However, data suggest that when D-glucose is present the electron 
transport chain is not essential in procylic form trypanosomes and ATP is derived 
via substrate level phosphorylation (Coustou, V et al. 2006). 
Phosphoglycerate kinase (EC 2.7.2.3) is cytosolic, and thus 3-phosphoglycerate 
(C00197) is produced in the cytosol rather than in the glycosome. This would 
lead to an imbalance in the glycosomal ATP-ADP balance; however, procylic 
trypanosomes express several additional enzymes to address this.  
Succinate is the major excreted end product, and is produced in both the 
mitochondrion and the glycosome by the succinate fermentation pathway 
(Coustou, V et al. 2008; Ebikeme, C et al. 2010).  
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Approximately 50% of the cytosolic PEP re-enters the glycosome (Coustou, V et 
al. 2006), where it is converted to oxaloacetate (C00036) by 
phosphoenolpyruvate carboxykinase (PEPCK; EC 4.1.1.49), or pyruvate by 
pyruvate phosphate dikinase (PPDK; EC 2.7.9.1); both reactions produce ATP. 
Oxaloacetate is subsequently converted to glycosomal succinate (C00042) by 
malate dehydrogenase (EC 1.1.1.37), fumarate hydratase (FH; EC4.2.1.2), and 
fumarate reductase (FRD; EC 1.3.1.6). However, there is conflicting evidence as 
to whether fumarate (C00122) is produced in the glycosome. Genome 
predictions for T. brucei indicated the existence of two class I fumarate 
hydratase genes encoding mitochondrial (FHm) and cytosolic (FHc) isoforms of 
FH. Both of these enzymes account for total cellular FH activity. Sub-cellular 
localisation experiments and proteomic analysis indicated that neither FH 
enzyme localised to the glycosome (Colasante, C et al. 2006; Coustou, V et al. 
2006). However, there is a cryptic PTS1 glycosomal targeting motif that may 
allow dual localisation of the enzyme depending on environmental conditions 
(Coustou, V et al. 2006); this may explain why glycosomal FH activity was 
previously detected (Besteiro, S et al. 2002). The glycosomal redox balance is 
maintained by the re-oxidisation of NADH by malate dehydrogenase and 
fumarate reductase. 
An alternative fate for glucose is conversion to glucose 6-phosphate (G6P), which 
then enters the pentose phosphate pathway (PPP). The main functions of the 
PPP in trypanosomatids is the regeneration of NADPH and the production of 
ribose 5-phosphate (R5P) for nucleotide biosynthesis (Barrett, MP 1997). A 
detailed overview of the PPP is provided in Chapter 4. 
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1.11.2 Amino-Acid Metabolism 
In addition to utilising glucose as an energy source, procyclic trypanosomes and 
Leishmania promastigotes can metabolise L-proline (C00148) (Balogun, RA 1974), 
although under standard experimental conditions used by many laboratories, 
procyclic trypanosomes principally prefer glucose (Lamour, N et al. 2005).  
Proline metabolism occurs solely in the mitochondrion and is degraded to three 
end products; succinate (C00042), carbon dioxide (CO2, C00011), and acetate 
(C00033) (van Weelden, SW et al. 2005). Succinate and CO2 are end products 
produced by the TCA cycle, and are subsequently secreted by the cell (Coustou, 
V et al. 2003). However, succinate can also be converted to malate (C00149) in 
a two step reaction by succinate dehydrogenase (EC 1.3.99.1) and mitochondrial 
fumarase (EC 4.2.1.2). It has been proposed that malate is then exported and 
converted to PEP by malate dehydrogenase (EC 1.1.1.37) and phosphoenol 
pyruvate carboxykinase (PEPCK, EC 4.1.1.49). PEP would then be converted to 
acetate as normal (van Weelden, SW et al. 2005). 
Energy, in the form of ATP, is produced by the conversion of succinyl-CoA 
(C00091) to succinate, and also as a result of the electron transport chain. The 
TCA cycle consumes NAD+, although this is replenished by the first stage of the 
electron transport chain (Figure 1-7). The cycle is directly linked to the electron 
transport chain complex II by succinate dehydrogenase.  
Both proline and glutamine (C00064) are converted to glutamate (C00025) 
before being further metabolised to 2-ketoglutarate (C00026) (Bringaud, F et al. 
2006). Threonine (C00188) is converted into amino oxobutyrate (AOB, C03508) 
by L-threonine dehydrogenase (TDH; EC 1.1.1.103), which is then converted into 
acetyl coenzyme A (Acetyl CoA, C00024) by coenzyme A (EC 2.3.1.29) (Lamour, 
N et al. 2005). As previously mentioned, acetyl CoA is used as a co-factor in the 
conversion of oxaloacetate (KEGG) to citrate by citrate synthase (EC 4.1.3.7), or 
is converted to acetate by acetate:succinate CoA-transferase (ASCT, EC 2.8.3.5) 
(Coustou, V et al. 2008). 
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1.11.3 Metabolic differences between trypanosomatids 
As trypanosomes and Leishmania originated from a common ancestor, it is not 
surprising that the genome sequencing projects of L. major, T. brucei, and T. 
cruzi revealed metabolic similarities at the genomic level. However, there are 
also notable differences related to central carbon metabolism (Opperdoes, FR 
and Coombs, GH 2007). Many of these differences can be attributed to the 
environmental conditions in which these parasites reside. The parasitophorous 
vacuole within mononuclear cells of the mammalian host provides an acidic 
environment, in which macromolecules are degraded to simple metabolites such 
as amino acids, lipids, and monosaccharides (Burchmore, RJ and Barrett, MP 
2001).  
Research has tended to focus on promastigotes, which are easier to work with 
than the amastigotes. The promastigotes are grown in a nutrient rich medium, 
for example SDM-79 or HOMEM, which may differ substantially from the nutrients 
available in the sandfly midgut. However, there are broad similarities with 
procylic trypanosome metabolism, as amino acids and glucose can be used as 
energy sources (Lamour, N et al. 2005; Bringaud, F et al. 2006). Sandflies are 
able to feed on nectar, which is comprised of a numerous sugars. Consequently, 
and in contrast to trypanosomes, Leishmania express enzymes, such as amylase 
or a sucrase-like protein, to metabolise these substrates (Blum, JJ and 
Opperdoes, FR 1994; Opperdoes, FR and Coombs, GH 2007). Genes to encode 
ribulokinase and xylulokinase are present in Leishmania genome; additionally, 
these enzymes have PTS targeting signal, indicating these enzymes localise to 
the glycosome. 
In Leishmania, methionine is fully oxidised, feeding into the TCA cycle, whereas 
in Trypanosoma, the end point is 2-ketobutyrate (C00109) due to the absence of 
the downstream enzymes. There are also differences in threonine metabolism. 
In T. brucei, threonine is converted to AOB and acetyl CoA (section 1.11.2), 
whereas in Leishmania, threonine is converted to glycine by the THF-dependent 
pathway, or alternatively, via 2-ketobutyrate (C00109) to succinyl CoA (C00091) 
(Opperdoes, FR and Coombs, GH 2007). Ascorbate is required for the ascorbate 
dependent peroxidise (L. major and T. cruzi) and the iron-ascorbate peroxidise 
(T. brucei), suggesting a role in the defence against oxidative stress. Neither 
ascorbate nor erythroascorbate have been detected in Leishmania, and the 
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source of D-arabinose, the precursor for the pathway, is not known (Opperdoes, 
FR and Coombs, GH 2007).  
 
Figure 1-6. Differences in Trypanosomatid amino acid metabolism. 
The amino acid metabolism in L. major compared with T. brucei and T. cruzi. Common biochemical 
reactions are shown in black, whereas reactions not present in trypanosomatids, but present in 
other eukaryotes are shown in grey. The representation of other differences is depicted in the key. 
Enzyme-catalysed reactions, for which no unambiguous gene identification could be made, are 
represented by a question mark. Abbreviations are as follows: AcAc, acetoacetate; AdoMet, 
adenosylmethionine; B, biopterin; Cit, citrulline; DHF, dihydrofolate; HMGCoA, 
hydroxymethylglutaryl CoA; OAA, oxaloacetic acid; Orn, ornithine; PGA, phosphoglyceric acid; 
qH2B, quinoid form of dihydrobiopterin; THF, tetrahydrofolate. Taken from Opperdoes, FR and 
Coombs, GH 2007. Permission to reproduce this image has been granted by Elsevier. 
A fully functional urea cycle is not thought to occur in L. major, T. brucei, or T. 
cruzi.  Arginine, ornithine and urea can only be produced by L. major, although 
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both L. major and T. brucei express ODC (Opperdoes, FR and Coombs, GH 2007). 
Amino Acid metabolism is depicted in Figure 1-6. Other metabolic differences 
include folate metabolism, haem synthesis, and amino acid synthesis 
(Opperdoes, FR and Coombs, GH 2007). 
1.11.4 Electron transport chain 
The electron transport chain consists of membrane protein complexes and redox 
reactions to transfer electrons from an electron donor, for example NADH, to an 
electron acceptor, for example molecular oxygen (O2) (Figure 1-7). These 
reactions occur in sequence, with the electron donor passing electrons to an 
acceptor of greater electro negativity. Electrons are shuttled between the 
immobile macromolecular protein complexes by the lipid soluble quinones, or 
the water soluble cytochromes. An electrochemical proton gradient, generated 
by the translocation of protons (derived from the Krebs cycle) from the 
mitochondrial matrix to the intermembrane space, allows ATP synthase to 
convert mechanical energy to chemical energy by utilising the proton flow back 
to the mitochondrial matrix to generate ATP (Boyer, PD 1997). 
H+ H+ H+ H+
I
II
III IV
AOX
Gly-3-P DHAP
Succinate Fumarate
O2
H2O
O2 H2O
ADP ATP
NADH NAD+
Q
©
 
Figure 1-7. Electron Transport Chain 
Complex I, NADH dehydrogenase, EC 1.6.5.3; complex II, succinate dehydrogenase, EC 1.3.5.1; 
complex III, cytochrome bc1 complex, EC 1.10.2.2; complex IV, cytochrome c oxidase EC 1.9.3.1; 
Gly-3-P, glycerol 3-phosphate; DHAP, dihydroxyacetone phosphate; AOX, alternative oxidase; ©, 
cytochrome c; Q, ubiquinone/ubiquinol. 
A major product of the Krebs cycle is NADH, which can be oxidised by Complex I 
(NADH dehydrogenase; EC 1.6.5.3) to generate NAD+ (which is then consumed by 
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enzymatic processes in the mitochondrion). During this process two electrons are 
removed from NADH, transferred to ubiquinone (Q), forming ubiquinol (QH2), 
and four protons are translocated from the mitochondrial matrix across the 
membrane to the intermembrane space, producing a proton gradient. 
Alternatively, electrons can be transferred, via FAD, to Q either by Complex II 
(succinate dehydrogenase; EC 1.3.5.1), through the conversion of succinate to 
fumarate, or by the conversion of Gly3P to DHAP.  In Complex III (cytochrome 
bc1 complex; EC 1.10.2.2), two electrons are removed from QH2, and 
transferred to two molecules of cytochrome c, located in the intermembrane 
space. Two protons are translocated from the mitochondrial matrix to the 
intermembrane space, and an additional two protons from cytochrome c are 
released to the intermembrane space, contributing to the proton gradient. Four 
electrons provided by cytochrome c are passed to Complex IV (cytochrome c 
oxidase; EC 1.9.3.1), where molecular oxygen (O2), the most electro negative 
acceptor, acts as the terminal acceptor for the electrons. Two molecules of 
water (H2O) are produced during this reaction. The translocation of four protons 
across the membrane contributes to the proton gradient. 
The efflux of protons from the mitochondrial matrix to the intermembrane space 
generates an electrochemical (proton) gradient. The F1FO-ATP synthase (EC 
3.6.3.14), consisting of a FO transmembrane component and a F1 water soluble 
component, utilises this proton gradient with the FO component acting as an ion 
channel to allow the flux of protons to flow back to the mitochondrial matrix. 
Indirect conformational changes of the two components allows the generation of 
ATP from ADP and inorganic phosphate (Boyer, PD 1997). 
The alternative oxidase (AOX), present in some organisms including protists, 
provides a cytochrome c independent method for the reduction of molecular 
oxygen. However, as electrons are obtained from QH2, this bypasses the proton 
translocation of complex III and complex IV, thus reducing ATP generation. 
Interestingly, T. brucei is entirely dependent on the AOX for respiration, thus 
the enzyme, trypanosome alternative oxidase (TAO), is an attractive drug target 
(Chaudhuri, M et al. 2006). Ascofuranone and salicylhydroxamic acid (SHAM) 
inhibit TAO. No functional TAO homolog has been detected in T. cruzi or L. 
major, consequently neither of these organisms are sensitive to compounds 
which inhibit the AOX (Opperdoes, FR and Coombs, GH 2007). 
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1.12 Proteomics 
The post-genomic era has seen the introduction of another ‘omics’ approach - 
proteomics (Mann, M et al. 2001; Aebersold, R and Mann, M 2003). Whilst 
genome sequence projects for many organisms have been completed, there is 
only so much one can infer from this information alone. Transcriptomics (the 
study of mRNA transcripts) can also yield useful information, although an incease 
in mRNA transcript does not necessarily mean an increase in protein level. 
However, for meaningful biological information, it is necessary to look beyond 
the genome, and investigate changes at the protein level. The proteome can be 
defined as the all proteins, including protein isoforms, polymorphisms and 
modifications, protein-protein interactions, that occur in a biological system 
under specific conditions (Pandey, A and Mann, M 2000). Technological advances 
allow for the identification and quantification of proteins from biological 
samples. 
1.12.1 DIGE 
Difference gel electrophoresis (DIGE) is a two-dimensional polyacrylamide gel 
electrophoresis (2-DE) technique to resolve complex mixtures of proteins from 
different samples on a single gel. In a 2-DE approach, proteins are separated by 
two properties in two dimensions; typically by charge in the first dimension using 
ioselectric focusing (IEF), and by molecular mass in the second dimension 
(O'Farrell, PH 1975). This approach has several drawbacks. Initially, a large 
quantity of protein is required as visualisation of the proteins is performed by 
staining the gel with colloidal coomassie blue (or silver stain), requiring 
approximately 500 µg or 50 µg respectively. Furthermore, technical variances 
between gels can make gel to gel comparisons difficult as many gels are required 
to perform a robust pairwise comparison of the protein samples. In DIGE, the 
protein samples are labelled with cyanine dyes prior to electrophoresis, which is 
more sensitive for protein detection than using a non-fluorescent post-stain 
(Shaw, J et al. 2003). One protein sample, derived from a wild type cell line or 
healthy tissue for example, can be labelled with either Cy3 or Cy5 fluorophore, 
and another protein sample, derived from a drug resistant cell line or diseased 
tissue, can be labelled with the other fluorophore (Unlu, M et al. 1997). These 
two protein samples can then be mixed together and run on a single gel, 
resulting in protein ‘spot map’. The cyanine dyes have low unspecific binding 
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(Enzo Life Sciences website), are structurally similar, and have distinct spectral 
properties. Therefore, proteins originating from different samples can be 
efficiently labelled and visualised using different excitation and emission filters 
(Lilley, KS and Friedman, DB 2004). Furthermore, an internal pooled standard 
consisting of equal quantities of protein from the two samples can be labelled 
with Cy2 to enable an accurate comparison of protein quantities between 
replicate gels (Alban, A et al. 2003). DIGE overcomes the problems of poor 
reproducibility and technical variance as two protein samples are run on the 
same gel; therefore there is co-migration of protein spots. Consequently, this 
reduces the number of gels required in order to generate robust and 
reproducible data. The use of cyanine fluorophores allows increased sensitivity 
as proteins of low expression levels can be labelled and accurately compared 
using computer algorithms (Shaw, J et al. 2003). Whilst identification of low 
abundance proteins by mass spectrometry can be difficult (Unwin, RD et al. 
2006), the recent and continual technological advances in mass spectrometry 
make this less of an issue. 
1.12.2 Labelling proteins 
The most common labelling reaction, known as DIGE minimal labelling, typically 
involves labelling only 1-5% of the total lysine residues of a protein (Unlu, M et 
al. 1997; Greengauz-Roberts, O et al. 2005; McNamara, LE et al. 2010). This 
approach, using N-Hydroxysiccinimide (NHS) ester linkage, ensures that a 
minority of proteins typically have one labelled lysine residue (Figure 1-8). If 
more than one lysine residue is labelled, multiple protein spots may appear on 
the gel in the form of a ‘charge train’, thus reducing the resolution.  
CyDye with NHS moiety
Lysine Residue CyDye labelled lysine
NHS
 
Figure 1-8. CyDye labelling reaction of lysine residues. 
The cyanine fluorophores are synthesised with reactive groups, such as the highly reactive NHS 
moiety, to allow conjugation with proteins or nucleic acids. The reaction between the NHS ester 
and the primary amine forms an amide bond between the cyanine fluorophore and the side chain of 
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the lysine residue; NHS is released in the process. Abbreviations - R1, CyDye; R2, Lysine residue; 
NHS, N-Hydroxysuccinimide. 
In contrast, saturation labelling involves labelling all of the cysteine residues 
with excess dye. Saturation cannot be achieved by labelling all lysine residues as 
the hydrophobicity of the cyanine dyes conjugated to the polar lysine residues 
causes proteins to precipitate from solution (Unlu, M et al. 1997; Greengauz-
Roberts, O et al. 2005). The main advantage of saturation labelling is an 
increased sensitivity in comparison to minimal labelling. Comparisons with as 
little as 5 µg of protein can be performed, in contrast to 50 µg for minimal 
labelling (Shaw, J et al. 2003). However, there are several limitations to 
saturation labelling of proteins. The most significant limitation is that cysteine is 
less common than lysine, thus restricting the number of proteins that can be 
detected. Random analysis of approximately 65,000 human proteins revealed 
3.7% of them did not contain a cysteine residue (Sitek, B et al. 2005). Whilst the 
majority of proteins are labelled, it is important to consider that some proteins 
will not be labelled. Furthermore, only Cy3 and Cy5 are available with 
maleimide chemistry for labelling cysteine residues, and therefore an internal 
standard labelled with the Cy2 fluorophore cannot be performed. Whilst 
increased sensitivity can be achieved by saturation labelling, allowing detection 
of reproducible changes in samples with low protein abundance, there can still 
be a problem in identifying proteins by mass spectrometry from an analytical 
gel. As saturation labelling is more applicable for the analysis of samples of low 
protein abundance, there can also be problems in identifying proteins if the 
protein concentration is too low. Experiments determined that loading between 
1 pmol and 10 pmol of each protein was necessary to identify a protein in a gel, 
despite mass spectrometry sensitivity in the femtomol range. Consequently, a 
second preparative gel is required to allow successful protein identification, 
although improvements in mass spectrometry, as previously mentioned, sample 
preparation, and handling will improve analysis and allow direct identification of 
proteins from the analytical gel (Greengauz-Roberts, O et al. 2005). 
1.12.3 Trypsin 
The differentially expressed protein spots are excised from the gel, 
enzymatically digested with trypsin, and the resulting peptide fragments are 
analysed by mass spectrometry. Trypsin cleaves peptide chains at the carboxyl 
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side of either lysine or arginine (except when either is followed by proline). 
Whilst it is possible to measure the exact mass of an intact protein, it is 
favourable to analyse peptide fragments for a number of reasons. (1) The 
physico-chemical properties of some proteins can lead to problems of 
insolubility, however digestion of a protein into peptide fragments can overcome 
this, and therefore the structure of the native protein is irrelevant (Steen, H and 
Mann, M 2004). This is particularly important when investigating membrane 
proteins, which require the use of detergents for solubilisation. As detergents 
are in excess in relation to proteins, and are easily ionised they can interfere 
with mass spectrometry. Therefore digestion of a protein into peptide fragments 
enables easier identification of membrane proteins. (2) MS instruments are more 
sensitive when measuring the masses of peptides than proteins. (3) Due to 
protein modifications it is difficult to identify a protein by mass spectrometry 
based on the exact mass, and conversely, the exact mass of an intact mature 
protein from its amino acid sequence (Steen, H and Mann, M 2004). (4) 
Specificity of trypsin is well defined, hydrolysing peptide bonds where the 
carbonyl group is supplied by an arginine or lysine residue, unless the carbonyl 
group is bound to an N-terminal proline residue. This makes it easy to predict 
peptide fragments by an in silico trypsin digest of protein databases. The use of 
a non-specific enzyme generates a complex subset of overlapping peptides which 
in turn requires improved chromatographic resolution and greater computational 
processing power (Wu, CC and Yates, JR, 3rd 2003). 
Using computer algorithms, it is possible to determine which proteins could give 
rise to the masses of specific peptides; although this approach is less reliable for 
complex protein samples. Consequently, tandem MS is preferred as the primary 
structure amino acid sequence can be obtained. 
1.13 Mass Spectrometry 
MS can be described as an analytical technique that accurately measures the 
mass, or more accurately, the mass to charge ratio (m/z) of ionised molecules 
(Walther, TC and Mann, M 2010), and has an important role in systems biology. 
In proteomics, MS provides the ability to measure the m/z ratio of specific 
peptide fragments (bottom-up approach), or intact mature proteins (top-down 
approach), although the later is more challenging. In metabolomics, MS can be 
used to measure the m/z ratio of ionised metabolites (section 1.15.2). 
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There are three main components to MS instruments. These are (i) ionisation of 
the molecule, or analyte, (ii) the mass analyser which allows the selection and 
detection of the desired ions, and finally (iii) the detection system which 
measures the m/z ratio. 
1.13.1 Ionisation 
The ‘soft’ ionisation technique used for biological samples ionises and vaporises 
a sample, without fragmenting it. With regards to a protein sample digested 
with trypsin, only the masses of the intact peptides are measured. The sample, 
in the liquid or solid phase, is ionised to the gas phase and becomes a charged 
molecule. The two methods of ionisation for proteomic approaches are Matrix-
Assisted Laser Desorption/Ionization (MALDI) and Electrospray Surface Ionization 
(ESI). 
In MALDI, the peptide sample, or analyte, is mixed with excess matrix solution, 
consisting of crystallised molecules in both aqueous and organic solvents to allow 
both hydrophilic and hydrophobic molecules to dissolve. The solution is applied 
to the MALDI plate to allow the solvents and water to evaporate, allowing the 
molecules to co-crystallise. A UV laser pulse is then directed at the co-
crystallised sample matrix. Consequently, a portion of the sample is vaporised 
and ionised as protons are transferred from the matrix to the analytes 
(Hillenkamp, F and Karas, M 1990). 
In ESI, the analyte is disolved in a volatile solvent which is then passed through a 
stainless steel capillary to a hypodermic needle. An electric field at the tip of 
the needle charges the surface of the solution as it is aersolised. The solvent 
evaporates until the charge density on the surface of the molecule reaches a 
critical point (Raleigh limit) and the droplet undergoes a ‘Coulombic explosion’ 
creating smaller droplets. This process is repeated until discrete quasi-molecular 
ions are produced, which are in turn suitable for mass spectrometry analysis 
(Fenn, JB et al. 1989). As molecules are prepared in the liquid phase, ESI is 
often combined with High Pressure Liquid Chromatography (HPLC) to separate 
molecules based on their polarity, prior to ionisation. Ionised analytes typically 
have multiple charges when generated by ESI, in contrast to single charges when 
generated by MALDI. 
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1.13.2 Mass to charge analysis 
Ions are subjected to electrostatic or magnetic fields and the resulting motion is 
a function of the mass to charge ratio. There are numerous ways to calculate 
this ratio, and consequently multiple different types of mass analysers have 
been developed; these include time of flight (ToF), quadrupole, ion-trap, 
orbitrap, and Fourier-transform ion cyclotron resonance (FT-ICR). The strengths 
and weaknesses (such as resolution, mass accuracy, sensitivity, dynamic range) 
of these various mass analysers are reviewed in (Domon, B and Aebersold, R 
2006). As there are a number of different methods of analysing molecules, there 
is the capability to combine these to utilise the advantages of multiple 
approaches. 
1.13.3 TOF 
In ToF mass spectrometry the m/z ratio is calculated by measuring the time 
taken for peptide ions to travel a fixed distance inside a vacuum tube. Peptides 
with a high m/z ratio take longer to travel down this tube than peptides of a low 
m/z ratio. 
1.13.4 Ion-trap 
The ion trap is capable of trapping ions in a quadrupolar field, thus accumulating 
ions within a specific range of interest. Ions, from a low m/z to a high m/z, are 
then ejected from the trap by changing the electrode voltages, which makes the 
ion trajectories unstable (Jonscher, KR and Yates, JR, 3rd 1997). The major 
advantage of this method is that ions are accumulated over time, thus increasing 
the signal to noise ratio (sensitivity) for analytes of low abundance. However, 
ion traps generally have poor resolution and poor mass accuracy. The 
introduction of linear ion traps (LITs) allows improved ion trapping,  
1.13.5 Orbitrap 
The Orbitrap is the most recent MS instrument, offering extremely high mass 
accuracy, resolution and sensitivity (Hu, Q et al. 2005). With the Orbitrap, the 
ions are injected into the instrument where they are confined by an 
electrostatic field. The ions oscillate around a central spindal due to the 
attraction towards the central electrode, counteracted by centrifugal forces. 
The oscillation frequency of these ions is inversely proportional to the square 
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root of the m/z ratio. The Orbitrap offers mass accuracy from 2-5 ppm (Hu, Q et 
al. 2005), although sub ppm accuracies can be obtained with an internal 
calibration (Olsen, JV et al. 2005). The LTQ orbitrap is the commercially 
available instrument, featuring ESI, a linear ion trap, and RF only quadrupole C-
trap. 
1.13.6 HPLC 
High pressure liquid chromatography is used to separate analytes by 
chromatography, and is appropriate for complex samples (Jandera, P 2011). 
Analytes, in the mobile phase, are forced through a column (stationary phase), 
and a detector determines the the time taken for this to occur. This is known as 
the retention time, and will vary depending on the the composition and ratio of 
the solvents used for the mobile phase, the flow rate of the mobile phase, and 
the interactions between analytes and the stationary phase. 
In normal phase (NP) chromatography, a non-polar, predominantly non aqueous 
solvent and a polar stationary phase are used to separate analytes (Jandera, P 
2011). Non-polar compounds are diluted first, whereas polar compounds are 
separated dute to slow elution. However, polar compounds have poor solubility 
in these solvents, which can be problematic. Conversely, in RP chromatography, 
a polar solvent and non-polar stationary phase are used to separate the analytes. 
Consequently, polar compounds are diluted first, with the non polar compounds 
separated over time. 
The stationary phase consists of silica peptides with specific polar or non-polar 
functional groups depending on the type of chromatography required. 
Chromatographic resolution improves as particle size decreases. The mobile 
phase may consist of a gradient where the compositions of solvents are altered 
over time, thus enabling compounds to elute sooner than normal. 
1.13.7 HILIC 
Hydrophilic Interaction Chromatography (HILIC) is an HPLC method used in the 
separate the polar / hydrophilic compounds (Alpert, AJ 1990). The liquid phase 
consists of water, typically between 5-40%, and a water-miscible polar organic 
solvent, usually acetonitrile (ACN), which is not only compatible with MS, but 
offers higher sensitivity. Elution is achieved by gradually increasing the quantity 
  Chapter 1, 55 
 
of water (Naidong, W 2003; Hemstrom, P and Irgum, K 2006). The technique is 
similar to normal phase (NP) chromatography, and orthogonal to reverse phase 
(RP) chromatography as polar compounds are retained longer than non-polar 
compounds (Boersema, PJ et al. 2008). 
Reverse phase chromatography is not suitable for the separation of polar 
compounds, as these compounds fail to bind to the column, and consequently, 
are eluted rapidly. A ZIC-HILIC column combined with an Orbitrap FT-MS has 
shown to be advantageous in separating polar metabolites from whole cell 
lysates (Kamleh, A et al. 2008). Separation of metabolites based on ploarity is 
achieved using acetonitrile and water. Metabolites which are less polar are 
eluted from the column first, whereas polar metabolites are retained. 
Consequently, metabolites are separated by hydrophobicity by chromatography, 
and then by mass using mass spectrometry. 
1.13.8 MS/MS 
In tandem mass spec (MS/MS) individual peptides can be targeted with sufficient 
energy to achieve fragmentation, and the subsequent m/z values of these 
ionised fragments are recorded. Fragmentation is mainly achieved through 
collision induced dissociation (CID) and electron capture dissociation (EID), in 
series with two TOF instruments. In CID the peptide will undergo multiple 
collisions with inert gas molecules until the ion accumulates enough vibrational 
energy to break the weakest chemical bonds, usually the amide bond of the 
peptide, generating b- (N-terminus) and y- (C-terminus) fragments. This 
approach is more appropriate for smaller peptides with no unstable 
modifications, as these bonds are weaker than the peptide bonds. In EID the 
positively charged peptide reacts with an electron donor generating a peptide 
fragment with an unpaired electron that is highly unstable. The peptide 
backbone splits at the Cα-C’ bond to generate c- (N terminus) and z- (C-
terminus) fragments. However charge reduction of the peptides is more common 
than fragmentation leading to a decrease in sensitivity (Mallick, P and Kuster, B 
2010). Other methods of fragmentation include electron capture dissociation 
(ECD) and post source decay (PSD). 
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1.14 The identification of proteins  
The identification of proteins is performed by peptide mass fingerprinting (PMF), 
sequence comparisons or MS/MS ion queries using the online MASCOT web 
application. The MASCOT search engine incorporates code from Molecular Weight 
Search (MOWSE), an early program for detecting proteins by mass fingerprinting 
from a mass list (Pappin, DJ et al. 1993), although includes probability based 
scoring (Perkins, DN et al. 1999). Searching the sequence of any FASTA format 
file is also possible; including protein sequences directly, or the translation of 
nucleic acid sequences. 
An in silico digest of a proteome database will yield a theoretical spectrum for 
each predicted peptide, which can then be compared to the experimental 
spectrum to gain peptide and protein identifications (Mallick, P and Kuster, B 
2010). Alternatively, de novo sequencing of peptide fragments can be used to 
determine the amino acid sequence as the mass difference between adjacent 
signals often differ by that of an amino acid. If no genome sequence is available 
then de novo sequencing is certainly more applicable, however the extensive 
number of completed genome projects (Kyrpides, NC 1999) favours the in silico 
approach. 
Careful consideration should be taken when preparing the samples so as to 
minimise unwanted protein modifications and proteolytic degradation. 
Consequently, harvested cells are lysed in a DIGE compatible lysis buffer 
containing chaotropic agents and CHAPS which aid protein solubility; protease 
inhibitors and keeping the samples on ice help prevent proteoloytic degradation. 
Lysis can be further aided by mechanical methods such as sonication or repeated 
freeze-thaw if necessary. As it is often necessary to precipitate protein samples, 
it is important to have enough starting material as this process leads to loss of 
proteins. Precipitation of protein samples is important for the concentration of 
proteins, and the removal of contaminants, although these can be reduced by 
using high quality reagents. 
1.15 Metabolomics 
Metabolomics can be defined as “the comprehensive (qualitative and 
quantitative) analysis of the complete set of all low molecular weight 
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metabolites present in and around growing cells at a given time during their 
growth or production cycle” (Mashego, MR et al. 2007). Low molecular weight 
metabolites are considered to be less than 1500 Da (Dunn, WB 2008). When we 
consider the other –omic disciplines in systems biology, the genome, proteome, 
and transcriptome are relatively static in comparison to the dynamic fluidity of 
the metabolome. Consequently, the study of metabolomics allows us to gain an 
instantaneous picture of the biological system at a particular time. This can 
provide a clearer insight into biological changes at the genomic, transcriptomic, 
or proteomic level. Furthermore, when we consider the metabolome of an 
organism, there are fewer metabolites than there are genes, transcripts or 
proteins (Kell, DB 2006). In theory, this should make the datasets more concise 
and easier to interperate; however, in reality, the datasets contain background 
ions, adducts, contaminants. 
Metabolomics can be either targeted or untargeted. A targeted approach 
involves the quantitative identification of structurally known and biochemically 
annotated metabolites, in relation to known metabolic pathways. In contrast, 
the untargeted approach is more difficult to interpret, with some of the peaks 
belonging to unknown metabolites for which no structural data may be available. 
However, both approaches can be aided through the use of isotopic labelling, 
which allows the detection of any products derived from the labelled substrate.  
Broadly speaking, there are three main areas of metabolomics; sample 
preparation, data aquistion (mass spectrometry or NMR), data analysis (the 
computational or bioinformatic approaches used to interperate data). 
1.15.1 Sample preparation 
The metabolomics approach varies depending on the biological system and the 
metabolites of interest. Consequently, careful experimental design is required to 
deal with numerous factors that include; metabolism quenching, metabolite 
extraction, sample storage, and the biological system being investigated. 
Metabolomics provides an insight into the metabolome at a precise point in 
time; therefore, both the time of metabolite extraction and metabolism 
quenching are extremely important to reflect the current state of the biological 
system of interest (Faijes, M et al. 2007). The metabolome of the organism may 
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change due factors such as age, gender, diet, or disease state. Alternatively, if a 
cell culture system is being investigated, then change to the temperature, cell 
cycle stage, culture medium, or atmospheric conditions may play a role. As a 
consequence, it is important to standardise these conditions as much as 
possible, or at least consider them during analysis.  
The quenching of metabolism should be rapid and performed at an extreme 
temperature to inhibit all possible enzymatic activity to prevent degradation of 
metabolites. A common method used to quench metabolism is treating the cells 
with an aqueous methanol solution at a temperature of -40 °C (de Koning, W and 
van Dam, K 1992). There have been numerous metabolite extraction protocols 
published, which vary depending on the organism. As the metabolome represents 
a wide range of compounds (sugars, amino acids, organic acids, fatty acids, 
nucleotides), which in turn provides a large chemical and physical variability, 
the solvent chosen will extract different metabolites. For example, 
acetonitrile:methanol:water (2:2:1) and water:isopropanol:methanol (2:2:5) 
were found to have sufficient coverage of the Saccharophagus degradans 
metabolome, in contrast to pure methanol or acetonitrile:water (1:1, v/v) (Shin, 
MH et al. 2010). Another study, using Lactobacillus plantum, found that cold 
methanol, boiling ethanol, and perchloric acid provided suitable coverage of the 
metabolome; however, both chloroform:methanol (1:1) and chloroform:water 
(1:1) were not as efficient (Faijes, M et al. 2007). The optimisation of 
metabolite extraction has also been investigated in Leishmania (Saunders, EC et 
al. 2010; t'Kindt, R et al. 2010), Saccharomyces cerevisiae (Villas-Boas, SG et al. 
2005), and E. coli (Chassagnole, C et al. 2002). 
If quenching and extraction are performed as two independent steps, then 
metabolite leakage during quenching must be considered (Mashego, MR et al. 
2007), although any method used for either metabolite extraction or metabolism 
quenching will result in metabolite loss (Dettmer, K et al. 2007). 
The optimal storage conditions vary depending on biological sample, and should 
be investigated prior to analysis to prevent, or minimize, degradation of 
metabolites. Blood, plasma and urine samples can be stored at -80 C for up to 6 
months, whereas plant materials can be stored at -80 C for up to 4 weeks with 
no changes to metabolome (t’Kindt R, personal communication). 
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These results suggest that it will not be possible to develop a standardized 
protocol for metabolome quenching, metabolite extraction, and sample storage, 
with experimental optimisation specific to the biological system and metabolites 
of interest. 
1.15.2 Data acquisition 
Data is aquired using NMR or mass spectrometry (section 1.13). Whilst NMR is not 
the most sensitive technique, it is both an accurate and reproducible method of 
detecting many metabolites (Gupta, N et al. 1999). One MS approach involves 
using gas chromatography (GC) coupled to MS (GC-MS) to quantity metabolites 
from Arabidopsis thaliana (Fiehn, O et al. 2000); however the main limitation of 
GC-MS is organic phosphates are not detected. Consequently, attention has 
focussed to an alternative chromatographic technique; HILIC (section 1.13.7) 
coupled to an Orbitrap Mass Spectrometer (section 1.13.5) in an attempt to 
resolve the global trypanosomatid metabolome (Kamleh, A et al. 2008; t'Kindt, R 
et al. 2010; Vincent, IM et al. 2010). The sample preparation method influences 
the metabolites which are detected (section 1.15.1), although it is possible to 
resolve more metabolites. The Orbitrap has a high mass accuracy, which whilst 
in the region of 2 ppm (Hu, Q et al. 2005), can be reduced to 0.21 ppm using 
internal background ions for provide additional calibration (Scheltema, RA et al. 
2008). The methods of data acquisition most likely outweigh the ability to 
interpret the data, therefore research should concentrate on optimising data 
analysis. 
1.15.3 Data analysis 
The data analysis step for the interpretation of metabolomic data is the weakest 
aspect of metabolomic experiments, although has improved in recent years. 
Data analysis can be further broken down into two distinct areas; the 
deconvolution of raw data files obtained from the mass spectrometer, and 
providing a biological context for the data. 
The successful processing of raw data relies on numerous factors; statistical 
analsysis to obtain reproducible data ignoring background noise, the ability to 
handle any related peaks derived from one particular parent metabolite peak 
(adducts, fragments, isotopes and multiply charged species), and the ability to 
differentiate between isomers (using retention time). The Xcalibur software 
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(Thermo) is a basic tool to identify peaks isolated from the FT-MS Orbitrap; 
however, is unable to identify the subtle differences between peaks of low 
intensity. Therefore, more advanced software for metabolomic data processing 
has been developed by the metabolomics community, and currently includes 
MZMatch (Scheltema, RA et al. 2011), XCMS (Smith, CA et al. 2006; Tautenhahn, 
R et al. 2010), IDEOM (Creek, DJ et al. 2012). Common feature of these 
approaches include retention time alignment, peak detection, peak matching, 
and assigning an identification with information derived from online metabolite 
databases. It is necessary to find the correct balance between filtering the false 
positives, whilst identifying and retaining reprocible peaks; MZMatch attempts to 
identify and combine related peaks. 
While the identification of metabolites is important, the graphical 
representation of the data is equally important. The MetaNetter plug-in for 
Cytoscape allowed the creation of an ab initio network using metabolomic data 
and a list of biological transformations (Jourdan, F et al. 2008). Similar to the 
exact mass of a metabolite, the biological transformations (for example 
dehydrogenation), also have an exact mass. Consequently, if two unknown exact 
masses differ by the exact mass of a particular biological transformation, then it 
is possible that these masses correspond to metabolites in the same pathway. 
From Metabolite to Metabolite (FMM) is a similar approach, which utilises all the 
enzymes in the KEGG database to reconstruct the metabolic pathways between 
metabolites (Chou, CH et al. 2009). The techniques used in these two methods 
attempt to identify relationships and links between metabolites that are not 
predicted to occur. However, to provide a biological context, the data needs to 
be compared to a reference metabolome, such as KEGG (Kanehisa, M and Goto, 
S 2000) and BioCyc (Caspi, R et al. 2010). The construction of these metabolic 
databases was made possible due to the availability of complete genome 
sequences which allowed the prediction of metabolites based on the presence of 
the genes which encode enzymes identified by classical biochemical techniques 
(Cottret, L et al. 2010). The MassTRIX webserver (Suhre, K and Schmitt-Kopplin, 
P 2008) and Pathos webserver (Leader, DP et al. 2011) present the opportunity 
to overlay, or compare experimental data with the KEGG pathways. 
Alternatively, the MetExplore web server offers the possibility to link 
metabolites identified in untargeted metabolomics experiments, within the 
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context of genome-scale reconstructed metabolic networks (Cottret, L et al. 
2010). 
1.15.4 Applications of metabolomics 
There are several useful applications of metabolomics. When we consider that 
the mode of action of many drugs used to treat trypanosomiasis or leishmaniasis 
is unknown, metabolomics could be a play a pivotal role in elucidating the mode 
of action. A statistical comparison of metabolomic fingerprints (metabolic 
snapshot) derived from biological samples treated with drugs of known and 
unknown modes of action can provide information useful information (Yi, ZB et 
al. 2007). Alternatively, a metabolic profiling approach (identify as many 
metabolic changes as possible) can be used to detect pertubations (both direct 
and indirect) to metabolome, induced by the addition of a particular drug (Le 
Roch, KG et al. 2008). Subsequent experimental approaches would then focus on 
genetic manipulation of the genome to knockout or knockdown the gene which 
encodes the protein of interest, in an attempt to confirm the interaction 
between the drug and protein. 
Another topical area of research is the identification of biomarkers associated 
with specific diseases. A biomarker can be defined as “biological molecules that 
represent health and disease states” (Lyons, TJ and Basu, A 2012). The 
identification of metabolites associated with infectious disease or non-infectious 
disease would allow the possibility to develop cheap, robust, specific medical 
tests for various conditions or diseases. One example of a biomarker is the 
detection of PSA (prostate specific antigen), which is used as an early indication 
of prostate cancer (Kuriyama, M et al. 1980). A metabolomics approach could be 
used to identify potential biomarkers. 
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2 Materials and methods
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2.1 Cell culture 
2.1.1 Leishmania 
Leishmania mexicana promastigotes (MNYC/BZ/62/M379) were maintained in 
HOMEM medium (Invitrogen, Paisley, Scotland), supplemented with 10% (v/v) 
heat-inactivated foetal calf serum (Biosera, Ringmer, UK) (Appendix 7.1.1). The 
starting density was approximately 1 x 105 cells/ml, and cells were sub-passaged 
when the reached stationary phase, approximately 2 x 107 cells/ml. 
Where necessary, antibiotics were added to the transgenic lines used and 
generated in this study at the following concentrations; Hygromycin B (Roche, 
Burgess Hill, UK) at 50 µg/ml, Nouseothricin (Lexsy NTC, Jena Bioscience, 
Germany) at 100 µg/ml, G418 (Sigma-Aldrich, Poole, UK) at 50 µg/ml, and 
puromycin (Calbiochem, Nottingham, UK) at 50 µg/ml. 
2.1.2 Trypanosomes 
Trypanosoma brucei procyclic form (PCF) strain 427 were cultivated in SDM79 
medium (Brun, R and Schonenberger 1979) or SDM80 (Lamour, N et al. 2005) at 
27°C supplemented with 10% (v/v) heat-inactivated foetal calf serum (Biosera, 
Ringmer, UK) (Appendix 7.1.1). For SDM80, the FCS was dialysed by 
ultrafiltration in a volume ratio of 10 parts 1x PBS to 1 part FCS. Dialysis was 
performed a total of four times. 
Dialysis tubing, with a molecular mass cut off of 10 kDa, was boiled in 10 mM 
NaHCO3, 1 mM EDTA pH 8.0 for 10 minutes. This was repeated twice, before 
being washed in ddH2O, and stored in 70 % ethanol at 4°C. The dialysis tubing 
was washed in 1x PBS prior to use. 
2.1.3 Determining cell density 
Cells were mixed with an equal volume of 1% formaldehyde in 1x PBS counted 
using an improved Neubauer haemocytometer. Four of the large boxes were 
counted in triplicate and the average multiplied by 2 x 104 to determine the 
number of cells per ml. For very dense cultures, cells were diluted 1 in 5 with 1% 
formaldehyde in 1x PBS, and the average count multiplied by 5 x 104 to 
determine the number of cells per ml. 
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2.1.4 Preparation of stabilates 
Leishmania promastigotes in the late log phase of growth were mixed in 1:1 
(v/v) with the stabilate freezing solution (70% FCS / 30% glycerol). This mixture 
was transferred to 1.5 ml CryoVials in 1 ml aliquots; the samples were then 
stored at -80°C overnight, before transferring to liquid nitrogen for long term 
storage. T. brucei procyclic cells were prepared as stated above; except the 
freezing solution was 70% cell culture medium / 30% glycerol. For the revival of 
stabilates, aliquots were defrosted at room temperature and immediately 
transferred to 9 ml culture medium at the appropriate temperature for growth. 
A 1 ml aliquot of this mixture was transferred to 9 ml to reduce the 
concentration of glycerol and any toxic waste products present. 
2.2 Isolation of genomic DNA 
2.2.1 Phenol-Choloroform Method 
Approximately 10 ml of late-log promastigotes were pelleted at 1500 g, washed 
in PBS, resuspended in 0.5 ml cell lysis buffer A (Appendix 7.2), and incubated 
overnight at 50°C. The solution was mixed with 1 volume of phenol, and 
incubated at room temperature for 5 minutes, before the upper layer was 
isolated by centrifugation at 855 g for 10 minutes. This was repeated twice using 
chloroform instead of phenol.  The upper aqueous layer was mixed with 2 
volumes of ethanol, and 0.1 volume 3M NaCl. The DNA precipitated from the 
solution, was carefully removed, and washed with 70% ethanol. The gDNA was 
pelleted, and resuspended in 100 µl dH2O. 
2.2.2 DNeasy Blood and Tissue Kit (QIAGEN) 
Alternatively, genomic DNA was isolated from a late-log culture of promastigotes 
using the DNeasy® Blood and Tissue Kit (QIAGEN, Crawley, UK) according to the 
manufacturer’s instructions. 
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2.3 Molecular Cloning Techniques 
2.3.1 Polymerase Chain Reaction 
PCR was used to amplify specific regions of DNA that would be used for 
molecular cloning, species identification, and to confirm integration in 
transfected cell lines. All oligonucleotides were synthesised by Eurofins MWG 
Operon (Ebersberg, Germany). 
The standard PCR reaction used is as follows; 1x reaction buffer (Promega, 
Southampton, UK), 1.5 mM MgCl2 (Promega, Southampton, UK), 0.3 µM of each 
primer, 0.3 µM dNTPs (Invitrogen, Paisley, Scotland), 1.25 U GoTaq (Promega, 
Southampton, UK), and between 1 and 5 ng of plasmid DNA, or 200 ng of gDNA. 
The amplification was performed using a thermal cycler (PTC200 DNA Engine 
Thermal Cycler, MJ Research). An initial denaturation step at 94°C for 1 minute 
was followed by between 25 and 35 cycles of 94°C for 30 seconds, an annealing 
temperature (Tm) specific for each set of primers for 30 seconds, and an 
extension step of 1 minute per kb of DNA. A final extension step at 72°C for 5 
minutes was followed by a holding temperature of 4°C. Failure to amplify 
specific products was often rectified by increasing the MgCl2 concentration 
gradually, or adding DMSO (Riedel-de Haën, Germany) to a final concentration of 
5%. 
For the amplification of transketolase from gDNA, KOD polymerase (Calbiochem, 
Nottingham, UK) was used. This high fidelity enzyme has an extremely quick 
extension time of 1 kb every 20 seconds. The reaction components used is as 
follows; 1x reaction buffer, 2 mM MgSO4, 5% DMSO, 0.8 mM dNTP, 0.3 µM MB250, 
0.3 µM MB251, 200 ng of template gDNA, 1 U KOD. The reaction volume was 50 
µl. The cycling conditions were as follows; an initial denaturation step at 95°C 
for 1 minute was followed by between 30 cycles of 95°C for 15 seconds, an 
annealing temperature of 63.4°C for 15 seconds, and an extension temperature 
of 68°C for 40 seconds. A final extension step at 68°C for 2 minutes was 
followed by a holding temperature of 4°C. The addition of DMSO was necessary. 
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2.3.2 Cloning PCR products 
The enzyme Taq polymerase adds a single ‘A’ residue at the 3’ end of each 
strand of the PCR product. This could be sub-cloned into the linear pGEM-T Easy 
vector (Promega, Southampton, UK) which has a single ‘T’ residue at the 3’ ends 
of each strand. This process is known as TA cloning. For DNA polymerases which 
do not add an ‘A’ residue at the 3’ end strand, such as KOD polymerase 
(Calbiochem, Nottingham, UK), it was necessary to incubate the PCR product 
with Taq polymerase at 72°C for 15 minutes immediately after the final 
extension temperature of the PCR reaction. This allowed ligation into the TA 
cloning vector. 
2.3.3 Olignucleotides 
Oligonucleotides were designed using Vector NTI (Invitrogen, Paisley, Scotland) 
and ordered from Eurofins MWG Operon (Ebersberg, Germany) (Table 2-1).  
2.3.4 DNA gel electrophoresis and gel extraction 
PCR products were fractionated on a 1% (w/v) agarose gel (Invitrogen, Paisley, 
Scotland), in 1x TAE (Appendix 7.2.2). SybrSafe™ DNA gel stain (Invitrogen, 
Paisley, Scotland) was added to the agarose at a 1x concentration to allow 
visualisation of the DNA fragments. The desired DNA fragments were excised 
from an agarose gel using a scalpel, and extracted using the QIAquick® Gel 
Extraction Kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Alternatively, PCR products were purified using the QIAquick® PCR 
Purification Kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. 
2.3.5 Ligations 
The 20 µl PCR product ligation reaction was prepared as follows; 50 ng of pGEM-
T easy vector, between 3 and 8 µl of eluted PCR product, 1 U T4 ligase 
(Promega, Southampton, UK), and a final concentration of 1x rapid ligation 
Buffer (Promega, Southampton, UK). The reaction was carried out overnight at 
4°C. DNA fragments from the pGEM-T easy intermediate vectors could be sub-
cloned into the destination vector by restriction digest, and ligation using the T4 
ligase as previously described.
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Table 2-1. Oligonucleotide Sequences used in this study. 
Oligonucleotide ID Sequence Description Length (nt) Restriction Site
SP 6 CATTTAGGTGACACTATAG sequencing oligo 19 n/a
T3 AATTAACCCTCACTAAAGGG sequencing oligo 20 n/a
T7 TAATACGACTCACTATAGGG sequencing oligo 20 n/a
M13 uni (-21) TGTAAAACGACGGCCAGT sequencing oligo 18 n/a
MB0037 ATGATTGAACAAGATGGATTGC Neomycin (S) 22 n/a
MB0038 TCAGAAGAACTCGTCAAGAAG Neomycin (AS) 21 n/a
MB0039 ATGAAAAAGCCTGAACTCAC Hygromycin (S) 20 n/a
MB0040 ACTCTATTCCTTTGCCCTCG Hygromycin (AS) 20 n/a
MB0079 TAGCGTCGACTGTGCTTGTGGGTGAGGGCG L. mexicana Transketolase 5'flank (S) 30 SalI
MB0080 TAGCAAGCTTGGCCGCTTCGCACCACACGA L. mexicana  Transketolase 5'flank (AS) 30 HindIII
MB0091 GCAGCTCAGCCGGCCCTCAC outer primer for Transketolase 5' flank (S) 20 n/a
MB0094 CGCTGTCACGGGCACGATAG outer primer for Transketolase 3' flank (AS) 20 n/a
MB0095 CTGGATCATTTTCCGATG Leishmania  ITS1 (S) 18 n/a
MB0096 TGATACCACTTATCGCACTT Leishmania ITS1 (AS) 20 n/a
MB0210 ACTAGTGATGAAGATTTCGGTG Streptothricin acetyltransferase (S) 22 n/a
MB0211 GGATCCTTAGGCGTCATCCTGT Streptothricin acetyltransferase (AS) 22 n/a
MB0212 ATGATTACGCTTGCTGTGGT antisense primer located in 5' DHFR to check integration 20 n/a
MB0213 TGTCTCTTGTCGGTGCTCAC sequencing oligo for pXG (5'FR) 20 n/a
MB0217 TAGCCCCGGGTGCTCCGAAACGTGAGGAAT L. mexicana  Transketolase 3'flank (S) 30 SmaI
MB0218 TAGCAGATCTACTTCCTTGCCCTTCCGATA L. mexicana  Transketolase 3'flank (AS) 30 BglII
MB0245 GTGGGTGGAGGGTTTGAGGCCGAC TKT 5' flanking region (use with MB212) 24 n/a
MB0250 TAGACTCGAGCTTCGCCTCTCTTCGTCGCCCT L. mexicana  Transketolase ORF (S) 32 XhoI
MB0251 TAGAGCGGCCGCCGCCTCTTCCGGTGTCATTC L. mexicana  Transketolase ORF (AS) 32 NotI
MB0333 AGCAAGGTGAGATGACAGGAGATCC within Neomycin 25 n/a
MB0334 CTGCGTGCCATGCCAAACCT within TKT 20 n/a
MB0337 TGTGCGCCTCAGTAGACCTTG Transketolase OUTER  (AS) 21 n/a
MB0340 ATGACCGAGTACAAGCCCACG Puromycin (S) 21 n/a
MB0341 TCGTAGAAGGGGAGGTTGCG Puromycin (AS) 20 n/a
MB0342 GCGGCATTTTGCCTTCCTGT B-Lactamase  (S) 20 n/a
MB0343 CCAATGCTTAATCAGTGAGGCACC B-Lactamase (AS) 24 n/a
MB0492 CTGATCGATTTTCGACGGCT L. mexicana  VDAC 1 (S) 20 n/a
MB0493 TACTGATCGCCCACCTTCGT L. mexicana  VDAC 1 (AS) 20 n/a
MB0494 TCACCGCCACGTCTAGGAAC L. mexicana  VDAC 2 (S) 20 n/a
MB0495 GTGGACATCACGCACTCACG L. mexicana  VDAC 2 (AS) 20 n/a   
Restriction sites are underlined in the sequence and the restriction enzymes are noted; n/a = not applicable; nt = nucleotides
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2.3.6 Transformations 
The chemically competent E. coli cell line JM109 (Promega, Southampton, UK) 
were transformed with the desired plasmid. 50 µl of cells were thawed on ice, 
mixed with 20 µl of ligation product (or 1 µl plasmid DNA), and left on ice for 30 
minutes. The cells were then heat-shocked at 42°C for 90 seconds, before being 
placed immediately on ice for 2 minutes. 200 µl of SOC medium or LB medium 
was added and the cells were incubated at 37°C for between 30 and 60 minutes, 
before being plated on LB agar plates supplemented with 100 µg/ml ampicillin 
(Sigma-Aldrich, Poole, UK). 
Single colonies were isolated from the plates using a sterile 200 µl pipette tip 
and grown in 5 ml of LB medium supplemented with 100 µg/ml ampicillin 
(Sigma-Aldrich, Poole, UK) for 16 hours in a shaking incubator. If necessary, 
colonies were screened by PCR, in a Taq DNA polymerase mediated reaction mix 
to determine whether the correct insert was present. PCR products were 
fractionated on an agarose gel as described in section 0. The following day, cells 
were pelleted at 4500 g for 10 minutes at 4°C, and the DNA was isolated using 
the QIAprep® Spin Miniprep Kit (Qiagen, Crawley, UK) according to the 
manufacturer’s instructions. The yield and quality of the plasmid DNA was 
determined using the NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
Presence of the specific DNA fragment was determined by PCR or restriction 
digest, and confirmed by sequencing (Eurofins MWG Operon, Ebersberg, 
Germany). 
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2.3.7 Plasmid generation 
DNA fragments were transferred between vectors by digesting with restriction 
endonucleases. Therefore, it was necessary to include restriction sites at the 5’ 
end of the oligonucleotides used in the PCR of certain DNA fragments. The 
plasmids used in this study are outlined in Table 2-2 and discussed in (Chapter 4 
and Chapter 5). 
Table 2-2. Plasmid constructs used in this study 
Plasmid ID Details
pMB-G39 L. mexicana  transketolase knockout construct conferring resistance to Hygromycin B
pMB-G40 L. mexicana  transketolase knockout construct conferring resistance to Nouseothricin.
pMB-G49 L. mexicana  transketolase ribosomal re-expression construct 
conferring resistance to Puromycin
pMB-G51 pGEM-T Easy (Promega) construct containing the L. mexicana transketolase open reading frame
pMB-G52 L. mexicana  transketolase episomal expression construct conferring 
resistance to G418
pMB-G53 Empty episomal expression construct conferring resistance to G418
pMB-G105 pGEM-T Easy (Promega) construct containing the L. mexicana VDAC1 open reading frame
pMB-G111 L. mexicana  VDAC1 episomal expression construct conferring 
resistance to G418
 
2.3.8 Preparation of glycerol stocks 
Glycerol stocks of transformed E. coli cell lines were prepared by mixing 0.5 ml 
of dense overnight culture, with 0.5 ml of 30% glycerol in LB medium. Glycerol 
stocks were stored at -80°C for future use. 
2.4 Southern Blotting 
Genomic DNA, at a concentration of between 1 and 10 µg, was digested 
overnight using between 5 and 50 U of restriction enzyme to ensure complete 
digest of the sample. The DNA fragments were fractionated on a 0.7% agarose 
gel at 1 volt cm-1. The gel was subjected to two depurination washes for 15 
minutes (Appendix 7.2.3), two denaturation washes for 30 minutes (Appendix 
7.2.4), and two neutralisation washes for 30 minutes (Appendix 7.2.5), before 
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the DNA was transferred to a Hybond-N membrane (Amersham, Chalfont St 
Giles, UK) overnight in the presence of 20x SSC transfer buffer (Appendix 7.2.6). 
The following day, the membrane was washed in 6x SSC, and the DNA was cross-
linked to the membrane by exposure to UV using the SpectroLinker XL-1000 UV 
Crosslinker (Advanced Engineering Ltd, Basingstoke, UK). The membrane was 
stained in 0.002% methylene blue (Sigma-Aldrich, Poole, UK) to visualise the 
DNA. 
Prehybridisation of the membrane was carried out for a minimum of two hours 
at 42°C in 50% formamide (Promega, Southampton, UK), 5 x SSC, 10 x Denhardt’s 
solution (Appendix 7.2.7), 1 % SDS, 20 mM NaH2PO4, 5 mM EDTA pH 8, and 0.2 
mg/ml denatured sonicated salmon sperm DNA (Stratagene, La Jolla, CA, USA). 
The probe was prepared using purified plasmid DNA fragments. The desired 
fragment (tkt ORF or tkt 3’ flank) were obtained from the appropriate plasmid 
construct (section 2.3.7), quantified using a 2-log DNA ladder (NEB, Hitchin, UK), 
and labelled with α32P (Perkin Elmer, Beaconfield, UK) by random priming using 
the Prime It II Kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s instructions. The radio-labeled probe was denatured at 95°C for 
5 minutes, and added to the membrane. Hybridisation was performed overnight 
at 42°C.  
The following day the solution was discarded, and the membrane incubated with 
preheated 0.1x SSC, 0.1% SDS and incubated at 56°C for 45 minutes to remove 
non-specific binding. Two additional wash stops at 58°C for 30 minutes were 
required. The southern blot was heat sealed, placed in a developing cassette 
with a sheet of KODAK Medical X-Ray Film General Purpose Blue (MXB), and 
exposed overnight at -80°C. 
2.4.1 Eluting the probe from a membrane 
The radiolabelled probe was eluted from the membrane by washing the 
membrane three times in a boiling 0.1% SDS solution. The membrane was then 
exposed to a film for 48 hours to ensure the probe had been removed. The 
membrane could then re-probed using a different probe as previously described 
in section 2.4. 
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2.5 Species Identification 
In order to confirm that the parasites used in this study were Leishmania 
mexicana, a simple PCR based approach was used (Schonian, G et al. 2003). A 
repeat region from the 18S ribosomal locus was amplified by PCR using 
oligonucleotides MB95 and MB96, and purified using the QIAquick® PCR 
Purification Kit (Qiagen, Crawley, UK). The eluted DNA was digested with HaeIII 
(Promega, Southampton, UK) and the products fractionated on 2% LE Agarose 
(NuSieve) + 1% regular agarose gel (Invitrogen, Paisley, Scotland) in 0.5x TAE. 
The gel was stained in a 100 ml 1x TAE with ethidium bromide (Sigma-Aldrich, 
Poole, UK) at a final concentration of 0.2 µg / ml. The restriction digest profiles 
were compared to those of known standards, thus enabling identification of the 
species. 
2.6 Transfection of Leishmania promastigotes 
2.6.1 Preparation of DNA 
Plasmid DNA was prepared and quantified as previously described (section 
2.3.6). A total of 50 µg of plasmid DNA was digested overnight with the 
appropriate restriction endonuclease enzymes. The DNA was then fractionated 
by electrophoresis and purified as previously described (section 2.3.4). A total of 
10 µg was required for each transfection event. 
2.6.2 Transfection and cloning 
L. mexicana promastigotes were transfected using the Amaxa system (Amaxa 
AG, Köln, Germany). Approximately 3 mL of a culture in the stationary phase of 
growth were pelleted at 1,250 g, and resuspended in the Human T-cell 
transfection buffer as described in the manufacturer’s instructions. 
Approximately 10 µg of DNA was added to this solution, and the mixture 
electroporated using program U-033. The electroporated cells were added to 10 
ml of pre-warmed HOMEM media, immediately split into 2 flasks to generate 
clones derived from independent transfection events, and incubated at 25 °C 
overnight in the absence of antibiotic selection. 
The following day, 4 ml of cell suspension is added to 20 ml of HOMEM 
supplemented with the appropriate antibiotic at 50 µg/ml to select parasites 
expressing the drug resistance marker. This was followed by two 12-fold serial 
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dilutions, all of which were plated out in 96-well plates at 200 µl per well to 
select clones. Plates were incubated at 25°C for three to four weeks; clonal cell 
lines were then analysed for correct integration of the DNA cassette. 
For Leishmania promastigotes expressing ectopic copies of a gene, the 
appropriate antibiotic was added to the medium 24 hours after transfection. 
These promastigote populations were maintained in the presence of antibiotic to 
prevent loss of the ectopic plasmid. 
2.7 Alamar Blue Assay 
The alamarBlue® assay (Raz, B et al. 1997) was used to determine the EC50 
values for a variety of trypanocidal and leishmaniacidal compounds. Briefly, 100 
µl of medium was added to each well in a 96-well plate. To generate serial 
dilutions of a drug, 100 µl was added to the first column, carefully mixed by 
pipetting, and transferred to the next column. This was repeated across the row, 
with the last column remaining drug free. Leishmania promastigotes at a 
concentration of 1 x 106 cells per ml were added each well, and incubated at 
25ºC for 72 hours, at which point 20 µl of resazurin (0.049 mM) was added to 
each well, and incubated for a further 24 hours. The plates were read using 
fluorometer (emission 530, excitation 595) (FLUOstar Optima, BMG Labtech). 
The fluorescence values could be plotted using GraphPad Prism5 to determine 
the EC50 values and the 95 % confidence interval values. 
2.8 Proteomic Analysis 
2.8.1 Protein Preparation and Precipitation 
The density of L. mexicana promastigotes in the mid-late log phase was 
determined as described in section 2.1.3. Approximately 1 x 108 cells were 
harvested and washed twice in 1x PBS, and then pelleted at 1,250 g for ten 
minutes. The pellet was then resuspended by vigorous pipetting in 1 ml of ice 
cold lysis buffer (Appendix 7.3.1) supplemented with 10 µg/ml DNase, 5 mM 
MgCl2, and a protease inhibitor cocktail. The cells were lysed by sonication (1-2 
seconds probe sonication followed by one minute on ice for three repetitions). 
The cell lysates were then incubated at room temperature for ten minutes, with 
gentle mixing, before being centrifuged at 16,000 g for 10 minutes to remove 
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the insoluble material. The supernatant was recovered and stored at -20°C for 
further analysis. 
The protein samples were then added to 4x sample volume of -20°C acetone, 
vortexed, and incubated overnight at -20°C. Samples were centrifuged at 16,000 
g for 10 minutes, and the pellets washed in 80 % acetone at -20°C. Samples were 
again centrifuged at 16,000 g for 10 minutes and the supernatant was discarded. 
The pellet was air dried for 5 minutes at room temperature, before being re-
suspended in lysis buffer (Appendix 7.3.1) containing a protease inhibitor 
cocktail (Appendix 7.3.2). Complete re-suspension involved vortexing, and 
vigorous mixing. The samples were centrifuged at 16,000 g for 10 minutes to 
remove any insoluble material and the supernatant was recovered and stored at 
-20°C. 
2.8.2 Bradford Assay 
The Bradford Assay was used to determine protein concentration. Bradford 
Reagent was diluted 5-fold in distilled water, filtered and stored at 4°C. A series 
of BSA (Promega, Southampton, UK) standards were prepared; the linear range 
of the assay is between X µg/ml and Y µg/ml. For the unknown protein sample, 
10 µl was mixed with 790 µl dH2O and 200 µl diluted Bradford Reagent. The 
protein samples were incubated for 30 minutes, and absorbance at OD595 was 
measured using a spectrophotometer. The absorbance values of the protein 
standards were plotted on a scatter graph using Microsoft Excel; unknown 
protein samples could be determined using the equation: y = mx + c. The protein 
concentration of the wild type and resistance samples were adjusted to 5 
mg/ml. 
2.8.3 Cyanine Dye Labelling 
Three protein samples are labelled with cyanine dyes at an alkaline pH; these 
samples are condition 1, condition 2, and a pooled standard. The pooled 
standard has equal quantities of protein from condition 1 and condition 2. 50 µg 
of each protein sample in a 10 µl volume is mixed with 400 pmol CyDye and 
incubated on ice in the dark for 30 minutes. The labelling reaction is stopped by 
the addition of 1 µl of 10 mM lysine, and incubated for a further ten minutes. 
Labelled samples can be stored at -80°C. 
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2.8.4 DiGE 
The cyanine labelled protein samples were mixed together and made up to 460 
µl with DiGE Rehydration Buffer (Appendix 7.3.3). This solution was then added 
to the Iso-Electric Focusing (IEF) ceramic tray, and an IEF strip (4-7) was laid gel 
side down, covered with 1 ml of immersion oil, and left overnight at conditions 
stated in Table 2-3. 
Table 2-3. Iso-Electric Focusing conditions. 
 
 
The IEF strips were removed from the ceramic dish with care, and washed in 10 
ml DiGE Equilibration Buffer 1 for 15 minutes (Appendix 7.3.4), 10 ml DiGE 
Equilibration Buffer 2 for 15 minutes (Appendix 7.3.5), and then briefly with 1x 
SDS running buffer, before being placed at the top of the large SDS gel. Hot 
agarose was used to hold the IEF strip in place. 
The proteins were separated overnight at 120 volts, with 1x SDS running buffer 
in the bottom chamber, and 2x SDS running buffer in the top chamber. 
Electrophoresis was stopped around one hour after the bromophenol blue dye 
had reached the bottom of the gel. Gels were scanned using the typhoon 
scanner, then fixed for two hours in DiGE fixing solution (Appendix 7.3.6). 
2.8.5 Colloidal Coomassie Staining 
Colloidal Coomassie blue was initially used to stain the protein gels. Colloidal 
Coomassie dye stock was prepared as follows; 50 g Ammonium sulphate, 6ml 85% 
phosphoric acid, dH2O to 500 ml, 10 ml Coomassie stock (5% Coomassie Brilliant 
Blue G-250 in dH2O). Initially, the gel was fixed for one hour (40% ethanol, 10% 
acetic acid), washed twice with dH2O for 10 minutes, and stained overnight in 
four parts Colloidal Coomassie dye stock to one part methanol. The staining step 
could be extended to improve sensitivity. 
Step Voltage (V) Time (hrs) Description
1 30 10 step and hold
2 300 2 step and hold
3 600 2 gradient
4 1000 2 gradient
5 8000 3 gradient
6 8000 8.5 step and hold
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2.8.6 SYPRO Orange Staining 
SYPRO® Orange was used as an alternative to Colloidal Coomassie stain due to 
increased sensitivity. Gels are fixed for a period of 1-2 hours in 7% acetic acid 
and 10% methanol. The gel was then stained in freshly prepared Sypro Orange 
Protein Gel Stain (Sigma-Aldrich, Poole, UK) (diluted 1:10,000) in 7% acetic acid 
and immediately scanned on Typhoon using the green laser (emission 580nm). 
2.8.7 Spot Picking and protein identification 
The gel images generated by the Typhoon scanner were processed by the 
DeCyder software, version 6 (GE Healthcare) to generate a pick list. To obtain 
peptide fragments from the gel, it was necessary to perform an in-gel trypsin 
digest. The desired gel spots were cut from the gel and initially washed in 100 
mM ammonium bicarbonate whilst shaking at room temperature for 1 hour, 
followed by a second wash step of 50% acetonitrile/100 mM ammonium 
bicarbonate. The proteins were then reduced by treatment with 3 mM DTT in 
100 mM ammonium bicarbonate at 60°C for 30 minutes. This was followed by 
alkylation step, involving treatment with 10 mM iodoacetamide at room 
temperature in the dark for 30 minutes. The gel pieces were washed with 50% 
acetonitrile/100 mM ammonium bicarbonate whilst shaking at room temperature 
for 1 hour, before dehydration with 100 µl acetonitrile at room temperature for 
10 minutes. Samples were then dried to completion using a speed vac, and 
rehydrated in an appropriate volume of trypsin (2 mg/ml in 25 mM ammonium 
bicarbonate). Digestion was performed overnight at 37°C. The supernatant was 
recovered, and the gel pieces washed with 50% acetonitrile for 10 minutes. This 
wash was pooled with supernatant initially recovered, and the sample dried to 
completion. The tryptic peptide fragments were solubilised in 0.5% formic acid, 
and fractionated on a nanoflow HPLC system (Dionex, Camberley, UK), before 
being analysed by ESI mass spectrometry on a Q-STAR® Pulsar I hybrid MS/MS 
System. Separation of peptides was achieved using a Pepmap C18 reversed phase 
column (Dionex, Camberley, UK), using a 5 – 85% acetonitrile gradient (in 0.5% 
v/v formic acid), over 45 minutes, with a flow rate was 0.2 µl / min. The mass 
spectrometric analysis involved a 3 second survey MS scan, followed by MS/MS 
analyses on the most abundant peptides (3 second per peak) in Information 
Dependent Acquisition (IDA) mode, choosing 2+ to 4+ ions above the threshold of 
30 counts, with dynamic exclusion for 120 seconds. The Applied Biosystems 
Analyst QS (v1.1.) software and the automated Matrix Science Mascot Daemon 
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server (v2.1.06) were used to analyse data generated using the Q-STAR® Pulsar I 
hybrid mass spectrometer. The Mascot search engine4 was used to assign 
probability based MOWSE scores to identify potential Leishmania protein 
matches. A tolerance of 1.2 Da was used for MS analysis, whereas 0.4 Da was 
used for MS/MS. Variable methionine oxidation was allowed in searches, and the 
carbanidomethylation of cysteines was selected as a fixed modification. 
2.9 Metabolomics 
2.9.1 Determining Glucose Concentration 
The levels of glucose present in the medium were measured over a 90 hour 
period. Leishmania promastigotes were counted, and approximately 5 x107 cells 
were pelleted and resuspended in 5 ml fresh medium. The promastigotes were 
incubated at 25°C, with samples taken at 0 hours (T0), 30 hours (T30), and 90 
hours (T90). An accurate cell count was obtained in triplicate, and a 500 µl 
aliquot was centrifuged at 1500 g for 10 minutes. The supernatant was 
recovered and stored at -20°C. 
Quantification of glucose concentration was determined using the Glucose 
Oxidase (GO) assay kit (Sigma-Aldrich, Poole, UK) according to the 
manufacturer’s instructions. 
The assay is accurate at determining between 20 and 80 µg glucose/ml. The 
concentration of glucose in HOMEM is approximately 15 mM; therefore 30 µl of 
HOMEM would contain 80 µg glucose. Therefore, 30 µl of sample would contain 
the maximum quantity of glucose in the present in the supernatant. As a control, 
HOMEM with no cells was used. 
The sample was diluted in a total volume of 1 ml ddH2O, and the reaction 
started by adding 2 ml of Assay reagent. The reaction was allowed to occur for 
30 minutes, before being stopped by the addition of 2 ml 12 N H2SO4. 
Absorbance at 540 nm was recorded, and the quantity of glucose present in each 
sample was derived from the glucose standards. 
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2.9.2 Preparation of metabolite extracts for FT-MS analysis 
Trypanosoma brucei procyclic form (PCF) strain 427 were cultivated in SDM80 as 
described in section 2.1.2. To generate a glucose-rich environment, the SDM80 
was supplemented with 10 mM D-glucose, and 0.1 mM proline. A glucose 
deficient medium was produced by supplementing SDM80 with 10 mM L-proline, 
and 0.1 mM D-glucose. 
Cells were cultured in 175 cm2 flasks (Corning®) at a volume of 100 ml per flask, 
where they typically reached densities of between 1 x 106 cells/ml (mid-log 
phase) and 1 x 107 cells/ml (late-log phase). The cells were pooled and then 
pelleted at 1,250 g for 10 minutes at 4°C. The low temperature would slow the 
rate of metabolism, minimising the degradation of intermediate metabolites.  
The cell pellet was re-suspended in 1 ml of serum free glucose-rich SDM80 or 
serum free glucose deficient SDM80, and kept of ice whilst an accurate cell 
count was determined (described in section 2.1.3). The volume was adjusted to 
reflect a final concentration of 1 x 109 cells/ml; and the cells were incubated at 
28°C for 30 minutes to allow steady state metabolism to re-establish after 
centrifugation. 
To obtain total metabolite extracts (both extracellular and intracellular), 0.2 mL 
aliquots of concentrated cell culture were applied into 0.8 mL 100% hot ethanol 
and incubated at 80°C for 2 minutes to lyse the cells and quench metabolism. 
The lysate chilled on ice for five minutes, briefly vortexed, and then centrifuged 
at 16,000 g for 2 minutes to remove any insoluble material. The supernatant was 
recovered, flash frozen in liquid nitrogen, and stored at -80°C prior to analysis. 
To obtain the extracellular metabolite extracts, 0.2 mL aliquots of concentrated 
cell culture were centrifuged at 4°C for 5 minutes to separate the cells and 
spent media. The supernatant was re-suspended in 0.8 mL 100% hot ethanol and 
incubated at 80°C. The cell pellet, containing the intracellular metabolites, was 
re-suspended in 1 mL 80% hot ethanol and incubated at 80°C. Cell lysates were 
processed as previously described for obtaining the total metabolites. 
2.9.3 Liquid Chromatography Mass Spectrometry 
Liquid Chromatography-Mass Spectrometry (LC-MS) data were acquired with a 
ZIC-HILIC column (5mm, 150 x 4.6mm; HiChrom, Reading, UK) coupled to a 
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Finnigan LTQ Orbitrap instrument (Thermo Fisher, Hemel Hempstead, UK). The 
analysis was performed using both positive and negative ionisation centroid 
modes of detection. Parameters included a mass scanning range of 50–1200 m/z, 
25,000 resolution, spray voltages +4.5 kV and -2.6 kV, capillary temperature 
200°C, the sheath gas flow rates 30 units, and the auxiliary gas flow rates 10 
units (Kamleh, A et al. 2008). The apparatus was operated by Muhammed Anas 
Kamleh at the University of Strathclyde.  
The LC/MS system (controlled by Xcalibur version 2.0, Thermo Fisher 
Corporation) was run in binary gradient mode. Solvent A was 0.1% v/v formic 
acid/water and solvent B was acetonitrile containing 0.1% v/v formic acid; the 
flow rate was 0.3 mL/min. A ZIC-HILIC column (5mm, 150 x 4.6mm; HiChrom, 
Reading, UK) was used for all analyses. The gradient was as follows: 80% B (0 
min) to 60% B at 8 min to 60% B at 24 min to 80% B at 32 min.  
2.9.4 Metabolomic data processing 
Initially, raw data files were supplied as Microsoft Excel files containing the m/z 
ratios of the 65,000 peaks of greatest intensity. This data was subsequently 
analysed using MetaNetter, a plug-in developed by Fabien Jourdan (INRA 
UMR1331, Toulouse, France), in an attempt to identify biochemical pathways. 
Alternatively, each raw data file was converted to mzXML using msconvert, and 
the metabolite signal peaks eluted from LC-MS apparatus were isolated, 
identified, and quanitated using the mzMatch software developed by Richard 
Scheltema (Max Planck Institute for Biochemistry, München, Germany) 
(Scheltema, RA et al. 2008; Scheltema, RA et al. 2011). The mzMatch software 
features a RSD filter which can be used to filter the data, thus reducing noise 
and non-reproducible peaks. The XML files contained a maximum of 460,000 
individual mass measurements in 800 scans, were converted to a human 
readable tab-delimited text file which could be interpreted using Microsoft Excel 
or Microsoft Access. 
2.9.5 Database development 
A significant proportion of this thesis focused on improving metabolomic data 
analysis methods. Initially, metabolite information was stored using Microsoft 
Excel, although as the quantity and complexity of data increased, it was 
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necessary to transfer these tables to Microsoft Access, which has a greater 
capacity to deal with large volumes of data. 
Microsoft Access uses SQL commands and macros to sort and query the data. 
There was no prior SQL programming knowledge involved in the development of 
the database; consequently, all information was obtained from Microsoft Office 
Access 2003 QuickSteps (John Cronan, Virginia Andersen, and Brenda Bryant 
Andersen), and an ‘Introduction to Access’ course run by IT Services, University 
of Glasgow. A significant extent of the process was trial and error, although 
advice was provided by Richard Scheltema (Max Planck Institute for 
Biochemistry, München, Germany), Richard Orton (School of Veterinary 
Medicine, University of Glasgow), and Fabien Jourdan (INRA UMR1331, Toulouse, 
France).
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3 Developing a database to analyse Kinetoplastid 
metabolomic experiments
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3.1 Introduction 
Technological advances over the last 20 years have propelled biological sciences 
into the genomics era. By the end of 2011, complete genome sequences existed 
for 3080 organisms (Kyrpides, NC 1999)5, and with the introduction of next 
generation sequencing this looks set to rise exponentially. However, there is a 
limit to what one can infer from the genetic sequence of an organism. The study 
of mRNA (transcriptomics) and proteins (proteomics) have become established 
over the last decade, and in turn, have generated a plethora of information 
about gene and protein regulation. Even then, these techniques focus on 
quantifying transcript or protein levels in a specific system, and ultimately 
confer no information on the activity of proteins within a system. 
FT-MS technology enables the mass measurement of low molecular weight 
compounds from a complex mixture, to sub PPM accuracies. The identification of 
metabolites, and their relative intensities, can provide a ‘snap shot’ of the 
metabolome that reflects the physiological state of a cell at a given time point. 
‘Omic’ technologies, by their global nature, generate large quantities of data, 
and metabolomics is no exception to this. The datasets are extremely data rich, 
and information poor, presenting a problem in the identification of metabolites. 
A raw data file obtained from the LTQ-Orbitrap yields approximately half a 
million masses. The greatest challenge is to identify the masses which are 
representative of genuine compounds, whilst eliminating those which are 
background noise. It is of course advantageous to know which metabolites are 
expected to change between two biological conditions, provided it is a 
manageable number. However, the global metabolomics approach provides an 
opportunity to investigate biological systems with no preconception as to which 
metabolites are fluctuating, thus reducing experimental bias. 
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Raw data Peak picking Filtering and processing I.D. Biological system
 
Figure 3-1. Metabolics pipeline.  
The main stages of data acquisition and data analysis for a metabolomic experiment. Raw data is 
acquired by mass spectrometry. Peak picking and the filtering and processing steps are performed 
by software such as Xcalibur or Sieve, Thermo Fisher Scientific. Identification of metabolites and 
their context within a biological system can be performed by MassTrix (Suhre, K and Schmitt-
Kopplin, P 2008), although alternative software is now available (Scheltema, RA et al. 2011). 
The metabolomic pipeline illustrates the main stages of data acquisition and 
data analysis (Figure 3-1). The LTQ-Orbitrap, or similar FT-MS instrument, is 
responsible for acquiring the raw data. It is common to use a chromatographic 
technique, such as hydrophilic interaction chromatography (HILIC), to separate 
metabolites prior to mass measurements by the LTQ-Orbitrap (Kamleh, A et al. 
2008). The HILIC approach is excellent in the separation of polar compounds, 
whereas lipophilic compounds will elute rapidly from the column (Kamleh, A et 
al. 2008). Altering the chromatographic separation technique or conditions may 
therefore affect the downstream data analysis. 
Software available from Thermo Fisher Scientific is capable of ‘peak picking’ and 
‘filtering and processing’; however, there are limitations to these software. The 
Xcalibur (version 2.0) software supplied with the LTQ-Orbitrap (Thermo Fisher 
Scientific) is responsible for peak picking. The user can explore a mass spectrum 
generated from a single sample, and derive a list of potential formulae for any 
measured mass. Even at a precision of 1 PPM it is not always possible to assign 
unambiguously a formula to an experimental mass given the number of possible 
elements (t'Kindt, R et al. 2010); although more possible if the biological 
context is taken into consideration (Suhre, K and Schmitt-Kopplin, P 2008). The 
Sieve software, also provided by Thermo Fisher Scientific, is a reasonably 
powerful tool that allows filtering and processing of the data. Sieve uses 
principle component analysis to distinguish which masses are statistically 
different in abundance and peak height between different samples; although 
this does ignore signals of low intensity, and focus on the most abundant signals. 
To date, the commercially available software does not focus on identifying 
metabolites in these data files, or attempt to put this data in a biological 
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context. Therefore, it is imperative that the metabolomics community develop 
computer software tools to analyse these datasets. 
MZMatch (Scheltema, RA et al. 2011) and MassTRIX (Suhre, K and Schmitt-
Kopplin, P 2008) are two approaches developed by research groups in the 
metabolomics community in the last few years. Whilst both approaches deal 
with the identification of experimental masses, MZMatch is capable of filtering 
and processing raw data, whereas MassTRIX provides a biological context for the 
identified metabolites. 
The MZMatch software, developed by Richard Scheltema (Max Planck Institute 
for Biochemistry, München, Germany),is capable of extracting and automatically 
aligning data from multiple measurements (Scheltema, RA et al. 2011), a task 
which the Xcalibur is unable to perform. This approach reduces the background 
noise and compiles a manageable list of reproducible masses with valid 
chromatograms. MZMatch compound identifications are provided through 
communication with the ChemSpider server, an online search engine which scans 
multiple biological compound databases that include both KEGG and HMDB. The 
retention time can be used to make an approximate distinction between 
isomeric compounds, although an orthogonal approach is required for a 
definitive identification. Whilst this is software is extremely powerful in the 
processing of raw data, there are deficiencies in the graphical representation of 
the results in a biological context. 
MassTRIX provides graphical representation of FT-MS data using the KEGG 
website (Suhre, K and Schmitt-Kopplin, P 2008). A peak list can be uploaded to 
the MassTRIX web server, and mapped against the KEGG metabolic networks of a 
chosen organism to provide metabolite identification and a biological context. 
There are two main concerns with this approach; firstly, the raw FT-MS data file 
requires processing prior to analysis by MassTRIX, and secondly, the analysis is 
limited to compounds only present in the KEGG database. Details of the 
MassTRIX web server were published after work in this chapter had started; 
therefore, there are notable similarities between the two approaches, however 
there are subtle differences. 
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3.2 Experimental approach 
Due to the change in environmental conditions that PCF and BSF trypanosomes 
experience during their lifecycle, energy metabolism has been extensively 
studied (van Weelden, SW et al. 2003; Besteiro, S et al. 2005; van Weelden, SW 
et al. 2005; Bringaud, F et al. 2006), however our knowledge is by no means 
complete. As procyclic trypanosomes are able to metabolise both D-glucose and 
L-proline, this provides a suitable model to study metabolic adaptations in 
response to changes in the principal carbon source. Whilst this particular 
experimental approach may not address metabolic changes in the human 
infective form or a clinically relevant species, the global metabolomics approach 
has the capability of detecting changes to the metabolome that are not 
predicted to occur. Traditionally, trypanosomatid enzymatic reactions have been 
identified experimentally using biochemical assays. However, in recent years, 
genome projects have identification of enzymes through inference from 
orthologous genes. 
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3.3 Aim 
The initial aim of the experiments in this chapter was to take a global 
metabolomics approach by extracting metabolites from procyclic trypanosomes, 
using liquid chromatography coupled to an ultra-high resolution LTQ-Orbitrap 
mass spectrometer, and confirm metabolic changes within central carbon 
metabolism that had been previously characterised. However, it became quickly 
apparent that the tools to analyse the data were insufficient to handle complex 
datasets. Consequently, the focus of the project shifted from trying to interpret 
this particular dataset, to constructing a database to address the data analysis 
issues encountered by the metabolomics community with the following aims: 
1. Produce a simple list of metabolites associated with trypanosomatids. Journal 
articles, biochemistry textbooks and online resources such as KEGG, provide an 
appropriate foundation for metabolites known to occur in these organisms, and 
are therefore expected to be present in datasets. 
2. Identify a suitable database program and construct a simple relational 
database with extensive details on metabolites. Whilst a simple list of 
metabolites in a Microsoft Excel table is a useful reference, it is necessary to 
associate metabolites with specific biochemical pathways and biochemical 
reactions. Furthermore, a database system provides an organised method of 
storing and relating data 
3. Develop a query to allow a user to analyse FT-MS derived experimental 
datasets. The raw data acquired during a metabolomic experiment is data rich 
and information poor. The current tools, such as Xcalibur (Thermo Fisher 
Scientific), support a targeted metabolomics approach where there are few 
metabolites of interest. However, if a global metabolomics approach is desired, 
there are insufficient tools to identify which metabolites are present in any 
given sample, and how those metabolites relate to a biological system. 
4. Improve the efficiency of searching for metabolites. Whilst the search engine 
on the KEGG website allows a user to search for metabolites by name, or 
synonym, it does not for instance, provide the ability to search for metabolite if 
only the molecular formula or exact mass are known. 
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3.4 Simple Metabolite Table 
There are many chemical compound and metabolite databases available online 
including KEGG (Kanehisa, M and Goto, S 2000)6 and LeishCyc 7, which provide a 
range of metabolite data for trypanosomes and Leishmania. Using this 
information, with some editing based on knowledge of the scientific literature, a 
table of trypanosomatid specific metabolites was constructed. This table 
included information such as metabolite names, molecular formula, exact mass, 
links to original source, and what metabolic pathways the metabolite was 
involved in8. 
Composing a table of metabolites associated with trypanosomatids allows the 
user to browse for metabolites of interest, and search for the respective mass or 
formula in the mass chromatograms using the Xcalibur software. Alternatively, a 
list of the 65,000 most intense peaks could be imported into Microsoft Excel, and 
the ‘find’ function could be used to search for a mass. However, these two 
methods rely on a hypothesis as to which metabolites or pathways are likely to 
change. Furthermore, the masses or formulae of the metabolites of interest can 
only be searched on an individual basis, which is often time consuming, and 
consequently impractical. Therefore, the ability to automatically search a large 
number of masses against a list of experimentally derived masses would greatly 
enhance the understanding of analysis of metabolomic datasets. 
Finally, the main advantage of an untargeted metabolomics approach to study 
global metabolism is that no prior hypothesis is required, as the technique has 
the potential to resolve the entire metabolome. It is of no real benefit to 
restrict the analysis to any one particular organism if it is possible to search a 
larger number of metabolites. 
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3.4.1.1 Mono-Isotopic Mass 
The exact mass, or mono-isotopic mass (MIM), of a compound is derived from the 
sum of the exact atomic mass of the most commonly occurring isotope. This 
differs from the average mass which takes into account the mass and abundance 
of all significant naturally occurring isotopes. For example, the exact mass of 
carbon is 12 amu, whereas the average mass of carbon is 12.0107 amu, as this 
takes into account the mass and abundance of both 12C and 13C (Table 3-1). As 
the metabolite data was acquired from different sources, the MIM for each 
metabolite had to be standardised to ensure consistency. Whilst database 
websites provide an exact mass, they do not provide a reference to the method 
used to calculate it. 
Table 3-1. Naturally occurring isotopes of carbon. 
Isotope Atomic Mass Unit Abundance
12C 12 0.9893
13C 13.00335484 0.0107  
The exact mass, or isotope atomic mass unit, and abundances of the significant naturally occurring 
isotopes of carbon 
An online exact mass calculator9 derives the MIM for any compound or 
metabolite if the user provides the molecular mass. The process is quite 
laborious as each molecular formula had to be entered on an individual basis. 
One method to improve this would be to have a function capable of doing this in 
Microsoft Excel; unfortunately, no Add-In capable of calculating the MIM was 
freely available. Consequently, a Microsoft Excel Add-In was developed in 
collaboration with Richard Orton (School of Veterinary Medicine, University of 
Glasgow). The exact mass of each individual element was obtained via the 
source code from the exact mass calculator10 and, using Microsoft Visual Basic 
Application, a script to calculate the MIM of a molecular formula from the sum 
of the individual elements was written.  The MIM Add-In described here provides 
an efficient method of calculating the MIM using Microsoft Excel for any number 
of metabolites in a table. 
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3.5 A suitable database program 
The initial step for creating a database was to identify a suitable database 
program from the several that are available; these include specialist programs 
such as Oracle or MySQL, or more simple applications such as Microsoft Access. 
Microsoft Access is a relational database management system with a graphical 
user interface. A database file is created using several different types of 
database objects that include tables, queries, macros and forms. Importantly, 
all information is managed from this single file and consequently, is easy to keep 
track of. 
In any database system the data are stored in tables; this is known as the back 
end of the database. A table is a collection of data arranged in rows and 
columns. Each column, or field, contains information about a specific type of 
information, such as the molecular formula of a metabolite; whereas each row, 
or record, contains information about a specific metabolite, such as metabolite 
name, molecular formula, and exact mass. A database that contains data in one 
table is known as a flat file system, whereas a database that contains more than 
one table is known as a relational database system. To develop a relational 
database, it is necessary to establish links between tables using common fields. 
Considered as the front end of a database, queries are used to view, modify, and 
analyse data in a number of different ways. Queries are constructed using 
Structured Query Language (SQL), although Access features a ‘query designer’ 
which is simple to use, and thus negates prior knowledge and understanding of 
SQL. When creating a query using this method, Access automatically generates 
the SQL statement in the background, which can then be viewed or edited in the 
‘SQL view’. Microsoft Access supports numerous different types of queries, 
although not all can created using the ‘query designer’ and have to be created 
directly in the ‘SQL view’. 
A select query can be are used to extract data from one or more tables, creating 
a dynaset. This information is dynamically linked back to the original data, and 
will therefore change if the original data is altered in any way. Parameters can 
be introduced into any query to request specific data; for example, to display 
any metabolites which have a molecular formula of ‘C6H12O6’. 
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There are a number of action queries that can be used to change data in specific 
tables. An update query can be used to make global changes to multiple records; 
for example, to add 22.98932 to every exact mass value to reflect the exact 
mass of a metabolite as a sodium adduct. It also is possible to delete specific 
records; for example, it is accepted that the Orbitrap cannot accurately 
measure the mass of ions less than 80 Da. Therefore, a delete query could be 
used to delete any metabolites which have a mono-isotopic mass of less than 80 
Da. An append query can be used to add a group of records from one table to 
another; for example, a table of recently discovered metabolites could be 
appended to an existing metabolite table. A final action query allows the user to 
make a new table from all or part of the data in one or more tables; this is 
similar to the select query, however instead a producing a dynaset, a new table 
is created in which the data is not dynamically linked to the original data. Whilst 
action queries as useful, they should be used cautiously, as the data in tables 
can be physically altered. 
Macroinstructions, or simply macros, can be used to perform a series of 
commands in one step, thus reducing the time spent executing each command 
individually. These are usually limited to simple commands such as opening or 
closing a table, or displaying a message box. 
An Access form provides a graphical and interactive front end to a database. A 
form is a database object and can be used to enter or view data, operate as a 
custom dialog box, or function as a switchboard to open other forms in the 
database.  
A form can be linked to one or more tables in the database, in which the form’s 
record source refers to the any fields in the underlying table(s). Any tabular data 
is viewed in the same style as a traditional record card. It is also possible to 
create a new record and enter the data on the form, which is then automatically 
added to original table(s). For a form to function as a custom dialog box, it must 
accept user input and carry out an action based on that input. Command buttons 
can be used on a form to activate pre-defined events such as a query or a 
macro. For example, a user can enter ‘C6H1206’ in a text box on a form, and use 
a command button to activate a query to select all metabolites with that 
specific molecular formula. These commands are controlled by the Visual Basic 
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(VB) code, an event-driven programming language. Through modification of this 
code, a single command button can be programmed to activate multiple queries 
and macros in a specific order, creating a one-step event-driven procedure. 
There are several advantages to using Access as an alternative to MySQL or 
Oracle. As Access is part of Microsoft Office, it is available on most desktop 
computers and is relatively user-friendly; any tabular data can be easily 
imported from Microsoft Excel or text files; and finally, whilst knowledge of both 
SQL and VB is useful, especially for more complex commands, it is not essential 
for the creation of a simple database. However, there are some disadvantages of 
using Access instead of any specialist database programs. A single database file 
with large volumes of data requires a lot of RAM and processing power to run 
queries efficiently; therefore, a database is often split into the back end and the 
front end and stored on web servers. This approach is used by Suhre and 
Schmitt-Koplin in the development of MassTRIX, in which the front end web 
server communicates with the back end data stored on the KEGG API directory 
(Suhre, K and Schmitt-Kopplin, P 2008). The ability for other applications to 
communicate with the back end of a database is extremely useful for academic 
projects which ultimately benefit the scientific community. 
Utilising the various features and functions of Access allows the dynamic 
development of a relational database file for the interrogation of experimental 
datasets and improved searching of metabolites. 
The simple metabolite table described in section 3.4 only contained around one 
thousand metabolites, most of which are found in trypanosomatids, compared 
with approximately twelve thousand metabolites, some of which not known to 
occur in trypanosomatid biochemistry, in the KEGG database. It was therefore 
advantageous to retrieve the metabolite data from the KEGG website to provide 
a comprehensive and structured back end to the database. 
3.5.1 Creating a flat file system 
KEGG provides detailed information on metabolites, enzymes, and metabolic 
pathways for a number of organisms. Furthermore, the KEGG website provides a 
user friendly GUI allowing the user to navigate between metabolic pathways, 
and search for metabolites and enzymes of interest. 
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All the KEGG information is stored in a tabular form in the FTP directory, and 
can be viewed at the following link11. This information can be extracted using a 
Java script and saved as text file, or simply copied and pasted into a text file. 
These text files can then be opened in Microsoft Excel, an appropriate program 
for editing and organising the information prior to using Microsoft Access. All 
Java scripts were written by Richard Scheltema (Max Planck Institute for 
Biochemistry, Munich, Germany). 
The following FTP directory link provides information on all the metabolites 
currently held within the KEGG database12. The information extracted from this 
directory included the metabolite name, molecular formula, exact mass, and the 
KEGG compound identifier – these attributes were identified as the most 
essential for the development of the database (Table 3-2). 
Table 3-2. Basic metabolite information extracted from KEGG 
Field Description
Metabolite The common name for the metabolite
MolecularFormula The chemical formula of the metabolite
CompCode The unique identifier for the metabolite
ExactMass The exact mass stated in KEGG  
 
The KEGG compound identifier, designated as the ‘CompCode’, is a unique value 
associated with each metabolite and is designated as the primary key. 
Furthermore, it is possible to generate a URL to the KEGG website using the 
CompCode as every metabolite in the KEGG database has its own web page. For 
example, trypanothione, a metabolite found in exclusively in trypanosomatids, 
has the following URL; http://www.genome.jp/dbget-
bin/www_bget?compound+C02090. The URL can be divided into two parts; a 
fixed section and a variable section. The fixed section 
‘http://www.genome.jp/dbget-bin/www_bget?compound+’ is the same 
regardless of the metabolite, whereas the variable section ‘C02090’ corresponds 
to the CompCode. Microsoft Excel has the ability to join the text strings of two 
or more cells using the ‘concatenate’ function. Therefore, we can generate the 
                                         
11
 ftp://ftp.genome.jp/pub/kegg/ 
12
 ftp://ftp.genome.jp/pub/kegg/ligand/compound/compound 
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URL to every metabolite in KEGG provided we know the CompCode. Similarly, 
there is also a webpage for an image of the structure of each metabolite, and a 
URL for this can be constructed using the same process. These URLs provide the 
user with a direct link from the metabolite table to KEGG. 
Table 3-3. Total KEGG Database 
Field Description Section
Metabolite The common name for the metabolite this section
MolecularFormula The chemical formula of the metabolite this section
CompCode The unique identifier for the metabolite this section
Exact_Mass_(MIM) Mono-Isotopic Mass of the metabolite 3.4.1.1.
KEGG_Link URL for the metabolite specific web page this section
Image_Link URL for the image of structure this section
InChI_ID IUPAC International Chemical Identifer 3.5.2.2.
Leishmania_major annotated in L. major 3.5.2.3.
Plasmodium_falciparum annotated in P. falciparum 3.5.2.3.
Trypanosoma_brucei annotated in T. brucei 3.5.2.3.
Trypanosoma_cruzi annotated in T. cruzi 3.5.2.3.
ALL_KEGG all metabolites in KEGG this section
Shortlist metabolites chosen by the user 3.7.5.
Measured_RT retention time added by the user 1.5.1.2.
 
A list of the fields present in the Total KEGG database, and the relevant section they are discussed 
in this chapter. 
As the method of calculating the KEGG exact mass values was not apparent, 
these were recalculated for each metabolite from the molecular formula using 
the MIM calculator (section 3.4.1.1). To ensure there were no major 
discrepancies, the difference between these two exact mass values was 
calculated. 
Extracting some basic information on metabolites from the KEGG FTP directory, 
and expanding this information using some simple Excel functions has created a 
table of metabolites that is representative of a diverse number of metabolic 
pathways and organisms. Unlike the simple metabolite table previously discussed 
(section 3.4), the information that is displayed in this table is correctly 
structured with a unique identifier, and can thus be used in the development of 
the back end of a relational database.  
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3.5.2 Creating a relational database 
Whilst the metabolite table (section 3.4) provides the user with basic 
information on metabolites, it lacks the detailed information on which 
organisms, metabolic pathways and reactions that the metabolites are involved 
in. To incorporate this information, the application must evolve from the flat 
file system containing one table, to a relational database system in which 
multiple tables are linked to one anther using a common entity. 
It was necessary to identify and retrieve the useful information from the KEGG 
FTP directory, and create distinct tables in Microsoft Excel which could then be 
imported into Microsoft Access. Furthermore, it was important to consider how 
the information in these tables would relate to one another, and identify 
suitable primary and foreign keys. 
3.5.2.1 Synonyms 
Some metabolites may have more than one name and therefore it was logical to 
include this information to improve the ability to search for metabolites. The 
KEGG FTP directory contains a table which lists synonyms (‘Name’) and their 
corresponding CompCode (‘Entry’)13; a Java script was then used to retrieve this 
information to create Table 3-4. 
Table 3-4. Synonyms – (metaSearch ‘Table_147’) 
Field Description
Metabolite_Synonym A given name for a metabolite
CompCode The unique identifier for the metabolite  
In this instance, the CompCode cannot act as the primary key as it can be 
present as a duplicate value; however, the CompCode does act as a foreign key 
as it refers to the primary key of the metabolite table (section 3.5.1). 
An example of a metabolite with numerous synonyms is trypanothione, which is 
also known as N1,N8-Bis(γ-L-glutamyl-L-cysteinyl-glycyl)spermidine; N1,N8-
Bis(glutathionyl)spermidine; TSH; or reduced trypanothione (Table 3-5). All of 
these names are correct, and should therefore be included in the database. 
                                         
13
 ftp://ftp.genome.jp/pub/kegg/ligand/compound/compound 
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Table 3-5. The synonyms for trypanothione listed in the KEGG database. 
CompCode Metabolite_Synonym
C02090 Trypanothione
C02090 N1,N8-Bis(γ-L-glutamyl-L-cysteinyl-glycyl)spermidine
C02090 N1,N8-Bis(glutathionyl)spermidine
C02090 TSH
C02090 Reduced trypanothione  
3.5.2.2 IUPAC International Chemical Identifier 
The IUPAC International Chemical Identifier, abbreviated to InChI, is a unique 
text string with multiple layers of information that may include the molecular 
formula, bond connectivity of atoms, stereochemistry, electronic charge, and 
isotope information14. Unlike the simplified molecular-input line-entry 
specification (SMILES) (Weininger, D 1988), every molecular structure has a 
unique InChI; an important attribute in database applications. Therefore, the 
InChI can be used to distinguish between isomeric compounds. Whilst the InChI is 
considered human readable, there are many computational algorithms available 
to convert the text string to the graphical representation of the compound. 
A list of KEGG compound ID’s and their respective InChI are stored on the KEGG 
FTP directory15; this information was extracted and imported into Microsoft 
Access (Table 3-6). To ensure that every metabolite in the total KEGG database 
table had an InChI, a query was used to update the ‘InChI_ID’ column using the 
‘CompCode’ as a common entity (section 3.5.1). 
Table 3-6. InChI (metaSearch ‘Table_112’) 
Field Description
InChI The IUPAC International Chemical Identifier
CompCode The unique identifier for the metabolite  
                                         
14
 http://www.iupac.org/inchi/index.html 
15
 ftp://ftp.genome.jp/pub/kegg/ligand/compound/compound.InChI 
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3.5.2.3 Metabolites specific for organisms 
One of the disadvantages for considering the entire KEGG metabolite database is 
that many of these metabolites are known not to be present in trypanosomatids. 
The KEGG FTP directory16 contains a list of KEGG compounds IDs for 1222 
organisms (129 eukaryotes, 1014 bacteria, and 79 archaea). Metabolite lists 
specific for Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, and 
Plasmodium falciparum were incorporated into Microsoft Access to provide the 
user with greater flexibility when analysing datasets. This approach is 
particularly useful as the database can be adapted to any organism of interest, 
provided it has been annotated in KEGG. As a column for each organism had 
been created in the total KEGG database (section 3.5.1), a query was used to 
update the value in these columns to ‘True’ if the metabolite was known to be 
present. Several simple queries were written to filter the metabolites based on 
organism; these can be selected using the appropriate command button (Figure 
3-2). 
 
Figure 3-2. Databases. 
The user can view metabolites from the Total KEGG database, or alternatively select one of the 
four organisms. 
                                         
16
 ftp://ftp.genome.jp/pub/kegg/pathway/organisms/ 
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3.5.2.4 Metabolites specific for reactions 
The ability to provide a link between the metabolites and biochemical reactions 
is extremely useful as it allows the user to select a metabolite and determine 
which biochemical reactions that metabolite is involved in.  
Information on biochemical reactions is available on the KEGG FTP directory17 
where ‘definition’ and ‘entry’ were identified as the essential attributes. The 
‘definition’ field contains a description of the reaction, and is thus a useful 
reference for the user. The ‘entry’ field contains a unique identifier for the 
reaction, denoted ‘KEGG_Reaction_ID’, and can be used to generate a URL to 
the KEGG website; this was performed in Microsoft Excel by the concatenation 
function as described in section 3.5.1. This table was imported into Microsoft 
Access and saved as ‘Table 142_KEGG_Reactions’ (Table 3-7).  
Table 3-7. KEGG biochemical reactions 
Field Description
KEGG_Reaction_ID The unique identifier for the reaction
Reaction_Name Description of the reaction
KEGG_Reaction_Hyperlink URL for the reaction specific web page
KEGG_Reaction_Image_Hyperlink URL for the image of reaction  
Whilst this table provides a description of the metabolites in the Reaction_Name 
field, it does not provide a list of the metabolites with any relevant attributes 
such as mass or molecular formula.  
However, the KEGG FTP directory contains a list of ‘KEGG_Reaction_IDs’ and 
‘CompCodes’18 which was copied and then imported into Microsoft Access. The 
resulting table was saved as ‘135_Reactions_CompCodes’ (Table 3-8). Duplicate 
values were permitted as one metabolite may be involved in many reactions, 
and one reaction must contain at least two metabolites. At a glance, this table 
contains no meaningful information; however is does act as an intermediate 
table providing a link between the metabolite and reaction tables.  
                                         
17
 ftp://ftp.genome.jp/pub/kegg/ligand/reaction/reaction 
18
 ftp://ftp.genome.jp/pub/kegg/ligand/reaction/reaction.lst 
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Table 3-8. KEGG biochemical reactions and metabolites 
Field Description
KEGG_Reaction_ID The unique identifier for the reaction
CompCode The unique identifier for the metabolite  
A significant improvement to the reaction information includes the introduction 
of EC numbers and linking them to the reaction information. Whilst this 
information is stored in the same location of the KEGG FTP directory, it is logical 
to separate the EC numbers from the reaction details to eliminate duplicate 
values. One enzyme may catalyse more than one reaction, and conversely, one 
reaction may be catalysed by more than one enzyme. Therefore, the most 
practical solution is to store the ‘KEGG_Reaction_ID’ and ‘EC numbers’ in a 
separate table, saved as ‘Table_136’, and allow duplicate values for both fields 
(Table 3-9). This information can be retrieved from the FTP directory19 using a 
Java script, or in this case, the table can be created manually to demonstrate 
the concept. 
Table 3-9. KEGG biochemical reactions and EC numbers 
Field Description
KEGG_Reaction_ID The unique identifier for the reaction
EC Enzyme Classification number  
The inclusion of EC numbers is meaningless, unless another table containing 
information on the enzyme names and EC numbers is introduced. The Expert 
Protein Analysis System (ExPASy) bioinformatic resource provides information on 
enzymes on the FTP site20, which can be accessed using a Java Script. 
Unfortunately the information on reactions and enzymes in metaSearch is 
incomplete due to time constraints. 
                                         
19
 ftp://ftp.genome.jp/pub/kegg/ligand/enzyme/enzyme 
20
 ftp://ftp.expasy.org/databases/enzyme/enzyme.dat 
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3.5.2.5 Metabolites specific for pathways 
Metabolic pathways are a convenient method of grouping together related 
metabolites. The metabolic pathways described in KEGG are one example of how 
metabolites may be grouped together. A list of pathway names and pathway IDs 
were obtained from the KEGG FTP directory. An additional field designated 
‘show’ was created retrospectively to allow certain pathways to be ignored as 
many KEGG pathways, such as ‘Insect Hormone Biosynthesis’, are not relevant to 
many biological systems (Table 3-10). 
Table 3-10. Pathway Names 
Field Description
Path_ID The unique identifier for the pathway
Pathway_Name The pathway name
Show can be used to toggle pathways on and off  
Also available from the KEGG FTP directory is a list of compound IDs and 
pathway IDs (Table 3-11); these can be used in an intermediate table to relate a 
metabolite to a metabolic pathway. Duplicate values may appear in both 
columns as there are many metabolites in one pathway, and any one metabolite 
may be present in more than one pathway. The ‘CC_hyperlink’ is a query 
generated attribute providing a hyperlink to the metabolite in the specific KEGG 
metabolic map. This is a concatenation of a fixed text string with the pathway 
code and compound ID to generate a URL. 
Table 3-11. Intermediate Compound-Pathway table 
Field Description
CompCode The unique identifier for the metabolite
Path_ID The unique identifier for the pathway
CC_Hyperlink hyperlink to a particular metabolite in a specific metabolic map  
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3.5.3 The database Schema 
The flat file system is a relatively simple method of storing specific information 
about metabolites such as molecular formulae and MIM. However, the 
introduction of the additional tables allows the development of a relational 
database system providing the ability to retrieve detailed information on each 
metabolite. 
For example, more detailed information on whether the metabolite is known to 
occur in biochemical reactions, metabolic pathways, or particular organisms can 
be linked table containing the basic metabolite information. Common fields in 
the various tables can be joined to one another, yielding a relational schema, as 
depicted in Figure 3-3. 
 
Figure 3-3. metaSearch relational schema. 
The schema illustrates the relationships between metabolites and higher order functional 
information including synonyms, biochemical reactions, associated enzymes, and the L. major 
gene accession number. 
The total KEGG database table was expanded with columns for InChI_ID, T. 
brucei, T. cruzi, P. falciparum, and L. major. A series of queries updated the 
information in these tables. 
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3.6 MetaSearch for analysis 
The most challenging aspect of this particular project is to extrapolate the 
relational database to enable a user to enter a list of experimental masses and 
to match these to the MIM of known metabolites. As this is a relational database, 
it is possible to retrieve the detailed information on these metabolites as 
described in section 3.5.2. The primary goal of metaSearch was the development 
of a simple program that allowed a user to compare a list of experimental 
masses derived from kinetoplastid metabolomic experiments with a list of 
masses from known metabolites. Whilst this is relatively straight forward to 
implement using an SQL statement, it was more challenging to make the process 
user friendly. Furthermore, metaSearch is a multi functional database file which 
allows the storage and analysis of metabolomic datasets. Additionally, it would 
be advantageous to be able to upload results directly into the database instead 
of pasting data into a table, potentially increasing the chances of a mistake. 
Two methods of analysis are described; the first involves selecting a particular 
dataset and finding out which potential metabolites are present, whereas the 
second focuses on finding a particular metabolite or mass irrespective of the 
experiment name. 
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3.6.1.1 Table of reference metabolites 
Ideally, the experimental masses are compared to the MIM’s of all the 
metabolites in the KEGG database; however, this requires substantial RAM and 
processing power. This problem was solved by creating a user defined 
intermediate table which would store the metabolites of interest (Table 3-12). It 
was necessary to include the MIM, molecular formula, CompCode, and the 
metabolite name in this table. As the purpose of this table is the temporary 
storage of data, which is at the discretion of the user, metabolite information 
can be selected by organism or metabolic pathway.  
Table 3-12. Information stored in the user defined ‘metabolite’ table 
Field Description
Exact_Mass_(MIM) Mono-Isotopic Mass of the metabolite
Formula The molecular formula of the metabolite
CompCode The unique identifier for the metabolite
Metabolite The metabolite name  
3.6.1.2  Table of experimental masses 
All the experimental data is stored in the masses table (Table 3-13). The 
important fields for demonstrating the analysis query are mass and experiment. 
The retention time and intensity can be obtained from the PeakML output and 
included in this table for future reference. Currently, PeakML does not provide a 
P-value, although the ability to perform a statistical test has been taken into 
consideration when writing the SQL statements. Each mass in this table is 
associated with an experiment name; therefore a simple SQL statement could 
retrieve all the experimental masses associated with a particular experiment. 
Table 3-13. Experimental masses (metaSearch ‘masses’) 
Field Description
MASS experimentally measured mass of the ion
retention_time time in which the ion elutes from the column
Intensity the measured intensity of the ion
PValue value for determining statistical significance
Experiment the name of the experiment  
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3.6.2 User friendly 
In Microsoft Access, the use of ‘queries’ and ‘forms’ provide a front end to the 
database; Queries allow the user to retrieve specific information from one or 
more tables, whereas forms greatly enhance the ability to generate an 
environment in which the user has both freedom to select the desired 
parameters and a controlled series of commands that can be followed. Command 
buttons can be implemented to allow the user to navigate between forms in a 
process similar to web pages. 
 
Figure 3-4. MetaSearch main switchboard. 
The main panel provides access to other forms and tables in the database through the use of 
command buttons and event procedures. The five options shown are as follows; databases, 
presents a list of tables which hold information of metabolites and proteins; input data (masses), 
opens a table to allow data to be uploaded to the software; analysing a dataset, allows the user to 
search their own data against metabolites from KEGG according to the desired parameters; 
search, allows the user to search the KEGG data for specific masses or metabolite names; quit, 
closure of the software. 
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3.6.3 Analysing a dataset  
As previously mentioned a simple SQL statement could retrieve all the masses 
associated with a particular experiment. The aim of this query was to take an 
experimentally measured mass, subtract or add ‘x’ PPM to yield two masses 
(mass – ‘x’ PPM and mass + ‘x’ PPM), and determine if there is a MIM of a known 
metabolite within this range. As the value of ‘x’ increases, the greater the 
chance of matching an experimental mass to a known MIM, however the rate of 
error also increases since an incorrect metabolite name may be matched to a 
mass. Under optimal conditions, the LTQ-Orbitrap has an accuracy of greater 
than 2 PPM therefore an acceptable value for ‘x’ is 2; however this is at the 
discretion of the user. 
To increase the flexibility of the search, the user must be able to select the 
appropriate parameters for the search which they wish to perform. Such 
parameters include the PPM tolerance, that organism that they wish to search 
against, and which experiment they wish to search. 
3.6.3.1 Analysis Command 
The analysis SQL statement must display all the experimental masses from a 
particular dataset that correspond to the MIM’s of known metabolites within a 
given PPM tolerance. A series of SQL statements were required to achieve this. It 
is possible to run each SQL statement individually; however, it was more user 
friendly to have a single command button to activate the SQL statements in the 
correct sequence. This event procedure was programmed using visual basic 
application (VBA). All of the SQL statements performed during the ‘analysis’ 
command sequence involve intentionally deleting information from tables, or 
appending information to tables. Microsoft Access has several warning messages 
alerting the user to prevent any accidental modification of data or tables. 
Therefore, the initial step of the sequence is to turn these warning messages off. 
A summary of these individual commands and the corresponding function are 
displayed in Table 3-14. 
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Table 3-14. Event procedure for the ‘Analysis’ command button.  
Order Command Function
1 249_Warnings_Off Turns off warning commands
2 071_Delete_all_records_in_131 Deletes all the records in table_131
3 065_Analysis
Compares the values in the 
dataset to those in the known 
metabolite table within the user 
chosen tolerance and adds the 
each formula to table_131
4 070_Delete_all_records_in_132 Deletes all the records in table_132
5 069_Add_Unique_Masses_To_New_Table_132
Filters duplicate formula from 
table_131 and adds them to as 
single records to table_132
6 250_Warnings_On Turns on warning commands
7 254_Open_Table_132
Opens the table_132 which 
contains the Molecular Formula, 
Mono Isotopic Mass and KEGG 
isomers
  
A series of SQL statements (0##) and macros (2##) activated by the ‘Analysis’ command button. 
The most important SQL statement is outlined in supplementary figure 8-9, 
although a simplied version is shown below in Figure 3-5. The MIM, formula, 
CompCode and retention time fields are selected from the ‘metabolites’ table 
and inserted into ‘131_Results’ when the MIM of the metabolite is between the 
experimental mass + two PPM, and experimental mass – two PPM, and if that 
experimental mass is found in the experiment titled ‘Leishmania Dataset’. 
------------------------------------------------------------------------------------------------------------------------------------------- 
INSERT INTO 131_Results ( [Exact_Mass_(MIM)], Formula, CompCode, RT_minutes ) 
SELECT DISTINCT Metabolites.[Exact_Mass_(MIM)], Metabolites.Formula, [109_Total KEGG database].CompCode, 
Masses.Retention_Time 
FROM Masses, [109_Total KEGG database] INNER JOIN Metabolites ON [109_Total KEGG 
database].Formula=Metabolites.Formula 
WHERE (((metabolites.[Exact_Mass_(MIM)]) Between Masses.Mass-(Masses.Mass/'1000000'*'2') And 
Masses.Mass+(Masses.Mass/'1000000'*'2')) And ((masses.Experiment)='Leishmania Dataset'); 
------------------------------------------------------------------------------------------------------------------------------------------- 
Figure 3-5. ‘Analysis’ SQL statement.   
The detail of any metabolite that corresponds to experimental mass within 2 PPM, provided that 
mass belongs to the ‘Leishmania dataset’, is appended to a table named ‘131_Results’. 
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The analysis does not involve matching experimental masses to all the KEGG 
metabolites due to memory and processing constraints; therefore, the INNER 
JOIN statement was deemed necessary to link the results back to ‘109_Total 
KEGG database’. This would indicate any isomers in the KEGG database 
regardless of whether they were present in the ‘metabolites’ table initially used 
in the analysis. For example, if a mass within two PPM of 260.029723 was 
detected in a dataset, the metabolite could be glucose 6-phosphate (G6P, 
C00092). Whilst G6P is known to be present in trypanosomatids, the user should 
not assume that the experimental mass is definitely that of G6P, as it could be 
any metabolite with this MIM. There are a total of 38 metabolites in the KEGG 
database with a MIM of 260.029723. One possible method of distinguishing 
isomers from one another is the point at which they elute from the 
chromatographic column. Therefore, the inclusion of measured retention time 
data in the ‘masses’ table, and an option to assign retention times to the KEGG 
metabolite table, provide the user with an extremely valuable resource allowing 
an educated decision as to which isomer is present. 
As previously stated, the results are appended to ‘131_Results’, an intermediate 
table containing information on MIM, molecular formula, CompCode and 
retention time (Table 3-15). There are no metabolite names present in this table 
as the KEGG compound ID is used to identify the compounds. However, prior to 
inserting any new records in this intermediate table, it is necessary to delete all 
previous records using a ‘delete’ query (Supplementary Figure 8-10).  
Table 3-15. Analysis 131_Results 
Field Description
Exact_Mass_(MIM) Mono-Isotopic Mass of the metabolite
Formula The molecular formula of the metabolite
CompCode The unique identifier for the metabolite
RT_minutes Elution time of the compound  
Table 131 provides a list of compounds which may be present in the 
experimental dataset. It is important to remember that the identification of an 
experimental mass is not indicative of a particular metabolite; it is indicative of 
one or more specific mono-isotopic elemental compositions. Therefore, it was 
necessary to refine the data in Table 131 by grouping all the results by ‘formula’ 
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and append these to Table 132 using an ‘append’ query (Supplementary Figure 
8-12). All previous data had to be deleted from this table by a delete ‘query’ 
(Supplementary Figure 8-11). This process removed isomeric entries, providing a 
list of distinct molecular formulae, which may be present in the experimental 
dataset (Table 3-16). The ‘KEGG_Isomers’ field is a count reflecting the number 
of isomers for each distinct molecular formula in the total KEGG database. A 
sub-datasheet linking the molecular formula attribute to the molecular formula 
attribute in the total KEGG database provides the user with the detailed 
metabolite information (section 3.5.1). 
Table 3-16. Analysis 132_Unique_Formula_RESULTS 
Field Description
Formula The molecular formula derived from the mass match
Exact_Mass_(MIM) Mono-Isotopic Mass
KEGG_Isomers The number of isomers in the KEGG database
RT_minutes Elution time of the compound  
The final steps of the visual basic program sequence used macros to turn the 
warning messages back on, and open the ‘132_Unique_Formula_RESULTS’ table 
to automatically present the user with the outcome of the analysis (section 
3.6.3.4). 
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3.6.3.2 Input data 
Whilst the user is able to enter their data directly into the ‘masses’ table, it is 
more convenient to paste the data into the intermediate table embedded in the 
‘Input Data’ form (Figure 3-6). An experiment name is entered into the 
‘Experiment Name’ text box. The ‘Add’ command button activates a series of 
SQL statements and macros to append the information to the ‘masses’ table, 
and then delete all the records in the intermediate table ready for the next data 
input. Navigation to the ‘Analysing a Dataset’ form is performed by clicking on 
the binoculars icon. 
 
Figure 3-6. MetaSearch Input Data Form. 
Experimental data can be pasted into the table embedded in the form. An Experiment name is 
entered in the ‘Experiment Name’ text box, and the data added to the ‘masses’ table using the 
‘Add’ command button. There are navigation links to ‘analysis’ and ‘home’ at the bottom of the 
form. 
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3.6.3.3 The analysis tab 
Use of the ‘analysis’ tab for analysing a dataset (Figure 3-7) does not require the 
user to have prior knowledge of SQL, thus maintaining the user-friendly aspect 
of metaSearch. The options available to the user include a series of command 
buttons, combo boxes and text boxes to input information and analyse 
experimental datasets. 
 
Figure 3-7. MetaSearch ‘Analysis’ Tab – analysing a dataset. 
After the input of experimental masses this form displays command buttons that allow the user to 
select which experimental dataset they wish to analyse, the organism to compare the experimental 
masses to, and the desired PPM tolerance. 
The left hand side of the form provides options for which metabolite table is 
used to match the experimental data to; currently there are four command 
buttons representing L. major, T. brucei, T. cruzi, and P. falciparum. There is 
also an option to choose a ‘user defined list’ that allows the user to create a 
custom reference table (described in section 3.7.5). Clicking any of these 
command buttons creates a table called ‘metabolites’. The user may view this 
table by clicking on the ‘view metabolite table’ command button. 
The right hand side of the form deals with the parameters for the SQL 
statement; these include the experimental dataset to be analysed and the PPM 
tolerance value. The ‘Experimental’ option is a combo box named ‘ExpList’ via 
which a SQL statement selects distinct experiments from the masses table 
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(QUERY_064). The PPM tolerance value is entered into a text box named 
‘PPMrange’. Links to the ‘ExpList’ and ‘PPMrange’ are used in the analysis query 
instead of ‘Leishmania Dataset’ and ‘2’ respectively. This allows the user to 
choose the desired experiment and PPM accuracy without having to directly alter 
the SQL statement. The ‘analyse’ command button activates the event sequence 
of SQL statements and macros (described in section 3.6.3.1). The ‘export list’ 
option presents the results in a simple table which can be copied to Microsoft 
Excel.  
At the top of the form there are links to the two other analysis tabs currently 
available; these are ‘metabolite search’ and ‘mass search’ (described in section 
3.6.4). There are several options at the bottom of the form to allow navigation 
to other forms in metaSearch; ‘Input’ (section 3.6.3.2); ‘Tables’ (section 
3.5.2.3); ‘Search’ (section 3.7); ‘Home’ (section 3.6.2). Additionally, there is a 
‘clear’ command button which deletes any value in the ‘PPMrange’ text box. 
3.6.3.4 Output 
The output of the analysis query is multi-layered, exploiting the relational 
database. The initial view, ‘Table_132’, displays the molecular formula, MIM, 
number of isomers in KEGG, and retention time (Figure 3-8A). These attributes 
were chosen as successfully matching an experimental mass to a MIM is 
indicative of a molecular formula rather than a particular metabolite. The 
number of isomers in KEGG is achieved by grouping the results in ‘Table_131’ by 
‘molecular formula’ and counting the number of the compounds in each group. 
The multi-layered aspect is achieved using sub-datasheets to relate the 
information in Table_132 to the main metabolite table by the molecular 
formula; clicking the ‘+’ symbol next to the formula will reveal all metabolites 
with that particular molecular formula. Additionally, there is another sub-
datasheet which links the metabolites to any biochemical reaction that the 
particular metabolite is involved in. For example, there is only one metabolite in 
the KEGG database with the molecular formula C27H47N9O10S2. This metabolite is 
trypanothione disulphide, and is known to occur in five biochemical reactions 
(Figure 3-8B). 
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Figure 3-8. The output of the analysis query. 
A – The initial view provides a list of molecular formulae, exact masses, the number of isomers, 
and retention times. B – Accessing the sub-datasheets utilises the relational aspect of the database 
to provide the user with more detailed information on the potential metabolite and any biochemical 
reactions the metabolite is involved in. 
The initial view of the results is of limited use as no metabolite names are 
mentioned; however, the introduction of sub-datasheets to reveal additional 
levels of information is particularly valuable. If this level of detail is not 
required, there is an option to view a simple list of potential metabolites 
(‘Export List’ on the ‘Analysis’ tab - section 3.6.3.3) using a SQL statement. 
Chapter 3, 111 
3.6.4 Searching datasets for a single metabolite or mass 
The current software used for metabolomic analysis tends to focus on one 
particular dataset. However, it is useful to search quickly for a metabolite of 
interest from all datasets, rather than searching every dataset individually. 
Table 3-17. Event procedure for the ‘Show metabolites’ command button.   
Order Command Function
1 249_Warnings_Off Turns off warning commands
2 078_delete_values_from_139 Deletes all the values in table_139
3 077_Specific_Metabolite_Search
Identifies any metabolite names which 
matches the text string entered by the user 
and stores them in table_139
6 250_Warnings_On Turns on warning commands
7 255_close_analysis_open_form_2
Opens the table_139 which contains the list 
of metabolites with MIM and molecular 
formula
 
A series of SQL statements  (0##) and macros (2##) activated by the ‘Show metabolites’ command 
button. 
In this two-step process, the user must initially search for the desired metabolite 
based on the partial or complete name (Figure 3-9A). Executing the ‘Show 
metabolites’ command button executes a series of SQL statements 
(Supplementary figures 8-13 and 8-14) and macros (Table 3-17), displaying all 
the possible metabolite names, in addition to their respective MIM and the 
molecular formula. The user then selects the desired metabolite, and enters a 
mass tolerance (Figure 3-9B). Finally, clicking the ‘Search’ command button 
activates a SQL statement (Supplementary figure 8-15) that will return a list of 
all experiments in which a mass corresponding to the MIM of that metabolite is 
present (Figure 3-9C). Both the experimentally measured mass and the MIM are 
displayed. 
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Figure 3-9. Searching for a specific metabolite. 
A – Text box to enter complete or partial metabolite name. B – Selection of potential metabolite 
names and a text box for entering the PPM tolerance. C – List of experiments in which an 
experimental mass corresponding to the MIM of a selected metabolite. 
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However, as the mass used in the query is obtained by selecting for metabolite 
name, this query will only work if the metabolite of interest is present in the 
KEGG database. Therefore, an additional query was written to allow a user to 
search for a mass within a given PPM tolerance in all datasets. To test this, the 
mass for phosphoenolpyruvate (C00074) was used with a PPM tolerance of 2 
(Figure 3-10A). The experiments returned were identical to those returned when 
selecting ‘phosphoenolpyruvate’ from the metabolite list, indicating that the 
query was working correctly (Figure 3-10B). 
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Figure 3-10. Searching for a specific mass.  
A – Text boxes to enter a mass and PPM tolerance. B – A list of experiments which contain an 
experimental mass within the PPM tolerance to the mass chosen. 
The ability to search all experimental datasets for a specific metabolite is 
incredibly useful. This feature is not known to have been included in any other 
metabolomic analysis software, thus providing metaSearch with a novel edge for 
metabolomic analysis. 
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3.7 Searching the KEGG Database 
As previously mentioned, the KEGG online database is an extremely useful 
resource; however, the ability to search for metabolites based on specific 
criteria is relatively inefficient. 
The Xcalibur software, supplied by Thermo Fisher Scientific, can only provide an 
experimental mass and molecular formula for an ionised compound. It is 
essential that the user can quickly determine which metabolite a particular mass 
or molecular formula may correspond to. Whilst the KEGG website search engine 
allows a user to search for metabolites using a metabolite name or KEGG 
compound ID, it does not allow the user to search for a mass or molecular 
formula. Therefore, it was necessary to provide the metabolomics community 
with a link between analytical software, such as Xcalibur, and a comprehensive 
metabolite database. 
A ‘Search’ form (Figure 3-11) and several SQL statements were introduced 
providing a front-end to the database. The form contains several text boxes and 
command buttons to allow the user to retrieve information on metabolites when 
only the mass, molecular formula, partial metabolite name, or KEGG compound 
ID are known. 
A B
 
Figure 3-11. Searching the KEGG database.  
The search options are displayed using two tabs. A – The ‘Simple KEGG search’ tab.  The user 
can enter various terms in the appropriate text boxes to search for metabolites within given mass 
ranges, particular names, molecular formulae, or KEGG compound ID’s. B – The ‘Advanced KEGG 
Search’ tab. The user can search the KEGG database for a specific mass within a chosen PPM 
tolerance. 
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3.7.1 Mass Searches 
To provide the user with greater flexibility when searching for a specific mass, 
two separate SQL commands were implemented. The first SQL command 
(Supplementary Figure 8-16) utilises ‘greater than’ and ‘less than’ logic 
statements to display any metabolite(s) between two the mass values entered by 
the user (Figure 3-11A). The second SQL command (Supplementary Figure 8-17) 
is slightly more complex, displaying any metabolite(s) within a specific mass 
with a chosen PPM tolerance value (Figure 3-11B). This is useful when the user 
wishes to search a single experimental mass against all metabolites in the KEGG 
database. A similar query, described in section 3.6.4, which involves searching 
for a specific mass in experimental datasets, instead of the KEGG metabolite 
database. Once the user has entered appropriate values in the ‘mass (MIM)’ and 
‘PPM tolerance’ text boxes, the command button will return any metabolite(s) 
within the PPM tolerance of the mass entered. If there is no mass match, the 
user has the option to provide the details of which experiment the mass came 
from and add the information to a separate table. Compiling a list of 
unidentified masses from a variety of experiments may allow identification of 
masses which recur in numerous experimental datasets. If more than one 
metabolite is returned in either mass search, then the metabolites are displayed 
in ascending order of the MIM. 
3.7.2 Molecular Formula Search 
Similar to searching for a mass, the ability to search for a specific molecular 
formula is also advantageous, particularly as the KEGG website does not 
facilitate this operation. The user must enter the complete molecular formula in 
the appropriate text box, with the respective command button activating a SQL 
statement (Supplementary Figure 8-18) displaying any metabolite(s) with that 
molecular formula. 
3.7.3 Metabolite Name Search 
Using the KEGG website it is possible to search all the synonyms for a partial 
metabolite name. As this is an appropriate method to search for a metabolite 
name, a SQL command was written that would perform the same function 
(Supplementary Figure 8-19). The user is required to enter a partial metabolite 
name in the appropriate text box on the search tab (Figure 3-11A). The 
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associated command button activates a query to retrieve that metabolite names 
from a table of synonyms, rather than the total KEGG metabolite table. The 
numbers of hits from a variety of text strings derived from the KEGG website and 
metaSearch synonym table were compared (Table 3-18). 
Table 3-18. Comparing the number of metabolite hits from KEGG website and Microsoft 
Access searches for metabolite names. Unique hits are shown in brackets. 
Search string KEGG website MetaSearch
‘phospho’ 351 531 (350)
‘phosphoenolpyruvate’ 1 1 (1)
‘enolpyruvate’ 3 3 (3)
‘sphoenolpy’ 1 2 (1)
‘py*te’ 0 220 (173)
‘phosp*ate’ 0 956 (613)  
The metaSearch SQL statement returns the same number of unique hits as the 
KEGG website search for the examples tested. The only exceptions to this are 
the additional hit for the text string ‘phospho’, as the KEGG website is updated 
on a daily basis, and any text string that contains a wildcard symbol. 
Interestingly, the KEGG website search, unlike Microsoft Access, does not 
support the use of wild cards. The wild card symbol ‘*’ can be used to replace 
any character, or sequence of characters, in a text string. This will generally 
result in a significant number of hits, although is useful approach if the user is 
unsure of the spelling for a specific metabolite. 
The metaSearch approach is more efficient than the KEGG website search as 
wildcard symbols are accepted. Aside from this, the two approaches produce the 
same results. 
3.7.4 KEGG Compound ID Search 
It is possible to search for the KEGG compound ID (CompCode) on the KEGG 
website. The KEGG compound ID is one of two unique identifiers that can be 
used to distinguish between isomers, the other being the InChI string. Therefore, 
an SQL statement (Supplementary Figure 8-20) and command button were 
implemented in metaSearch so the user can obtain information on a specific 
compound if they know the KEGG compound code. This is the least useful search 
Chapter 3, 117 
as the principal role of the CompCode is to function as a primary key in relating 
information from one table to another. 
3.7.5 Defining the shortlist 
The shortlist option provides a link between searching the database for KEGG 
metabolites and analysing experimental data. As previously discussed, the user is 
required to select one of four parasitic organisms for analysis of an experimental 
dataset (section 3.6.3.3). This is an extremely powerful function providing the 
user with the option to assemble a metabolite table of interest, and compare 
these masses to a list of experimental masses (Figure 3-7). 
When performing any search described in section 3.7, a column labelled 
‘shortlist’ is displayed on the left hand side of the results. The shortlist attribute 
is a true/false value, and is displayed as a check box, allowing the user to simply 
toggle metabolites ‘true’ or ‘false’. For example, selecting various metabolites 
during searches for a specific metabolite name (Figure 3-12A), molecular 
formula (Figure 3-12B), or KEGG compound ID (Figure 3-12C) may result in a list 
of metabolites which need not be specific to any particular pathway or organism 
(Figure 3-12D). This list can be viewed using the ‘View Shortlist’ command 
button on the ‘search tab’ (Figure 3-11A). A SQL command will return any 
metabolites which have the value ‘true’ in the shortlist column. The shortlist 
can be cleared by updating all the values to ‘false’ using the ‘Reset Shortlist’ 
command button. Alternatively, the information can be saved to a separate 
table for future use by clicking the ‘Save Shortlist’ command button. 
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Figure 3-12. Compiling a shortlist.  
The shortlist column contains a checkbox which can be toggled ‘true’ or ‘false’ depending on 
whether the metabolite is of interested to the user. A – Metabolite name search for ‘trypanothione’. 
B – Molecular formula search for ‘C5H9NO2’. C – KEGG compound ID search for ‘C00077’. D – 
The shortlist of metabolites checked during the three searches. 
3.8 The metaSearch Database 
The metaSearch database can be found on the CD at the back of this thesis21. 
Please follow the instructions below; 
1. When the database is opened, a ‘Security Warning’ will appear, click ‘Open’. 
2. View > Database Objects > Forms 
3. Forms are listed in alphabetical order, double click on the ‘Main Panel (Start 
Here)’. 
4. A small example dataset ‘Leishmania Dataset’ is provided for analysis. 
                                         
21
 Refer to CD: metaSearch 3.0.mdb 
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3.9 Pathos 
Pathos, produced in collaboration with David Leader and Hani Ajahdali 
(Bioinformatics Research Centre, University of Glasgow), is a data-analysis tool 
from the Scottish Metabolomics Facility that allows a user to upload and analyse 
a processed data file from a metabolomic experiment (Leader, DP et al. 2011)22. 
Whilst the concept of this web facility is based on metaSearch, the ability to 
communicate with the KEGG metabolic maps provides a potential for improved 
analysis. 
Once the user has uploaded a file for analysis an organism, ionisation mode, 
adduct status, and ppm tolerance must be chosen from the drop down menu. 
The processing of results is quicker than that of MassTrix, as the web facility 
does not directly interact with the KEGG website, instead using the table of 
metabolites from the metaSearch access database as a reference. The output is 
a summary of potential identifications divided into the broad areas of 
metabolism used by KEGG (Figure 3-13). The potential metabolite identifications 
can be viewed as a list of metabolites for each area, for example ‘arginine and 
praline metabolism’, or alternatively, through graphical representation of an 
annotated KEGG map. Furthermore, if a list of masses with paired intensity 
values from two conditions are supplied, the metabolites on the KEGG map will 
be annotated as blue or red if more intense in one condition, or as yellow if the 
intensities in the two conditions are roughly equal. Finally, if a specific organism 
has been selected, the enzymes identified as being present in that organism are 
also highlighted on the KEGG map. Enzyme annotation is determined by KEGG; 
not by the user or the Metabolomics Web Facility. 
 
                                         
22
 http://motif.gla.ac.uk/Pathos/index.html 
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Figure 3-13. Metabolomics Web Facility - screenshot.  
The parameters chosen by the user are displayed in the drop down menus at the top of the page. 
From the sample dataset, 172 of the 342 have a potential identification; 32 of these are related to 
‘arginine and proline metabolism’, although this does include isomeric compounds. These can be 
viewed as a list by clicking the ‘V’ in the green box, or an annotated KEGG map for ‘arginine and 
proline metabolism’ can be generated. 
The ability to obtain annotated KEGG maps based on the analysis of an 
experimental dataset is extremely useful, and a feature that metaSearch could 
not perform. Whilst MassTRIX is capable of providing a similar analysis, it cannot 
generate KEGG maps annotated to reflect changes in intensity between two 
conditions. 
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3.10 Discussion 
Metabolomics is a rapidly developing field in systems biology. Significant 
improvements have been made in the area of high resolution mass spectrometry; 
the ability to analyse and interpret raw metabolomic datasets on a global scale 
has been largely neglected.  
The metabolome can be defined as “the quantitative complement of low-
molecular-weight metabolites present in a cell under a given set of physiological 
conditions” (Kell, DB et al. 2005). Consequently, the identification of 
compounds, and an understanding of how they relate to one another provides an 
insight on cellular function. 
Metabolites are interconnected through biochemical reactions. In biochemistry 
textbooks, and online resources such as BioCyc (Caspi, R et al. 2010) or KEGG 
(Kanehisa, M and Goto, S 2000), the metabolites are typically grouped into 
classical biochemical pathways that are easy to understand. The global analysis 
of metabolomic datasets can be performed using MassTrix (Suhre, K and Schmitt-
Kopplin, P 2008), which compares the experimental data with the KEGG 
metabolites. KEGG maps are also annotated during the analysis. 
In a cell, metabolites are not conveniently grouped into pathways. Therefore, 
why should metabolomic analysis focus be restricted to comparing experimental 
data to a reference pathway? Convenience is probably the most compelling 
reason. The relationships between biochemical pathways can often be difficult 
to visualise, primarily due to some metabolites occurring in more than one 
pathway; thus the pathways can be rather rigid or inflexible. However, the 
information stored within databases such as KEGG remains the same, 
irrespective of how the information is displayed. Utilising this information it is 
possible to breakdown the non-existent physical barriers between biochemical 
pathways, instead concentrating on how these metabolites relate to one another 
in a global sense. This approach has been used a number of applications. 
MetaNetter allows the construction of ab initio metabolic networks based on 
biochemical transformations (Jourdan, F et al. 2008), whereas MetExplore 
includes all metabolic pathways, irrespective of organism, creating a metabolic 
network (Cottret, L et al. 2010).  
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A similar approach was used in metaSearch. Whilst metaSearch lacks 
visualisation of metabolomic networks, primarily due to computational 
limitations, an attempt has been made to remove the boundaries between 
pathways. The results from the analysis of experimental data are initially 
displayed as molecular formulae, with sub-datasheets providing information on 
the metabolites, and the reactions they are involved in (refer to Figure 3-8B). 
MetaSearch is a relational database produced using Microsoft Access, with 
metabolite information retrieved from the KEGG FTP site23. 
Microsoft Access is ‘well suited to small, department applications’ 24, and 
consequently was an ideal choice for this project. The single database file can 
operate on any computer providing Microsoft Access has been installed, and does 
not require internet access, unless the user wishes to utilise any hyperlinks 
provided in the tables. The processed metabolomic data can be stored in the 
database, or alternatively, kept as Microsoft Excel files and imported into the 
database when necessary. Furthermore, it is relatively straightforward to 
implement additional queries or macros, import and export data, and design 
forms to provide a user friendly GUI. Whilst the database described here is able 
to compare smaller datasets derived from PeakML, comparisons involving larger 
experimental datasets and larger lists of known metabolites require a large 
quantity of processing power to efficiently complete any analysis. 
MetaSearch, like MassTRIX, uses mass matching to identify compounds where 
each mass in the dataset is compared to the MIMs of a selection of metabolites 
from the KEGG database within a chosen PPM tolerance. It is advantageous to 
match an experimental dataset to as large a compound or metabolite database 
as possible. However, this will generate many false positives in the context of a 
biological system. It is important to remember that mass matching does not 
identify a potential metabolite; it identifies a potential molecular formula. 
Therefore, mass matching alone cannot distinguish between isomeric 
compounds, although a likely identification can often be proposed when 
considering the organism in question. The final identification of a metabolite 
must include further identification steps such as retention time comparisons or a 
tandem mass spectrometry approach. 
                                         
23
 http://www.kegg.jp/kegg/download/ 
24
 http://technet.microsoft.com/en-gb/library/cc917612.aspx 
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MetaSearch responds to these challenges in several ways. Firstly, the user can 
analyse data that has already been processed by PeakML; therefore, peaks 
should be reproducible and dataset should contain less noise. Secondly, the user 
may assign retention times for a series of standards to the KEGG metabolites. 
This allows a manual comparison of retention times between an experimental 
mass and possible compound. Finally, the user is able to view how many isomeric 
compounds are present in the KEGG database for each mass match, and which of 
these have been annotated as occurring in T. brucei (or any other organism of 
interest). It is important to recognise any biologically occurring isomers of the 
most likely identification, rather than overlook or ignore these possible 
alternatives. 
If a targeted metabolomic analysis is required, it is possible to search against a 
specific metabolic pathway, or any list of metabolites defined by the user. Even 
using a targeted approach it is essential that the user knows of any isomeric 
compounds that are present in a different pathway of the same organism, as 
well as any naturally occurring metabolite. 
The diversity of the cell lines investigated, and the diversity of experimental 
techniques utilised in performing metabolomic experiments, creates diverse sets 
of metabolites. A single dataset is not diverse. Consequently, it is advantageous 
to have the ability to ignore the boundaries between datasets, and take a 
holistic view of the data. As multiple metabolomic datasets can be stored in 
metaSearch, it is possible to search all the experimental datasets for a KEGG 
metabolite by partial name, or search for any experimental mass within a given 
PPM tolerance. This is not possible using MassTRIX as each experimental dataset 
is uploaded and analysed individually, rather than stored in a specific location, 
and analysed when necessary. These particular approaches are extremely 
important, as the user can rapidly search for a metabolite or mass of interest, 
without confining the search to a particular dataset. Whilst these queries are 
extremely useful, the necessity to store all experimental data in a single file and 
the processing power required to perform the queries, make this an unrealistic 
approach using Microsoft Access. However, if the data were to be stored on a 
web server, then the processing power would not be an issue. 
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A limitation of the KEGG website search engine was the inability to search for a 
specific mass or molecular formula, both of which are important in metabolomic 
analysis. This issue was addressed in metaSearch with queries to return any 
metabolites within a given PPM tolerance of a mass, return any metabolites 
between two masses, or return any metabolites of a specific molecular formula. 
Searching for a metabolite by a name or partial name is possible on the KEGG 
website; this feature is retained in metaSearch. 
Interpreting a metabolomic dataset using MassTRIX will result in the 
identification of the metabolites present in that dataset in relation to a specific 
organism, and map these as differentially coloured objects on KEGG pathways. 
Whilst it is easy to navigate between the KEGG metabolic pathways, they are 
viewed as distinct entities which, conceptually, is a reductionist approach not 
suitable for global metabolomic analysis. This can be demonstrated when 
considering the fate of glucose 6-phosphate, which, depending on cellular 
requirements can supply both the glycolytic pathway and the PPP. Additionally, 
F6P and Ga3P, produced by the oxidative branch of the PPP, can supply the 
glycolytic pathway. Considering the dynamic relationship between these 
pathways it would be confusing to interpret differential data on two separate 
KEGG maps. Therefore, it would be advantageous to adopt a holistic approach 
and view both pathways as a single entity. This is a limitation of KEGG, rather 
than MassTRIX, which ultimately is capable of annotating any KEGG map. 
The From Metabolite to Metabolite (FMM) server is capable of investigating 
which biochemical reactions are required to convert one metabolite to another 
(Chou, CH et al. 2009). Whilst this is limited to the KEGG reaction data, the 
approach does consider that the two metabolites may be present in different 
KEGG maps. Although this particular approach is not particularly useful in the 
analysis of experimental data, the concept of linking metabolites on different 
KEGG maps is convenient. 
Unfortunately, the KEGG metabolic networks and biochemical reaction data 
make no differentiation between mammalian and insect stages of the parasites. 
This is an important consideration due to the changes in nutrient availability and 
gene expression during the parasite lifecycle; consequently, there will be 
changes to the metabolome and proteome. The classical biochemical 
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approaches, typical of the pre-genomics era, have provided the trypanosomatid 
community with a plethora of detailed biochemical and enzymatic data for 
various strains and life cycle stages. The trypanosomatid community should 
make a greater effort to collate and integrate this data with bioinformatic 
approaches such as KEGG. An accurate representation of the enzymes expressed 
and metabolites present during various life cycle stages on interactive metabolic 
pathways would provide a true biological context that is both robust and 
meaningful to any experimental ‘omic’ data. 
A number of methods for analysing metabolomic data exist. The introduction of 
approaches such as MetaNetter, MetExplore, and the database described in this 
chapter demonstrates that looking at metabolism in a global sense can provide 
alternative information to simply restricting the analysis to a particular pathway 
or organism. These complementary techniques will further enhance our 
understanding of global metabolism.
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4 Genetic manipulation of L. mexicana 
transketolase
Chapter 4, 127 
4.1 The Pentose Phosphate Pathway 
The pentose phosphate pathway (PPP) provides an alternative route to glycolysis 
for the oxidation of glucose (Barrett, MP 1997). The main functions of the PPP 
are the generation of ribose 5-phosphate (R5P; C00117), essential for nucleotide 
biosynthesis, and the regeneration of NADPH, important in the defence against 
oxidative stress and in producing reducing equivalents for anabolic processes 
such as lipid biosynthesis (Barrett, MP 1997). Futhermore, the pathway produces 
several phosphorylated sugars which can feed back into the glycolytic pathway, 
in the case of fructose 6-phosphate (F6P; C00085) and glyceraldehyde 3-
phosphate (GA3P; C00118), or alternatively are used as precursors in 
biosynthetic reactions, in the case of erythrose 4-phosphate (E4P; C00279) which 
is used in the biosynthesis of aromatic amino acids in some organisms. The 
pathway can be divided into two sections; the oxidative section, and the non-
oxidative section.  
4.1.1 Oxidative Branch 
The oxidative section consists of three reactions converting one mole of glucose-
6-phosphate (G6P; C01172) to one mole of D-ribulose 5-phosphate (Ru5P; 
C00199), 2 moles of NADPH (C00005), and one mole of CO2. NADPH (C00005) is a 
hydride donor, and is used in many biosynthetic reactions, or in the defence 
against oxidative stress. The fate of G6P is governed by the cellular 
requirements for ATP, R5P and GA3P. NADPH inhibits glucose-6-phosphate 
dehydrogenase (G6PDH; EC 1.1.1.49), thus inhibiting the PPP. The flux through 
the PPP increases when NADPH is oxidised. The oxidative section of the pathway 
is often regarded as irreversible under normal physiological conditions. Ru5P is 
the end product of the oxidative section of the pathway, and the precursor for 
the non-oxidative section. 
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Figure 4-1. The Pentose Phosphate Pathway.  
The pathway is divided into an oxidative branch and a non-oxidative branch. Metabolites: - G6P, 
glucose 6-phosphate; 6PGL, 6-phosphogluconolactone; 6PG, 6-phosphogluconate; Ru5P, ribulose 
5-phosphate; R5P, ribose 5-phosphate; Xu5P, xylulose 5-phosphate; S7P, sedoheptulose 7-
phosphate; GA3P, glyceraldehyde 3-phosphate; E4P, erythrose 4-phosphate; F6P, fructose 6-
phosphate. Enzymes: - 1, hexokinase; 2, glucose-6-phosphate dehydrogenase; 3, 6-
phosphogluconolactonase; 4, 6-phosphogluconate-dehydrogenase; 5, pentosephosphate 
isomerase; 6, ribulose-5-phosphate epimerase; 7, transketolase; 8, transaldolase. Pathways linked 
to the PPP are shown in red. 
4.1.2 Non-oxidative Branch 
The non-oxidative section of the PPP is responsible for generating a variety of 
sugar phosphates. Both F6P and GA3P can feed back into the glycolytic pathway. 
Also generated are sedoheptulose 7-phosphate (S7P; C05382), a component of 
some bacterial cell walls, and E4P, a precursor for many vitamins and aromatic 
amino acid biosynthesis in some organisms. 
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4.1.3 PPP activity in Trypanosomatids 
All the enzymes of the PPP have been identified in T. brucei procyclic form cells 
(Cronin, CN et al. 1989) L. mexicana promastigotes (Maugeri, DA et al. 2003), 
although transketolase (EC 2.2.1.1) and ribulose 5-phosphate epimerase (EC 
5.1.3.1) were absent in the bloodstream form trypanosome (Cronin, CN et al. 
1989). The quantity of glucose available to the bloodstream form trypanosome 
may indicate non-oxidative branch of the PPP is not required; however the 
presence of transaldolase (EC 2.2.1.2) may signify the involvement of additional 
enzymes, which are not part of the classical pathway. In T. cruzi, all of the 
classical enzymes were identified from all four developmental stages, and that 
glucose consumption through the PPP increased by 2-fold (Maugeri, DA and 
Cazzulo, JJ 2004). Specific activities for each of the L. mexicana PPP enzymes 
(Maugeri, DA et al. 2003) and T. cruzi PPP enzymes (Maugeri, DA and Cazzulo, JJ 
2004) were also determined. The L. mexicana promastigote enzymes of the 
oxidative branch were found to have greater activity than those from T. brucei 
procyclic form; a possible hypothesis was the greater demand for NADPH 
required when the promastigotes infect macrophages (Maugeri, DA et al. 2003).  
4.1.4 Roles in Biology 
The primary functions of the pentose phosphate pathway are the regeneration of 
NADPH, production of ribose 5-phosphate for nucleotide biosynthesis, and the 
production of erythrose 4-phosphate for aromatic amino acid biosynthesis. 
4.1.4.1 NADPH regeneration 
The oxidative section of the PPP is responsible for the regeneration of NADPH, a 
co-factor used in many enzymatic reactions including the maintenance of 
reduced thiols and fatty acid biosynthesis. Glutathione (GSH; C00051) is the 
major thiol produced in cells and plays an important role in defending cells 
against oxidative stress by the detoxification of reactive oxygen species and free 
radicals. However, this process requires glutathione to donate an electron, 
causing glutathione to become reactive. Two reactive gluathione molecules can 
react with one another forming oxidised glutathione (GSSG; C00127), which is 
then converted back to GSH by gluathione reductase, an enzyme requiring 
NADPH as a co-factor. 
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Whilst glutathione is responsible for the neutralisation of free radicals and 
reactive oxygen species in the majority of cell types, trypanosomatids possess a 
unique thiol named trypanothione to perform this role. Trypanothione, an 
amphiprotic compound, is an unusual derived form of glutathione consisting of 
two molecules of GSH that are linked by one molecule of spermidine (C00315) 
(Fairlamb, AH et al. 1985). In a similar fashion to glutathione, trypanothione can 
exist in an oxidised (T(SH)2, C03170) or reduced (T(S)2, C02090) state. 
Trypanothione-disulfide reductase (TryR, EC 1.8.1.12) is specific to 
trypanosomatids, essential for parasite survival, and as a consequence is 
considered as a possible target for drug development. The enzyme requires FAD 
as a cofactor, and catalyses the following reaction; Trypanothione + NADP+ <=> 
Trypanothione disulfide + NADPH + H+. The NADPH regenerated by the oxidative 
branch of the PPP is essential to maintain trypanothione in the reduced form, 
thereby protecting the cells from oxidative stress and free radicals.  
4.1.4.2 Nucleotide Biosynthesis 
Ribose 5-phosphate (C00117) is necessary for the synthesis of ribonucleotides 
which are subsequently incorporated into nucleic acids. There are numerous 
methods for the synthesis of R5P; from the Ru5P generated by the oxidative 
section using pentosephosphate isomerase, the non-oxidative section from GA3P 
and S7P acting as the ketose donor, or finally by the phosphorylation of free 
ribose (C00121) by ribokinase (EC: 2.7.1.15). 
4.2 Transketolase 
The phosphorylated sugars present in the non-oxidative branch of the PPP are 
substrates for a number of metabolic pathways (Figure 4-1), and as a result 
transketolase (TKT; EC 2.2.1.1) and transaldolase (TAL; EC 2.2.1.2) are 
responsible for the interconversion of these phosphorylated sugars depending on 
cellular requirements. 
Transketolase is classically believed to catalyse two reversible reactions in the 
non-oxidative branch of the PPP (Figure 4-1) with the transfer of a 2-carbon 
glycoaldehyde subunit from a ketose donor, to an aldose acceptor. Typical 
biochemical reactions performed by transketolase include the transfer of a 2-
carbon subunit from Xu5P to either R5P or E4P, resulting in the production of 
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GA3P and S7P or F6P respectively. However, some tkt enzymes utilise a broad 
range of substrates; both phosphorylated and non-phosphorylated sugars. This 
has led to tkt having industrial and commercial value, for example, in the 
synthesis of aromatic amino acids. 
Transketolase has been identified in a wide range of organisms, including 
trypanosomatids (Cronin, CN et al. 1989; Maugeri, DA and Cazzulo, JJ 2004; 
Veitch, NJ et al. 2004). Whilst activity has been identified in T.brucei procyclics 
(Stoffel, SA et al. 2011) and L. mexicana promastigotes (Veitch, NJ et al. 2004), 
the enzyme was found to be absent in both T.brucei bloodstream form (Cronin, 
CN et al. 1989). It was inconclusive as to whether tkt was present in L. mexicana 
amastigotes due to a lack of controls, although the enzyme was present in L. 
mexicana axenic amastigotes (Veitch NJ, PhD Thesis). However, the enzyme has 
been identified in all 4 major development stages of T. cruzi (Maugeri, DA and 
Cazzulo, JJ 2004). 
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4.2.1 Structure 
The crystal structures of transketolase have been determined for several 
species; including Saccharomyces cerevisiae (Lindqvist, Y et al. 1992), Homo 
sapiens (Mitschke, L et al. 2010), and L. mexicana (Veitch, NJ et al. 2004). The 
L. mexicana tkt protein was shown to be structurally similar to S. cerevisiae tkt, 
with an amino acid sequence identity of 50.4% (Veitch, NJ et al. 2004). 
Transketolase is functional as a dimer, requiring one calcium ion and one 
thiamine pyrophosphate (TPP; C00068) molecule per subunit. TPP is a co-factor 
in many enzymatic reactions, and is required by transketolase to catalyse the 
reaction. The three-dimensional structure of S. cerevisiae tkt identified several 
residues thought to be important in the binding of the TPP, and also in the 
binding and stabilisation of the substrate (Lindqvist, Y et al. 1992; Nilsson, U et 
al. 1997). The interactions between the TPP and L. mexicana transketolase 
enzyme are illustrated in Figure 4-2. 
The diphosphate group of the TPP molecule interacts with the Ca2+ ion through 
two oxygen atoms of the diphosphate group, whereas the side chains of Asp155 
and Asn185, and the oxygen atom present in the main chain of Ile187 interact 
with the Ca2+ ion. Additionally, hydrogen bonding occurs between the 
diphosphate group and several conserved residues including His66, His261, 
Asp183 and Gly156. The remaining portion of the TPP interacts with several 
amino acids from both residues, and as a result is bound within the two subunits. 
The pyrimidine ring is located within a pocket of conserved residues from the 
second subunit. Several conserved residues from the second subunit (denoted by 
an *) that include Phe432*, Phe435*, and Tyr438* form a pocket in which the 
pyrimidine ring binds through hydrophobic interactions. Furthermore, hydrogen 
bonding occurs between the pyrimidine ring and Gly114, His472*, Leu116, and 
Glu409*. The C4 methyl group of the thiazolium ring forms hydrophobic 
interactions with the side chains of Val114* and Leu377*, both of which are from 
the second subunit. The negative charge present on the Asp376* is thought to 
compensate for the positive charge of the thiazolium ring (Lindqvist, Y et al. 
1992). Consequently, the only atom of the TPP molecule that is accessible from 
solution is the carbon atom at the C-2 position of thiazolium ring. 
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Figure 4-2. Schematic diagram of the interactions of TPP at the cofactor binding site of L. mexicana transketolase.  
The TPP molecule is indicated in blue lines and blue text, whereas the amino acid residues are black lines and black text. Asterisk, amino acid residues from the 
second sub-unit; dashed red lines, possible hydrogen bonds; dashed black lines, ligands between the protein and calcium ion; green circle, the hydrophobic pocked 
binding the pyramidine ring; blue circle, hydrophobic interactions between the C-4 methyl group of the thaizolium ring; red circle, C-2 atom of the thaizolium ring. 
Reproduced from Lindqvist, Y et al. 1992.
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A deep cleft between the two subunits allows transketolase to interact with a 
broad range of keto and aldo sugars. An example involving E4P is shown in Figure 
4-3. The aldehyde oxygen atom of the acceptor substrate (or the ketol oxygen 
atom of the ketose donor) can form hydrogen bonds with the side chains of 
His26* and His 261*, and the C-2 hydroxyl group interacts with the side chain of 
Asp467. These interactions not only stabilise the substrate, but also bring the C-
1 carbon of the substrate within 4 Å of the C-2 carbon atom of the thiazolium 
ring of TPP or the α,β-dihydroxyethyl TPP complex (C13378) (Lindqvist, Y et al. 
1992; Nilsson, U et al. 1997). If the donor or acceptor substrate is 
phosphorylated, then the oxygen atoms of the phosphate group form hydrogen 
bonds with His459, Arg518, and Ser380. An additional interaction between the 
side chain of Arg353 and the phosphate group forms a salt bridge (Nilsson, U et 
al. 1997). A non-phosphorylated substrate does not bind as tightly to 
transketolase as a phosphorylated substrate; subsequently, the efficiency of the 
reaction decreases when substrates are not phosphorylated (Nilsson, U et al. 
1997). 
Arg353Arg518
Ser380
His26*
His261*
His459
Asp467
Glu408
 
Figure 4-3. Schematic view of the interactions of erythrose 4-phosphate with L. mexicana 
holo-transketolase.  
Possible hydrogen bonds are indicated by dashed lines. R = -CH2-CH2-P2O7H3. Asterisks denote 
residues from the second subunit. Adapted from Nilsson, U et al. 1997. 
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Activity of the S. cerevisiae transketolase enzyme could be impaired by targeting 
these conserved residues by site-directed mutagenesis, thus confirming their 
importance in enzyme activity (Nilsson, U et al. 1997). Unsurprisingly, the 
majority of residues involved in the binding of TPP and the substrate are 
conserved between transketolase enzymes isolated from different species 
(Veitch, NJ et al. 2004). The L. mexicana transketolase enzyme has 671 amino 
acid residues per subunit, with a molecular weight of approximately 74 kDa per 
monomer (Veitch, NJ et al. 2004). 
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4.2.2 Reaction mechanism 
The biochemical reaction performed by transketolase follows a ping-pong 
mechanism in which a 2-carbon glycoaldehyde subunit is transferred from a 
ketose donor to an aldose acceptor (Figure 4-4). The ketose donor substrate, for 
example F6P, is bound within a deep cleft between the two transketolase 
subunits (Section 4.2.1). Catalysis is initiated by the deprotonation of the C-2 
carbon atom of the thiazolium ring of TPP. This is followed by the nucleophilic 
attack of the carbonyl carbon atom of the F6P, resulting in the cleavage of the 
bond between the C-2 and C-3 carbon atoms. The ketol group remains bound to 
the C-2 carbon atom of the thiazolium ring, forming α,β-dihydroxyethyl thiamine 
diphosphate (C13378), whilst the resulting aldose, in this case E4P, is released. 
GA3P then binds within the active site, reacts with α,β-dihydroxyethyl thiamine 
diphosphate and forms Xu5P. 
(1)
(2)
(3)
(5)
(4)
 
Figure 4-4. Transketolase reaction mechanism. 
First part of the ping-pong reaction mechanism of transketolase. (1) Deprotonation of the C-2 
carbon atom of the thiazolium ring; (2), the resulting carbanion attacks the carbonyl carbon of the 
ketose donor substrate; (3), the carbon-carbon bond between the C-2 and C-3 carbon atoms of the 
ketose is cleaved; (4), the ketol group remains covantently bound to the C-2 carbon atom of the 
thiazolium ring; (5), the aldose is released from the enzyme. In the second part of the reaction an 
aldosugar acceptor binds in the substrate cleft, and the order of chemical steps is then reversed. 
Adapted from Nilsson U et al 1997. 
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4.2.3 Localisation 
In Leishmania all of the PPP enzymes currently annotated, with the exception of 
transaldolase, have a perixisomal targeting signal (PTS); these are divided into 
C-terminal PTS-1 or N-terminally located PTS-2 glycosomal targeting signal 
(Opperdoes, FR and Szikora, JP 2006). However, some proteins do lack a PTS1 or 
PTS2 targeting signal and may enter the glycosome by ‘piggybacking’ on proteins 
that does posses a PTS targeting signal (Opperdoes, FR and Szikora, JP 2006; 
Galland, N et al. 2007). There are two ORFs which code for ribulose 5-phosphate 
3-epimerase (Ru5PE, EC: 5.1.3.1), one with a glycosomal targeting signal, and 
one without. In L. mexicana promastigotes, transketolase is localised to both the 
glycosome and the cytosol; although the majority of the enzyme is located to 
the cytosol (Veitch, NJ et al. 2004). In T.brucei, transketolase was also shown to 
have a PTS1 targeting signal. Interestingly, phosphoglucose isomerise (PGI; EC 
5.3.1.9) is 90% cytosolic in L. mexicana, whereas it is almost exclusively 
glycosomal in T.brucei. PGI is required for the conversion of F6P to G6P for the 
regeneration of NADPH via the oxidative branch of the PPP. Leishmania spp have 
high levels of cytosolic trypanothione, which is maintained in the reduced form 
(C02090) by NADPH and TryR. The cytosolic localisation of PGI indicates that a 
substantial percentage of the oxidative section of the PPP occurs in the cytosol 
in order to reduce the cytosolic NADP+ (C00006) to maintain the high levels of 
NADPH. In T. cruzi the PPP enzymes were identified as being cytosolic, however 
it is possible that all are present in the glycosome at low levels (Maugeri, DA and 
Cazzulo, JJ 2004). The evidence suggests that in trypanosomatids the PPP occurs 
in both the cytosol and the glycosome. 
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4.3 Aim 
Preliminary data indicated that transketolase knockouts in procyclic form 
trypanosomes were found to be hypersensitive to pentamidine and compounds 
that induced oxidative stress (Stoffel, SA et al. 2011). 
To determine the biological role of transketolase (LmjF24.2060, EC 2.2.1.1) in L. 
mexicana promastigotes the gene was deleted by targeted gene disruption, and 
the phenotype of the transketolase-null mutants was investigated. 
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4.4 Targetted Gene Disruption of the L. mexicana TKT 
gene 
4.4.1 Constructs 
In order to target both tkt alleles in L. mexicana, plasmids were generated 
containing either a hygromycin B phosphotransferase (HYG) gene or a 
streptothricin acetyltransferase (SAT) gene, flanked by DHFR-TS untranslated 
regions for constitutive expression of the drug resistance markers. This region 
was flanked with DNA sequences immediately upstream and downstream of the 
tkt ORF. These constructs are derivatives of those used for the deletion of the L. 
mexicana cysteine peptidase B (lmcpb) gene array (Mottram, JC et al. 1996). 
To generate knockout construct pMB-G40, a 396-bp region immediately upstream 
(5') of the tkt gene was amplified using primers MB79 and MB80. The amplified 
product was digested with HindIII/SalI, and cloned into the pGL520 vector 
(Mottram Laboratory, University of Glasgow). A 600-bp region downstream (3') of 
the tkt gene was amplified using MB217 and MB218. The amplified product was 
digested with SmaI/BglII, and cloned into the knockout vector to give pMB-G40 
(Figure 4-5). The knockout vector was sequenced by Eurofins MWG Operon 
(Ebersberg, Germany) to ensure that the ligation of both the 5’ TKT and 3’ TKT 
flanks had occurred correctly.  
Leishmania are diploid organisms and therefore a second round transfection 
using a different antibiotic and selection marker is required to delete both 
alleles. The streptothricin acetyltransferase gene from pMB-G40 was replaced 
with the hygromycin B phosphotransferase from pGL345 (Mottram Laboratory, 
University of Glasgow) following a BamHI/SpeI digestion to give pMB-G39. The 
HYG gene was sequenced by Eurofins MWG Operon (Ebersberg, Germany) to 
ensure that ligation had occurred correctly. 
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pMB-G40
6627 bp
Streptothricin acetyltransferase CDS
B-Lactamase CDS
DHFR 5' UTR
DHFR 3' UTRE. coli ori
Transketolase 3' UTR
Transketolase 5' UTR
BamHI (1851)
BglII (3825)
HindIII (2)
Sma I (3221)
Spe I (1319)
Sal I (376)
Sal I (3370)  
Figure 4-5. pMB-G40 – Transketolase Knockout Vector.  
The features are as follows; horizontal green line, TKT flanks; solid green arrow, DHFR flanks; 
solid orange arrows, ORFs for streptothricin acetyltransferase and β-lactamase. The major 
restriction sites used for cloning are also indicated; unique restriction sites are shown in red, and 
the numbers in parenthesis indicate the position on the plasmid. 
Chapter 4, 141 
4.4.2 First round transfection 
The TKT knockout cassette conferring resistance to hygromycin B (Figure 4-6) 
was released from the vector by restriction digest with HindIII/BglII, and upon 
transfection (section 2.6.2) of this DNA, homologous recombination of the 
knockout cassette should occur at the tkt locus. 
Hygromycin B phosphotransferase CDS
DHFR 5' UTR
DHFR 3' UTR
Transketolase 3' UTRTransketolase 5' UTR
BamHI (2351)HindIII (2)
Sma I (3721)
Spe I (1319)
BglII (4325)
Sal I (376) Sal I (3870)
 
Figure 4-6. Transketolase knockout cassette with the Hygromycin B phosphotransferase 
drug marker.  
The features are as follows; horizontal green line, TKT flanks; solid green arrow, DHFR flanks; 
solid orange arrow, hygromycin B phosphotransferase CDS. The major restriction sites used for 
cloning are also indicated; unique restriction sites are shown in red. 
Limiting dilutions in 96-well plates were used to clone the cells. Poisson 
distribution states that if the population in each well was derived from a single 
cell, then 37% of the wells would have no growth. The average number of cells 
per well can be calculated using the following equation; m = -LN(F0), where ‘m’ 
is the average number of cells per well and ‘F0’ is the frequency of wells 
receiving no cells. 
After the first round transfection the percentage of negative wells in the first 
two plates for both populations was less than 37%, indicating that the cells may 
not be clonal. However, more than 37% of the wells in the 3rd plate for both 
populations were negative, indicating that the populations in the positive wells 
were likely to have been derived from a single cell. The average numbers of 
cells in the 3rd plate were calculated to be 0.065 and 0.076 per well for 
populations A and B respectively. These results are summarised in Table 4-1. 
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Table 4-1. Analysis of the first round transfection.  
Pop. A Pop. B Pop. A Pop. B Pop. A Pop. B
Plate 1 (6-fold) 0 0 0.00 0.00 n.c n.c
Plate 2 (72-fold) 29 24 0.29 0.24 1.23 1.43
Plate 3 (864-fold) 94 93 0.94 0.93 0.06 0.08
% negative wells F0 m
  
The percentage of negative wells, the frequency of wells receiving no cells (F0), and the calculated 
average number of cells per well (m) are shown for the three dilutions of both populations of 
potential single allele knockout cells. n.c. = not calculated. 
A total of 13 clones were recovered from both plates. To ascertain whether one 
allele for the tkt gene had been deleted from any of these clones, a series of 
PCR reactions were performed. 
4.4.3 PCR Screen 
The genomic DNA isolated from the thirteen potential single allele knockout 
clones was screened by PCR for the internal transcribed spacer 1 (ITS1) region to 
confirm the presence of Leishmania gDNA (Schonian, G et al. 2003). One clone 
was negative for this marker and was therefore excluded from any further 
screens. The remaining twelve clones were screened for the presence of the 
HYG gene, episomes, and successful integration at the TKT locus. These findings 
are displayed in Figure 4-7, and summarised in Table 4-2. 
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Figure 4-7. PCR analysis of L. mexicana single allele transketolase knockout clones. 
A - Screen for episomal copies using Sp6 and MB212 to generate an expected product of 535 bp; 
B - Screen for 5’ integration using MB91 and MB212 to generate an expected product of 651 bp; C 
- Screen for 3’ integration using MB94 and MB213 to generate an expected product of 749 bp. The 
lanes on each of the images are as follows, A; 1, 100 bp ladder; 2, plasmid DNA; 3, negative 
control; 4, clone A1; 5, clone A2; 6, clone A3; 7, clone A4; 8, clone A6; 9, clone B1; 10, clone B2; 
11, clone B3; 12, clone B4; 13, clone B5; 14, clone B6; 15, clone B7; 16, 100 bp ladder. B and C; 1, 
WT DNA; 2, negative control; 3, 100 bp ladder; 4, clone A1 ;5, clone A2; 6, clone A3; 7, clone A4; 
8, clone A6; 9, clone B1; 10, clone B2; 11, clone B3; 12, clone B4; 13, clone B5; 14, clone B6; 15, 
clone B7; 16, 100 bp ladder. The 100 bp ladder is supplied by Promega. 
Presence of the HYG gene was detected using MB39 and MB40, and thus any 
sample positive for this marker would indicate a successful electroporation 
event. All clones tested were found positive for this marker. 
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The restriction digest of the plasmid DNA to release the knockout cassette is not 
always successful with uncut plasmid contaminating the sample. This can be 
reduced by fractionating the restriction digest on an agarose gel, and extracting 
the DNA from the appropriate fragment using a commercial kit. However, uncut 
plasmid may remain at low levels, with Leishmania parasites retaining the ability 
to express the antibiotic selection marker from the plasmid. Therefore, it is 
extremely important that cell lines are tested for presence of episomes using 
oligonucleotides Sp6 and MB212. These primers amplify across the HindIII 
restriction site; no PCR product will be generated if the plasmid has been 
digested efficiently. Clones which are positive for an episomal copy of the 
knockout cassette can be disregarded from future analysis.  
Similarly the clones were tested for integration of knockout cassette at both the 
5’ and 3’ flanks. Primers were selected that would anneal outside the 
recombination sites; therefore any product generated would be specific to a 
successful integration. Oligonucleotides MB91 and MB212 would generate a PCR 
product of approximately 650 bp if the cassette had integrated correctly at the 
5’ flank. Similarly, oligonucleotides MB94 and Mb213 would generate a PCR 
product of approximately 750 bp if the cassette had integrated correctly at the 
3’ flank. It is evident that six clones were positive for integration at the 5’ and 
3’ recombination sites (Table 4-2). 
Table 4-2. Summary of PCR analysis for potential TKT single allele gene knockouts 
PCR Product ITS 1 HYG episome 5' integration 3' integration
MB95 MB39 Sp6 MB91 MB94
MB96 MB40 MB212 MB212 MB213
Clone A1 ● ● - ● ●
Clone A2 ● ● ● - -
Clone A3 ● ● - ● ●
Clone A4 ● ● - ● ●
Clone A5 - nd nd nd nd
Clone A6 ● ● - ● -
Clone B1 ● ● - ● ●
Clone B2 ● ● ● - -
Clone B3 ● ● ● - -
Clone B4 ● ● - ● ●
Clone B5 ● ● ● - -
Clone B6 ● ● - - ●
Clone B7 ● ● - ● ●
Olignucleotides
 
Legend; ●, positive; -, negative; nd, not done. 
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In summary, the PCR analysis indicated that of the twelve clones analysed, all 
were positive for the hyg gene, four were episomal, one had apparently 
integrated at the 5’ flank but not at the 3’ flank, whereas another had 
integrated at the 3’ flank but not at the 5’ flank, and six were identified as 
being single allele knockout cell lines. Clone B1 was selected for a second round 
transfection to delete the second allele. It is imperative that the single allele 
knockout clones are analysed thoroughly prior to transfection with the second 
knockout cassette to ensure that the correct clone is selected. 
4.4.4 Second round transfection 
The single allele knockout cell line (clone B1) was transfected with the tkt 
knockout construct conferring resistance to nourseothricin in an attempt to 
disrupt the second transketolase allele. 
A total of seven potential double knockout clones (5 from population A, and 2 
from population B) were recovered from the second round transfection 
(summarised in Table 4-3), although one of these did not survive long enough to 
allow genomic DNA to be extracted. These were screened for the presence of 
the ITS1 repeat, the SAT resistance gene, and most importantly, the 
transketolase gene. 
Table 4-3. Analysis of the first round transfection.  
Population A Population B
Plate 1 (6-fold) 100.0 100.0
Plate 2 (72-fold) 58.3 44.8
Plate 3 (864-fold) 5.2 2.1
  
The percentage of positive wells in the three dilution plates for each population of potential ∆lmtkt 
cells. 
All of the clones were positive for the ITS1 repeat region, indicating the 
presence of Leishmania genomic DNA (Figure 4-8A). Amplification of the 
transketolase gene was possible from five of the clones, however, not from 
clone B1.A1 (Figure 4-8B). These results suggest that deletion of the 
transketolase gene has been successful in clone B1.A1, although had been 
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retained in the other clones isolated. Interestingly, only two of the clones (B1.A1 
and B1.A2) were positive for the SAT antibiotic resistance marker (data not 
shown), indicating that the drug pressure may have been too low to successfully 
select for parasites expressing the SAT resistance gene. A summary of the PCR 
results are shown in Table 4-4. 
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Figure 4-8. PCR analysis of L. mexicana double allele transketolase knockout clones. 
A - Screen for ITS1 region using MB95 and MB96 to generate an expected product of 350 bp; B - 
Screen for transketolase using MB250 and MB251 to generate an expected product of 2100 bp. 
The lanes on each of the images are as follows, A; 1, 100 bp ladder; 2, clone B1.A1; 2, clone 
B1.A1; 3, clone B1.A2; 4, clone B1.A3; 5, clone B1.A4; 6, clone B1.A5; 7, clone B1.B1. B; 1, 1 kbp 
ladder; 2, clone B1.A1; 2, clone B1.A1; 3, clone B1.A2; 4, clone B1.A3; 5, clone B1.A4; 6, clone 
B1.A5; 7, clone B1.B1. Both DNA ladders were supplied by Promega. 
Table 4-4. Summary of PCR analysis for potential TKT double allele gene knockouts 
PCR product ITS 1 SAT TKT
Oligo (s) MB95 MB210 MB250
Oligo (as) MB96 MB211 MB251
Clone B1.A1 ● ● -
Clone B1.A2 ● ● ●
Clone B1.A3 ● - ●
Clone B1.A4 nd nd nd
Clone B1.A5 ● - ●
Clone B1.B1 ● - ●
Clone B1.B2 ● - ●  
Legend; ●, positive; -, negative; nd, not done. 
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Whilst PCR is a suitable approach to screen potential double knockout clones, it 
is not the most reliable. Therefore, the deletion of the transketolase gene was 
confirmed by Southern Blotting. 
4.4.5 Southern Blot Analysis 
In order to confirm that tkt had been deleted from the genome, the technique 
of Southern blotting was used. The L. major tkt DNA sequence was subjected to 
a GeneDB BLAST search against the L. mexicana contigs. The sequence of L. 
mexicana contig_0000588 was viewed and annotated using the vector NTI 
software (Invitrogen, Paisley). Digestion of genomic DNA with NruI would 
generate appropriate sized fragments of 2.2 kb and 3.2 kb when probed with a 
1.5 kb section of the tkt ORF. A second restriction enzyme, BamHI, was chosen 
as this had been previously tested (Nicola Veitch, PhD thesis), however the exact 
location of a downstream BamHI restriction site remains unknown as it is located 
on another contig. A schematic diagram of the TKT locus is shown in Figure 4-9. 
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Figure 4-9. Schematic representation of the L. mexicana Transketolase locus. 
A - endogenous transketolase locus. B - transketolase locus upon successful integration of the 
HYG knockout cassette. C - transketolase locus upon successful integration of the SAT knockout 
cassette. The ORF’s are indicated by a solid black arrow, the TKT flanking regions are indicated by 
a striped box, and the restriction sites are indicated by a vertical line. The exact size of the 
downstream BamHI fragement (denoted ‘x’) is currently unknown due to incompletion of the L. 
mexicana genome project. The size of the downstream BamHI fragment (denoted ‘y’) for either 
knockout cassette integration is 0.5 kb smaller than ‘x’. Scale bar represents 1 kb. 
Initially, the six potential double allele knockout clones were analysed by 
Southern blot, which indicated that five of the clones had retained the tkt gene 
(data not shown). This result was consistent with the PCR screen which indicated 
that transketolase failed to amplify in clone B1A1; however, it was present in 
the five other clones (Table 4-4). Therefore, genomic DNA was isolated from 
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wild type lmTKT+/+, single allele knockout (Clone B1) and the lmtkt-/- (Clone 
B1A1) L. mexicana promastigotes, and digested with either NruI or BamHI. 
The blot was probed with a 1.5 kb section of the full length ORF obtained from 
pMB-G52 using a BamHI / SacI double digest (Figure 4-10A). Wild type gDNA 
digested with BamHI was predicted to give a single band greater than 10 kb 
(Nicola Veitch, PhD Thesis). This is evident with a single large band greater than 
10 kb (lane 2), a signal half as intense in the single allele knockout (lane 3), and 
no band in the double allele knockout (lane 4). Similarly, the expected bands of 
2.2 kb and 3.2 kb produced by an NruI digest are evident for the wild type gDNA 
(lane 5), with the signal half as intense in the single allele knockout (lane 6), 
and no bands in the double allele knockout (lane 7), indicating that the 
transketolase gene had been deleted. The membrane was stripped and re-
probed with the 5’ transketolase UTR which is approximately 0.4 kb (Figure 
4-10B). It was expected that the probe would anneal to a fragment of 16.7 kb 
for the WT gDNA (Figure 4-9A), a fragment of 18.5 kb for DNA containing the 
HYG cassette Figure 4-9B), and a fragment of 18.0 kb for DNA containing the SAT 
cassette Figure 4-9C). For the NruI digest it was expected that the probe would 
anneal to a 2.2 kb fragment for WT gDNA (Figure 4-9A), a 6.7 kb fragment for 
gDNA containing the HYG cassette (Figure 4-9B), and 6.2 kb fragment for gDNA 
containing the SAT cassette (Figure 4-9C). These expectations are consistent 
with the results obtained (Figure 4-10B). 
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Figure 4-10. Southern blot demonstrating knockout of the transketolase gene for L. 
mexicana.  
A: - membrane probed with a 1.5 kb section of the TKT ORF. B: - membrane striped and re-probed 
with a 0.4 kb section of the 5’ flank. Each sample contains 10 µg gDNA and are loaded as follows - 
1, 1 kb DNA ladder (Promega); 2, BamHI digest of lmTKT+/+ gDNA; 3, BamHI digest of lmTKT+/- 
gDNA; 4, BamHI digest of clone B1.A1 gDNA; 5, NruI digest of lmTKT+/+ gDNA; 6, NruI digest of 
lmTKT+/- gDNA; 7, NruI digest of clone B1.A1 gDNA; 8, 1 kb DNA ladder (Promega). 
The results indicate that transketolase is clearly absent from the double allele 
knockout, confirming targeted gene replacement. Additionally, the intensity of 
the bands in the single allele knockout are half as intense as in the wild type, 
indicating a 50% reduction in the DNA coding for tkt. 
4.5 Ribosomal expression of transketolase 
For stable integration into the ribosomal locus, a derivative of pSSU-int (Misslitz, 
A et al. 2000), pGL631 (Prof. JC Mottram, University of Glasgow) was used. The 
tkt PCR fragment was ligated into the pGEM-T Easy vector, and sub-cloned into 
pGL631 using NotI and XhoI. The cassette can integrate at six locations on each 
allele at the ribosomal locus, with possible variation in gene expression, 
depending on integration site (Hilley JD, personal communication). 
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Unfortunately the coverage for this region of the L. mexicana genome was poor, 
possibly due to the complexity in assembling repeat regions, therefore making it 
difficult to determine the location(s) of the tkt gene(s). Consequently, it was 
decided to focus on designing an over-expression construct, using that to over-
express tkt in the wild type, and generate tkt re-expression in the null mutants. 
4.6 Over-expression of TKT in L. mexicana 
To over-express TKT the pNUS-HnN vector was used (Tetaud, E et al. 2002). This 
vector acts as an episome within the Leishmania cell. An intergenic region 
between PGKA and PGKB of Crithidia fasciculata was used to direct maturation 
of the target gene and NEO drug resistance marker. Upstream of the target gene 
is the 5’ untranslated region of PGKB, which directs trans-splicing, and the 3’ 
untranslated region from C. fasciculata GSPS was used for polyadenylation of the 
NEO drug resistance marker.  No protomer is required to drive transcription. 
Unfortunately the XhoI and NotI restriction sites flanking the TKT could not be 
used to sub-clone transketolase from pMB-G51 into the pNUS-HnN vector. 
Consequently, an alternative cloning strategy was required. This involved 
removing the N-terminal HIS Tag, thrombin cleavage site and MCS by an EcoRI 
restriction digestion and dephosphorylation of the vector backbone to prevent 
re-ligation. The TKT gene from pMB-G51 was digested with EcoRI, and ligated 
with the dephosphorylated over-expression construct. A total of 27 bacterial 
clones were screened by PCR for the presence of the tkt gene. As the tkt gene 
could integrate in either orientation, five clones positive for tkt were selected at 
random and screened for orientation by restriction digest. Restriction digests of 
plasmid DNA with either BamHI or SacI would give rise to different sized 
products depending on the orientation of the gene (Figure 4-11A and Figure 
4-11B). If the gene is orientated correctly then a BamHI restriction digest will 
generate two products approximately 3.8 kB and 4.5 kB in size, whereas 
incorrect orientation will generate two products approximately 6.2 and 2.1 kB in 
size. Similarly, a SacI restriction digest will yield products approximately 7.9 kB 
and 0.4 kB if the tkt gene is correctly orientated, or products approximately 6.5 
kB and 1.8 kB if incorrectly orientated. The restriction digest profiles for both 
BamHI and SacI indicate that in clones 7 and 10 the transketolase ORF was 
correctly orientated (Figure 4-11C). 
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Figure 4-11. Determining the correct orientation of the transketolase ORF. 
A – Plasmid map with the TKT ORF in the correct orientation. BamHI digest should yield products 
3795 bp and 4536 bp. SacI digest should yield products 7963 bp and 368 bp. B – Plasmid map 
with the TKT ORF in the incorrect orientation. BamHI digest should give products 6266 bp and 
2065 bp. SacI digest should give products 6511 bp and 1820 bp. C – Restriction Digest of plasmid 
DNA to screen for correct orientation of transketolase. The samples are as follows; 1, 1 Kb ladder; 
2, clone 7; 3, clone 10; 4, clone 11; 5, clone 17; 6, clone 27; 7, 1 Kb ladder; 8, clone 7; 9, clone 10; 
10, clone 11; 11, clone 17; 12, clone 27; 13, 1 Kb ladder. The DNA in lanes 2-6 have been digested 
with BamHI, wherease the DNA in lanes 8-12 have been digested with SacI. The 1 Kb ladder was 
supplied by Promega. 
To generate a construct which could be used as a negative control, the tkt ORF 
was digested with NotI and XhoI, and the vector backbone ligated with the 100 
bp MCS from the pGL631 vector, to give plasmid pMB-G53. This construct was 
used as a negative control for transfections involving the tkt over-expression 
construct. Wild type and transketolase knockout promastigotes successfully 
transfected with the ectopic constructs were analysed by PCR. Promastigotes 
were screened for the presence of a 2 kB fragment from within the tkt gene to 
within the Neomycin resistance marker (specific to the tkt over-expression 
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construct) (Figure 4-12A), and for the presence of the Neomycin 
phosphotransferase gene (present in all constructs) (Figure 4-12B). These results 
confirm the transfection of the correct plasmids into the correct cell lines. 
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Figure 4-12. PCR analysis of L. mexicana TKT over-expression cell lines. 
A - Screen for TKT-NEO fragment using MB334 and MB334 to generate an expected product of 2 
kb; B - Screen for neomycin using MB37 and MB38 to generate an expected product of 750 bp. 
The lanes on each of the images are as follows, A; 1, 1 kb ladder; 2, wt pMB-G52A; 3, wt pMB-
G52B; 4, wt pMB-G53A; 5, wt pMB-G53B; 6, tkt -/- pMB-G52A; 7, tkt -/- pMB-G52B; 8, tkt -/- pMB-
G53A; 9, tkt -/- pMB-G53B; 10, pMB-G52; 11, pMB-G53; 12, 1 kb ladder. B; 1, 1 kb ladder; 2, wt 
pMB-G52A; 3, wt pMB-G52B; 4, wt pMB-G53A; 5, wt pMB-G53B; 6, tkt -/- pMB-G52A; 7, tkt -/- 
pMB-G52B; 8, tkt -/- pMB-G53A; 9, tkt -/- pMB-G53B; 10, 1 kb ladder. DNA ladders were supplied 
by Promega. 
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4.7 Transketolase sequence 
To generate a construct for the re-expression of transketolase in the L. 
mexicana tkt knockouts, the ORF was amplified from gDNA, and ligated into the 
pGEM-T easy vector (Promega, Southampton, UK). The DNA sequences of two 
independently derived tkt clones were aligned with the L. mexicana tkt 
sequence (GenBank accession ID AJ427448) (Supplementary Figure 8-2). Two 
single base substitutions were identified at nucleotide positions 234 and 875. 
The first was identified as a silent mutation at amino acid position 78, whereas 
the second mutation induced an amino acid change at amino acid position 275 
(A275T) (Supplementary Figure 8-1). Whilst a change from alanine to threonine 
may have consequences in the folding or activity of the protein, particularly 
post-translation modifications exploiting the threonine hydroxy group, sequence 
alignment with tkt from other Leishmania species all revealed a threonine 
residue at position 275 (Figure 4-13). This would suggest that the L. mexicana 
tkt sequence (GenBank accession ID AJ427448) is incorrect at amino acid 
position 275. 
                        241                               *  280 
    L. braziliensis TKT MIVQTTTIGYGSSKQGTEKVHGAPLGDEDIASVKTKFGRD 
        L. infantum TKT MIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANVKTKFGRD 
           L. major TKT MIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANVKTKFGRD 
        L. mexicana TKT MIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKAKFGRD 
L. mexicana TKT Clone 1 MIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKTKFGRD 
Figure 4-13. Alignment of transketolase residues 241 to 280 from several Leishmania spp. 
Gene sequences for L. infantum (LinJ.24.21.50), L. braziliensis (LbrM.24.2140) and L. major 
(LmjF.24.2060) were obtained from TriTrypDB, whereas the gene sequence from L. mexicana was 
obtained from GenBank (accession ID AJ427448). Both L. mexicana strains were 
MNYC/BZ/62/M379, and from the same laboratory. The amino acid difference at residue 275 is 
indicated with an asterisk.  
4.8 Phenotypic Analysis 
4.8.1 Growth curve 
The growth of the lmTKT+/-, lmtkt-/-, and lmtkt-/- TKT ribosomal re-expression 
cell lines were compared to that of the WT L. mexicana promastigotes (Figure 
4-14). Both the single allele knockout and the lmtkt-/- cell lines have a slightly 
longer initial lag phase than the WT cell line; however there is little difference 
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in the mean generation time (WT, 13.5 hours; lmTKT+/- cell single allele 
knockout, 14 hours; lmtkt-/-, 15 hours). Additionally, the stationary phase 
concentration of the WT cell line is approximately 2 x 107 cells per ml, compared 
with approximately 1 x 107 cells per ml for the lmtkt-/- cell line. Ribosomal re-
expression of TKT had similar growth rates and maximum densities when 
compared to the wild type cells. These results were displayed on a linear scale 
to highlight a potential difference in maximum growth density. Therefore, TKT is 
not essential for growth or survival under the standard laboratory conditions 
used in these experiments. The growth phenotype described here for L. 
mexicana is similar to the growth phenotype of T.brucei lmtkt-/- procyclic 
trypanosomes which was unaltered when compared to WT procyclic 
trypanosomes (Stoffel, SA et al. 2011). 
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Figure 4-14. Growth of genetically manipulated L. mexicana promastigotes. 
Wild type (WT), TKT single allele knockout (lmTKT+/-), tkt-null (lmtkt-/-), and tkt-null:TKT-
complemented (lmtkt-/- TKT ribosomal re-expression) L. mexicana promastigotes cell lines were 
counted over a 7 day period. No antibiotics were applied to the lmTKT+/- or lmtkt-/-cell lines, 
however the TKT re-expression cell lines were grown in the presence of 10 µg/ml puromycin. Three 
cultures of each cell line were counted to generate a mean value +/- SEM (n = 3). 
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4.8.2 Over-expression of Transketolase 
The growth of the wild type L. mexicana promastigote cell lines transfected with the 
transketolase over-expression construct were compared to those which were transfected 
with the empty vector (Figure 4-15). The populations containing the empty vector had a 
slower lag phase than those with the transketolase over-expression construct; however 
there is no obvious effect on growth with each population possessing a similar mean 
generation time 
(
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Figure 4-17). The maximum density of the stationary phase promastigotes was 
approximately the same for each population irrespective of whether the cells were 
transfected with the empty vector or the tkt over-expression construct. 
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Figure 4-15. Effect on the growth of L. mexicana wild type cells transfected with episomal 
constructs. 
Two distinct populations over-expressing the TKT enzyme were compared with two distinct 
populations containing the empty vector over a 7 day period. All cell lines were grown in the 
presence of 50 µg/ml G418. Two cultures of each cell line were counted to generate a mean value 
+/- SEM. 
The growth of lmtkt-/- mutant populations transfected with the transketolase 
over-expression construct were compared to those which were transfected with 
the empty vector (Figure 4-16). The populations which contained the empty 
vector had a significantly increased lag time, in addition to a stationary phase 
density of around 9 x 106 cells per ml. The populations with the transketolase 
over-expression construct had a stationary phase density of approximately 1.5 x 
107 cells per ml. Additionally, the lmtkt-/- cell populations containing the empty 
vector were not viable for a period of more than three weeks, despite the stable 
nature of lmtkt-/- null cell line with no episomal construct. 
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Figure 4-16. Effect on the growth of L. mexicana TKT null (lmtkt-/-) cells transfected with 
episomal constructs. 
Two distinct populations over-expressing the TKT enzyme were compared with two distinct 
populations containing the empty vector over a 7 day period. All cell lines were grown in the 
presence of 50 µg/ml G418. Two cultures of each cell line were counted to generate a mean value 
+/- SEM. 
The mean generation time of the lmtkt-/- cells over-expressing TKT were slightly lower than 
those which contained the empty vector, and in addition were comparable to the mean 
generation times of the wild type cells with the over-expression construct or empty vector 
(
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Figure 4-17). 
Chapter 4, 159 
 
lmTKT+/+ (over-expression population A)
lmTKT+/+ (over-expression population B)
lmTKT+/+ (empty vector A)
lmTKT+/+ (empty vector B)
lmtkt-/- (over-expression population A)
lmtkt-/-(over-expression population B)
lmtkt-/-(empty vector A)
lmtkt-/-(empty vector B)
 
Figure 4-17. Mean generation time of L. mexicana promastigotes transfected with episomal 
constructs. 
The over-expression of tkt has no effect on the growth of wild type L. mexicana 
promastigotes. Additionally, there is no difference in growth between wild type 
and lmtkt-/- cells when TKT is over-expressed.  
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4.8.3 Medium colour change 
Initial observations indicated differences in the colour of the medium between 
the wild type and tkt knockout cell line. A similar phenotype was observed in the 
glucose transporter knockout (lmgt-/-) cell line (Burchmore, RJ et al. 2003). To 
further investigate this, wild type, lmTKT+/-, lmtkt-/-, and lmgt-/- L. mexicana 
promastigotes were grown for a period of two weeks. After two weeks of 
growth, the cells will have reached stationary phase (for growth curves refer to 
Figure 4-14; (Burchmore, RJ et al. 2003), with the number of viable cells 
declining steadily. 
lmTKT+/+ lmTKT+/- lmtkt-/- lmgt-/-
 
Figure 4-18. L. mexicana promastigote HOMEM acidification. 
Promastigotes in the stationary phase of growth exhibit various degrees of medium acidification. 
The acidification of the lmtkt-/- is not as pronounced as the wild type cell line, despite similar cell 
densities. The lmgt-/-, which is unable to transport glucose, is shown as a control. 
The medium from the wild type cell lines was yellow, whereas the medium from 
the tkt knockout cell line was orange, indicating a higher pH. The medium colour 
from the single allele knockout cell line was between yellow and orange. The 
glucose transporter knockout cell line, designated lmgt-/-, is unable to 
metabolise glucose, and as a consequence, the medium does not change colour. 
These observations indicate that the colour change of the medium may be linked 
to the expression of transketolase. Furthermore, the phenotypic similarity to the 
glucose transporter knockout cell line suggests a possible link between 
transketolase and glucose metabolism. The colour change that occurs during the 
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growth of L. mexicana promastigotes in cultures may be the result of the 
excretion of organic acids that are produced from the partial metabolism of 
glucose. The lmgt-/- promastigotes cannot utilize exogenous glucose, and 
release significantly reduced amounts of succinate and pyruvate due to a 
metabolic shift from glycolysis to amino acid metabolism (Dhilia Lamasudin, 
personal communication), which may account for the slower rate of medium 
acidification. The slower rate of medium colour change in the lmtkt-/- cell line 
is also consistent with reduced metabolism of glucose. These observations do not 
take into consideration cell density, which could have a significant influence.  
4.8.4 Glucose Utilisation 
To investigate a potential metabolic shift, the glucose consumption of the 
∆lmtkt null cell line was compared to that of the parental wild type cell line 
using an enzymatic assay. The Glucose Oxidase (GO) Assay was used to 
determine the quantity of free glucose remaining in the supernatant at various 
time points (0 hours, T0; 30 hours, T30; 90 hours, T90) from three independent 
experiments (section 2.9.1).  
The linear range of the glucose oxidase assay is between 20 and 80 µg of 
glucose. HOMEM contains 3 g of D-glucose per litre (16.66 mM); therefore, 30 µl 
of supernatant will contain a maximum of 80 µg glucose. A series of glucose 
standards were quantified resulting in the following equation: y = 53.724x - 
13.031; where ‘y’ represents the quantity of glucose in µg and ‘x’ represents the 
absorbance at 595 nm. The R-squared value was 0.9582.  
Three independent cell cultures were set up for the L. mexicana wild type and 
lmtkt-/- cell lines, in the late log phase of growth, at approximately 1 x 107 cells 
per ml. The quantity of glucose in supernatant and the cell densities were 
determined at T0, T30 and T90. This would allow the glucose consumption to be 
normalised against cell numbers. 
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Figure 4-19. Utilisation of glucose by L. mexicana promastigotes.  
The quantity of glucose remaining in the medium, and cell numbers were determined for three time 
points; T0, T30, and T90. The available glucose is expressed as ug/ml normalised to 1x 107 cells. 
The assays were performed on three separate cultures for each cell line (n = 3). 
The quantity of glucose available in the medium for the wild type promastigotes 
decreased from approximately 70 µg/ml/1x107 cells to 20 µg/ml/1x107 cells in 
the first 30 hours; compared to a decrease from approximately 70 µg/ml/1x107 
cells to 30 µg/ml/1x107 cells for the lmtkt-/- promastigotes. After 90 hours, the 
medium from both cell lines contained approximately 20 µg of glucose/ml/1x107 
cells. These results indicate that there is no significant difference in glucose 
consumption between the wild type and lmtkt-/- cell lines, despite the clear 
difference in acidification of the medium. This would suggest that whilst    
lmtkt-/- promastigotes are not excreting organic acids at the same rate as the 
wild type promastigotes, they do metabolise similar levels of glucose. A change 
in secreted end products rather than change in rate of glucose consumption is 
thus inferred. 
The concentration of glucose determined by the GO assay at T0 was 10.2 mM, 
however, the HOMEM recipe in the laboratory states a concentration of 
approximately 16 mM. After 90 hours, this decreases to 7.0 mM and 9.3 mM for 
the wild type and lmtkt-/- promastigotes respectively. This suggests that once 
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the cells reach the maximum density of approximately 2.5x107 cells per ml, 
glucose consumption decreases significantly. 
The promastigotes require NADPH to defend against oxidative stress. Whilst the 
oxidative branch of the PPP can function normally in the lmtkt-/- cell line, the 
absence of TKT means that R5P cannot be converted to glycolytic intermediates 
by the non-oxidative branch. Therefore, a significant proportion of G6P enters 
the PPP to regenerate NADPH, and these molecules cannot re-enter the 
glycolytic pathway as another phosphorylated sugar at a later stage. 
4.8.5 Sensitivity of L. mexicana to oxidative stress and drugs 
In procyclic form T.brucei, transketolase knockouts were initially reported to be 
more sensitive than wild type cells to oxidative stress induced by exposure to 
methylene blue and H2O2. Conversely, trypanosomes over-expressing 
transketolase were less sensitive to these compounds than trypanosomes 
expressing endogenous levels of TKT (Stoffel SA, personal communication). 
Furthermore, transketolase knockouts were hypersensitive to pentamidine, 
whereas the cells over-expressing transketolase were less sensitive to 
pentamidine. These results suggest that a possible mode of action for 
pentamidine in procyclic form trypanosomes is through the generation oxidative 
stress, and that transketolase is important in defending the cells against 
oxidative stress. Therefore, the sensitivity of the L. mexicana wild type cell line 
to methylene blue and pentamidine were compared to the transketolase 
knockout cell line and the transketolase knockout cell lines re-expressing 
transketolase. 
The transketolase knockout cell line was twice as sensitive to pentamidine as 
the wild type cell line (wild type, 241.4 nM; lmtkt-/-, 118.3 nM). The tkt null 
cell line re-expressing transketolase from the ribosomal locus had a similar level 
of sensitivity to the wild type cell lines (lmtkt-/- ribosomal re-expression G49, 
267.1 nM). However, the cells re-expressing transketolase from an ectopic 
plasmid were slightly less sensitive to pentamidine than the lmtkt-/- cell line, 
although were still more sensitive than the wild type cell line (lmtkt-/- episomal 
re-expression G52A, 177.8 nM; lmtkt-/- episomal re-expression G52B, 147.7 nM). 
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There is very little difference in sensitivity to methylene blue between the wild 
type and lmtkt-/- cell lines (wild type, 4.309 µM; Lm∆TKT null, 3.542 µM).The 
lmtkt-/- cell lines re-expressing transketolase were more sensitive to methylene 
blue than the wild type or lmtkt-/- cell lines. As the cell lines re-expressing 
transketolase were not doing so from the endogenous locus, the cells were 
grown in the presence of G418 or puromycin to maintain a high level of gene 
expression. This may have had an effect of the EC50 values observed. 
Table 4-5. Pentamidine EC50 values for L. mexicana promastigotes. 
Cell Line EC50 Pentamdine (nM) 95% Confidence Interval
lmWt 241.4 212.3 to 273.8 nM
lmtkt-/- 118.3 104.8 to 133.3 nM
lmtkt-/- re-expression (G49) 267.1 227.9 to 301.4 nM
lmtkt-/- re-expression (G52A) 177.8 153.7 to 202.8 nM
lmtkt-/- re-expression (G52B) 147.7 132.0 to 164.6 nM  
Cell lines are as follows; wild type (lmWT), tkt null mutant (lmtkt-/-), ribosomal TKT re-expression 
(lmtkt-/- re-expression G49) and episomal TKT expression (lmtkt-/- re-expression G52A and lmtkt-/- 
re-expression G52B). (n=3) 
Table 4-6. Methylene blue EC50 values for L. mexicana promastigotes. 
Cell Line EC50 Methylene Blue (µM) 95% Confidence Interval
lmWt 4.3 4.2 to 4.5 µM
lmtkt-/- 3.5 3.3 to 3.8 µM
lmtkt-/- re-expression (G49) 1.6 1.3 to 2.0 µM
lmtkt-/- re-expression (G52A) 1.0 0.9 to 1.2 µM
lmtkt-/- re-expression (G52B) 1.1 0.9 to 1.3 µM  
Cell lines are as follows; wild type (lmWT), tkt null mutant (lmtkt-/-), ribosomal TKT re-expression 
(lmtkt-/- re-expression G49) and episomal TKT expression (lmtkt-/- re-expression G52A and lmtkt-/- 
re-expression G52B). Started at 4 x 105, (n=3) 
In the absence of transketolase, L. mexicana promastigotes are twice as 
sensitive to pentamidine as the wild type promastigotes; re-introducing 
transketolase to the knockout cell line decreased sensitivity to pentamidine. 
However, there was little difference in sensitivity to methylene blue between 
the wild type and TKT knockout cell line. 
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As previously mentioned, the procyclic form T.brucei cells over-expressing tkt 
were shown to be less sensitive to pentamidine and methylene blue. Therefore, 
the alamar blue assay was used to compare the sensitivity of L. mexicana WT 
cell lines transfected with episomal copies of the tkt gene or the empty vector 
to both pentamidine and methylene blue. The two cell populations over-
expressing transketolase were not significantly more resistant to pentamidine or 
methylene blue than the populations that contained the empty vector (Table 4-7 
and Table 4-8). The cell populations that contained the empty vector were 
approximately 4-fold less sensitive to pentamidine (1.117 µM and 1.09 µM) than 
the wild type cell line (241.4 nM), and approximately 2-fold less sensitive to 
methylene blue (8.93 µM and 9.07 µM) than the wild type cell line (4.309 µM). 
These assays were performed whilst the cells were grown under drug pressure 
with G418 which makes a direct comparison difficult. However, this may account 
for the difference between the EC50 values obtained for the wild type cell line 
and those obtained for the two wild type cell populations transfected with the 
empty vector. 
Table 4-7. Pentamidine EC50 values for L. mexicana wild type promastigotes transfected with 
the TKT over-expression construct.  
Cell Line EC50 Pentamdine (µM) 95% Confidence Interval
lm WT TKT overexpressor A 1.24 1.20 to 1.29 µM
lm WT TKT overexpressor B 1.41 1.37 to 1.46 µM
lm WT empty vector A 1.12 1.05 to 1.20 µM
lm WT empty vector B 1.09 1.06 to 1.13 µM  
Started at 2 x 105 cells per ml (n=3) 
Table 4-8. Methylene Blue EC50 values for L. mexicana wild type promastigotes transfected 
with the TKT over-expression construct.  
Cell Line EC50 Methylene Blue (µM) 95% Confidence Interval
lm WT TKT overexpressor A 11.47 8.58 to 14.18 µM
lm WT TKT overexpressor B 10.70 8.43 to 12.98 µM
lm WT empty vector A 8.93 8.12 to 9.74 µM
lm WT empty vector B 9.07 7.86 to 10.39 µM  
Started at 2 x 105 cells per ml (n=3) 
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These results suggest that the over-expression of transketolase does not play a 
significant role in the defence against oxidative stress in L. mexicana 
promastigotes. The flux through the oxidative branch of the PPP is determined 
by cellular requirements for NADPH and R5P; with the non-oxidative branch 
functioning to convert sugar phosphates to glycolytic intermediates, which can 
be diverted back through the oxidative branch of the PPP if necessary. However, 
if the cells are grown in a glucose rich environment, it may not be necessary to 
recycle the sugar phosphates produced by the oxidative branch of the PPP as 
G6P is readily available. As the L. mexicana promastigotes are grown in HOMEM, 
a glucose rich medium, the over-expression of transketolase does not increase 
the flux of G6P through the oxidative branch of the PPP. Therefore, the rate 
NADPH regeneration is unaltered, and thus the sensitivity to oxidative stress 
remains the same. 
4.8.6 Metabolomic Analysis 
A metabolomic analysis was carried out in collaboration with the Metabolomics 
Facility in Toulouse. Parasite samples were sent to colleagues in Bordeaux 
(Bringaud F, Université Victor Segalen, Bordeaux) and prepared for analysis in 
Toulouse. 
The lmtkt-/- cells do not acidify the medium to the same extent as the wild type 
cells (section 4.8.3); yet consume similar quantities of glucose per 1 x 107 cells 
over a 90 hour time period.  
Transketolase is a key enzyme in the non-oxidative branch of the PPP that 
provides a link between the ribulose 5-phosphate and the glycolytic 
intermediates F6P and G3P. If there is significant flux through the non-oxidative 
branch of the PPP then the promastigotes must respond by dealing with the 
accumulation of Ru5P. 
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Figure 4-20. A comparison of intracellular levels of ribose 1-phosphate (R1P) in L. mexicana. 
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Figure 4-21. A comparison of intracellular levels of ribose 5-phosphate (R5P) in L. mexicana. 
 
The metabolomic analysis indicates that there is an accumulation of ribose 1-
phosphate (R1P) Figure 4-20) and ribose 5-phosphate (R5P) (Figure 4-21) in the 
lmtkt-/- cell line when compared to the wild type cells. The re-expression of 
TKT from the ribosomal locus in the lmtkt-/- cell line reverses this phenotype to 
concentrations similar to that of the wild type. 
The first enzyme in the non-oxidative branch of the PPP is ribulose-5-phosphate 
isomerase (EC 5.3.1.6) which converts Ru5P to R5P. Deletion of TKT results in 
the accumulation of R5P, consistent with its production by the isomerase and 
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loss of consumption by transketolase. According to KEGG, R5P can be converted 
to a range of metabolites in Leishmania parasites (Table 4-9).  
Whilst it is possible to produce Xu5P via Ru5P, the absence of TKT prevents the 
conversion of Xu5P to G3P. Therefore, the deletion of TKT prevents any flux 
through the oxidative branch of the PPP returning to the glycolytic pathway. If 
the concentration of R5P increases it is not surprising that the concentration of 
R1P also increases since R1P can be produced from R5P by phosphoglucomutase 
(EC 5.4.2.2), although it is unknown whether the Leishmania enzyme can 
catalyse this reaction.  
Leishmania parasites which do not express TKT would not be expected to be 
able to produce S7P, an intermediate metabolite in the non-oxidative branch of 
the PPP, from R5P. When the wild type and lmtkt-/- cell lines are compared, 
there is a 14-fold reduction in sedoheptulose 7-phosphate in the tkt knockout 
cell line (Figure 4-22). However, the re-expression of TKT in the null cell line 
does not return the sedoheptulose 7-phosphate levels to that of the wild type, 
instead only a 2.5-fold increase is observed.
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Table 4-9. Metabolic fates of Ribose 5-phosphate. 
Metabolite Abbreviation KEGG CompCode Enzyme EC number Accession_ID
Sedoheptulose 7-phosphate S7P C05382 TKT 2.2.1.1 LmjF24.2060
Ribulose 5-phosphate Ru5P C00199 ribose 5-phosphate isomerase 5.3.1.6 LmjF28.1970 
Ribose 1-phosphate R1P C00620 phosphoglucomutase 5.4.2.2 LmjF21.0640
D-Ribose C00121 ribokinase 2.7.1.- LmjF27.0420
5-Phospho-alpha-D-ribose 1-diphosphate PRPP C00119 ribose-phosphate pyrophosphokinase 2.7.6.1 LmjF08.0510
The five reversible reactions listed by KEGG for ribose 5-phosphate
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Figure 4-22. A comparison of intracellular levels of sedoheptulose 7-phosphate (S7P) in L. 
mexicana. 
No standard commercially available for sedoheptulose 7-phosphate. 
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Figure 4-23. A comparison of intracellular levels of erythrose 4-phosphate (E4P) in L. 
mexicana. 
No calibration curve for erythrose 4-phosphate. 
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In the tkt null cell line there is a 23-fold increase in E4P when compared to the 
wild type cell line (Figure 4-23). Re-expressing tkt in the tkt null cell line 
reduces E4P.  
The reduced level of S7P and increased level of E4P is intriguing. S7P is usually 
produced by transketolase when a 2-carbon subunit is transferred from Xu5P to 
R5P. E4P is then produced when transaldolase transfers a 3-carbon from S7P to 
GA3P, and transketolase transfers a 2-carbon subunit from Xu5P to E4P, creating 
F6P. The increase in E4P indicates a source of this metabolite independent of 
TKT. 
If there is an alternative method of producing S7P, then transaldolase can create 
F6P and E4P if GA3P is present as an acceptor. It is possible to produce S7P from 
both E4P and DHAP, sedoheptulose 1,7-bisphosphate acting as an intermediate 
metabolite (Figure 4-24A). However, as E4P would be required as a substrate, 
this reaction alone would not account for the elevated levels of E4P.  
Another possibility is that there is an enzyme with phosphoketolase activity, in 
which F6P is converted to E4P and acetyl phosphate (C00227) (Figure 4-24B). No 
trypanosomatid enzyme with this function has currently been identified, 
although it would be of considerable interest to find such an enzyme. If this 
were the case, why would the cells produce excess E4P at the expense of 
consuming F6P, an important glycolytic intermediate?  
Whilst there is no known biochemical or enzymatic mechanism to transfer a 1-
carbon subunit from R5P or Xu5P to GA3P creating E4P, it does remain a 
theoretical, yet unlikely possibility. 
Leishmania parasites have been shown to possess ribokinase which converts D-
ribose to R5P (Ogbunude, PO et al. 2007). However, it is unknown whether this 
reaction can operate in reverse. If so, this would allow the parasites to 
metabolise R5P and excrete D-ribose. The T. brucei ribokinase enzyme is 
capable of dephosphorylating R5P (Kerkhoven E, personal communication). 
Additionally, trypanosomes grown in C13 labelled D-glucose produce C13 labelled 
D-ribose (Anderson JJ, personal communication), indicating that ribokinase may 
dephosphorylate R5P in vivo and excrete ribose.
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Figure 4-24. Alternative methods of E4P production. 
A - Production of S7P from E4P and DHAP. B - Production of E4P from F6P. Only the main 
reaction pair metabolites (defined by KEGG) are shown. E4P, Erythrose 4-phosphate (C00279); 
DHAP, Dihydroxyacetone phosphate (C00111); S1,7bP, Sedoheptulose 1,7-bisphosphate 
(C00447); S7P, Sedoheptulose 7-phosphate (C05382); 4.1.2.13, aldolase; 3.1.3.11, fructose-
bisphosphatase; 3.1.3.37, sedoheptulose-bisphosphatase; 4.1.2.22, fructose-6-phosphate 
phosphoketolase. Enzymes not known to be present in T. brucei or L. major are shown in red, 
those present in T. brucei but not L. major are shown in blue, and those present in both T. brucei 
and L. major are shown in black. 
Finally, R5P can be converted to nucleic acids via PRPP. It was reported that 
10.9% of D-glucose is incorportated into nucleic acids in L. mexicana (Maugeri, 
DA et al. 2003); therefore, D-glucose flux through the oxidative branch of the 
PPP must be at least 10%. Additionally, 56.7% of D-Ribose was incorporated into 
nucleic acids (Maugeri, DA et al. 2003). This would suggest that 43.3% of the D-
Ribose has an alternative fate which may include flux through the non-oxidative 
branch of the PPP to form glycolytic intermediates. It would be unlikely for 
Leishmania to produce excess ribonucleotides if they were not required by the 
cell. 
Interestingly, the concentration of phosphoenolpyruvate (PEP) decreases from 
150 nM in the wild type to 20 nM in TKT knockout cell line. Re-expression of TKT 
in the null background increases the PEP concentration to 70 nM (Figure 4-25). 
These results suggest that less D-glucose is converted to PEP, although do not 
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necessarily indicate that the flux of G6P through the glycolytic pathway is 
reduced. 
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Figure 4-25. A comparison of intracellular concentrations of phosphoenolpyruvate (PEP) in 
L. mexicana. 
A proposed model for glucose catabolism in the glycosome is shown in Figure 
4-26. Whilst cellular requirements are responsible for the fate of G6P; 
environmental conditions may be responsible for the fate of R5P. If D-Glucose is 
unlimited then there is no need to utilise the non-oxidative branch of the PPP to 
divert flux through the glycolytic pathway, or back through the oxidative branch 
of the PPP. However, there is an ATP-ADP balance in the glycosome, with the 
net gain of ATP occurring in the cytosol during the conversion of PEP to pyruvate 
by pyruvate kinase (PK; EC 2.7.1.40). The phosphorylation of glucose in the 
glycosome requires 1 mole of ATP per mole of D-glucose, and thus any flux 
through the oxidative branch of the PPP would consume more ATP than could be 
replenished by the glycolytic pathway. It has been reported that L. mexicana 
promastigotes are capable of phosphorylating free ribose for the synthesis of 
nucleotides (Maugeri, DA et al. 2003). If ribokinase is able to dephosphorylate 
R5P, and this reaction occurred in the glycosome, then this would provide a 
mechanism to re-generate ATP and maintain the glycosomal ATP-ADP balance 
without utilising the non-oxidative branch of the PPP. If the cells are in a 
glucose deficient environment, for example in the midgut of a tsetse fly or 
sandfly, it is advantageous to convert any R5P to glycolytic intermediates to fuel 
the oxidative branch of the PPP and regenerate NADPH. In a glucose rich 
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environment, for example the mammalian bloodstream, the trypanosome is able 
to divert more G6P through the oxidative branch of the PPP if under increased 
levels of stress. 
Non-Oxidative 
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Figure 4-26. Proposed model for glucose catabolism in the glycosome.  
The selected metabolites of the glycolytic pathway and the oxidative and non-oxidative branches of 
the PPP are shown. The solid arrows indicate a single metabolic step and dashed arrows indicate 
multiple metabolic steps. The green box shows metabolic reactions known to occur in the 
glycosome and include the first seven steps of glycolysis, whereas the yellow box indicates 
reactions that may occur in the glycosome based on the presence of a peroxisome targeting signal. 
It is unknown whether the dephosphorylation of ribose 5-phosphate to form D-ribose and ATP, 
shown in red, is possible in vivo. End products of aerobic glucose catabolism include incompletely 
oxidised products such as succinate, L-alanine, acetate; the complete oxidisation of glucose results 
in the production of CO2. Abbreviations - G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; 
G3P, glyceraldehyde 3-phosphate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; R5P, 
ribose 5-phosphate. 
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Table 4-10. Impact of transketolase deletion in L. mexicana on the concentration of intracellular metabolites. 
mean (µM) SD mean (µM) SD mean (µM) SD
6-phosphogluconate 6PG C00345 0.26 0.04 0.26 0.08 0.03 0.01
ribose 1-phosphate R1P C00620 0.35 0.00 0.63 0.06 0.32 0.01
ribose 5-phosphate R5P C00117 0.21 0.02 2.40 0.20 0.09 0.03
erythrose 4-phosphate E4P C00279 2.87* 0.14* 67.30* 7.78* 2.07* 0.34*
sedoheptulose 7-phosphate S7P C05382 11.83† 1.40† 0.83† 0.13† 2.16† 0.31†
phosphoenolpyruvate PEP C00074 0.15 0.01 0.02 0.00 0.07 0.01
fructose 6-phosphate F6P C05345 0.20 0.01 0.14 0.02 0.05 0.01
fructose 1,6-bisphosphate F1,6BP C05378 0.05 0.00 0.03 0.00 0.02 0.01
2-phosphoglycerate 2PG C00631
3-phosphoglycerate 3PG C00197 
glucose 1-phosphate G1P C00103 0.40 0.05 0.24 0.04 0.07 0.01
glucose 6-phosphate G6P C00668 1.58 0.09 1.26 0.21 0.45 0.12
glycerol 3-phosphate Gly3P C00093 0.39 0.07 0.16 0.01 0.14 0.02
mannose 6-phosphate M6P C00275 0.20 0.02 0.05 0.01 0.04 0.00
fumarate C00122 0.30 0.06 0.20 0.02 0.16 0.02
malate C00149  1.32 0.09 0.91 0.14 0.88 0.09
succinate C00042 5.10 0.06 4.15 0.38 12.37 1.09
2-Oxoglutarate 2OG C00026 0.28 0.01 0.33 0.00 0.19 0.03
cis-aconitate CA C00417 0.02 0.01 0.02 0.00 0.02 0.00
citrate C00158 1.47 0.09 2.31 0.09 1.69 0.13
orotate C00295 0.01 0.00 0.01 0.00 0.01 0.00
0.28 0.05
lmTKT+/+ lmtkt-/- lmtkt-/-  re-expressionKEGG IDAbbreviationMetabolite
0.060.970.56 0.04
 
* no calibration curve for E4P, values expressed as area ratio 12C/13C;†, no standard commercially available for sedoheptulose-7-phosphate, values expressed as area 
ratio 12C/13C; SD, standard deviation. 
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4.8.7 Interaction of TKT with PEX5 
In L. mexicana, transketolase was shown to have dual localisation between 
cytosolic and glycosomal compartments (Veitch, NJ et al. 2004) (section 4.2.3). 
However, it is not known how only a proportion of the enzyme localises to the 
glycosome. One possible explanation involves a conformational change in 
quaternary structure of the enzyme. 
Glycosomal enzymes have a peroxisomal targeting signal (PTS), which interacts 
with the peroxin receptor on the glycosome surface, to facilitate localisation to 
the glycosome (Jardim, A et al. 2000). There are two types of PTS; a C-terminal 
PTS-1 which interacts with Pex5, and N-terminal PTS-2 which interacts with 
Pex7. 
The PTS-1 is a carboxy terminal tripeptide motif, generally accepted as SKL, or 
derivatives with conservative substitutions at any of the three residues (Sommer, 
JM et al. 1992); the consensus sequence has been reported as 
(S/C/A),(K/R/H),(L/M) (Galland, N et al. 2007). For example, in T. brucei 427, 
the TKT PTS-1 motif is SHL, whereas in L. donovani, the TKT PTS-1 motif is SKM. 
The PTS-2 is an amino terminal nonapeptide motif with the following consensus 
sequence (R/K),(L/V/I),X5,(H/Q),(L/A), where X denotes any amino acid 
(Galland, N et al. 2007). The majority of glycosomal enzymes are thought to 
enter the glycosome via Pex5; consequently there is little data on Pex7 and PTS-
2 interactions. 
The interaction between the human peroxisomal targeting signal receptor 1 
(PXR1; GenBank accession ID U19721) (Dodt, G et al. 1995) of HsPex5 and the 
HsPST1 recognition motif is shown in Figure 4-27. The equivalent amino acids for 
the L. donovani peroxin 5 (LdPEX5; GenBank accession ID AAF67841) are shown 
in parenthesis. 
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Figure 4-27. Interaction of Pex5 and PTS1. 
Residues involved in the interaction of HsPex5 and PTS1. The PTS1 targeting signal (highlighted 
in red) is shown as YQSKL (in L. donovani this corresponds to SFSKM), hydrogen bonds are 
highlighted in blue, residues forming invariant interactions are highlighted in green, and those 
forming variable interactions are highlighted in black. Amino acid residue positions are shown for 
the interaction of HsPex5 and PTS1; the equivalent residues for L. donovani Pex5 (GenBank 
accession ID AAF67841) are shown in parenthesis. Figure adapted from Lanyon-Hogg T et al 
2010. Permission to reproduce this image has been granted by John Wiley and Sons. 
The crystal structure of L. mexicana TKT revealed that the PTS-1 protrudes from 
a crevice at the surface of the enzyme (Veitch, NJ et al. 2004). A 
conformational change, possibly due to substrate binding, may alter the 
flexibility of the C-terminal tail, and enable the SKM glycosomal targeting motif 
to alternate between a buried and exposed (Figure 4-28). A comparative 
sequence analysis between the L. donovani and L. mexicana sequences revealed 
that both enzymes have a serine-lysine-methionine (SKM) glycosomal targeting 
signal at the C-terminus of the TKT subunit, and the enzymes have a 92.1 % 
amino acid sequence identity (Supplementary Figure 8-3). 
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Figure 4-28. The alternating position of the Leishmania transketolase (TKT) PTS-1 (SKM) 
targeting signal. 
A – Transketolase enzyme with an ‘exposed’ PTS-1 (SKM) motif prior to binding of the substrate 
‘S’. B – Transketolase enzyme with a ‘buried’ PTS-1 (SKM) motif after binding of the substrate ‘S’. 
To investigate the association between the glycosomal LdPEX5 receptor and the 
LdTKT enzyme, the gene was cloned and expressed in E. coli (Clarke A, 
University of Glasgow). The cells expressing the LdTKT enzyme were sent to 
Professor Armando Jardim (McGill University, Montreal, Canada). The interaction 
between LdPEX5 and LdTKT was investigated in the presence of a range of 
substrates. As the concentration of transketolase increases, the absorbance 
measurements increase indicating an increase in interaction between 
transketolase and PEX5 (Figure 4-29). However, in the presence of ribose 5-
phosphate there is an increase in the dissociation constant for the TKT-LdPEX5 
interaction, and consequently, there is a decrease in the quantity of TKT binding 
to the LdPEX5. This does not occur in the presence of either F6P or Xu5P, unless 
R5P is also present. These results suggest that the in the presence of R5P there 
is a conformational change in TKT enzyme, and the SKM targeting signal is no 
longer exposed and able to interact with PEX5. 
Chapter 4, 179 
No substrate
Xu5P
F6P
R5P
R5P Xu5P
Xu5P F6P
 
Figure 4-29. Interaction of LdTKT with LdPEX5. 
Abbreviations; LdPEX5, Leishmania donovani peroxin 5; Xu5P, Xylulose 5-phosphate; F6P, 
Fructose 6-phosphate; R5P, Ribose 5-phosphate. 
These preliminary results indicate a decrease in interaction between the PEX5 
receptor and the L. donovani PTS-1 in the presence of R5P. This suggests that 
substrate availability; in this case R5P, has reduced the accessibility of the PTS-1 
motif to the PEX5 receptor, and consequently, might influence the sub-cellular 
localisation of TKT. This hypothesis could be investigated by generating a mutant 
enzyme which has additional amino acid residues prior to the PTS-1 motif, and is 
therefore unable to retract the PTS-1 in response to a conformational change. It 
would also be useful to create a tkt enzyme with no PTS-1 motif as a control.  
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4.9 Discussion 
To investigate whether transketolase (LmjF24.2060, EC 2.2.1.1), a key enzyme 
in the non-oxidative branch of the pentose phosphate pathway, was essential in 
L. mexicana promastigotes, the gene was targeted for deletion.  
The successful generation of transketolase null cell line indicates that the 
enzyme is non-essential in L mexicana promastigotes, when grown in a rich 
growth medium. There was no significant reduction in growth rate between the 
tkt null cells and the wild type cells under standard laboratory conditions, 
although the maximum cell density in the knockout cells is slightly lower than 
the wild type. 
The lmtkt-/- cells were twice as sensitive to pentamidine compared to the wild 
type cells, although there was almost no difference for methylene blue. It would 
appear that the absence of tkt has no effect on the regeneration of NAPDH (in 
contrast to the results observed by Stoffel SA). It may be of more interest to 
investigate glucose consumption in tkt knockout cells that are subject to 
oxidative stress. However, this would only be of interest if glucose was in 
limiting supply, and that the non-oxidative branch of the PPP was essential to 
return metabolites to the glycolytic pathway. In the case of T. brucei BSF cells, 
glucose is in high abundance, and as a result the cells can increase the uptake of 
glucose to meet NADPH demands, without jeopardising ATP production via 
glycolysis. This would explain why no tkt enzyme was detected in BSF 
trypanosomes (Cronin, CN et al. 1989). 
The pentose phosphate pathway functions to produce R5P for nucleotide 
biosynthesis and regenerate NADPH to defend against oxidative stress (Barrett, 
MP 1997). There was an accumulation of R5P in the knockout cell line, indicating 
that a functional transketolase enzyme, and thus the non-oxidative branch of 
the PPP, is responsible for metabolising a significant proportion of the R5P. The 
elevated levels of E4P would suggest that an alternative method of E4P 
production, independent of transketolase, is functional in L. mexicana, although 
the exact biochemical reactions remain uknown. 
Interestingly, the lmtkt-/- promastigotes do not acidify the medium to the same 
extent as the wild type cell line. Analysis of the spent medium indicated that 
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there was no significant difference in the quantity of glucose consumed per cell, 
and thus the cells undergo a metabolic shift in the absence of transketolase. It 
would appear that a functional non-oxidative branch of the PPP is required to 
recycle phosphorylated sugars, and return them to the glycolytic pathway. If 
transketolase is absent, then any flux through the oxidative branch of the PPP is 
unable to return to the glycolytic pathway. This may account for the reduced 
acidification of the medium, as less glucose is converted to organic acids for 
excretion. Instead, intracellular levels of R5P and R1P increase. 
There are several logical experiments which follow up from the initial 
observations regarding the colour change of the medium, presence of E4P, and 
the theory of a hidden or exposed PTS-1 targeting signal. 
1. Incubate cells in C13 labelled D-glucose 
In the absence of transketolase there remains a question as to what happens 
with the Ru5P, the end product of the oxidative branch of the PPP. Is there any 
mechanism by which flux can return to the glycolytic pathway? The classical 
pentose phosphate pathway would indicate not. R5P produced could be 
incorporated into nucleic acids or excreted as D-Ribose, both of which could be 
detected if labelled D-glucose was used. It is also possible that in the presence 
of methylene blue, the flux through the oxidative branch of the PPP would 
increase to meet the cellular NADPH demand. 
2. Incubate cells in C13 labelled D-ribose. 
D-ribose is converted to R5P, and, in the absence of TKT, cannot continue 
through the non-oxidative branch of the PPP. If D-ribose is converted to 
intermediate metabolites of the non-oxidative branch of the PPP or the 
glycolytic pathway, it would indicate there are additional enzymes responsible 
for these metabolic changes. 
3. Investigate transaldolase activity in the wild type and ∆TKT null cells. 
Typically, E4P is produced when transaldolase transfers a 3-carbon subunit from 
S7P to GA3P. If transaldolase activity in the tkt null cells is detected, then this 
would imply that there is an additional source of S7P. If there is no transaldolase 
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activity, then it should be possible to generate a translaldolase knockout in the 
tkt null cell line. This would confirm a source of E4P independent of the classical 
non-oxidative branch of the PPP. 
4. Introduce a mutant enzyme into the TKT null background 
One of the most useful aspects of generating a knockout cell line is the ability to 
introduce a mutant copy of the gene back into the cell, and investigate the 
effects of that mutant enzyme. Initial studies could focus on the comparing 
metabolic profiles and enzyme localisation studies if changes are made to the 
PTS-1 targeting signal. If the PTS-1 targeting signal is capable of alternating 
between a buried and exposed state, then it should be possible to introduce 
several glycine residues prior to the PTS1. This would ensure that the targeting 
signal was always exposed, regardless of the substrates available. Furthermore, 
the PTS-1 targeting signal could be deleted to prevent glycosomal localisation. 
These mutant proteins could be introduced into the lmtkt-/- cell line; metabolic 
profiles and TKT localisation could be compared. 
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5 Pentamidine resistance in L. mexicana 
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5.1 Introduction 
Aromatic diamidines (AD), such as pentamidine isethionate, have been 
extensively studied and shown to have potent activity against a wide range of 
microorganisms, including the protozoan parasites of the Trypanosoma and 
Leishmania spp (Bray, PG et al. 2003). 
Pentamidine isethionate, first synthesised in the 1930’s (Sands, M et al. 1985), 
has been used in the treatment of the first stage of Trypanosoma brucei 
gambiense infections. However, the drug is less useful against late stage 
infections; pentamidine does not cross the BBB efficiently, and consequently, 
does not accumulate in the CNS to sufficient levels (Bray, PG et al. 2003). 
Pentamidine is less useful in the treatment of Trypanosoma brucei rhodeseinse 
infections, as invasion of the CNS is rapid in comparison to T.b. gambiense 
infections. There is no widespread resistance to pentamidine in the field (Bray, 
PG et al. 2003), and in addition, was found to be effective against cell lines 
resistant to arsenicals (Van Hoof, LM 1947). The drug has also  been used in the 
treatment of both visceral and mucocutaneous leishmaniasis since 1952, as an 
alternative to pentavalent antimonials which for many years were used in the 
first line of defence (Sands, M et al. 1985; Becker, I et al. 1999; Croft, SL et al. 
2006). Antimony resistant Leishmania mexicana amazonensis (WR 227) and L. 
donovani (WR 271) amastigotes are susceptible to concentrations of pentamidine 
that can be achieved in human serum (Berman, JD 1982). 
Whilst pentamidine is effective in the treatment of HAT, the drug does pose 
several problems; these include toxicity issues, high production costs, 
distribution difficulties, and the fact the drug can only be administered 
parenterally, either intramuscularly or intravenously. Pentamdine and other 
aromatic diamidine compounds are cationic, and thus are not effective by oral 
administration. 
5.1.1 Cellular target of diamidines 
The definitive cellular target and mode of action of the AD compounds remains 
unknown (Paine, MF et al. 2010); however, several theories have been 
postulated. 
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There have been many observations that pentamidine accumulates in the 
mitochondrion (Ludewig, G et al. 1994; Lanteri, CA et al. 2004), binding to the 
kinetoplast DNA (kDNA). Disruption of the kDNA network is evident with an 
increase in free minicircles, indicative of inhibition of mitochondrial 
topoisomerase II (Shapiro, TA 1993). 
The kDNA has a higher adenine and thymine content than nuclear DNA which 
might explain a preferential binding to this organelle given the higher binding 
efficiency of diamidines for the minor groove of AT rich DNA. It has been 
demonstrated that mice infected with a dyskinetoplast strain of trypanosomes 
do not survive when treated with berenil. However, mice infected with a wild 
type strain are cured upon the induction of berenil treatment, thus indicating 
that the presence of an intact kinetoplast is an essential target for diamidine 
action. (Agbe, A and Yielding, KL 1995). A dyskinetoplastid strain of T. brucei 
was approximately 4-fold more resistant to pentamidine when compared to the 
isogenic parental cell line (Gould MK, personal communication) indicating that 
whilst the kinetoplast is a target for pentamidine, other cellular targets are 
likely to play a prominent role. 
5.1.2 Biological target of diamidines 
Crystalisation studies between AD compounds and the DNA duplex 
d(CGCGAATTCGCG) indicates these compounds bind with high affinity to a 
central AATT sequence within the minor groove of the DNA through a series of 
non-covalent and non-intercalative interactions  (Hajduk, SL 1978; Nguyen, B et 
al. 2002). There is also a clear correlation between the molecular structure and 
biological activity of these compounds, with the molecular curvature of the 
compound critical for recognition. Ideally the amidine groups should be located 
at the para- positions of the phenol rings, as is the case with pentamidine and 
furamidine (also know as DB75, an aromatic diamidine that in its methoxy 
prodrug form DB289 entered clinical trials against human African trypanosomiasis 
(Paine MF et al., 2010)). Conversely, meta- substituted analogues such as DB359 
have reduced anti parasitic properties as the compound does not complement 
the curvature of the DNA, and consequently binds more weakly to the central 
AATT sequence. The amidine residues are able to form H-bonds bases at the 
bottom of the minor groove (Nguyen, B et al. 2002). Further stabilisation of the 
complex is achieved via Wan der Waals interactions between the groove wall and 
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the diamidine compound, and electrostatic interactions between anionic charges 
on the DNA backbone and the amidine charges (Paine, MF et al. 2010). 
5.2 Pentamidine and trypanosomatids 
In recent years, a number of pentamidine resistant trypanosome (Berger, BJ et 
al. 1995; Bridges, DJ et al. 2007) and pentamidine resistant Leishmania 
(Basselin, M et al. 1997; Basselin, M et al. 2002; Mukherjee, A et al. 2006) cell 
lines have been generated in vitro. Whilst there may be significant differences 
between laboratory-derived drug resistant cells and field isolates, the ability to 
generate drug resistant lines in the laboratory and compare them to isogenic 
progenitor cell lines has been crucial in developing our understanding of 
resistance mechanisms. For example, protozoan parasites are unable to 
synthesise purines de novo, and consequently obtain these metabolites from 
their hosts (Bellofatto, V 2007). Therefore, research has focused on the 
transport mechanisms in which pentamidine, and other related diamidine 
compounds, enter the cells.  
5.2.1 Pentamidine transport in trypanosomes 
Transporters have been identified as the mechanism by which AD compounds 
cross biological membranes; the rate of diffusion is slow, and thus it takes 
several days for these compounds to kill parasites in vitro. The aminopurine 
transporter TbAT1/P2 (Tb927.5.286b) (Carter, NS and Fairlamb, AH 1993; Maser, 
P et al. 1999) recognises compounds with adenine-, adenosine-, amidine-, and 
melamine moieties (Paine, MF et al. 2010), and is the main transporter for 
diamidine compounds, responsible for approximately half of the pentamidine 
uptake in trypanosomes (de Koning, HP 2008). Loss of the P2 transporter confers 
increased resistance to pentamidine (Matovu, E et al. 2003), DB75 (Lanteri, CA 
et al. 2006), and diminazene (Barrett, MP et al. 1995). However, the loss in 
sensitivity towards these diamidine compounds is minor, indicating the existence 
of multiple pentamidine transporters (de Koning, HP 2001; de Koning, HP and 
Jarvis, SM 2001). These include the High-affinity pentamidine transporter 
(HAPT1), and the Low-affinity pentamidine transporter (LAPT1) (de Koning, HP 
and Jarvis, SM 2001). 
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High level resistance to pentamidine was achieved through resistance induction 
in a cell line lacking the TbAT1 gene. Biochemical characterisation of this cell 
line, designated TbAT1 -/- B48, indicated the loss of the HAPT, however the 
LAPT activity remaining unchanged (Bridges, DJ et al. 2007). The genes 
responsible for encoding HAPT and LAPT have not currently been identified at 
the molecular level. 
The existence of multiple transporters involved in pentamidine uptake may offer 
an explanation as to why clinical resistance is not widespread; despite extensive 
use, it remains the drug of choice in more than 90% of cases. 
5.2.2 Pentamidine transport and efflux in Leishmania 
Whilst pentamidine enters trypanosomes via an aminopurine transporter, P2, and 
other transporters whose substrate specificity is not known, this is not the case 
in Leishmania. In L. mexicana, pentamidine is transported into the cells by an 
unknown pentamidine transporter, designated LmexPT1, with similar affinity to 
that of the LAPT in trypanosomes. The drug rapidly accumulates in the 
mitochondrion via an unknown carrier or transporter, with significant quantities 
binding to the kDNA within minutes (Basselin, M et al. 2002). However, it has 
also been postulated that polyamine transporters are responsible for uptake in 
both L. donovani and L. amazonesis as pentamidine competively inhibits 
polyamine uptake (Basselin, M et al. 1996). However, polyamines do not inhibit 
pentamidine uptake in L. mexicana ruling these carriers out (Basselin, M et al. 
2002). 
A common transport system does exist for the aromatic diamidine compounds in 
L. mexicana (Basselin, M et al. 2002) and L. donovani (Mukherjee, A et al. 2006), 
as demonstrated by the competitive inhibition of pentamidine transport using 
several aromatic diamdine compounds including propamidine, stilbamidine, 
berenil and DAPI. 
Interestingly, pentamidine is a competitive inhibitor of arginine transport in L. 
mexicana promastigotes and amastigotes; however conversely, arginine does not 
inhibit pentamidine transport. This implies that whilst pentamidine interacts 
with the arginine transporter, it does not enter the parasite via this transporter 
(Basselin, M et al. 2002). Similarly, pentamidine was found to be a non-
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competitive inhibitor of both putrescine and spermidine transport in various 
Leishmania species (Basselin, M et al. 2000), although does not enter the 
parasites via these transporters. 
To determine the specificity of the pentamidine transporter, a total of 52 
commonly occurring Leishmania metabolites, including polyamines, amino acids, 
nucleosides, and nucleobases, were tested to see if they inhibited uptake of 
pentamidine (Basselin, M et al. 2002). None of these were shown to inhibit 
pentamidine transport. The only inhibition observed was with two peptides rich 
with basic amino acids, various inorganic divalent cations, and Taurocholate 
(C05122). Interestingly, and in contrast to the situation in trypanosomes, 
pentamidine was not inhibited by nucleosides and nucleobases, despite 
considerable homology between the trypanosome nucleoside transporter TbAT1 
and L. donovani nucleoside transporters LdNT1.1 and LdNT1.2. 
A comparison between drug resistant and drug sensitive L. mexicana 
promastigotes and amastigotes indicated that there was no difference in the 
affinity for pentamidine or the rates of uptake between the two cell lines 
(Basselin, M et al. 2002). This suggests that in these particular cell lines, and in 
contrast to trypanosomes, there was no genetic alteration to the transport 
system responsible for uptake at the plasma membrane, and pentamidine enters 
both wild type and resistant cells via the same plasma membrane transporter. 
DAPI, a fluorescent analogue of pentamidine, binds to the kDNA in wild type 
cells, but not pentamidine resistant cells (Basselin, M et al. 2002). However, if 
the resistant cells are treated with digitonin, a compound which permeabilises 
cell membranes, then DAPI is able to accumulate in the mitochondrion and bind 
to kDNA in a manner similar to that in wild type cells. Therefore, the resistant 
cells have a diminished ability to transport pentamidine and similar compounds 
into the mitochondrion and kinetoplast, as opposed to a reduction in the ability 
of these compounds to bind to the kDNA. 
In pentamdine resistant L. mexicana promastigotes there is a decreased 
mitochondrial membrane potential (MMP), resulting in less pentamidine 
accumulating in the mitochondrion and kinetoplast (Basselin, M et al. 2002). 
Consequently, the majority of pentamidine remains in the cytosol, or as 
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membrane-associated pentamidine, both of which are removed from the cell by 
efflux pumps. This model is depicted in Figure 5-1. 
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Figure 5-1. Model for pentamidine uptake in Leishmania mexicana promastigotes. 
Pentamidine is transported to the cytoplasm by a pentamidine transporter, with similar affinity to the 
Trypanosome LAPT1, and is concentrated in the mitochondrion by an unknown carrier or channel. 
Abbreviations: M, mitochondrion; C, cytoplasm; N, nucleus; F, flagellum; LmexPT1, Leishmania 
mexicana pentamidine transporter 1; E, efflux pump; U, unknown carrier or transporter. 
An energy dependent efflux pump is thought to be responsible for removing 
membrane associated and cytosolic pentamidine from L. mexicana (Basselin, M 
et al. 2002). The resistance phenotype has no influence on the rate of 
pentamidine efflux, with similar rates reported for both the wild type and 
resistant cells, implying that the efflux system cannot explain the resistance 
phenotype. The efflux pump can be inhibited with Trifluoperazine (TFP; 
D08636), PCP, and Verapamil (D02356), all of which are known inhibitors of the 
P-glycoprotein transporter. Consequently, similar levels of pentamidine 
accumulate in the cytoplasm of resistant cells as would normally accumulate in 
the wild type cells (Basselin, M et al. 2002). A similar study in L. donovani 
indicated that pentamidine resistant cells in the presence of these P-
glycoprotein inhibitors accumulated pentamidine to similar levels as cells in the 
absence of inhibitors, thus suggesting that the L. donovani pentamidine efflux 
system is not as prominent as in L. mexicana (Mukherjee, A et al. 2006). 
5.2.3 Accumulation of pentamidine in trypanosomatids 
The effectiveness of AD has been attributed to selective accumulation by the 
pathogen, before the host cell. Pentamidine, and other aromatic diamidine 
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compounds, rapidly accumulate to toxic levels in trypanosomatids (millimolar), 
concentrating in the nucleus and mitochondrion. Whilst these compounds bind to 
DNA in both the nucleus and kinetoplast, the cationic nature of these drugs 
suggests that pentamidine binds to numerous proteins in the cell, and thus 
interferes with numerous cellular processes. 
Pentamidine resistant trypanosomes accumulated pentamidine at a slower rate 
than pentamidine sensitive trypanosomes, although both were equally as 
sensitive to the same millimolar concentrations (Damper, D and Patton, CL 
1976). The deletion of the P2 transporter (Matovu, E et al. 2003) and loss of the 
HAPT through stepwise exposure to pentamidine (Bridges, DJ et al. 2007) in 
bloodstream form T. brucei leads to a reduction in the uptake of pentamidine 
and related diamidine compounds. These data imply that the mode of resistance 
in the cell lines investigated was due to alterations to the transporters on the 
plasma membrane, and consequently leads to a reduction in drug accumulation. 
In Leishmania the situation is more complex, as the rate of uptake remains 
similar for both wild type and pentamidine resistant parasites. However, 
pentamidine resistant L. mexicana (Basselin, M et al. 2002) and pentamidine 
resistant L. donovani (Mukherjee, A et al. 2006) have a reduced mitochondrial 
membrane potential (MMP), demonstrated using rhodamine-123 (C11190). 
Therefore, less pentamidine accumulates in the mitochondrion, with the 
majority remaining in the cytosol. Consequently, cytosolic or membrane-
associated pentamidine is removed from the cell by efflux pumps (section 
5.2.2). 
5.2.4 Summary of pentamidine and trypanosomatids 
Whilst pentamidine and related diamidine compounds target the mitochondrion, 
binding to the kDNA, in both Leishmania and trypanosomes, the mechanisms of 
drug resistance are distinctly different. In trypanosomes, alterations to various 
nucleoside and nucleobase transporters on the plasma membrane causes a 
reduction in drug uptake resulting in less pentamidine accumulating in the cell. 
In Leishmania there is no difference in drug uptake between wild type and 
pentamidine resistant strains, however a reduced mitochondrial membrane 
potential causes less pentamidine to accumulate in the mitochondrion, with 
efflux pumps removing the cytosolic pentamidine. 
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5.2.5 Pentamidine in Yeast 
In Saccharomyces cerevisiae, low concentrations of pentamidine inhibit growth 
on non-fermentable energy sources; whereas high concentrations induce a 
‘petite’ phenotype, typical of mutations in the mitochondrial genome (Ludewig, 
G et al. 1994). DB75, a structural analogue of pentamidine, is fluorescent at high 
concentrations. In both yeast and trypanosomes, DB75 localises to, and 
accumulates in, the mitochondrion; and as a result inhibits mitochondrial 
function (Lanteri, CA et al. 2004; Lanteri, CA et al. 2008). These data suggest 
that the mitochondrion is the primary cellular target for the diamidine 
compounds. Additionally, pentamidine has been reported to inhibit ATP-
dependent DNA topoisomerases (Ludewig, G et al. 1994) and mitochondrial 
topoisomerase II in trypanosomes (Shapiro, TA 1993). 
A pentamidine resistance gene, mitochondrial integral inner membrane protein  
PNT1, was identified in S. cerevisiae (Ludewig, G et al. 1994). The copy number 
of this gene was linked with pentamidine resistance. Cells in which the PNT1 
gene had been disrupted were hypersensitive to pentamidine, whereas those 
expressing more copies of the gene were hyposensitive to pentamidine (Ludewig, 
G et al. 1994). 
Pentamidine resistant Leishmania mexicana have a reduced mitochondrial 
membrane potential (Basselin, M et al. 2002), and therefore less pentamidine 
accumulates in the mitochondrion, with the majority remaining in the cytosol. 
Cytosolic or membrane-associated pentamidine is removed from the cell by 
efflux pumps. 
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5.3 Summary of L. donovani pentamidine resistance 
Pentamidine resistant Leishmania donovani promastigotes were generated in 
vitro by gradually increasing drug pressure until cells were capable of growth in 
8 µM pentamidine (Mukherjee, A et al. 2006). This pentamidine resistant cell 
line was designated R8. 
In that study, the pentamidine resistant cells were cross-resistant to other 
diamidine compounds including propamidine, stilbamidine, berenil, DAPI, and 
DB99; however, there was no cross-resistance to substrates of multidrug 
resistant proteins, in contrast to L. mexicana (Basselin, M et al. 2002), or 
antimonial compounds. 
Also in that study, wild type parasites treated with pentamidine and the 
pentamide resistant line were shown to have a reduced ability to take up 
Rhodamine -123 in comparison to untreated wild type cells, thus indicating a 
decrease in the MMP. 
Furthermore, short term radio-labelled uptake assays did not reveal any 
difference in pentamidine uptake between the wild type and resistant lines. 
However a 5.4 fold difference was evident over three hours. The intracellular 
concentration of wild type and resistant cells were 3.8 µM and 0.77 µM 
respectively. 
Whilst no diamidine transporter has been identified at the molecular level, there 
is biochemical evidence of two pentamidine transporters in L. donovani 
promastigotes. One of which is a saturable high affinity transporter present at 
the plasma membrane, and the second is a non-saturable low affinity 
transporter, which is not as prominent in the resistant line, at the mitochondrial 
membrane. In contrast to L. mexicana, there is no evidence of pentamidine 
efflux in L. donovani. 
A proteomic analysis was carried out on the R8 line compared with its wild type 
precursor (Poonam Tewary, NCI NIH, Washington D.C.). Using Difference gel 
electrophresis (DiGE), several modulated proteins were identified. Interestingly, 
the glycolytic enzymes phosphoglucose isomerise (PGI; EC 5.3.1.9) and enolase 
(EC 4.2.1.11) were up-regulated 3.55-fold and 6.67-fold respectively, in the 
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resistant cell line, suggesting an increased demand for glucose. However, the 
5.97-fold down-regulation of pyruvate kinase (PK; EC 2.7.1.40) in the resistant 
cell line indicates a reduction in the conversion of phosphoenolpyruvate (PEP; 
C00074) to pyruvate. In the proposed model for Leishmania central carbon 
metabolism, PEP is first converted to pyruvate, before re-entering the 
glycosome where it is converted to succinate (Rosenzweig, D et al. 2008). Down 
regulation of PK would result in a reduction in glycolytic flux as this step would 
form a ‘bottle neck’ in the pathway. However, the model for procylic form 
trypanosomes is different; PEP is thought to re-enter the glycosome, where it is 
converted to succinate (Ebikeme, C et al. 2010). Consequently, there would be a 
down regulation in acetate production, compensated by an increase in succinate 
production. The accumulation of pentamidine in the cytosol of resistant 
parasites could have an influence on pyruvate kinase levels, given the enzyme is 
cytosolic.  
Table 5-1. Proteins down-regulated in the L. donovani pentamidine resistant (R8) cells.  
Protein Protein Accesion ID Average Ratio
Pyruvate kinase LmjF35.0030 5.97
Beta tubulin LmjF33.0798 4.83
Aspartate aminotransferase LmjF35.0820 3.19
Proteosome reg subunit 5 LmjF22.0620 3.02  
Peptides were matched against the L. major protein database. Only proteins greater than a three-
fold difference are shown. 
Table 5-2. Proteins up-regulated in the L. donovani pentamidine resistant (R8) cells. 
Protein GeneDB Accesion ID Average Ratio
NADP dependent alcohol dehydrogenase LmjF23.0360 27.04
Methionine synthase LmjF31.0010 13.58
Carboxypeptidase LmjF33.2540 9.58
Transketolase LmjF24.2060 8.19
Enolase LmjF14.1160 6.67
Hypothetical protein, conserved LmjF25.2010 6.57
Amino peptidase LmjF11.0630 5.95
Proteosome beta 1 subunit LmjF12.0030 5.73
ATP dependent dead box helicase LmjF35.0370 4.44
Carboxypeptidase LmjF33.2540 4.38
Aspartyl tRNA synthatase LmjF30.0460 4.26
Glucose-6-phosphate isomerase LmjF12.0530 3.55
t complex prt LmjF23.1220 3.42
thiol dependent reductase LmjF33.0240 3.17
proteosome reg non ATPase subunit 5 LmjF21.0760 3.06
fumarate hydratase LmjF29.1960 3.04  
Peptides were matched against the L. major protein database. Only proteins greater than a three-
fold difference are shown. 
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The comparative proteomic analysis of the wild type and pentamidine resistant 
(R8) L. donovani cell lines indicated a significant number of modulated proteins. 
However, prior to further proteomic analysis, and subsequent gene knockout 
investigations and metabolomic analysis, it was necessary to confirm that these 
cell lines were isogenic to confirm that the adaptations were due to pentamidine 
resistance, and not to differences between species. 
Chapter 5, 195 
5.4 Species Identification 
Leishmania species are morphologically very similar, and are therefore difficult 
to distinguish from one another by microscopic examination. It is important to 
distinguish medically relevant species of Leishmania from one another so the 
most appropriate treatment can be administered; especially in geographical 
areas where multiple Leishmania species co-exist. Furthermore, identification 
based on clinical symptoms is not always possible as some species may cause 
multiple clinical manifestations of the disease. A diagnostic PCR and restriction 
digest was developed to distinguish between medically relevant species 
(Schonian, G et al. 2003). Although this approach was intended for the 
identification of field isolates; it is also a suitable method for the identification 
of laboratory species. 
Amplification of the ribosomal ITS1 located between the genes coding for the ssu 
and the 5.8S rRNA (Schonian, G et al. 2003) produces a PCR product that varies 
in size and nucleotide sequence depending on the Leishmania species (Davila, 
AM and Momen, H 2000). Subsequent digestion of these PCR products using the 
restriction endonuclease HaeIII produces a RFLP pattern which can be used to 
distinguish between clinically relevant species as illustrated in Figure 5-2A 
(Schonian, G et al. 2003). This approach was used to genotype the wild type and 
pentamidine resistant (R8) L. donovani cell lines 
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Figure 5-2. Leishmania Species Identification. 
Digestion of amplified ITS1 regions of different Leishmania species with the restriction 
endonuclease HaeIII. A – Restriction digest profiles of medically relevant Leishmania spp. 
Reproduced from Schönian G et al 2003. Permission to reproduce this image has been granted by 
Elsevier. B – Restriction digest profiles of the L. donovani wild type (wt) and pentamidine resistant 
(R8) cell lines, and other species used in the laboratory. The lanes are as follows, A; 1, 123 bp 
ladder; 2, L. donovani MHOM/IN/80/DD8; 3, L. infantum MHOM/TN/80/IPT1; 4, L. chagasi 
MHOM/PA/79/WR317; 5, L. aethiopica MHOM/ET/94/Gere; 6, L. tropica MHOM/SU/74/SAF-K27; 
7, 100 bp ladder; 8, L. major MHOM/SU/73/5ASKH; 9, L. mexicana MHOM/MX/85/SOLIS; 10, L. 
amazonensis MHOM/BZ/73/M2269; 11, L. braziliensis MHOM/BZ/75/M2903; 12, L. guyanensis 
MHOM/BR/75/M4147; 13, L. panamensis MHOM/CR/87/NEL3; 14, 123 bp ladder. B; 1, 100 bp 
ladder; 2, L. donovani MHOM/IN/1983/AG83 wild type; 3, L. donovani MHOM/IN/1983/AG83 
pentamidine resistant (R8); 4, L. infantum JPCM5 MCAN/ES/98/LLM-877; 5, 100 bp ladder; 6, L. 
mexicana MNYC/BZ/62/M379; 7, L. major LV39c5 MRHO/SU/1959/Neal P; 8; negative control; 9, 
100 bp ladder. The 100 bp marker was supplied by Promega. 
The results of the species identification test indicate that the wild type L. 
donovani AG83 and the derived pentamidine resistant (R8) cell lines currently 
present in the laboratory were not isogenic as they did not produce identical 
HaeIII restriction digest profiles (Figure 5-2B – lanes 2 and 3). Subsequently, a 
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comparison with the HaeIII restriction digest profiles published by Schönian G. et 
al 2003 suggested that the L. donovani AG83 wild type cell line may be L. 
tropica (Figure 5-2A – lane 6). Furthermore, the L. infantum control gDNA used 
in the experiment (Figure 5-2B – lane 4) has the same restriction digest profile as 
L. major (Figure 5-2A - lane 8; Figure 5-2B – lane 7). These results highlight the 
importance of regularly testing parasite cell lines to minimise the chances of any 
mistakes occurring. The RFLP profiles of the L. donovani (Figure 5-2A – lane 2), 
L. infantum (Figure 5-2A – lane 3), and L. mexicana (Figure 5-2A – lane 9) are 
similar, but the following differences are observed. The two lower bands of the 
L. mexicana profile run slightly higher than the corresponding bands for the L. 
donovani and L. infantum; additionally, there difference in size between the 
two bands is greater in L. mexicana. Given the similarities between these cell 
lines it is essential to use the appropriate experimental controls to discriminate 
between these species which are routinely used in the Wellcome Trust Centre 
for Molecular Parasitology, Glasgow. 
As the L. donovani wild type and pentamidine resistant cell lines kept at the 
University of Glasgow did not appear to be isogenic, it was necessary to 
investigate the genotype of the original cell lines stored at Jawaharlal Nehru 
University, New Dehli, India. The analysis of theses cell lines, courtesy of Prof. 
Rentala Madhubala (School of Life Sciences, Jawaharlal Nehru University, New 
Delhi, India), was inconclusive in determining that these lines were L. donovani 
and isogenic. There appeared to be two fragments in the wild type sample 
(Figure 5-3 – lane 1), corresponding to ~180 bp and ~ 100 bp; however, an 
additional fragment of ~250 bp was present in the resistant line (Figure 5-3 – 
lane 3). It is possible that this fragment could arise from the incomplete 
restriction digest of ITS1. The expected sizes of the fragments for the L. 
donovani are approximately 200 bp, 90 bp, and 60 bp. The absence of a 
definitive 3rd fragment in both wild type AG83 and the R8 are unlikely to be due 
to PCR error, as the ITS1 is a tandem repeat region, and therefore should 
amplify easily. Sequence analysis of the ITS1 region may provide a clear 
indication as to whether these particular cell lines are L. donovani, or another 
Leishmania spp. 
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Figure 5-3. L. donovani species identification. 
Digestion of amplified ribosomal internal transcribed spacer 1 (ITS 1) regions of the L. donovani 
AG83 (MHOM/IN/1983/AG83) wild type and R8 cell lines with the restriction endonuclease HaeIII. 
The lanes are as follows; 1, L. donovani AG83 wild type; 2, 100 bp ladder; 3, L. donovani R8. The 
supplier of the 100 bp ladder is unknown. Image supplied by Prof. Rentala Madhubala, School of 
Life Sciences, Jawaharlal Nehru University, New Delhi, India. 
In summary, these results do not demonstrate that the lines are that of L. 
donovani and isogenic, and as a consequence it was decided to select new 
pentamidine resistant lines for further analysis. 
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5.5 Generating pentamidine resistant promastigotes 
As the analysis of the ITS1 spacer region indicated that the L. donovani wild type 
and pentamidine resistant (R8) cell lines in our possession were non-isogenic, 
and therefore of limited value to try and understand specific changes associated 
with drug resistance. Consequently, it was necessary to generate an alternative 
pentamidine resistant cell line. 
Initially, wild type L. mexicana promastigotes were grown in various 
concentrations of pentamidine (Table 5-3); and cell growth compared to that of 
control cells grown in the absence of pentamidine. These results indicate that 
250 nM pentamidine is too toxic for wild type cells, and that 125 nM pentamidine 
is the maximum concentration that is tolerated by the cells. Additionally, cells 
at 62.5 nM and 31.25 nM pentamidine appeared to grow normally, indicating the 
pentamidine accumulation may not be sufficient to perturb the physiological 
state of the cell. In order to maximise the chance of generating a resistant cell 
line, the pentamidine drug pressure was applied to two independent wild type 
cell lines. 
Table 5-3. Growth of wild type L. mexicana at various concentration of pentamidine 
Pentamidine [nM] Growth rate observations
500 cells died
250 cells died
125 cells grew slowly
62.5 cells grew at a similar rate to the control
31.25 cells grew at a similar rate to the control
0 cells appeared to grow normally  
Pentamidine resistant L. mexicana were raised in the laboratory by stepwise 
exposure to increasing drug pressure, starting at 125 nM pentamidine, until cells 
capable of growth in 8 µM pentamidine had been selected. This drug 
concentration was chosen based on the final dose selected under drug pressure 
achieved for the R8 pentamidine resistant L. donovani cell line (Mukherjee, A et 
al. 2006). 
The progress of the pentamidine resistance induction is shown in Figure 5-4. The 
scatter graph depicts the maximum pentamidine concentration the cells were 
subjected to, and survived in, over the course of 330 days. Whilst two 
independent cell lines were generated, only one cell line was chosen for 
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analysis. It is important to remember that two independently derived clonal cell 
lines will not necessarily have the same mechanism of resistance, and that any 
mechanism of resistance could be one of many. 
The cells were normally grown at two different pentamidine concentrations; a 
concentration equal to previous passage, and one that was double the previous 
passage. This process ensured that if the higher concentration of pentamidine 
was toxic to the cells, there was a back-up cell culture at a tolerated 
concentration of pentamidine. A reduced growth phenotype was evident when 
the cells were introduced to a higher drug pressure than the previous passage. 
However, if the cells were maintained at a constant selection pressure, the 
reduced growth phenotype was less pronounced at further passages. At various 
points, the cells were cloned by limiting dilution in the absence of drug 
pressure; these are indicated by red dots (Figure 5-4). Immediately after a 
clonal line was generated, the cells were returned to a concentration of 
pentamidine to which the cells were previously exposed. The resistant strain 
generated, designated B5111, was capable of surviving in pentamidine 
concentrations 64-fold higher than those tolerated by the wild type parental 
strain. 
The acquisition of resistance was non-linear; for example, 4 µM pentamidine was 
the maximum concentration that the cells were able to tolerate for around 100 
days between day 190 and day 290, however, approximately 20 days later (day 
310) the cells were able to survive at a concentration of 8 µM. This would 
suggest that a single event is responsible for a sudden increase in resistance, or 
that multiple events contribute to a sudden increase in resistance. Similar 
observations have been noted in the generation of pentamidine resistant 
Trypanosoma brucei (Bridges D 2006, PhD Thesis) and diminazine resistance in 
Trypanosoma evansi (Osman, AS et al. 1992). 
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Figure 5-4. Acquisition of resistance to pentamidine over time in L. mexicana wild type 
promastigotes. 
The blue dots indicate the maximum concentration of pentamidine in which the cells were growing 
at a rate comparable to the wild type cell line. The red dots indicate the points at which the resistant 
parasites were cloned (in the absence of pentamidine) and cryo-preserved. 
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5.6 Species Identification 
The discrepancy between the authenticity of the L. donovani AG83 wild type and 
pentamidine resistant R8 cell lines reiterates the importance of genotyping cell 
lines prior to any comparative analysis. Therefore, the L. mexicana wild type 
and pentamidine resistant cell lines were genotyped to ensure the both cell lines 
were isogenic as previously described (section 5.4). The gDNA isolate from other 
Leishmania species routinely used in the lab were used as controls. 
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Figure 5-5. Species Identification. 
Digestion of amplified ribosomal internal transcribed spacer 1 (ITS 1) regions of the different 
Leishmania species with the restriction endonuclease HaeIII. The lanes are as follows; 1, 100 bp 
ladder; 2, L. mexicana wild type; 3, L. mexicana pentamidine resistant; 4, L. mexicana positive 
control; 5, L. major; 6, L. infantum; 7, L. donovani wild type; 8, L. donovani pentamidine resistant 
(R8). The 100 bp ladder is supplied by Promega. 
The RFLP profiles generated by HaeIII restriction digests for both the L. 
mexicana wild type and L. mexicana pentamidine resistant lines (Figure 5-5 – 
lanes 2 and 3 respectively) were identical to the profiles obtained from the L. 
mexicana control cell line (Figure 5-5 – lane 4; provided by Professor JC 
Mottram), and those outlined in Schonian G. et al. 2003. Furthermore, the RFLP 
profiles generated from the L. major, L. infantum, and L. donovani control gDNA 
samples were identical to those described in Schonian G. et al. 2003. 
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These results demonstrated that the L. mexicana wild type and L. mexicana 
pentamidine resistant lines described in this thesis are isogenic, and that any 
differences between them are not due to speciation differences. 
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5.7 Phenotypic Analysis 
5.7.1 Growth phenotype 
The growth of L. mexicana pentamidine resistant cells in both the presence and 
absence of 8 µM pentamidine was compared to that of the wild type cell line. 
The resistant cells grown in the absence of pentamidine had a similar growth 
phenotype to the wild type cell line; however, the wild type cells reached a 
stationary phase density of around 1.8 x107 cells per ml, compared to 1.6 x 107 
cells per ml for the resistant cell line. The pentamidine resistant cell line grown 
in the presence of pentamidine had a slight increase in the lag time when 
compared to those grown in the absence of pentamidine; however, both these 
cell lines a maximum density of 1.6 x 107 cells per ml. 
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Figure 5-6. Effect on the growth of wild type and pentamidine resistant L. mexicana 
promastigotes.  
The cell lines were counted over a 7 day period, with the pentamidine resistant line grown in both 
the absence and presence of 8 µM pentamidine. Three cultures of each cell line were counted to 
generate a mean value +/- SEM. 
5.7.2 Alamar Blue Assay 
Whilst the pentamidine resistant line generated was capable of growth in 8 µM 
pentamidine, compared to 0.125 µM pentamidine for the parental cell line. It 
was also necessary to determine the EC50 value, the concentration of drug which 
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inhibits 50 % of cellular function, of both the wild type and pentamidine 
resistant lines to determine the toxicity of pentamidine and other potential 
leishmaniacidal compounds. 
The Alamar Blue assay is an effective assay to measure metabolic function and 
cellular activity in a variety of organisms (Raz, B et al. 1997). The assay involves 
the conversion of resazurin, a blue non-fluorescent dye, to resorufin, a pink 
fluorescent dye. The EC50 value can be easily calculated for each compound, and 
then compared with one another. This assay was used to determine the 
sensitivity to pentamidine, and a range of leishmaniacidal compounds, of both 
the pentamidine resistant clone B5111 and the parental cell lines. These results 
are displayed in Figure 5-7 and summarised in Table 5-4. 
The pentamidine resistant cell line expressed cross-resistance to both 
diminazine (8.7-fold) and DB75 (7.6-fold) (Table 5-4). These data suggest that 
diminazine and DB75 share a common transport mechanism and mode of action 
to that of pentamidine.  
Interestingly, there was only moderate cross resistance (2.0-fold) to DB766, an 
arylimidamine (AIA) compound, indicating that this compound may have an 
alternative mode of action. DB766 is a structural analogue of cationic 
diamidines, although differ from diamidine compounds in their physicochemical 
properties (they are more lipophilic at a neutral pH) and their bioavailability 
(Wang, MZ et al. 2010). Also described as ‘reverse amidines’, they are more 
active against intracellular parasites, such as Leishmania and T. cruzi, than 
dimaidine compounds (Wang, MZ et al. 2010). Previous studies have 
demonstrated they exhibit sub-micromollar 50 % inhibitory concentrations for 
drug assays involving Leishmania amastigotes (Stephens, CE et al. 2003), and 
sub-nanomolar concentrations in Leishmania promastigotes assays (Rosypal, AC 
et al. 2008). The EC50 value obtained for the wild type L. mexicana 
promastigotes is 1.25 nM (with a 95 % CI of 1.18 to 1.32 nM). These results are 
around the expected value for this class of compound.  
The mechanism in which AIA compounds act is not yet known, however studies 
involving T. cruzi indicate ultrastructural alterations in the nucleus, 
mitochondrion, and organisation of microtubules (Silva, CF et al. 2007). Also 
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affected is the proton electrochemical potential gradient of the mitochondrial 
membrane. These observations are consistent with L. mexicana treated with 
pentamidine (Basselin, M et al. 2002). This may be one of the reasons why there 
is a 2-fold cross resistance for DB766 with the pentamidine resistant cell line. 
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Figure 5-7. Alamar Blue Assay Graphs. 
A – pentamidine. B – DB75. C – DB766A. D – Diminazine. E – Rotenone. F – DFMO. G – 
methylene blue. H – SHAM. The L. mexicana wild type are shown in red, and the L. mexicana 
pentamidine resistant are shown in blue. n = 3, (diminazene; n = 2); error bars = ±SEM. 
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Figure 5-8. Drug structures of compounds tested 
A – Pentamidine; B – DB75; C – DB766; D – Diminazine; E – Rotenone; F – DFMO; G – methylene 
blue; H – SHAM; I – DB1876; J – DB1880; K – Metronidazole. 
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Table 5-4. Summary of EC50 values for compound tested for their Leishmaniacidal effects. 
EC50 95 % CI EC50 95 % CI
Pentamidine 0.57 µM 0.54 to 0.61 µM 11.27 µM 8.45 to 15.05 µM 19.8
Diminazene 4.89 µM 4.4 to 5.4 µM 42.5 µM 36.8 to 49.0 µM 8.7
DB75 0.34 µM 0.33 to 0.34 µM 2.58 µM 2.52 to 2.64 µM 7.6
DB766 1.25 nM 1.18 to 1.32 nM 2.47 nM 2.43 to 2.52 nM 2.0
Methylene Blue 4.46 µM 4.36 to 4.57 µM 7.43 µM 7.13 to 7.75 µM 1.7
SHAM 351 µM 341 to 362 µM 388 µM 374 to 402 µM 1.1
Rotenone 14.0 µM 13.2 to 14.9 µM 10.9 µM 10.6 to 11.2 µM 0.8
DFMO 2.80 µM 2.61 to 3.01 µM 1.16 µM 1.11 to 1.22 µM 0.4
L. mexicana  wt L.mexicana  PentRes
Drug Difference
 
EC50, effective concentration 50%; 95 % CI, 95 % confidence interval; n = 3, (diminazene; n= 2);  
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Pentamidine resistant cells are slightly more sensitive to methylene blue (1.7-
fold) and eflornithine (2-fold) than the progenitor wild type cell lines. Methylene 
blue oxidises NADPH, thus reduces cellular levels of NADPH, generating a 
situation similar to oxidative stress (Maugeri, DA et al. 2003). NADPH can be 
produced by the PPP (Chapter 4). These data suggests that the flux through the 
PPP is increased in the pentamidine resistant cells, or that NADPH production by 
an alternative mechanism, for example, the conversion of malate to pyruvate by 
NADP-dependent malate dehydrogenase (EC 1.1.1.38), is increased. Eflornithine 
is an inhibitor of ornithine decarboxylase (ODC; EC 4.1.1.17) (section 1.10.3). 
Pentamidine resistant L. donovani and L. amazonesis were both reported to have 
reduced levels of putrescine; this was attributed to a decrease in putrescine 
uptake, increase in putrescine efflux, and lower levels of ODC (Basselin, M et al. 
1997). If pentamidine resistant cells have reduced levels of ODC, then it could 
be expected that these cells will be more sensitive to eflornithine. 
There was no difference in sensitivity to rotenone (0.8-fold), an inhibitor of 
Complex I of the electron transport chain, or SHAM (1.1-fold), an inhibitor of the 
T. brucei alternative oxidase (AO), between the wild type and pentamidine 
resistant cells. These results suggest that pentamidine, and subsequent 
resistance to pentamidine, does not affect, nor is involved in changes to 
Complex I or the AOX (although the presence of a bona fide alternative oxidase 
like protein in Leishmania is not certain. (Van Hellemond, JJ et al. 1998) 
reported its absence although an ortholgue of the T. brucei AO gene has been 
annotated as a putative alternative oxidase in L. infantum (LinJ.36.4600) and 
other Leishmania species but not yet characterized) (section 1.11.4). 
Several compounds tested were not effective against L. mexicana wild type or 
the pentamidine resistant promastigotes, as observed by the failure to convert 
resazurin to resarufin. These included the following drugs; DB1876 starting at 1 
µM, DB1880 starting at 1 µM, and metronidazole starting at 1 mM. The structure 
of DB766 is closely related to both DB1876 and DB1880; however DB1876 and 
DB1880 have piperidine rings attached via the ether linakge. The compounds all 
have the melamine recognition motif, necessary for transport into T. brucei by 
the P2 transporter (Carter, NS and Fairlamb, AH 1993); although this mechanism 
may not be used for transport by Leishmania spp. These additions may make the 
molecule too large, or too inflexible, for the transporter(s) which recognises and 
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transports DB766, thus reducing the effectiveness of these compounds. The 
mode of action of metronidazole involves the reduction of nitro group to 
generate short-lived cytotoxic intermediates which interact with 
macromolecules and DNA (Muller, M 1983). Failure for this compound to act on 
L. mexicana would indicate that the drug does not enter the cell (unlikely as 
uptake is by diffusion), or that metabolic pathways of low redox potential, 
effective at reducing nitroimidazoles, are not as prevalent in Leishmania as in 
other species. 
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5.8 DiGE Analysis 
The proteome of the L. mexicana wild type and pentamidine resistant cells were 
compared by differential gel electrophoresis (DiGE) (Unlu, M et al. 1997). 
A total of 20 protein spots at least 3-fold up-regulated in the pentamidine 
resistant line were detected by the DeCyder software, with 17 of them 
identified by MASCOT25 (Table 5-5). A further four protein spots were found to be 
down-regulated at least 3-fold in the pentamidine resistant line, and 
subsequently identified.   
Table 5-5. Proteins upregulated greater than 3-fold in the pentamidine resistant cell line. 
Protein Protein Accesion ID EC number
2,4-dihydroxyhept-2-ene-1,7-dioic acid aldolase, putative LmjF25.2010 4.1.2.-
eEF1B beta 1 LmjF34.0820 n/a
glutamine synthetase, putative LmjF06.0370 6.3.1.2
glyceraldehyde 3-phosphate dehydrogenase, glycosomal LmjF30.2970 1.2.1.12
hypothetical protein, conserved LmjF24.1970 n/a
hypothetical protein, conserved LmjF03.0820 n/a
hypothetical protein, conserved LmjF35.2450 n/a
hypothetical protein, conserved LmjF19.0340 n/a
mannose-1-phosphate guanyltransferase    LmjF23.0110 2.7.7.13
microtubule associated protein-like protein LmjF19.0860 n/a
peptidase m20/m25/m40 family-like protein  LmjF31.1890 n/a
peroxidoxin LmjF23.0040 1.11.1.-
potassium channel subunit-like protein LmjF01.0820 n/a
protein kinase-like protein LmjF27.1800 n/a
S-adenosylhomocysteine hydrolase LmjF36.3910 1.16.1.8
seryl-tRNA synthetase, putative LmjF11.0100 6.1.1.11
tryparedoxin peroxidase LmjF15.1040 1.11.1.15
 
The peptide fragments isolated from L. mexicana were compared with the L. major protein 
database 
                                         
25
 http://www.matrixscience.com/ 
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5.8.1 The down-regulation of flagellar proteins 
The paraflagellar road (PFR) is network of woven cytoskeletal filaments 
connected to axoneme along the length of the flagellum and has an essential 
role in cell motility  (Bastin, P et al. 1998; Maga, JA and LeBowitz, JH 1999; 
Maga, JA et al. 1999). A transmission electron microscopy (TEM) image of the 
flagellum is shown in (Figure 5-9).  
 
Figure 5-9. TEM image of the L. mexicana cytoskeletan 
The flagellum, originating at the basal body and emerging from the flagellar pocket, consists of the 
paraflagellar rod, axoneme and attachment fibres. Abbreviations; P, paraflagellar rod; A, axoneme; 
B, basal body. Scale bar 1 µM. Maga, JA and LeBowitz, JH (1999). 
Arising from the basal body, the flagellum is composed of the paraflagellar rod 
and the axoneme. In Trypanosoma and Leishmania there are two PFR proteins, 
PFR-1 and PFR-2, with molecular masses of 70-80 kDa and 68-72 kDa 
respectively. These proteins are highly conserved, with over 60 % amino acid 
identity (Bastin, P et al. 1998; Maga, JA and LeBowitz, JH 1999). Furthermore, 
there is at least 80 % amino acid identity between T. brucei, T. cruzi, and L. 
major for both PFR-1 and PFR-2 (Maga, JA and LeBowitz, JH 1999). Several 
additional minor proteins are known to localise to the flagellum, however the 
roles of these remain unknown (Woods, A et al. 1989; Woodward, R et al. 1994). 
Several proteins associated with the flagellum were down regulated in the L. 
mexicana pentamidine resistant cell line. These included PFR-1D 
(LmxM.08_29.1750, LmxM.08_29.1760), PFR 2C (LmxM.16.1430), and a 
component of the axoneme (LmxM.20.1400). The DiGE comparison images for 
the PFR proteins and the component of the axoneme are displayed in Figure 5-10 
and Figure 5-11 respectively. 
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Figure 5-10. DIGE comparison images of the Paraflagellar Rod 1 (PFR-1D) and Paraflagellar 
Rod 2 (PFR-2C) proteins 
An approximate 3-fold down-regulation in the pentamidine resistant cell line; A – 2D DIGE image of 
Pentamidine sensitive cell line (wild type); B – 2D DIGE image of Pentamidine resistant (clone 
B5111); C – 3D Intensity map Pentamidine sensitive cell line (wild type); D – 3D intensity map 
Pentamidine resistant (clone B5111). 
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Figure 5-11. DIGE comparison images of a component of the axoneme. 
An approximate 4-fold down-regulation in the pentamidine resistant cell line; A – 2D DIGE image of 
Pentamidine sensitive cell line (wild type); B – 2D DIGE image of Pentamidine resistant (clone 
B5111); C – 3D Intensity map Pentamidine sensitive cell line (wild type); D – 3D intensity map 
Pentamidine resistant (clone B5111). 
When the pentamidine resistant promastigotes are observed using a light 
microscope, they appear to have reduced motility, rounder bodies, and a shorter 
flagellum. Morphologically, they appear more similar to amastigotes than 
promastigotes. 
In L. mexicana, deletion of PFR-2C (Santrich, C et al. 1997), PFR-1D (Maga, JA et 
al. 1999), or both PFR-1D and PFR-2C (Maga, JA et al. 1999) are possible in 
promastigotes, indicating that these genes are not essential for parasite survival. 
However, in these null mutants a native PFR structure was not formed, with 
cells moving four to five times slower than wild type cells. Consequently, both 
these proteins are essential for a functional flagellum. The knockout cell lines 
were viable as axenic amastigotes, however preliminary results indicate that 
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PFR2 is required for the effective colonisation of the sandfly midgut (Maga, JA et 
al. 1999); no follow-up data is known to have been published. In T. brucei, loss 
of PFR-A, analogous to PFR-2C, is lethal (Hunger-Glaser, I and Seebeck, T 1997), 
whilst RNAi knockdown of the corresponding mRNA transcript resulted paralysed 
cells, although growth was reported to be normal (Bastin, P et al. 1998).  The 
phenotype of the pentamidine resistant lines with respect to reduced motility is 
consistent with the reduction in paraflagellar rod proteins.  However, it is not 
clear how a causal link between reduced paraflagellar rod proteins would cuase 
pentamidine resistance. 
The promastigotes described in this chapter were selected in the presence of 
pentamidine over the course of a year, and as a consequence, any changes at 
the –omic or phenotypic level may be due to exposure to pentamidine, the 
length of time in continuous culture, or a combination of both these factors.  
If pentamidine does have an effect on mitochondrial metabolism, then the 
ability to regenerate ATP by oxidative phosphorylation may be reduced. One 
possible explanation for the down-regulation of the flagellar proteins in the 
presence of pentamidine could be an attempt by the parasite to conserve ATP. 
This ATP could subsequently be used to fuel the efflux pump(s) (Bradley, G et al. 
1988) which are responsible for the exclusion of pentamidine from the cytosol 
(Basselin, M et al. 2002), or alternatively the ATP could be used for other 
cellular processes. 
On the other hand, these data could be explained by the length of time in 
continuous culture. Promastigotes grown in vitro may have no selective 
advantage in retaining a full length flagellum, therefore flagellar proteins are 
suitable proteins to down-regulate. This hypothesis is difficult to investigate as 
there may be multiple mechanisms in which Leishmania promastigotes may 
become resistant to pentamidine, or indeed any drug. A second independent 
culture was generated, but not analysed due to time constraints. However, even 
if the two cell lines did not have similar proteomic changes, it does not 
necessarily imply that the down-regulation of flagellar proteins is not a genuine 
response when the cells are challenged with pentamidine. Instead it would 
appear it is either a direct or indirect response, to one mechanism of 
pentamidine resistance in Leishmania promastigotes. 
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As previously mentioned, L. mexicana PFR1D and/or PFR2C knockout cell lines 
exist (Maga, JA et al. 1999). It would be interesting to compare the sensitivity to 
pentamidine, and other diamidine compounds, in both these knockout cell lines, 
with the progenitor wild type cell line. 
A range of further experiments to learn more about possible links between the 
observed changes to the flagellum and the pentamidine resistance phenotype 
will be of interest in future work. 
5.8.2 Unidentfied protein 
There was an unidentified protein which was 12-fold upregulated in the 
pentamidine resistance line. This protein spot was situated near the base of the 
gel, suggesting a protein of low molecular weight (15-20 kDa). Additionally, the 
protein was slightly left of centre, indicating a pI in the region of 4.5 - 5.5. 
Identification of this protein, and the subsequent over-expression of the protein, 
would be of considerable interest in relation to pentamidine resistance. 
A B
 
Figure 5-12. DIGE comparison of the unidentified protein illustrated by 3D intensity map 
An approximate 12-fold up-regulation in the pentamidine resistant cell line; A – Pentamidine 
sensitive cell line (wild type); B – Pentamidine resistant (clone B5111). 
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5.9 Voltage Dependent Anion Channel 
The voltage dependent anion channel (VDAC; Tb927.2.2510) is the main 
metabolite transporter in the outer mitochondrial membrane of procyclic form 
T. brucei (Pusnik, M et al. 2009). The VDAC could be the mechanism by which 
pentamidine enters the mitochondrion. 
The TbVDAC locus was deleted by homologous recombination (Pusnik, M et al. 
2009). Phenotypic analysis indicated that the VDAC -/- mutants failed to grow in 
the absence of glucose, whereas the control cells, designated as VDAC +/+, grew 
at a normal rate. These data suggests that in the absence of VDAC, SLP is 
essential; proline and other amino acids are unable to enter the mitochondrion 
and fuel OP. 
Given a possible role of VDAC in pentamidine uptake, a BLAST search of the L. 
mexicana genome using the T. brucei VDAC ORF was performed. It revealed two 
hypothetical genes with 56.1 % and 51.3 % sequence identity. These were 
identified as LmxM.02.0460 and LmxM.02.0450, and were consequently named as 
VDAC-1 and VDAC-2 respectively. These two proteins have a 40.6 % sequence 
identity with one another (Supplementary Figure 8-8). Suitable primers were 
designed for the amplification of the both VDAC-1 and VDAC-2 by PCR. The PCR 
was performed in triplicate to enable the sequencing of three independent 
clones from both the wild type and pentamidine resistant cell lines. 
Sequence alignments of the replicates indicated no differences (data not 
shown). The sequences derived from the wild type and resistant cell lines were 
compared with a reference sequence obtained from tritrypDB (Aslett, M et al. 
2011)26. For VDAC-1, there was a single nucleotide difference at position 785 
(reference strain - cytosine; lab strains - thymine) (Supplementary Figure 8-4), 
which results in an amino acid difference at position 262 (reference strain - 
alanine, GCC; lab strains - valine, GTC) (Supplementary Figure 8-6). There were 
no differences for VDAC-2 (Supplementary figures 8-5 and 8-7). 
To investigate whether the Leishmania promastigotes were sensitive to 
pentamidine when VDAC was over-expressed, transgenic cell lines expressing 
VDAC-1 from an episomal locus were generated. The pNUS-HnN over-expression 
                                         
26
 http://tritrypdb.org 
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construct (Tetaud, E et al. 2002) was digested with EcoRI, releasing the MCS and 
N-terminal His tag, and the resulting plasmid backbone was treated with SAP to 
prevent self re-ligation. The VDAC-1 ORF was digested from the intermediate 
pGEM-T easy vector, pMB-G105, using EcoRI, and sub-cloned into the over-
expression construct, yielding VDAC-1 over-expression construct pMB-G111. 
Wild type L. mexicana promastigote cells were transfected with the VDAC-1 
over-expression construct or the empty vector, and grown in 50 µg/ml G-418, 
selecting parasites that express the neomycin acetyltransferase gene present in 
the over-expression construct. The cells over-expressing VDAC-1 did not survive 
in G-418, whereas the control cell line with no over-expression of VDAC-1 did 
survive. These data suggest that the over-expression of VDAC-1 in L. mexicana is 
lethal. One possible method to circumvent this problem would be to reduce the 
concentration of G-418 used to select successful transfected cell lines, in an 
attempt to reduce the expression of VDAC-1. It has been reported that increased 
G-418 concentrations can increase the expression of the desired protein (Tetaud, 
E et al. 2002). 
No differences in VDAC are apparent in the selection of pentamidine resistance 
in Leishmania.  However, a failure to successfully achieve over-expression and 
lack of time to produce knockout cells leaves the question open as to whether 
VDAC is involved in pentamidine uptake into the mitochondrion of Leishmania.   
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5.10 Pentamidine susceptibility of cells grown in different 
carbon sources 
As diamidine compounds target the mitochondrion (Ludewig, G et al. 1994; 
Lanteri, CA et al. 2008), it was hypothesised that cells grown in a glucose 
deficient environment would be more sensitive to pentamidine and oxidative 
stress, than cells grown in a glucose rich environment, given the relative 
contribution of mitochondrial metabolism in these two conditions. 
Procyclic form trypanosomes offered a model to test this hypothesis due to the 
availability of different growth media. These cells are normally cultured in 
SDM79, although can be easily adapted to grow in SDM80, a culture medium 
lacking glucose (Lamour, N et al. 2005). Initially, cells were grown in SDM80 
supplemented with 5 mM D-glucose (C00031) and 5 mM L-proline (C00148). To 
induce a metabolic shift, cells were then grown in a glucose-rich environment 
(10 mM D-glucose and 0.1 mM L-proline) or proline-rich environment (10 mM L-
proline and 0.1 mM D-glucose). Those grown in a glucose-rich environment will 
derive energy primarily via substrate level phosphorylation through glycolysis, 
whereas those grown in the proline-rich environment will obtain energy 
primarily via mitochondrial oxidative phosphorylation. As a control, cells were 
also maintained in SDM80 supplemented with 5 mM glucose and 5 mM proline. 
Those grown in the proline-rich environment had a pentamidine EC50 of 5.0 nM 
(95 % CI of 4.2 to 5.9 nM), whereas those grown in a glucose-rich environment 
had an EC50 of 21.6 nM (95 % CI of 19.5 to 23.9 nM). This corresponds to a 4- fold 
difference in the EC50 values between these two carbon sources. Cells grown in 5 
mM glucose and 5 mM proline had an EC50 of 24.6 nM (95 % CI of 20.0 to 31.7 
mM), and as expected, were similar to those grown in the glucose rich medium. 
These results are summarised in Table 5-6.  
Table 5-6. Pentamidine EC50 values for T. brucei 427 procylic form trypanosomes grown in 
different carbon sources. 
EC50 Pentamidine (nM) 95% Confidence Interval
5 mM Glucose + 5 mM Proline 24.6 20.0 to 31.7 nM
10 mM Glucose + 0.1 mM Proline 21.6 19.5 to 23.9 nM
10 mM Proline + 0.1 mM Glucose 5.0 4.2 to 5.9 nM  
n=3 
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Methylene blue is an agent capable of stimulating oxidative stress.  The 
methylene blue EC50 value derived from the cells grown in a proline-rich 
environment was 0.23 µM, although the 95 % Confidence Interval could not be 
calculated using GraphPad Prism software. However, exclusion of 7 data points 
(Supplementary Table 8-1) enabled the calculation of an EC50 value at 0.22 µM 
and 95% Confidence intervals between 0.13 µM and 0.37 µM. Those grown in the 
glucose-rich environment had an EC50 of 0.42 µM (95 % CI of 0.39 to 0.44 µM). 
This corresponds to a 2- fold difference in the EC50 values between these two 
carbon sources. Cells grown in 5 mM glucose and 5 mM proline had an EC50 of 
0.61 µM (95 % CI of 0.58 to 0.65 µM). These results is summarised in Table 5-7. 
Table 5-7. Methylene blue EC50 values for T. brucei 427 procylic form trypanosomes grown 
in different carbon sources. 
EC50 Methylene Blue (µM) 95% Confidence Interval
5 mM Glucose + 5 mM Proline 0.61 0.58 to 0.65 µM
10 mM Glucose + 0.1 mM Proline 0.42 0.39 to 0.44 µM
10 mM Proline + 0.1 mM Glucose 0.22 0.13 to 0.37 µM  
n=3 
These results indicate that procylic trypanosomes grown in a glucose-deficient 
environment are more sensitive to both pentamidine and methylene blue, and 
that low concentrations of D-glucose may affect the organisms ability to 
regenerate NADPH (Chapter 4). This could be related to an ability of 
pentamidine and methylene blue to generate oxidative stresses more readily in 
cells using respiration as their primary energy source. 
Chapter 5, 222 
5.11 Discussion 
The initial aim of this chapter was a proteomic comparison between the L. 
donovani wild type and pentamidine resistant R8 cell lines (Mukherjee, A et al. 
2006) , although this was not possible as the PCR diagnostic test described in this 
chapter indicated these cell lines were not isogenic.  These data demonstrated 
the importance of ensuring that cell lines are what they are believed to be, prior 
to further comparative analyses. The diagnostic PCR test described by Schonian 
G. et al (2003) is simple, accurate and rapid. Where cell lines have been 
genetically manipulated, for example gene knockout, appropriate PCR 
experiments can confirm the gene of interest is no longer present, and has been 
replaced with drug resistance markers. There is no justifiable reason to not test 
cell lines on a regular basis, as unfortunately, mistakes do happen. The L. 
mexicana wild type and pentamidine resistant lines described in Basselin M. et al 
(2002) could not be located, and for this reason, it was necessary to generate a 
new pentamidine resistant in vitro, by step wise exposure to pentamidine. This 
resistant cell line was capable of growth in 8 µM pentamidine, approximately 64-
fold greater than the wild type, and had an EC50 value of 11.3 µM, approximately 
20-fold greater than the wild type. These data are consistent with previous 
studies that indicated it was possible to induce resistance to pentamidine at 
concentrations in the low micromolar range (Basselin, M et al. 2002; Mukherjee, 
A et al. 2006). The pentamidine resistant line described in this chapter was cross 
resistant to the diamidine compounds diminazene and furamidine, have a similar 
mode of action. Other pentamidine resistant Leishmania and trypanosome cell 
lines show cross resistance to diamidine compounds (Basselin, M et al. 2002; 
Mukherjee, A et al. 2006; Bridges, DJ et al. 2007).  
Whether assessment of drug modes of action through selection of resistance in 
vitro is the best way of identifying modes of action is a topic of debate. 
One of the main arguments against this approach is the length of time it can 
take to generate a drug resistant line. Any changes could be due to the time in 
culture, rather than the selective pressure of pentamidine. For example, the 
changes in the flagellar proteins could be due to pentamidine resistance, or 
alternatively, the length of time these parasites spent in continuous culture. A 
DiGE experiment can indicate numerous changes to the proteome, although if 
these changes are not genuinely associated with drug resistance, the data are 
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meaningless. Selecting multiple resistant lines, and determining whether they 
have similar changes associated with resistance can add significantly to the 
interpretation of such data. However, multiple mechanisms of resistance may be 
possible. Two independent lines were selected here, but time restraints 
prevented analysis of the second line. 
An alternative method would be to investigate differences between field isolates 
which are either sensitive or resistant to a specific drug. Whilst it would be easy 
to confirm that the field isolates were the same species, it would be more 
necessary to demonstrate they were the same strain (Lewin, S et al. 2002; 
Schonian, G et al. 2003). Strain variations amongst a Leishmania species could 
account for subtle variations at the genomic, proteomic or metabolomic level. 
However, by increasing the number of drug-sensitive and drug-resistant isolated 
analysed, it would be possible to identify any changes occurring across multiple 
datasets. 
Using DiGE to investigate drug resistance mechanisms in field isolates might be a 
suitable approach as not only has the technique become well established in 
recent years, the proteome is stable for a short period of time, sufficient for 
protein sample preparation. However, in the absence of isogenic backgrounds, 
there is likely to be a significant degree of protein level variability between 
isolated. The metabolome is even more fluid and dynamic than the proteome, 
and as a consequence, more susceptible to erratic fluctuations. However, a 
metabolomic comparison of field isolates indicated changes in the phospholipid 
composition of the membrane (t'Kindt, R et al. 2010), suggesting an increase in 
membrane fluidity may be related to the changes in drug uptake observed in 
these drug-resistant isolates. Alterations in lipid metabolism was also observed 
in pentamidine resistant L. mexicana (Basselin, M and Robert-Gero, M 1998). 
Another question relates to the use of promatigotes in learning about drug 
resistance. The promastigote is the insect stage of the parasite, and whilst 
culturing promastigotes is routine and well established, it might be more 
appropriate to give more consideration to the effect of drugs on amastigotes, 
the clinically relevant life cycle stage. The process of culturing amastigotes is 
more complex than promastigotes, as this requires the harvesting and infection 
of macrophages.  It has therefore been common practise to identify biochemical 
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modes of action in the easier to manipulate promastigote form, and then to 
determine whether such mechanisms translate to amastigotes and given our 
ultimate aim of dissecting biochemical pathways associated with resistance this 
study also studied the procyclic cells.   
The fact that it was necessary to select new pentamidine resistant lines for 
analysis meant that substantial time constraints were introduced meaning that 
the planned metabolomic work and additional follow up on the proteomics work 
were not possible.  However, the cell lines will now be available for such follow 
up.   
In addition to the hypothesis-free pursuit of mechanisms of diamidine resistance 
I also pursued specific hypotheses that emerged based on new information 
derived over the time frame of the project.  For example, the VDAC has been 
identified as the main mitochondrial metabolite transporter in T. brucei (Pusnik, 
M et al. 2009) and we hypothesised that this protein might be a main carrier of 
pentamidine into mitochondria, and given loss of mitochondrial accumulation of 
diamidines has been related to resistance, its loss might be associated with 
resistance. However, we could not identify differences at the genomic level in 
either of two VDAC orthologues in our sensitive or pentamidine resistant L. 
mexicana lines. Attempts to over-express one of these proteins in L. mexicana 
promastigotes was unsuccessful which is consistent with over-expression of VDAC 
in a range of organisms inducing apoptotic cell death (Shoshan-Barmatz, V et al. 
2010). In T. brucei, procyclics which lack the VDAC protein are still capable of 
replicating the mitochondrion, and given that mitochondrial substrate-level 
phosphorylation is essential, this implies an additional mechanism for nucleotide 
transport into the mitochondrion (Bochud-Allemann, N and Schneider, A 2002; 
Pusnik, M et al. 2009). Increasing numbers of mitochondrial membrane protein 
are now being characterised in T. brucei and it will be of interest to determine 
which are involved in pentamidine uptake (Pusnik, M et al. 2011).  
In addition, I studied a hypothesis that metabolic changes could influence 
sensitivity to pentamidine. For this purpose I used procyclic T. brucei due to the 
presence of different media in which either substrate level phosphorylation 
(glucose rich medium) or oxidative phosphorylation (proline rich medium) are 
the major mechanisms of ATP production.  Procyclic form trypanosomes were 
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more sensitive to both pentamidine and the oxidiatve stress inducing agent 
methylene blue when grown in a glucose-deficient environment. Possible 
explanations for these results could involve the trypanosomes inability to rapidly 
regenerate NADPH to protect against the oxidative stress induced by methylene 
blue, or that the amino acid metabolism is affected due to the accumulation of 
pentamidine in the mitochondrion. However, when trypanosomes are grown in 5 
mM D-glucose and 5 mM L-proline, there is a slight reduction in sensitivity to 
both pentamidine and methylene blue, when compared to cells grown in a 
glucose-rich and proline-deficient environment. A possible explanation for this 
result could involve the presence of sufficient glucose for NADPH regeneration, 
and the presence of sufficient proline to sustain growth via OP. When glucose is 
the only carbon source present, this must fuel both NADPH and ATP production. 
However, more detailed analysis of metabolism would be required to resolve 
this. 
It would be useful to adapt Leishmania promastigotes to a custom made 
medium, either HOMEM or SDM-79/SDM80, and compare the susceptibility to 
both pentamidine and methylene blue when grown in glucose-deficient and 
glucose-rich environments. As Leishmania promastigotes are able to metabolise 
ribose, using it as a carbohydrate source (Berens, RL et al. 1980) it would be 
interesting to determine if the presence of ribose, in the absence of glucose, is 
sufficient for NADPH regeneration, thus reducing sensitivity to oxidative stress. 
These experiments would be relevant to the L. mexicana tkt null cell line, 
which, under standard growth conditions, show little difference in sensitivity to 
pentamidine when compared with the wild type cells (Chapter 4). 
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6 General Discussion 
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There is an urgent need to develop new compounds to combat trypanosomiasis 
and leishmaniasis, as many of the current drugs are toxic, expensive, and 
difficult to administer. Drug resistance is also a growing concern. If we 
understand how these drugs work (i.e. the mode of action), or how resistance is 
acquired, then our ability to control these diseases will improve. 
In this study, a pentamidine resistant L. mexicana promastigote cell line was 
generated in vitro, by step wise exposure to pentamidine. These cells were cross 
resistant to other diamidine compounds, consistent with previous studies 
(Basselin, M et al. 2002; Mukherjee, A et al. 2006). Proteomic analysis using 
DiGE revealed differences in proteins associated with the flagellum. These 
changes may be genuinely associated with pentamidine resistance or, 
alternatively, they may be due to the length of time spent in continuous culture 
during resistance induction. It may be more beneficial to investigate changes to 
the proteome (and metabolome) over a shorter period of time to minimise 
indirect changes. 
The successful deletion of the transketolase gene from the Leishmania genome 
indicates that this gene is not essential in the promastigote form of the parasite, 
at least under standard laboratory conditions. There was a moderate increase in 
sensitivity to pentamidine in the knockout cell line, although no difference in 
the sensitivity to methylene blue was detected, indicating that NADPH 
regeneration is not affected in the knockout cell line. Interestingly, a reduction 
in the acidification of the growth medium observed during these experiments 
may indicate changes in the end products that are excreted by the cell (either a 
reduction in organic acids, or an increase in ammonia). Metabolomic profiling 
revealed that an alternative mechanism of E4P production may be present in 
Leishmania, although further experiments are necessary. A targeted 
metabolomics approach, using labelled substrates, might reveal the existence of 
alternative enzymatic reactions. The presence of additional enzymes in 
carbohydrate metabolism is not unrealistic given the range of sugars that the 
Leishmania promastigotes are exposed to in the sandfly midgut (Opperdoes, FR 
and Coombs, GH 2007). If substrate availability is able to initiate a 
conformational change in transketolase through exposure of the PTS targeting 
signal, the knockout cell lines provide a null background of endogenous TKT, to 
allow the characterisation of cell lines expressing mutant TKT. 
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This thesis presents a simple metabolite database that is able to query complex 
metabolomic datasets, and provide a biological context in relation to KEGG 
(Kanehisa, M and Goto, S 2000). KEGG is an excellent resource for metabolites, 
biochemical reactions, and metabolic pathways, although the rigid nature of 
depicting classical biochemical pathways can be a hindrance when considering a 
global metabolomics approach. The Human Metabolome Database (HMDB) 
(Wishart, DS et al. 2009) is another excellent resource, although it is obviously 
specific for human metabolites. However, the metabolite information in these 
databases is often acquired through the annotation of enzymes, with an 
assumption that metabolites associated with a particular enzyme are present in 
the metabolome. 
It is imperative that the metabolomics community resolve the metabolome of 
specific biological systems so as to provide reference metabolomes to aid 
untargeted metabolomics. There are no shortages of cell lines to analyse using 
metabolomic techniques, and there are no shortage of biological questions to 
ask. Unfortunately, there is a lack of appropriate software programs to analyse 
the data, and as a consequence data is produced faster than it can be analysed. 
However, there are encouraging signs with the introduction of IDEOM (Creek, DJ 
et al. 2012) and PeakML (Scheltema, RA et al. 2011) for the analysis of raw 
metabolomic data, although the interpretation of peaks (and related peaks) is 
subjective. Alternatively, MassTrix (Suhre, K and Schmitt-Kopplin, P 2008) and 
Pathos (Leader, DP et al. 2011) were designed to communicate with the KEGG 
database. Whilst metaSearch is a basic program, the ability to rapidly match 
data acquired from a high resolution mass spectrometer against a list of known 
masses to provide a tabular view of results is certainly useful. The conventional 
method to view relationships between metabolites is through classical 
biochemical pathways, although attitudes towards this approach are changing 
through the introduction of programs such as MetExplore to visualise metabolic 
changes (Cottret, L et al. 2010). Efforts should concentrate on integrating the 
elements of raw data analysis and network visualisation. 
Adopting the approaches used in other disciplines may accelerate the rate at 
which metabolomics, particularly untargeted metabolomics, develops as a 
technique. For example, the advent of DNA sequencing by Frederick Sanger in 
the 1970’s, eventually enabled the sequencing of entire genomes. At the end of 
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2011, complete genome projects existed for 3080 organisms (Kyrpides, NC 1999). 
The Human Genome Project (HGP)27, started in 1990, took 13 years to complete 
(and is constantly revised). More recently, projects such as TriTrypDB (Aslett, M 
et al. 2011), specific to Leishmania and Trypanosoma, and PlasmoDB 
(Aurrecoechea, C et al. 2009), specific to Plasmodium, have become essential 
resources for genomic or functional genomic studies. These databases provide 
reference genomes that allow straightforward comparisons with sequence data 
derived in the laboratory. A reference metabolome, derived from metabolomic 
data, would become a fundamental analysis tool for the metabolomics 
community. There are however various challenges that have to be addressed. 
These include the standardisation of metabolite sample preparation method(s), 
and the robust identification of metabolites by orthogonal approaches. The 
coverage of such a reference metabolome would be by no means complete. 
However, it would provide a solid foundation for the interpretation of 
untargeted metabolomic studies, in particularly how parasites respond to 
individual drugs.
                                         
27
 http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml 
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7 Appendices 
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7.1 Cell Culture medium 
7.1.1 HOMEM 
NaH2PO4 157 mg 
NaCl 6.8 g 
MgSO4.7H2O 200 mg 
KCl 400 mg 
NaHCO3 300 mg 
Sodium Pyruvate 110 mg 
D-Glucose 3 g 
L-Glutamine 292 mg 
P-aminobenzoic Acid 1 mg 
HEPES 5.96 g 
D-Biotin 0.1 mg 
Phenol red (dissolved in 5 ml 0.1 M NaOH) 15 mg 
Vitamins 100 X (Sigma, M6895) 10 ml 
 
Choline chloride 100 mg/l 
D-Calcium pantothenate 100 mg/l 
Folic Acid 100 mg/l 
Nicotinamide 100 mg/l 
Pyridoxal hydrochloride 100 mg/l 
Riboflavin 10 mg/l 
Thiamine hydrochloride 100 mg/l 
I-Inositol 200 mg/l 
KCl 200 mg/l 
KH2PO4 200 mg/l 
NaCl 8 g/l 
Na2HPO4 1.15 g/l 
 
MEM non-essential amino acids 100 X (Gibco, 11140035) 10ml 
 
Glycine 750 mg/l 
L-Alanine 890 mg/l 
L-Asparagine 1320 mg/l 
L-Aspartic acid 1330 mg/l 
L-Glutamic Acid 1470 mg/l 
L-Proline 1150 mg/l 
L-Serine 1050 mg/l 
 
Essential amino acids 50 X (Sigma, M5550) 30 ml 
 
L-Arginine 6.32 g/l 
L-Cystine.2HCl 1.564 g/l 
L-Histidine.HCl.H2O 2.1 g/l 
L-Isoleucine 2.625 g/l 
L-Leucine 2.62 g/l 
L-Lysine 3.625 g/l 
L-Methionine 755 mg/l 
L-Phenylalanine 1.65 g/l 
L-Threonine 2.38 g/l 
L-Tryptophan 510 mg/l 
L-Tyrosine 1.8 g/l 
L-Valine 2.34 g/l 
 
Produced by Invitrogen; For 1 litre; pH 7.3; store at 4ºC. 
 
Foetal Calf Serum 100 ml 
 
Chapter 7, 232 
7.1.2 SDM-80 
NaH2PO4 157 mg 
NaCl 6.8 g 
MgSO4.7H2O 151 mg 
KCl 400 mg 
CaCl2.2H2O 250 mg 
L-Arginine 100 mg 
L-Methionine 70 mg 
L-Phenylalanine 80 mg 
L-Threonine 350 mg 
L-Tyrosine 100 mg 
Taurine 160 mg 
L-Alanine 200 mg 
L-Asparagine 13.2 mg 
L-Aspartate 13.3 mg 
L-Glutamate 14.7 mg 
L-Glutamine 200 mg 
Glycine 7.5 mg 
L-Serine 60 mg 
HEPES 8 g 
MOPS 5 g 
NaHCO3 2.2 g 
Pyruvate 220 mg 
Mercaptoethanol (neat) 35 µl 
Hypoxanthine 14 mg 
Thymidine 4 mg 
Vitamins 100 X (Sigma, M6895) 10 ml 
Essential amino acids 50 X (Gibco BRL, 1130-036) 20 ml 
Hemin (dissolved in 0.1 M NaOH) 5 mg 
Phenol red (dissolved in 0.1 M NaOH) 15 mg 
Dialysed Foetal Calf Serum 100 ml 
 
Glucose-rich; 1.802 g D-glucose and 0.0115 g L-proline 
Proline-rich; 1.151 g L-proline and 0.0180 g D-glucose 
 
For 1 litre; pH 7.4; filter sterilise; store at 4ºC. 
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7.2 Molecular Biology Reagents 
7.2.1 Cell lysis buffer A 
10 mM Tris-Cl pH 8.0 
100 mM EDTA 
1% Sarkosyl 
100 µg Proteinase K per 0.5 ml (add fresh each time) 
7.2.2 1x TAE 
Tris acetate (pH 8.5) 40 mM 
EDTA 1 mM 
7.2.3 Depurination solution 
22.7 ml 11 M HCl 
977.3 ml dH20 
7.2.4 Denaturation solution 
20g NaOH 
87.664g NaCl 
Make to I litre 
7.2.5 Neutralisation solution 
87g NaCl 
1 M Tris-HCl pH7.4 
Make to 1 litre 
7.2.6 20x SSC 
88.23 g NaCl 
175.32 g Trisodiumcitrate 
Make to 1 litre 
pH7-8 
7.2.7 50x Denhardts 
1% (w/v) Ficoll 400 
1% (w/v) Polyvinylpyrrolidone 
1% (w/v) Bovine Serum Albumin (Sigma-Aldrich, Poole, UK, Fraction V) 
Filter and store at -20 °C 
7.3 Proteomics 
7.3.1 Cell Lysis Buffer B 
6 M Urea 
2 M Thiourea 
4 % CHAPS 
25 mM Tris 
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7.3.2 Protein Inhibitor Cocktail 
Leupetin 100 µg/ml 
Pefabloc 500 µg/ml 
Pepstatin 5 µg/ml 
Phenantrholine 1 mM 
EDTA 1 mM  
EGTA 1 mM 
7.3.3 DiGE Rehydration Buffer 
6 M Urea 
2 M Thiourea 
4% CHAPS 
0.5% IPG buffer 
65 mM DTT 
Trace bromophenol blue 
7.3.4 DiGE Equilibration Buffer 1 
2 % SDS 
50 mM Tris-HCl pH 8.8 
6 M urea 
30 % (v/v) glycerol 
0.002% bromophenol blue 
100 mg of DTT per 10 ml 
7.3.5 DiGE Equilibration Buffer 2 
2 % SDS 
50 mM Tris-HCl pH 8.8 
6 M urea 
30 % (v/v) glycerol 
0.002% bromophenol blue 
250 mg of Idoacetamide per 10 ml 
7.3.6 DiGE fixing solution 
40% ethanol 
10% acetic acid 
0.05% SDS 
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                               1                                                                                                100 
        L. mexicana TKT    (1) MASIEKVANCIRCLAADIVQGGKSGHPGTPMGMAPMSAVLWTEVMKYNSQDPDWVDRDRFVMSNGHGCALQYALLHMAGYNLTMDDLKGFRQDGSRTPGH 
L. mexicana TKT Clone 1    (1) MASIEKVANCIRCLAADIVQGGKSGHPGTPMGMAPMSAVLWTEVMKYNSQDPDWVDRDRFVMSNGHGCALQYALLHMAGYNLTMDDLKGFRQDGSRTPGH 
L. mexicana TKT Clone 2    (1) MASIEKVANCIRCLAADIVQGGKSGHPGTPMGMAPMSAVLWTEVMKYNSQDPDWVDRDRFVMSNGHGCALQYALLHMAGYNLTMDDLKGFRQDGSRTPGH 
                               101                                                                                              200 
        L. mexicana TKT  (101) PERFVTPGVEVTTGPLGQGIANAVGLAIAEAHLAATFNRPGYNIVDHYTYVYCGDGCLMEGVCQEALSLAGHLALEKLIVIYDSNYISIDGSTSLSFTEQ 
L. mexicana TKT Clone 1  (101) PERFVTPGVEVTTGPLGQGIANAVGLAIAEAHLAATFNRPGYNIVDHYTYVYCGDGCLMEGVCQEALSLAGHLALEKLIVIYDSNYISIDGSTSLSFTEQ 
L. mexicana TKT Clone 2  (101) PERFVTPGVEVTTGPLGQGIANAVGLAIAEAHLAATFNRPGYNIVDHYTYVYCGDGCLMEGVCQEALSLAGHLALEKLIVIYDSNYISIDGSTSLSFTEQ 
                               201                                                                       *                      300 
        L. mexicana TKT  (201) CHQKYVAMGFHVIEVKNGDTDYEGLRKALAEAKATKGKPKMIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKAKFGRDPQKKYDVDDDVRAVFRMHID 
L. mexicana TKT Clone 1  (201) CHQKYVAMGFHVIEVKNGDTDYEGLRKALAEAKATKGKPKMIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKTKFGRDPQKKYDVDDDVRAVFRMHID 
L. mexicana TKT Clone 2  (201) CHQKYVAMGFHVIEVKNGDTDYEGLRKALAEAKATKGKPKMIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKTKFGRDPQKKYDVDDDVRAVFRMHID 
                               301                                                                                              400 
        L. mexicana TKT  (301) KCSAEQKAWEELLAKYTAAFPAEGAAFVAQMRGELPSGWEAKLPTNSSAIATRKASENCLAVLFPAIPALMGGSADLTPSNLTRPASANLVDFSSSSKEG 
L. mexicana TKT Clone 1  (301) KCSAEQKAWEELLAKYTAAFPAEGAAFVAQMRGELPSGWEAKLPTNSSAIATRKASENCLAVLFPAIPALMGGSADLTPSNLTRPASANLVDFSSSSKEG 
L. mexicana TKT Clone 2  (301) KCSAEQKAWEELLAKYTAAFPAEGAAFVAQMRGELPSGWEAKLPTNSSAIATRKASENCLAVLFPAIPALMGGSADLTPSNLTRPASANLVDFSSSSKEG 
                               401                                                                                              500 
        L. mexicana TKT  (401) RYIRFGVREHAMCAILNGLDAHDGIIPFGGTFLNFIGYALGAVRLAAISHHRVIYVATHDSIGVGEDGPTHQPVELVAALRAMPNLQVIRPSDQTETSGA 
L. mexicana TKT Clone 1  (401) RYIRFGVREHAMCAILNGLDAHDGIIPFGGTFLNFIGYALGAVRLAAISHHRVIYVATHDSIGVGEDGPTHQPVELVAALRAMPNLQVIRPSDQTETSGA 
L. mexicana TKT Clone 2  (401) RYIRFGVREHAMCAILNGLDAHDGIIPFGGTFLNFIGYALGAVRLAAISHHRVIYVATHDSIGVGEDGPTHQPVELVAALRAMPNLQVIRPSDQTETSGA 
                               501                                                                                              600 
        L. mexicana TKT  (501) WAVALSSIHTPTVLCLSRQNTEPQSGSSIEGVRHGAYSVVDVPDLQLVIVASGSEVSLAVDAAKALSGELRVRVVSMPCQELFDAQPDTYRQAVLPAGVP 
L. mexicana TKT Clone 1  (501) WAVALSSIHTPTVLCLSRQNTEPQSGSSIEGVRHGAYSVVDVPDLQLVIVASGSEVSLAVDAAKALSGELRVRVVSMPCQELFDAQPDTYRQAVLPAGVP 
L. mexicana TKT Clone 2  (501) WAVALSSIHTPTVLCLSRQNTEPQSGSSIEGVRHGAYSVVDVPDLQLVIVASGSEVSLAVDAAKALSGELRVRVVSMPCQELFDAQPDTYRQAVLPAGVP 
                               601                                                                  672 
        L. mexicana TKT  (601) VVSVEAYVSFGWEKYSHAHVGMSGFGASAPAGVLYKKFGITVEEVVRTGRELAKRFPDGTAPLKNSSFSKM- 
L. mexicana TKT Clone 1  (601) VVSVEAYVSFGWEKYSHAHVGMSGFGASAPAGVLYKKFGITVEEVVRTGRELAKRFPDGTAPLKNSSFSKM- 
L. mexicana TKT Clone 2  (601) VVSVEAYVSFGWEKYSHAHVGMSGFGASAPAGVLYKKFGITVEEVVRTGRELAKRFPDGTAPLKNSSFSKM- 
Figure 8-1. L. mexicana Transketolase amino acid seqeuence alignment. 
Alignment of the L. mexicana TKT amino acid sequence (GeneBank accession ID AJ427448) with two independently derived clones. An amino acid 
change from alanine to threonine, donated by an asterisk, is located at residue 275. 
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                            1                                                                                                100 
L. mexicana TKT ORF     (1) ATGGCCTCCATTGAGAAGGTGGCAAACTGCATCCGCTGCCTCGCGGCGGACATTGTCCAGGGCGGCAAGAGTGGCCACCCAGGCACGCCGATGGGCATGG 
        TKT Clone 1     (1) ATGGCCTCCATTGAGAAGGTGGCAAACTGCATCCGCTGCCTCGCGGCGGACATTGTCCAGGGCGGCAAGAGTGGCCACCCAGGCACGCCGATGGGCATGG 
        TKT clone 2     (1) ATGGCCTCCATTGAGAAGGTGGCAAACTGCATCCGCTGCCTCGCGGCGGACATTGTCCAGGGCGGCAAGAGTGGCCACCCAGGCACGCCGATGGGCATGG 
                            101                                                                                              200 
L. mexicana TKT ORF   (101) CGCCGATGTCAGCGGTCCTGTGGACGGAAGTGATGAAGTACAACAGCCAGGATCCTGACTGGGTCGACCGCGACCGCTTCGTCATGTCGAACGGGCACGG 
        TKT Clone 1   (101) CGCCGATGTCAGCGGTCCTGTGGACGGAAGTGATGAAGTACAACAGCCAGGATCCTGACTGGGTCGACCGCGACCGCTTCGTCATGTCGAACGGGCACGG 
        TKT clone 2   (101) CGCCGATGTCAGCGGTCCTGTGGACGGAAGTGATGAAGTACAACAGCCAGGATCCTGACTGGGTCGACCGCGACCGCTTCGTCATGTCGAACGGGCACGG 
                            201                              ˇ                                                               300 
L. mexicana TKT ORF   (201) CTGCGCACTGCAGTACGCCCTGCTGCACATGGCAGGCTACAACCTCACCATGGACGACCTGAAGGGATTCCGCCAAGATGGCTCCCGCACCCCTGGCCAC 
        TKT Clone 1   (201) CTGCGCACTGCAGTACGCCCTGCTGCACATGGCGGGCTACAACCTCACCATGGACGACCTGAAGGGATTCCGCCAAGATGGCTCCCGCACCCCTGGCCAC 
        TKT clone 2   (201) CTGCGCACTGCAGTACGCCCTGCTGCACATGGCGGGCTACAACCTCACCATGGACGACCTGAAGGGATTCCGCCAAGATGGCTCCCGCACCCCTGGCCAC 
                            301                                                                                              400 
L. mexicana TKT ORF   (301) CCCGAGCGTTTCGTGACGCCCGGGGTGGAGGTGACGACCGGGCCACTTGGCCAGGGTATTGCAAACGCGGTCGGACTGGCGATTGCCGAGGCGCACCTTG 
        TKT Clone 1   (301) CCCGAGCGTTTCGTGACGCCCGGGGTGGAGGTGACGACCGGGCCACTTGGCCAGGGTATTGCAAACGCGGTCGGACTGGCGATTGCCGAGGCGCACCTTG 
        TKT clone 2   (301) CCCGAGCGTTTCGTGACGCCCGGGGTGGAGGTGACGACCGGGCCACTTGGCCAGGGTATTGCAAACGCGGTCGGACTGGCGATTGCCGAGGCGCACCTTG 
                            401                                                                                              500 
L. mexicana TKT ORF   (401) CCGCCACGTTCAACCGCCCGGGATACAACATCGTTGATCACTACACTTACGTGTACTGTGGTGACGGTTGTCTGATGGAGGGTGTGTGCCAGGAGGCGCT 
        TKT Clone 1   (401) CCGCCACGTTCAACCGCCCGGGATACAACATCGTTGATCACTACACTTACGTGTACTGTGGTGACGGTTGTCTGATGGAGGGTGTGTGCCAGGAGGCGCT 
        TKT clone 2   (401) CCGCCACGTTCAACCGCCCGGGATACAACATCGTTGATCACTACACTTACGTGTACTGTGGTGACGGTTGTCTGATGGAGGGTGTGTGCCAGGAGGCGCT 
                            501                                                                                              600 
L. mexicana TKT ORF   (501) CTCCCTCGCCGGCCACCTCGCCCTGGAGAAGCTCATCGTCATCTATGACAGCAACTACATCTCCATCGACGGCTCGACAAGCCTCTCCTTCACGGAACAG 
        TKT Clone 1   (501) CTCCCTCGCCGGCCACCTCGCCCTGGAGAAGCTCATCGTCATCTATGACAGCAACTACATCTCCATCGACGGCTCGACAAGCCTCTCCTTCACGGAACAG 
        TKT clone 2   (501) CTCCCTCGCCGGCCACCTCGCCCTGGAGAAGCTCATCGTCATCTATGACAGCAACTACATCTCCATCGACGGCTCGACAAGCCTCTCCTTCACGGAACAG 
                            601                                                                                              700 
L. mexicana TKT ORF   (601) TGCCACCAGAAGTACGTGGCCATGGGTTTCCACGTGATCGAGGTCAAAAACGGTGACACTGACTACGAGGGCCTGCGCAAGGCACTGGCGGAGGCCAAGG 
        TKT Clone 1   (601) TGCCACCAGAAGTACGTGGCCATGGGTTTCCACGTGATCGAGGTCAAAAACGGTGACACTGACTACGAGGGCCTGCGCAAGGCACTGGCGGAGGCCAAGG 
        TKT clone 2   (601) TGCCACCAGAAGTACGTGGCCATGGGTTTCCACGTGATCGAGGTCAAAAACGGTGACACTGACTACGAGGGCCTGCGCAAGGCACTGGCGGAGGCCAAGG 
                            701                                                                                              800 
L. mexicana TKT ORF   (701) CCACGAAGGGCAAGCCGAAGATGATTGTGCAAACCACAACGATTGGGTTCGGGTCTTCGAAGCAGGGAACGGAGAAGGTGCACGGCGCGCCGCTGGGTGA 
        TKT Clone 1   (701) CCACGAAGGGCAAGCCGAAGATGATTGTGCAAACCACAACGATTGGGTTCGGGTCTTCGAAGCAGGGAACGGAGAAGGTGCACGGCGCGCCGCTGGGTGA 
        TKT clone 2   (701) CCACGAAGGGCAAGCCGAAGATGATTGTGCAAACCACAACGATTGGGTTCGGGTCTTCGAAGCAGGGAACGGAGAAGGTGCACGGCGCGCCGCTGGGTGA 
                            801                   *                                                                          900 
L. mexicana TKT ORF   (801) AGAGGATATCGCCAACATCAAGGCAAAATTTGGCCGCGACCCGCAGAAGAAGTACGACGTCGACGACGACGTCCGCGCTGTGTTCAGGATGCACATCGAT 
        TKT Clone 1   (801) AGAGGATATCGCCAACATCAAGACAAAATTTGGCCGCGACCCGCAGAAGAAGTACGACGTCGACGACGACGTCCGCGCTGTGTTCAGGATGCACATCGAT 
        TKT clone 2   (801) AGAGGATATCGCCAACATCAAGACAAAATTTGGCCGCGACCCGCAGAAGAAGTACGACGTCGACGACGACGTCCGCGCTGTGTTCAGGATGCACATCGAT 
      Continued over page  
Figure 8-2. L. mexicana Transketolase DNA sequence alignment. 
Alignment of the L. mexicana TKT ORF sequence (GeneBank accession ID AJ427448) with two independently derived clones. Point mutations are 
denoted by a caron (silent mutation) or an asterisk (mutation conferring an amino acid change), and are located at nucleotides 234 and 823 respectively. 
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                            901                                                                                             1000 
L. mexicana TKT ORF   (901) AAGTGTTCCGCGGAACAGAAGGCGTGGGAGGAACTCTTGGCGAAGTACACAGCCGCGTTCCCGGCCGAGGGTGCCGCCTTTGTGGCGCAGATGAGGGGCG 
        TKT Clone 1   (901) AAGTGTTCCGCGGAACAGAAGGCGTGGGAGGAACTCTTGGCGAAGTACACAGCCGCGTTCCCGGCCGAGGGTGCCGCCTTTGTGGCGCAGATGAGGGGCG 
        TKT clone 2   (901) AAGTGTTCCGCGGAACAGAAGGCGTGGGAGGAACTCTTGGCGAAGTACACAGCCGCGTTCCCGGCCGAGGGTGCCGCCTTTGTGGCGCAGATGAGGGGCG 
                            1001                                                                                            1100 
L. mexicana TKT ORF  (1001) AGCTGCCGTCTGGGTGGGAGGCGAAGCTCCCGACGAACTCCTCGGCCATCGCGACGCGCAAGGCGAGCGAGAACTGCCTGGCTGTGCTCTTCCCGGCCAT 
        TKT Clone 1  (1001) AGCTGCCGTCTGGGTGGGAGGCGAAGCTCCCGACGAACTCCTCGGCCATCGCGACGCGCAAGGCGAGCGAGAACTGCCTGGCTGTGCTCTTCCCGGCCAT 
        TKT clone 2  (1001) AGCTGCCGTCTGGGTGGGAGGCGAAGCTCCCGACGAACTCCTCGGCCATCGCGACGCGCAAGGCGAGCGAGAACTGCCTGGCTGTGCTCTTCCCGGCCAT 
                            1101                                                                                            1200 
L. mexicana TKT ORF  (1101) CCCGGCTCTCATGGGCGGATCGGCTGACCTCACGCCGAGCAACCTGACGCGCCCCGCGTCGGCAAACTTGGTGGACTTCTCGTCGAGCAGCAAGGAGGGT 
        TKT Clone 1  (1101) CCCGGCTCTCATGGGCGGATCGGCTGACCTCACGCCGAGCAACCTGACGCGCCCCGCGTCGGCAAACTTGGTGGACTTCTCGTCGAGCAGCAAGGAGGGT 
        TKT clone 2  (1101) CCCGGCTCTCATGGGCGGATCGGCTGACCTCACGCCGAGCAACCTGACGCGCCCCGCGTCGGCAAACTTGGTGGACTTCTCGTCGAGCAGCAAGGAGGGT 
                            1201                                                                                            1300 
L. mexicana TKT ORF  (1201) CGCTACATTCGCTTCGGTGTCCGTGAACATGCCATGTGCGCCATCCTCAACGGTCTCGACGCCCATGATGGTATCATCCCGTTCGGCGGCACCTTCCTCA 
        TKT Clone 1  (1201) CGCTACATTCGCTTCGGTGTCCGTGAACATGCCATGTGCGCCATCCTCAACGGTCTCGACGCCCATGATGGTATCATCCCGTTCGGCGGCACCTTCCTCA 
        TKT clone 2  (1201) CGCTACATTCGCTTCGGTGTCCGTGAACATGCCATGTGCGCCATCCTCAACGGTCTCGACGCCCATGATGGTATCATCCCGTTCGGCGGCACCTTCCTCA 
                            1301                                                                                            1400 
L. mexicana TKT ORF  (1301) ACTTCATCGGCTACGCCCTTGGTGCAGTGCGCCTCGCCGCGATTTCTCACCACCGCGTCATCTACGTGGCGACACACGACAGCATCGGCGTTGGCGAGGA 
        TKT Clone 1  (1301) ACTTCATCGGCTACGCCCTTGGTGCAGTGCGCCTCGCCGCGATTTCTCACCACCGCGTCATCTACGTGGCGACACACGACAGCATCGGCGTTGGCGAGGA 
        TKT clone 2  (1301) ACTTCATCGGCTACGCCCTTGGTGCAGTGCGCCTCGCCGCGATTTCTCACCACCGCGTCATCTACGTGGCGACACACGACAGCATCGGCGTTGGCGAGGA 
                            1401                                                                                            1500 
L. mexicana TKT ORF  (1401) CGGGCCAACCCACCAGCCTGTCGAGTTGGTGGCTGCCCTGCGTGCCATGCCAAACCTGCAGGTGATACGTCCTAGCGACCAGACAGAGACGAGCGGTGCG 
        TKT Clone 1  (1401) CGGGCCAACCCACCAGCCTGTCGAGTTGGTGGCTGCCCTGCGTGCCATGCCAAACCTGCAGGTGATACGTCCTAGCGACCAGACAGAGACGAGCGGTGCG 
        TKT clone 2  (1401) CGGGCCAACCCACCAGCCTGTCGAGTTGGTGGCTGCCCTGCGTGCCATGCCAAACCTGCAGGTGATACGTCCTAGCGACCAGACAGAGACGAGCGGTGCG 
                            1501                                                                                            1600 
L. mexicana TKT ORF  (1501) TGGGCTGTTGCACTGTCTAGTATTCACACTCCAACGGTTCTGTGTCTGAGCCGCCAGAACACCGAGCCGCAGTCGGGGTCGAGCATCGAGGGTGTGAGGC 
        TKT Clone 1  (1501) TGGGCTGTTGCACTGTCTAGTATTCACACTCCAACGGTTCTGTGTCTGAGCCGCCAGAACACCGAGCCGCAGTCGGGGTCGAGCATCGAGGGTGTGAGGC 
        TKT clone 2  (1501) TGGGCTGTTGCACTGTCTAGTATTCACACTCCAACGGTTCTGTGTCTGAGCCGCCAGAACACCGAGCCGCAGTCGGGGTCGAGCATCGAGGGTGTGAGGC 
                            1601                                                                                            1700 
L. mexicana TKT ORF  (1601) ACGGCGCCTACTCGGTGGTGGATGTGCCCGACCTGCAGCTCGTGATCGTGGCGAGCGGCTCGGAGGTGTCGCTGGCGGTGGATGCTGCCAAAGCGCTCTC 
        TKT Clone 1  (1601) ACGGCGCCTACTCGGTGGTGGATGTGCCCGACCTGCAGCTCGTGATCGTGGCGAGCGGCTCGGAGGTGTCGCTGGCGGTGGATGCTGCCAAAGCGCTCTC 
        TKT clone 2  (1601) ACGGCGCCTACTCGGTGGTGGATGTGCCCGACCTGCAGCTCGTGATCGTGGCGAGCGGCTCGGAGGTGTCGCTGGCGGTGGATGCTGCCAAAGCGCTCTC 
                            1701                                                                                            1800 
L. mexicana TKT ORF  (1701) GGGTGAGCTGCGCGTAAGGGTCGTGTCGATGCCGTGCCAGGAGCTCTTCGACGCACAACCGGATACGTACCGCCAGGCTGTGCTCCCCGCGGGTGTGCCG 
        TKT Clone 1  (1701) GGGTGAGCTGCGCGTAAGGGTCGTGTCGATGCCGTGCCAGGAGCTCTTCGACGCACAACCGGATACGTACCGCCAGGCTGTGCTCCCCGCGGGTGTGCCG 
        TKT clone 2  (1701) GGGTGAGCTGCGCGTAAGGGTCGTGTCGATGCCGTGCCAGGAGCTCTTCGACGCACAACCGGATACGTACCGCCAGGCTGTGCTCCCCGCGGGTGTGCCG 
                            1801                                                                                            1900 
L. mexicana TKT ORF  (1801) GTGGTGTCGGTGGAGGCGTACGTCAGTTTTGGCTGGGAGAAATACTCCCATGCGCACGTGGGCATGTCCGGCTTCGGTGCCTCGGCCCCGGCGGGTGTGC 
        TKT Clone 1  (1801) GTGGTGTCGGTGGAGGCGTACGTCAGTTTTGGCTGGGAGAAATACTCCCATGCGCACGTGGGCATGTCCGGCTTCGGTGCCTCGGCCCCGGCGGGTGTGC 
        TKT clone 2  (1801) GTGGTGTCGGTGGAGGCGTACGTCAGTTTTGGCTGGGAGAAATACTCCCATGCGCACGTGGGCATGTCCGGCTTCGGTGCCTCGGCCCCGGCGGGTGTGC 
                            1901                                                                                            2000 
L. mexicana TKT ORF  (1901) TATACAAGAAGTTTGGAATTACCGTCGAGGAAGTGGTGAGGACGGGCCGTGAGTTGGCCAAGCGCTTCCCCGATGGCACGGCGCCGCTCAAGAACTCTTC 
        TKT Clone 1  (1901) TATACAAGAAGTTTGGAATTACCGTCGAGGAAGTGGTGAGGACGGGCCGTGAGTTGGCCAAGCGCTTCCCCGATGGCACGGCGCCGCTCAAGAACTCTTC 
        TKT clone 2  (1901) TATACAAGAAGTTTGGAATTACCGTCGAGGAAGTGGTGAGGACGGGCCGTGAGTTGGCCAAGCGCTTCCCCGATGGCACGGCGCCGCTCAAGAACTCTTC 
                            2001        2016 
L. mexicana TKT ORF  (2001) ATTCAGCAAGATGTAA 
        TKT Clone 1  (2001) ATTCAGCAAGATGTAA 
        TKT clone 2  (2001) ATTCAGCAAGATGTAA 
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                           1                                                                                                100 
L. donovani TKT ORF    (1) MASIEKIANCIRCLAADIVQGGKSGHPGTPMGMAPVSAVLWTEVMKYNSQDPNWVDRDRFVMSNGHGCALQYALLHMAGYDLTMDDLKGFRQDGSRTPGH 
L. mexicana TKT ORF    (1) MASIEKVANCIRCLAADIVQGGKSGHPGTPMGMAPMSAVLWTEVMKYNSQDPDWVDRDRFVMSNGHGCALQYALLHMAGYNLTMDDLKGFRQDGSRTPGH 
                           101                                                                                              200 
L. donovani TKT ORF  (101) PERFVTPGVEVTTGPLGQGIANAVGLAMAESHLAARFNRPGHELVNHYTYVYCGDGCLMEGVCQEALSLAGHLALEKLIVIYDSNYICIDGATNLSFTEQ 
L. mexicana TKT ORF  (101) PERFVTPGVEVTTGPLGQGIANAVGLAIAEAHLAATFNRPGYNIVDHYTYVYCGDGCLMEGVCQEALSLAGHLALEKLIVIYDSNYISIDGSTSLSFTEQ 
                           201                                                                                              300 
L. donovani TKT ORF  (201) SHQKYVSMGFHVIEVENGDTDYDGLRKALAEAKATKGKPKMIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANVKTKFGRDPNKKYDVDEDVRAVFKMHME 
L. mexicana TKT ORF  (201) CHQKYVAMGFHVIEVKNGDTDYEGLRKALAEAKATKGKPKMIVQTTTIGFGSSKQGTEKVHGAPLGEEDIANIKTKFGRDPQKKYDVDDDVRAVFRMHID 
                           301                                                                                              400 
L. donovani TKT ORF  (301) KCSAEQKAWEERLAKYTAAFPAEGAAFVAQMKGELPSGWEAKLPTNSSAIATRKASENCLAVLFPAIPALMGGSADLTPSNLTRPASANLVDFSSSSNEG 
L. mexicana TKT ORF  (301) KCSAEQKAWEELLAKYTAAFPAEGAAFVAQMRGELPSGWEAKLPTNSSAIATRKASENCLAVLFPAIPALMGGSADLTPSNLTRPASANLVDFSSSSKEG 
                           401                                                                                              500 
L. donovani TKT ORF  (401) RYIRFGVREHAMCAILNGLDAHGGIIPFGGTFLNFIGYALGAVRLAAISHHRVIYVATHDSIGVGEDGPTHQPVELVAALRAMPNLQVMRPSDQTETSGA 
L. mexicana TKT ORF  (401) RYIRFGVREHAMCAILNGLDAHDGIIPFGGTFLNFIGYALGAVRLAAISHHRVIYVATHDSIGVGEDGPTHQPVELVAALRAMPNLQVIRPSDQTETSGA 
                           501                                                                                              600 
L. donovani TKT ORF  (501) WAVALSSAHTPTVLCLSRQSTVPQSGSSIDGVKRGAYTVVEVPDPQLVIVASGSEVSLAVDAAKVLSGELCVRVVSMPCQELFDAQPDAYRKSVLTEGVP 
L. mexicana TKT ORF  (501) WAVALSSIHTPTVLCLSRQNTEPQSGSSIEGVRHGAYSVVDVPDLQLVIVASGSEVSLAVDAAKALSGELRVRVVSMPCQELFDAQPDTYRQAVLPAGVP 
                           601                                                                  672 
L. donovani TKT ORF  (601) VVSVEAYVSFGWEKYSHAHVGMSGFGASAPAGVLYKKFGITVEEVVETARRLTARFPNRTAPLKNSSFSKM- 
L. mexicana TKT ORF  (601) VVSVEAYVSFGWEKYSHAHVGMSGFGASAPAGVLYKKFGITVEEVVRTGRELAKRFPDGTAPLKNSSFSKM- 
Figure 8-3. Alignment of transketolase amino acid sequences from L. donovani and L. mexicana. 
Alignment of the L. donovani TKT (MHOM/NP/03/BPK282A1; EMBL accession ID E9BH77) and L. mexicana TKT (Laboratory strain) amino acid 
sequences. There is a 92.1 % sequence identity. 
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                          1                                                                                                100 
L. mexicana VDAC-1 ORF    (1) ATGTCGCAGTGGCAATCCTCCAAGGGGTCGGCCGCGAAGGTCTACGCCACCCCTTCCCTCTTCAAGGACTACAACAAGCTCACGAAGGATCTGCTCACGA 
      VDAC-1 Wild_Type    (1) ATGTCGCAGTGGCAATCCTCCAAGGGGTCGGCCGCGAAGGTCTACGCCACCCCTTCCCTCTTCAAGGACTACAACAAGCTCACGAAGGATCTGCTCACGA 
       VDAC-1 Pent_Res    (1) ATGTCGCAGTGGCAATCCTCCAAGGGGTCGGCCGCGAAGGTCTACGCCACCCCTTCCCTCTTCAAGGACTACAACAAGCTCACGAAGGATCTGCTCACGA 
                              101                                                                                              200 
L. mexicana VDAC-1 ORF  (101) AGGACTTCCCCACGCCGAATAAGTGGGTCCTGGAGTGCAAGTACAAGGGCCCCAAGGACACCTTCTTCATCAACCCCAAGGCTAACTCCGATGGCAAGAT 
      VDAC-1 Wild_Type  (101) AGGACTTCCCCACGCCGAATAAGTGGGTCCTGGAGTGCAAGTACAAGGGCCCCAAGGACACCTTCTTCATCAACCCCAAGGCTAACTCCGATGGCAAGAT 
       VDAC-1 Pent_Res  (101) AGGACTTCCCCACGCCGAATAAGTGGGTCCTGGAGTGCAAGTACAAGGGCCCCAAGGACACCTTCTTCATCAACCCCAAGGCTAACTCCGATGGCAAGAT 
                              201                                                                                              300 
L. mexicana VDAC-1 ORF  (201) GTCGGCTGACATCGAGTACGTCGCGGCGTGCAACGGCGGCCTAAAGGTCACCGTGACCCCTGACATCATGCGTGAGGTCAAGGCCACGGCCCACTACACG 
      VDAC-1 Wild_Type  (201) GTCGGCTGACATCGAGTACGTCGCGGCGTGCAACGGCGGCCTAAAGGTCACCGTGACCCCTGACATCATGCGTGAGGTCAAGGCCACGGCCCACTACACG 
       VDAC-1 Pent_Res  (201) GTCGGCTGACATCGAGTACGTCGCGGCGTGCAACGGCGGCCTAAAGGTCACCGTGACCCCTGACATCATGCGTGAGGTCAAGGCCACGGCCCACTACACG 
                              301                                                                                              400 
L. mexicana VDAC-1 ORF  (301) ATCCAGGGCCACAAGGTGGCGGTGGCTCTGCAGCGCCTCCAGGACAAGTACCACTACGAGATCAGCCACGAGACTTGCGTGGCTCTCTCGAAACGCGCAA 
      VDAC-1 Wild_Type  (301) ATCCAGGGCCACAAGGTGGCGGTGGCTCTGCAGCGCCTCCAGGACAAGTACCACTACGAGATCAGCCACGAGACTTGCGTGGCTCTCTCGAAACGCGCAA 
       VDAC-1 Pent_Res  (301) ATCCAGGGCCACAAGGTGGCGGTGGCTCTGCAGCGCCTCCAGGACAAGTACCACTACGAGATCAGCCACGAGACTTGCGTGGCTCTCTCGAAACGCGCAA 
                              401                                                                                              500 
L. mexicana VDAC-1 ORF  (401) GCATCAACGAGAAACTTACGCCGACTCATGTGGAGCTGGGCATGGGCATCGACGTGGCACCGAACTGCCAGGTCGGCTGTGGTGCCACGTATGATATTGG 
      VDAC-1 Wild_Type  (401) GCATCAACGAGAAACTTACGCCGACTCATGTGGAGCTGGGCATGGGCATCGACGTGGCACCGAACTGCCAGGTCGGCTGTGGTGCCACGTATGATATTGG 
       VDAC-1 Pent_Res  (401) GCATCAACGAGAAACTTACGCCGACTCATGTGGAGCTGGGCATGGGCATCGACGTGGCACCGAACTGCCAGGTCGGCTGTGGTGCCACGTATGATATTGG 
                              501                                                                                              600 
L. mexicana VDAC-1 ORF  (501) CGCCAACGACTGCAACTGGAACATCGGCTGCCGCTATGCGGGGAGGGGCTGCGAGATGGCGGTGCGCACGAACCGCCTGAAAACTTACCATACAAGCGCC 
      VDAC-1 Wild_Type  (501) CGCCAACGACTGCAACTGGAACATCGGCTGCCGCTATGCGGGGAGGGGCTGCGAGATGGCGGTGCGCACGAACCGCCTGAAAACTTACCATACAAGCGCC 
       VDAC-1 Pent_Res  (501) CGCCAACGACTGCAACTGGAACATCGGCTGCCGCTATGCGGGGAGGGGCTGCGAGATGGCGGTGCGCACGAACCGCCTGAAAACTTACCATACAAGCGCC 
                              601                                                                                              700 
L. mexicana VDAC-1 ORF  (601) AGCGCTCCCTGCTCCTTCATGCTTAACGGCAACAGGTGCATGATGCGCGCCGCCGTCGAGGTGATGTGCGGACGTGGTCTTGGCGACAAGGGTGTCGCGG 
      VDAC-1 Wild_Type  (601) AGCGCTCCCTGCTCCTTCATGCTTAACGGCAACAGGTGCATGATGCGCGCCGCCGTCGAGGTGATGTGCGGACGTGGTCTTGGCGACAAGGGTGTCGCGG 
       VDAC-1 Pent_Res  (601) AGCGCTCCCTGCTCCTTCATGCTTAACGGCAACAGGTGCATGATGCGCGCCGCCGTCGAGGTGATGTGCGGACGTGGTCTTGGCGACAAGGGTGTCGCGG 
                              701                                                                                 *            800 
L. mexicana VDAC-1 ORF  (701) TCACCGTGGGGGTGGAGGCCACGTGCCCGGTGCACCCGGCCAACACAATAAAGGCTCGCGTGGACCGGGACATGAAGTGGGCGGCCGCCTACATCGTCAA 
      VDAC-1 Wild_Type  (701) TCACCGTGGGGGTGGAGGCCACGTGCCCGGTGCACCCGGCCAACACAATAAAGGCTCGCGTGGACCGGGACATGAAGTGGGCGGTCGCCTACATCGTCAA 
       VDAC-1 Pent_Res  (701) TCACCGTGGGGGTGGAGGCCACGTGCCCGGTGCACCCGGCCAACACAATAAAGGCTCGCGTGGACCGGGACATGAAGTGGGCGGTCGCCTACATCGTCAA 
                              801                                                                      876 
L. mexicana VDAC-1 ORF  (801) GATGGCGGACAACTGGACTGCGTGCCTCTCGTGGGACGAGAACATGAAGGTTGGCGTGCAGATGACGCACTCGTAG 
      VDAC-1 Wild_Type  (801) GATGGCGGACAACTGGACTGCGTGCCTCTCGTGGGACGAGAACATGAAGGTTGGCGTGCAGATGACGCACTCGTAG 
       VDAC-1 Pent_Res  (801) GATGGCGGACAACTGGACTGCGTGCCTCTCGTGGGACGAGAACATGAAGGTTGGCGTGCAGATGACGCACTCGTAG 
Figure 8-4. VDAC-1 DNA sequence alignment. 
Alignment of the L. mexicana VDAC-1 ORF sequence (LmxM.02.0460) with the sequences derived from the wild type and pentamidine resistant lab 
strains. Point mutations are denoted by an asterisk (mutation conferring an amino acid change), and is located at nucleotide 875. 
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                              1                                                                                                100 
L. mexicana VDAC-2 ORF    (1) ATGACAACCCTCTTCAAGGATTACAGCAAGGGCAGCAATGACTTGCTTACCAAGAACTTTTCCAGCTGCGGCGCGTGGAAGGTCGAGAGCAAGAGCAAGG 
      VDAC-2 Wild_Type    (1) ATGACAACCCTCTTCAAGGATTACAGCAAGGGCAGCAATGACTTGCTTACCAAGAACTTTTCCAGCTGCGGCGCGTGGAAGGTCGAGAGCAAGAGCAAGG 
       VDAC-2 Pent_Res    (1) ATGACAACCCTCTTCAAGGATTACAGCAAGGGCAGCAATGACTTGCTTACCAAGAACTTTTCCAGCTGCGGCGCGTGGAAGGTCGAGAGCAAGAGCAAGG 
                              101                                                                                              200 
L. mexicana VDAC-2 ORF  (101) CCCCCAAAGGCACGTATGCCCTCACGACCACCTCCAACACCCACGGTGACGTGAAGTTGGATATCGAGGGGCTGACGGGCGACGGCGCCTATTATGGCAA 
      VDAC-2 Wild_Type  (101) CCCCCAAAGGCACGTATGCCCTCACGACCACCTCCAACACCCACGGTGACGTGAAGTTGGATATCGAGGGGCTGACGGGCGACGGCGCCTATTATGGCAA 
       VDAC-2 Pent_Res  (101) CCCCCAAAGGCACGTATGCCCTCACGACCACCTCCAACACCCACGGTGACGTGAAGTTGGATATCGAGGGGCTGACGGGCGACGGCGCCTATTATGGCAA 
                              201                                                                                              300 
L. mexicana VDAC-2 ORF  (201) GCTCTGCTTCACGTCGAAGGACCTCACCGACATCCAGCTCACCGTCCGCGCCGAGGACCTCGATAACCACCGCGTGGAGGCCATCATTGGCCACAAGGGC 
      VDAC-2 Wild_Type  (201) GCTCTGCTTCACGTCGAAGGACCTCACCGACATCCAGCTCACCGTCCGCGCCGAGGACCTCGATAACCACCGCGTGGAGGCCATCATTGGCCACAAGGGC 
       VDAC-2 Pent_Res  (201) GCTCTGCTTCACGTCGAAGGACCTCACCGACATCCAGCTCACCGTCCGCGCCGAGGACCTCGATAACCACCGCGTGGAGGCCATCATTGGCCACAAGGGC 
                              301                                                                                              400 
L. mexicana VDAC-2 ORF  (301) CCGGCGGTGTGCGATATATCGGTGGAGGTCAACCACCAGACGGTAAGGCCGATAGCGGGGGGCTGCCTGAGCGTCAACGAAAAGTTTACGCAGAAGGCCG 
      VDAC-2 Wild_Type  (301) CCGGCGGTGTGCGATATATCGGTGGAGGTCAACCACCAGACGGTAAGGCCGATAGCGGGGGGCTGCCTGAGCGTCAACGAAAAGTTTACGCAGAAGGCCG 
       VDAC-2 Pent_Res  (301) CCGGCGGTGTGCGATATATCGGTGGAGGTCAACCACCAGACGGTAAGGCCGATAGCGGGGGGCTGCCTGAGCGTCAACGAAAAGTTTACGCAGAAGGCCG 
                              401                                                                                              500 
L. mexicana VDAC-2 ORF  (401) TGGAGTTGGCGCTCAGCATGGCCGCCGTTGACGGCGTTCAGGTCGGCTGCGGCACCAAGTATGACCTCAAGTCGAAGACAATCGACTGGACGGCGGGGTG 
      VDAC-2 Wild_Type  (401) TGGAGTTGGCGCTCAGCATGGCCGCCGTTGACGGCGTTCAGGTCGGCTGCGGCACCAAGTATGACCTCAAGTCGAAGACAATCGACTGGACGGCGGGGTG 
       VDAC-2 Pent_Res  (401) TGGAGTTGGCGCTCAGCATGGCCGCCGTTGACGGCGTTCAGGTCGGCTGCGGCACCAAGTATGACCTCAAGTCGAAGACAATCGACTGGACGGCGGGGTG 
                              501                                                                                              600 
L. mexicana VDAC-2 ORF  (501) CCGCATGGAGGCCAAGAACGGTCTTGTGATGACGGCGCAGACGAACCGGTCGCTCGACGTCACGGCGAGCATGATTTCCAAGGCCGCACTGCACCCAAAG 
      VDAC-2 Wild_Type  (501) CCGCATGGAGGCCAAGAACGGTCTTGTGATGACGGCGCAGACGAACCGGTCGCTCGACGTCACGGCGAGCATGATTTCCAAGGCCGCACTGCACCCAAAG 
       VDAC-2 Pent_Res  (501) CCGCATGGAGGCCAAGAACGGTCTTGTGATGACGGCGCAGACGAACCGGTCGCTCGACGTCACGGCGAGCATGATTTCCAAGGCCGCACTGCACCCAAAG 
                              601                                                                                              700 
L. mexicana VDAC-2 ORF  (601) TTCCAGCCGTGCGTGGCAGCCACCGTGACGATGAACCCGCAATCGATGACATGGGACGGCTCCGTGGCACTGGAGTGGGGTTGTCAGGTGATTCTCGGCA 
      VDAC-2 Wild_Type  (601) TTCCAGCCGTGCGTGGCAGCCACCGTGACGATGAACCCGCAATCGATGACATGGGACGGCTCCGTGGCACTGGAGTGGGGTTGTCAGGTGATTCTCGGCA 
       VDAC-2 Pent_Res  (601) TTCCAGCCGTGCGTGGCAGCCACCGTGACGATGAACCCGCAATCGATGACATGGGACGGCTCCGTGGCACTGGAGTGGGGTTGTCAGGTGATTCTCGGCA 
                              701                                                                                              800 
L. mexicana VDAC-2 ORF  (701) ACGCGGCCAAGATTCGCTTCAGCAAGAACCTCGACTGGGTCGCCTCGTACATCGCCAACCTGCGCGACGGCTGGACGGTGGTGCTGTCGATGGACAAGAC 
      VDAC-2 Wild_Type  (701) ACGCGGCCAAGATTCGCTTCAGCAAGAACCTCGACTGGGTCGCCTCGTACATCGCCAACCTGCGCGACGGCTGGACGGTGGTGCTGTCGATGGACAAGAC 
       VDAC-2 Pent_Res  (701) ACGCGGCCAAGATTCGCTTCAGCAAGAACCTCGACTGGGTCGCCTCGTACATCGCCAACCTGCGCGACGGCTGGACGGTGGTGCTGTCGATGGACAAGAC 
                              801                            834 
L. mexicana VDAC-2 ORF  (801) CATGAGGGCGGGTCTGACGCTCACTCGCAACTGA 
      VDAC-2 Wild_Type  (801) CATGAGGGCGGGTCTGACGCTCACTCGCAACTGA 
       VDAC-2 Pent_Res  (801) CATGAGGGCGGGTCTGACGCTCACTCGCAACTGA 
Figure 8-5. VDAC-2 DNA sequence alignment. 
Alignment of the L. mexicana VDAC-2 ORF sequence (LmxM.02.0450) with the sequences derived from the wild type and pentamidine resistant lab 
strains. 
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1                                                                                                100 
VDAC-1 (LmxM.02.0460) (1) MSQWQSSKGSAAKVYATPSLFKDYNKLTKDLLTKDFPTPNKWVLECKYKGPKDTFFINPKANSDGKMSADIEYVAACNGGLKVTVTPDIMREVKATAHYT 
VDAC-1 (Lab)     (1) MSQWQSSKGSAAKVYATPSLFKDYNKLTKDLLTKDFPTPNKWVLECKYKGPKDTFFINPKANSDGKMSADIEYVAACNGGLKVTVTPDIMREVKATAHYT 
101                                                                                              200 
VDAC-1 (LmxM.02.0460) (101) IQGHKVAVALQRLQDKYHYEISHETCVALSKRASINEKLTPTHVELGMGIDVAPNCQVGCGATYDIGANDCNWNIGCRYAGRGCEMAVRTNRLKTYHTSA 
VDAC-1 (Lab)  (101) IQGHKVAVALQRLQDKYHYEISHETCVALSKRASINEKLTPTHVELGMGIDVAPNCQVGCGATYDIGANDCNWNIGCRYAGRGCEMAVRTNRLKTYHTSA 
201                                                          *                          291 
VDAC-1 (LmxM.02.0460) (201) SAPCSFMLNGNRCMMRAAVEVMCGRGLGDKGVAVTVGVEATCPVHPANTIKARVDRDMKWAAAYIVKMADNWTACLSWDENMKVGVQMTHS 
VDAC-1 (Lab)  (201) SAPCSFMLNGNRCMMRAAVEVMCGRGLGDKGVAVTVGVEATCPVHPANTIKARVDRDMKWAVAYIVKMADNWTACLSWDENMKVGVQMTHS 
Figure 8-6. Alignment of VDAC-1 amino acid sequences from L. mexicana. 
Alignment of the L. mexicana VDAC-1 amino acid sequence (LmxM.02.0460) with the sequence derived from the wild type lab strain. The amino acid 
change, located at residue 262, is denoted by an asterisk. 
 
1                                                                                                100 
VDAC-2 (LmxM.02.0450) (1) MTTLFKDYSKGSNDLLTKNFSSCGAWKVESKSKAPKGTYALTTTSNTHGDVKLDIEGLTGDGAYYGKLCFTSKDLTDIQLTVRAEDLDNHRVEAIIGHKG 
VDAC-2 (Lab)  (1) MTTLFKDYSKGSNDLLTKNFSSCGAWKVESKSKAPKGTYALTTTSNTHGDVKLDIEGLTGDGAYYGKLCFTSKDLTDIQLTVRAEDLDNHRVEAIIGHKG 
101                                                                                              200 
VDAC-2 (LmxM.02.0450) (101) PAVCDISVEVNHQTVRPIAGGCLSVNEKFTQKAVELALSMAAVDGVQVGCGTKYDLKSKTIDWTAGCRMEAKNGLVMTAQTNRSLDVTASMISKAALHPK 
VDAC-2 (Lab)  (101) PAVCDISVEVNHQTVRPIAGGCLSVNEKFTQKAVELALSMAAVDGVQVGCGTKYDLKSKTIDWTAGCRMEAKNGLVMTAQTNRSLDVTASMISKAALHPK 
201                                                                       277 
VDAC-2 (LmxM.02.0450) (201) FQPCVAATVTMNPQSMTWDGSVALEWGCQVILGNAAKIRFSKNLDWVASYIANLRDGWTVVLSMDKTMRAGLTLTRN 
VDAC-2 (Lab)  (201) FQPCVAATVTMNPQSMTWDGSVALEWGCQVILGNAAKIRFSKNLDWVASYIANLRDGWTVVLSMDKTMRAGLTLTRN 
Figure 8-7. Alignment of VDAC-2 amino acid sequences from L. mexicana. 
Alignment of the L. mexicana VDAC-2 amino acid sequence (LmxM.02.0450) with the sequence derived from the wild type lab strain. 
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                       1                                                                                                100 
VDAC-1 (LmxM.02.0460) (1) MSQWQSSKGSAAKVYATPSLFKDYNKLTKDLLTKDFPTPNKWVLECKYKGPKDTFFINPKANSDGKMSADIEYVAACNG--GLKVTVTPDIMREVKATAH 
VDAC-2 (LmxM.02.0450) (1) ----------------MTTLFKDYSKGSNDLLTKNFSSCGAWKVESKSKAPKGTYALTTTSNTHGDVKLDIEGLTGDGAYYGKLCFTSKDLTDIQLTVRA 
                        101                                                                                              200 
VDAC-1 (LmxM.02.0460) (99) YTIQGHKVAVALQR---LQDKYHYEISHETCVALS-KRASINEKLTPTHVELGMGIDVAPNCQVGCGATYDIGANDCNWNIGCRYAGR-GCEMAVRTNRL 
VDAC-2 (LmxM.02.0450) (85) EDLDNHRVEAIIGHKGPAVCDISVEVNHQTVRPIAGGCLSVNEKFTQKAVELALSMAAVDGVQVGCGTKYDLKSKTIDWTAGCRMEAKNGLVMTAQTNRS 
201                                                                                            298 
VDAC-1 (LmxM.02.0460) (194) KTYHTSASAPCSFMLNGNRCMMRAAVEVMCGRGLGDKGVAVTVGVEATCPVHPANTIKARVDRDMKWAAAYIVKMADNWTACLSWDENMKVGVQMTHS 
VDAC-2 (LmxM.02.0450) (185) LDVTASMISKAALHPKFQPCVAATVTMNPQ-----SMTWDGSVALEWGCQVILGNAAKIRFSKNLDWVASYIANLRDGWTVVLSMDKTMRAGLTLTRN 
Figure 8-8. Alignment of VDAC-1 and VDAC-2 amino acid sequences from L. mexicana. 
Amino acid sequences were obtained from TriTrypDB (Aslett, M et al. 2011)28. There is a 40.6 % sequence identity. 
                                         
28
 http://tritrypdb.org 
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INSERT INTO 131_Results ( [Exact_Mass_(MIM)], Formula, CompCode ) 
SELECT DISTINCT Metabolites.[Exact_Mass_(MIM)], Metabolites.Formula, [109_Total KEGG database].CompCode 
FROM Masses, [109_Total KEGG database] INNER JOIN Metabolites ON [109_Total KEGG database].Formula = Metabolites.Formula 
WHERE (((Metabolites.[Exact_Mass_(MIM)])>(([Masses].[Mass]-([Forms]![Analysis]![PPMrange]/1000000)*[Masses].[Mass])) And 
(Metabolites.[Exact_Mass_(MIM)])<([Masses].[Mass]+(([Forms]![Analysis]![PPMrange]/1000000)*[Masses].[Mass]))) AND ((Masses.Experiment)=[Forms]![Analysis]![ExpList]) AND 
(([Forms]![Analysis]![TTestDW])='No')) OR (((Metabolites.[Exact_Mass_(MIM)])>(([Masses].[Mass]-([Forms]![Analysis]![PPMrange]/1000000)*[Masses].[Mass])) And 
(Metabolites.[Exact_Mass_(MIM)])<([Masses].[Mass]+(([Forms]![Analysis]![PPMrange]/1000000)*[Masses].[Mass]))) AND ((Masses.Experiment)=[Forms]![Analysis]![ExpList]) AND 
((Masses.PValue)<=[Forms]![Analysis]![PValueDW])); 
Figure 8-9. SQL: 065_Analysis 
DELETE [131_Results].Formula, [131_Results].[Exact_Mass_(MIM)], [131_Results].CompCode 
FROM 131_Results 
WHERE ((([131_Results].Formula) Like "*") AND (([131_Results].[Exact_Mass_(MIM)]) Like "*") AND (([131_Results].CompCode) Like "*")); 
Figure 8-10. SQL: 071_Delete_all_records_in_131 
DELETE [132_Unique_Formula_RESULTS].Formula, [132_Unique_Formula_RESULTS].[Exact_Mass_(MIM)] 
FROM 132_Unique_Formula_RESULTS 
WHERE ((([132_Unique_Formula_RESULTS].Formula) Like "*") AND (([132_Unique_Formula_RESULTS].[Exact_Mass_(MIM)]) Like "*")); 
Figure 8-11. SQL: 070_Delete_all_records_in_132 
INSERT INTO 132_Unique_Formula_RESULTS ( Formula, [Exact_Mass_(MIM)], KEGG_Isomers ) 
SELECT [131_Results].Formula, [131_Results].[Exact_Mass_(MIM)], Count([131_Results].Formula) AS CountOfFormula 
FROM 131_Results 
GROUP BY [131_Results].Formula, [131_Results].[Exact_Mass_(MIM)] 
HAVING (((Count([131_Results].Formula))>0)) 
ORDER BY Count([131_Results].Formula); 
Figure 8-12. SQL: 069_Add_Unique_Masses_To_New_Table_132 
DELETE [139_Specific_Metabolites].[Exact_Mass_(MIM)] 
FROM 139_Specific_Metabolites 
WHERE ((([139_Specific_Metabolites].[Exact_Mass_(MIM)]) Like "*")); 
Figure 8-13. SQL: 078_delete_values_from_139 
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INSERT INTO 139_Specific_Metabolites ( Metabolite, [Exact_Mass_(MIM)], Formula, CompCode ) 
SELECT [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula, [109_Total KEGG database].CompCode 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].Metabolite) Like "*" & [Forms]![Analysis]![metabolite] & "*")); 
Figure 8-14. SQL: 077_Specific_Metabolite_Search 
SELECT Masses.MASS, Masses.Experiment, Forms!Specific_Metabolite_Search_2!Metabolite_List AS [MIM of chosen metabolite] 
FROM Masses 
WHERE (((Masses.MASS) Between ([Forms]![Specific_Metabolite_Search_2]![Metabolite_List]-
(0.000001*[Forms]![Specific_Metabolite_Search_2]![Metabolite_List]*[Forms]![Specific_Metabolite_Search_2]![ppm_tolerance])) And 
([Forms]![Specific_Metabolite_Search_2]![Metabolite_List]+(0.000001*[Forms]![Specific_Metabolite_Search_2]![Metabolite_List]*[Forms]![Specific_Metabolite_Search_2]![ppm_tolerance])))); 
Figure 8-15. SQL: 081_search_the_masses_table_for_specific_metabolite 
SELECT [109_Total KEGG database].Shortlist, [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula, [109_Total KEGG 
database].CompCode, [109_Total KEGG database].KEGG_Link, [109_Total KEGG database].Image_Link, [109_Total KEGG database].InChi_ID 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].[Exact_Mass_(MIM)]) Between [Forms]![Multiple CompCode Search]![LOWER_MASS] And [Forms]![Multiple CompCode Search]![UPPER_MASS])) 
ORDER BY [109_Total KEGG database].[Exact_Mass_(MIM)]; 
Figure 8-16. SQL: Mass Search (037) 
SELECT [109_Total KEGG database].Shortlist, [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].[Exact_Mass_(MIM)]) Between ([Forms]![Multiple CompCode Search]![Input MIM]-(0.000001*[Forms]![Multiple CompCode Search]![Input MIM]*[Forms]![Multiple CompCode 
Search]![PPM_Tolerance])) And ([Forms]![Multiple CompCode Search]![Input MIM]+(0.000001*[Forms]![Multiple CompCode Search]![Input MIM]*[Forms]![Multiple CompCode Search]![PPM_Tolerance])))) 
ORDER BY [109_Total KEGG database].[Exact_Mass_(MIM)]; 
Figure 8-17. SQL: Mass (MIM) Search (038) 
SELECT [109_Total KEGG database].Shortlist, [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula, [109_Total KEGG 
database].CompCode, [109_Total KEGG database].KEGG_Link, [109_Total KEGG database].Image_Link, [109_Total KEGG database].InChi_ID 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].Formula)=[Forms]![multiple CompCode Search]![Input Molecular Formula])); 
Figure 8-18. SQL: Molecular Formula Search (019) 
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SELECT [109_Total KEGG database].Shortlist, [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula, [109_Total KEGG 
database].CompCode, [109_Total KEGG database].KEGG_Link, [109_Total KEGG database].Image_Link, [109_Total KEGG database].InChi_ID 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].Metabolite) Like "*" & [Forms]![Multiple CompCode Search]![Enter Metabolite Name] & "*")); 
Figure 8-19. SQL: Metabolite Search (018) (A11) 
SELECT [109_Total KEGG database].Shortlist, [109_Total KEGG database].Metabolite, [109_Total KEGG database].[Exact_Mass_(MIM)], [109_Total KEGG database].Formula, [109_Total KEGG 
database].CompCode, [109_Total KEGG database].KEGG_Link, [109_Total KEGG database].Image_Link, [109_Total KEGG database].InChi_ID 
FROM [109_Total KEGG database] 
WHERE ((([109_Total KEGG database].CompCode)=[Forms]![multiple CompCode Search]![Input KEGG CompCode])); 
Figure 8-20. SQL: KEGG CompCode Search (031) (A12) 
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Table 8-1. Fluorescence readings used to calculate the methylene blue EC50 values 
log (M) [Methylene Blue]
-5.1 6207.3 5558.7 5313.3 5024.3 4482.7 4441.7 5799.0 4674.7 5101.0
-5.4 7802.3 6817.7 6735.0 6062.0 5816.0 5119.0 7017.7 5613.3 6278.7
-5.7 10400.7 9008.3 8719.0 7844.3 7358.7 6663.3 8957.3 7296.0 8101.7
-6.0 16225.7 13924.0 13257.7 15832.7 10777.7 10600.3 9016.0 10556.7 7901.3
-6.3 44757.3 41395.7 34112.7 24283.0 20258.3 22283.0 5739.7 9208.3 5241.7
-6.6 53414.7 51828.7 53464.0 57089.0 48651.7 55694.3 20059.3 15671.0 9200.0
-6.9 56118.0 53779.0 55259.3 58183.7 57614.7 58380.0 52556.7 54403.3 54051.7
-7.2 57458.0 55677.7 56893.0 58056.0 58000.3 58172.7 52777.0 54212.0 54180.0
-7.5 57841.7 56309.7 56964.7 57969.7 57981.0 58005.7 52640.0 54019.3 54476.0
-7.8 57494.3 56866.7 57025.0 57686.7 58055.3 58071.3 52044.3 54217.3 53856.7
-8.1 57263.0 56465.0 56824.7 57585.0 57778.0 57974.3 51715.3 53747.7 53775.3
-9.0 57308.3 55539.3 54275.3 56674.3 55677.3 57681.7 47630.7 53525.7 53580.7
Proline-richGlucose and Proline Glucose-rich
 
The seven values excluded from the proline-rich growth conditions are highlighted in grey.
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